{
  "abacavir": {
    "adverseEffects": {
      "common": [
        "Nausea",
        "headache",
        "insomnia",
        "fatigue."
      ],
      "serious": [
        "Hypersensitivity Reaction (HSR): Multi-organ clinical syndrome. Symptoms include fever, rash, fatigue, malaise, and gastrointestinal (nausea, vomiting, diarrhea) and respiratory (cough, dyspnea) symptoms.",
        "Lactic acidosis and severe hepatomegaly with steatosis."
      ]
    },
    "brandNames": [
      "Ziagen"
    ],
    "category": "Antiretroviral",
    "contraindications": [
      "Presence of the HLA-B*5701 allele.",
      "Prior hypersensitivity reaction to abacavir.",
      "Moderate or severe hepatic impairment."
    ],
    "dose": "Adults: 600 mg once daily or 300 mg twice daily, orally.",
    "drugClass": "Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
    "genericName": "Abacavir",
    "indications": "Treatment of Human Immunodeficiency Virus (HIV-1) infection, always in combination with other antiretroviral agents.",
    "lactationInfo": "Abacavir is excreted in human milk. The CDC recommends that HIV-infected mothers in the U.S. should not breastfeed to avoid postnatal transmission of HIV.",
    "moaSteps": [
      "Abacavir is a prodrug that passively diffuses into cells. Inside the cell, it is converted by cellular enzymes through sequential phosphorylation steps into its active triphosphate metabolite, carbovir triphosphate (CBV-TP).",
      "CBV-TP is a structural analog of deoxyguanosine triphosphate (dGTP). It competes with the natural dGTP for incorporation into viral DNA by the HIV reverse transcriptase enzyme.",
      "CBV-TP lacks a 3'-hydroxyl group on its ribose sugar moiety. Once the HIV reverse transcriptase incorporates CBV-TP into the growing viral DNA strand, no further nucleotides can be added. This results in the termination of DNA chain elongation, thus halting viral replication."
    ],
    "name": "Abacavir (Ziagen)",
    "pharmacokinetics": {
      "absorption": "Rapidly and extensively absorbed after oral administration with high bioavailability (~83%). Food does not significantly affect absorption.",
      "distribution": "Widely distributed throughout the body, including into the cerebrospinal fluid (CSF). Volume of distribution is approximately 0.8 L/kg. It is about 50% bound to plasma proteins.",
      "excretion": "Primarily excreted in the urine (~83%) as metabolites, with only a small fraction (~2%) excreted as unchanged drug. The terminal half-life is approximately 1.5 hours.",
      "metabolism": "Metabolized in the liver primarily by two pathways: alcohol dehydrogenase to form a carboxylate metabolite, and glucuronosyltransferase (UGT) to form a glucuronide conjugate. It is not significantly metabolized by CYP450 enzymes."
    },
    "precautions": [
      "BOXED WARNING: A severe and potentially fatal HSR is strongly associated with the HLA-B*5701 allele. All patients must be screened before starting. If an HSR is suspected, the drug must be permanently discontinued and never re-challenged.",
      "NRTIs as a class can cause lactic acidosis and severe hepatomegaly.",
      "Some studies suggest a potential increased risk of myocardial infarction."
    ],
    "pregnancyCategory": "Category C. Use should be considered if the potential benefit justifies the potential risk. It is included in some preferred regimens for pregnant women with HIV.",
    "riskFactors": [
      "HLA-B*5701 positive status is the strongest risk factor for HSR.",
      "Underlying coronary artery disease or multiple cardiovascular risk factors.",
      "Hepatic impairment."
    ]
  },
  "acyclovir": {
    "adverseEffects": {
      "common": [
        "Nausea",
        "vomiting",
        "diarrhea",
        "headache",
        "malaise."
      ],
      "serious": [
        "Renal failure (especially with IV or high doses in dehydrated patients)",
        "neurotoxicity (confusion, hallucinations, seizures)",
        "thrombotic thrombocytopenic purpura (TTP)"
      ]
    },
    "brandNames": [
      "Zovirax",
      "Sitavig"
    ],
    "category": "Antiviral",
    "contraindications": [
      "Hypersensitivity to acyclovir or valacyclovir."
    ],
    "dose": "Varies by indication. Genital Herpes (initial): 200 mg PO 5 times/day for 7-10 days. Shingles: 800 mg PO 5 times/day for 7-10 days.",
    "drugClass": "Antiviral, Guanosine Analog",
    "genericName": "Acyclovir",
    "indications": "Treatment of herpes simplex virus (HSV-1, HSV-2) infections (e.g., genital herpes, cold sores), varicella-zoster (chickenpox), and herpes zoster (shingles).",
    "lactationInfo": "Excreted in breast milk; use with caution.",
    "moaSteps": [
      "Acyclovir is a synthetic purine nucleoside analogue that is selectively phosphorylated by viral thymidine kinase (TK).",
      "It is first converted to acyclovir monophosphate by the virus-specific TK.",
      "Cellular enzymes (guanylate kinase) then convert the monophosphate to diphosphate, and other enzymes convert the diphosphate to acyclovir triphosphate (ACV-TP).",
      "ACV-TP is the active form. It competes with deoxyguanosine triphosphate (dGTP) for viral DNA polymerase.",
      "When incorporated into the growing viral DNA strand, it acts as a chain terminator because it lacks the 3'-hydroxyl group, thus halting DNA replication."
    ],
    "name": "Acyclovir (Zovirax)",
    "pharmacokinetics": {
      "absorption": "Poorly and variably absorbed from the GI tract (bioavailability ~10-20% for 200-800 mg doses). Absorption is not affected by food.",
      "distribution": "Widely distributed into body tissues and fluids, including CSF (approx 50% of plasma levels). Low protein binding (9-33%).",
      "excretion": "Primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion. Half-life is ~2.5-3.3 hours in adults with normal renal function.",
      "metabolism": "Not significantly metabolized. Converted to a minor, inactive metabolite."
    },
    "precautions": [
      "Risk of renal impairment. Ensure adequate hydration to prevent crystalluria.",
      "Dose adjustment is required in renal impairment.",
      "Use with caution in patients with underlying neurological abnormalities."
    ],
    "pregnancyCategory": "Category B. Has been used in pregnancy without evidence of harm.",
    "riskFactors": [
      "Renal impairment",
      "dehydration",
      "concomitant use of other nephrotoxic drugs."
    ]
  },
  "albuterol": {
    "adverseEffects": {
      "common": [
        "Tremor",
        "nervousness",
        "headache",
        "tachycardia (fast heart rate)",
        "palpitations",
        "dizziness",
        "insomnia."
      ],
      "serious": [
        "Paradoxical bronchospasm (worsening of breathing)",
        "hypokalemia (low potassium)",
        "cardiovascular events (arrhythmias, angina)"
      ]
    },
    "brandNames": [
      "ProAir HFA",
      "Ventolin HFA",
      "Proventil HFA",
      "AccuNeb"
    ],
    "category": "Bronchodilator",
    "contraindications": [
      "Hypersensitivity to albuterol or milk proteins (in some dry powder inhalers)."
    ],
    "dose": "Inhalation (MDI): 2 inhalations (90 mcg/puff) every 4-6 hours as needed. Nebulization: 2.5 mg 3-4 times daily as needed.",
    "drugClass": "Short-acting beta-2 adrenergic agonist (SABA)",
    "genericName": "Albuterol (also known as Salbutamol)",
    "indications": "Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma, COPD). Prevention of exercise-induced bronchospasm.",
    "lactationInfo": "Excretion in breast milk is unknown; use with caution.",
    "moaSteps": [
      "Albuterol is a selective beta-2 adrenergic receptor agonist.",
      "Binding to beta-2 receptors on the smooth muscle of the airways (bronchi) activates adenylyl cyclase.",
      "This increases intracellular levels of cyclic AMP (cAMP).",
      "Increased cAMP leads to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations.",
      "This results in relaxation of bronchial smooth muscle, leading to bronchodilation."
    ],
    "name": "Albuterol (ProAir, Ventolin)",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed after inhalation. Onset of action is within 5-15 minutes.",
      "distribution": "Peak effect in 30-60 minutes. Duration of action is 4-6 hours.",
      "excretion": "Primarily excreted in the urine as metabolites and unchanged drug.",
      "metabolism": "Metabolized in the liver to an inactive sulfate conjugate."
    },
    "precautions": [
      "Use of a SABA more than 2 days/week for symptom relief generally indicates inadequate long-term control.",
      "Use with caution in patients with cardiovascular disease (e.g., coronary insufficiency, arrhythmias, hypertension), hyperthyroidism, or diabetes mellitus."
    ],
    "pregnancyCategory": "Category C. Use if potential benefit justifies potential risk.",
    "riskFactors": [
      "Cardiovascular disease",
      "diabetes",
      "hyperthyroidism",
      "seizure disorders."
    ]
  },
  "allopurinol": {
    "adverseEffects": {
      "common": [
        "Rash (most common)",
        "nausea",
        "vomiting",
        "diarrhea",
        "elevated liver enzymes."
      ],
      "serious": [
        "Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)",
        "hypersensitivity syndrome (DRESS)",
        "hepatotoxicity",
        "bone marrow suppression."
      ]
    },
    "brandNames": [
      "Zyloprim",
      "Lopurin",
      "Aloprim (IV)"
    ],
    "category": "Antigout Agent",
    "contraindications": [
      "Hypersensitivity to allopurinol."
    ],
    "dose": "Gout (mild): 200-300 mg/day PO. (Moderate to severe): 400-600 mg/day PO. Max 800 mg/day. Doses >300 mg should be divided.",
    "drugClass": "Xanthine Oxidase Inhibitor",
    "genericName": "Allopurinol",
    "indications": "Management of gout (primary or secondary hyperuricemia). Management of hyperuricemia associated with chemotherapy (tumor lysis syndrome). Management of recurrent calcium oxalate kidney stones.",
    "lactationInfo": "Allopurinol and oxypurinol are excreted in breast milk; use with caution.",
    "moaSteps": [
      "Allopurinol and its primary active metabolite, oxypurinol, inhibit the enzyme xanthine oxidase.",
      "Xanthine oxidase is responsible for the conversion of hypoxanthine to xanthine, and xanthine to uric acid.",
      "By blocking this enzyme, allopurinol decreases the production of uric acid in the body.",
      "This lowers both serum and urinary uric acid concentrations, helping to prevent gout attacks and kidney stones."
    ],
    "name": "Allopurinol (Zyloprim)",
    "pharmacokinetics": {
      "absorption": "Well absorbed from the GI tract (~80-90%).",
      "distribution": "Not protein-bound. Distributed in total body water.",
      "excretion": "Both allopurinol and oxypurinol are excreted in the urine. Allopurinol half-life is ~1-2 hours. Oxypurinol half-life is long (~15-20 hours), allowing for once-daily dosing.",
      "metabolism": "Rapidly metabolized by xanthine oxidase to its active metabolite, oxypurinol."
    },
    "precautions": [
      "Risk of SCARs is significantly higher in patients with the **HLA-B*5801 allele**, especially in Han Chinese, Korean, and Thai populations. Genetic screening is recommended for these groups before starting.",
      "Discontinue immediately if any rash occurs.",
      "An acute gout attack may be precipitated during the initial stages of therapy; co-administer colchicine or an NSAID for the first 3-6 months.",
      "Requires dose reduction in renal impairment."
    ],
    "pregnancyCategory": "Category C. Use if potential benefit justifies potential risk.",
    "riskFactors": [
      "HLA-B*5801 allele",
      "renal impairment",
      "concurrent use of thiazide diuretics (increases rash risk)."
    ]
  },
  "alprazolam": {
    "adverseEffects": {
      "common": [
        "Drowsiness",
        "sedation",
        "dizziness",
        "ataxia (impaired coordination)",
        "fatigue",
        "slurred speech",
        "memory impairment."
      ],
      "serious": [
        "Respiratory depression (especially with opioids)",
        "severe hypotension",
        "anterograde amnesia",
        "paradoxical reactions (anxiety, agitation)",
        "abuse, misuse, and addiction."
      ]
    },
    "brandNames": [
      "Xanax",
      "Xanax XR",
      "Niravam"
    ],
    "category": "Anxiolytic, Sedative-Hypnotic",
    "contraindications": [
      "Hypersensitivity to alprazolam or other benzodiazepines",
      "acute narrow-angle glaucoma",
      "concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)."
    ],
    "dose": "Anxiety: 0.25-0.5 mg PO 3 times daily, titrate to max 4 mg/day. Panic Disorder: 0.5-1 mg PO 3 times daily, titrate to max 10 mg/day.",
    "drugClass": "Benzodiazepine (Short-acting)",
    "genericName": "Alprazolam",
    "indications": "Management of anxiety disorders. Short-term relief of anxiety. Treatment of panic disorder, with or without agoraphobia.",
    "lactationInfo": "Excreted in breast milk; not recommended.",
    "moaSteps": [
      "Alprazolam is a positive allosteric modulator of the GABA-A receptor.",
      "It binds to a specific site (the benzodiazepine site) on the GABA-A receptor complex, which is separate from the GABA binding site.",
      "This binding enhances the effect of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid).",
      "It increases the *frequency* of chloride channel opening, leading to an influx of chloride ions.",
      "This hyperpolarizes the neuron, making it less excitable and resulting in CNS depression (anxiolytic, sedative, and anticonvulsant effects)."
    ],
    "name": "Alprazolam (Xanax)",
    "pharmacokinetics": {
      "absorption": "Rapidly and well absorbed from the GI tract. Peak concentration in 1-2 hours.",
      "distribution": "Widely distributed. Crosses the blood-brain barrier. 80% bound to plasma proteins.",
      "excretion": "Excreted in the urine as metabolites. Half-life is ~11.2 hours.",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4, to several metabolites (alpha-hydroxyalprazolam is the main active one)."
    },
    "precautions": [
      "BOXED WARNING (Risks from Concomitant Use with Opioids): Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients for whom alternative treatments are inadequate.",
      "BOXED WARNING (Abuse, Misuse, and Addiction): Risk of abuse, misuse, and addiction, which can lead to overdose or death. Assess risk before prescribing and monitor regularly.",
      "BOXED WARNING (Dependence and Withdrawal): Physical dependence and severe, life-threatening withdrawal reactions can occur. Taper dose slowly when discontinuing.",
      "Use with caution in elderly, debilitated patients, and those with hepatic or renal impairment."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm. Use is associated with congenital malformations (cleft palate) and neonatal withdrawal.",
    "riskFactors": [
      "Concomitant opioid use",
      "history of substance abuse",
      "elderly patients",
      "hepatic impairment."
    ]
  },
  "amiodarone": {
    "adverseEffects": {
      "common": [
        "Nausea/vomiting",
        "constipation",
        "anorexia",
        "hypotension (with IV)",
        "photosensitivity",
        "blue-gray skin discoloration",
        "corneal microdeposits (visual halos)."
      ],
      "serious": [
        "Pulmonary toxicity (fibrosis, pneumonitis)",
        "hepatotoxicity (liver failure)",
        "proarrhythmias (Torsades de Pointes)",
        "thyroid abnormalities (hypo/hyperthyroidism)",
        "optic neuropathy/neuritis (can lead to blindness)."
      ]
    },
    "brandNames": [
      "Pacerone",
      "Cordarone",
      "Nexterone (IV)"
    ],
    "category": "Antiarrhythmic",
    "contraindications": [
      "Hypersensitivity to amiodarone or iodine",
      "severe sinus-node dysfunction",
      "2nd or 3rd-degree AV block",
      "cardiogenic shock."
    ],
    "dose": "PO (Loading): 800-1600 mg/day for 1-3 weeks. (Maintenance): 200-400 mg/day.",
    "drugClass": "Antiarrhythmic (Class III)",
    "genericName": "Amiodarone",
    "indications": "Management of life-threatening recurrent ventricular fibrillation (VF) or hemodynamically unstable ventricular tachycardia (VT) refractory to other therapy.",
    "lactationInfo": "Excreted in breast milk in significant amounts; not recommended.",
    "moaSteps": [
      "Amiodarone is a complex drug with effects of all four Vaughn-Williams antiarrhythmic classes.",
      "Primary action (Class III): Blocks potassium channels, which prolongs the repolarization phase and the effective refractory period (ERP) in all cardiac tissues (atria, AV node, ventricles).",
      "Class I action: Blocks inactivated sodium channels.",
      "Class II action: Non-competitive alpha and beta-adrenergic blocking (anti-sympathetic) effects.",
      "Class IV action: Weak calcium channel blocking effects.",
      "Also causes vasodilation, leading to a decrease in cardiac workload."
    ],
    "name": "Amiodarone (Pacerone, Cordarone)",
    "pharmacokinetics": {
      "absorption": "Slow and variable absorption (~20-80% bioavailability). Food (especially high-fat) increases absorption.",
      "distribution": "Extremely large volume of distribution and extensive tissue accumulation (especially in adipose tissue, liver, lungs). Highly protein-bound (>96%).",
      "excretion": "Excreted primarily via the biliary route; minimal renal excretion. Has an extremely long and variable half-life (average 58 days, range 25-100 days).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4 and CYP2C8 to an active metabolite, N-desethylamiodarone (DEA)."
    },
    "precautions": [
      "BOXED WARNING (Toxicity): For life-threatening arrhythmias only. Has multiple, serious toxicities (pulmonary, hepatic, proarrhythmic) that can be fatal. Patients must be hospitalized for loading dose.",
      "BOXED WARNING (Pulmonary Toxicity): Can cause a hypersensitivity pneumonitis or interstitial/alveolar pneumonitis (fibrosis) that can be fatal. Monitor with chest X-ray and pulmonary function tests.",
      "BOXED WARNING (Hepatotoxicity): Can cause liver injury, which may be fatal. Monitor LFTs.",
      "BOXED WARNING (Proarrhythmia): Can worsen arrhythmias. Monitor EKG for QT prolongation (risk of Torsades de Pointes).",
      "Inhibits multiple CYP enzymes (3A4, 2C9, 2D6) and P-glycoprotein, leading to many significant drug interactions (e.g., warfarin, digoxin, statins)."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm (e.g., neonatal hypothyroidism) due to high iodine content.",
    "riskFactors": [
      "Pre-existing lung disease",
      "high cumulative dose",
      "pre-existing liver disease",
      "thyroid disease."
    ]
  },
  "amitriptyline": {
    "adverseEffects": {
      "common": [
        "Sedation",
        "drowsiness",
        "dizziness",
        "dry mouth (xerostomia)",
        "constipation",
        "urinary retention",
        "blurred vision",
        "weight gain",
        "orthostatic hypotension."
      ],
      "serious": [
        "Cardiotoxicity (arrhythmias, QT prolongation)",
        "seizures",
        "bone marrow suppression",
        "suicidal thoughts and behaviors (especially in young adults)."
      ]
    },
    "brandNames": [
      "Elavil"
    ],
    "category": "Antidepressant",
    "contraindications": [
      "Hypersensitivity to TCAs",
      "acute recovery period after myocardial infarction",
      "concomitant use with MAOIs (within 14 days)."
    ],
    "dose": "Depression (Outpatient): 75 mg/day PO in divided doses, or 50-100 mg at bedtime. Max 150 mg/day. (Inpatient): Up to 300 mg/day.",
    "drugClass": "Tricyclic Antidepressant (TCA)",
    "genericName": "Amitriptyline",
    "indications": "Treatment of depression. Off-label uses include chronic pain (e.g., neuropathic pain, fibromyalgia), migraine prophylaxis, and insomnia.",
    "lactationInfo": "Excreted in breast milk; use with caution.",
    "moaSteps": [
      "Amitriptyline is a tricyclic antidepressant.",
      "It increases the synaptic concentrations of norepinephrine (NE) and serotonin (5-HT) by blocking their reuptake at the presynaptic neuronal membrane.",
      "It is thought that its antidepressant effect is due to this potentiation of noradrenergic and serotonergic neurotransmission.",
      "It also has significant anticholinergic (muscarinic), antihistaminic (H1), and alpha-1 adrenergic blocking properties, which account for many of its side effects (e.g., sedation, dry mouth, orthostatic hypotension)."
    ],
    "name": "Amitriptyline (Elavil)",
    "pharmacokinetics": {
      "absorption": "Well absorbed, but undergoes significant first-pass metabolism.",
      "distribution": "Widely distributed, including into the CNS. Highly protein-bound (~95%).",
      "excretion": "Primarily excreted in the urine as metabolites. Half-life is ~10-28 hours.",
      "metabolism": "Extensively metabolized in the liver by CYP2D6 and CYP2C19 to an active metabolite, nortriptyline, which is also a TCA."
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults (18-24) with major depressive disorder. Monitor closely for worsening and suicidality.",
      "High risk of overdose, which can be fatal (due to cardiotoxicity and seizures). Prescribe smallest quantity possible.",
      "Use with caution in elderly (high anticholinergic burden), patients with cardiovascular disease, seizure disorders, or benign prostatic hyperplasia (BPH)."
    ],
    "pregnancyCategory": "Category C. Neonatal withdrawal has been reported.",
    "riskFactors": [
      "Cardiovascular disease",
      "seizure disorder",
      "elderly",
      "history of suicide attempt."
    ]
  },
  "amlodipine": {
    "brandNames": [
      "Norvasc",
      "Katerzia"
    ],
    "category": "Antihypertensive",
    "drugClass": "Calcium Channel Blocker (Dihydropyridine)",
    "genericName": "Amlodipine",
    "indications": "Treatment of hypertension. Treatment of chronic stable angina and vasospastic (Prinzmetal's) angina.",
    "moaSteps": [
      "Amlodipine is a dihydropyridine calcium channel blocker.",
      "It inhibits the influx of calcium ions across cell membranes into vascular smooth muscle cells and cardiac muscle cells.",
      "It acts primarily on peripheral blood vessels, causing vasodilation (widening of the vessels).",
      "This vasodilation reduces peripheral vascular resistance, which in turn lowers blood pressure.",
      "In angina, it dilates coronary arteries and reduces cardiac workload, decreasing myocardial oxygen demand."
    ],
    "name": "Amlodipine (Norvasc)",
    "pharmacokinetics": {
      "absorption": "Slowly and almost completely absorbed from the GI tract (Bioavailability ~64-90%). Peak plasma concentrations in 6-12 hours.",
      "distribution": "Highly protein-bound (~97%). Large volume of distribution, indicating extensive tissue distribution.",
      "excretion": "Excreted primarily in the urine as inactive metabolites (~60%). The long elimination half-life (30-50 hours) allows for once-daily dosing.",
      "metabolism": "Extensively metabolized in the liver, primarily by the CYP3A4 enzyme, to inactive metabolites."
    },
    "dose": {
      "initialDose": "Hypertension (Adult): 5 mg PO once daily. Angina (Adult): 5-10 mg PO once daily.",
      "maxDose": "10 mg PO once daily.",
      "notes": "Can be taken with or without food. Geriatric patients or those with hepatic impairment should be started at 2.5 mg daily."
    },
    "adverseEffects": {
      "common": [
        "Peripheral edema (swelling of ankles and legs - most common)",
        "headache",
        "dizziness",
        "fatigue",
        "flushing",
        "palpitations (a feeling of a fast-beating or pounding heart)."
      ],
      "serious": [
        "Severe hypotension (low blood pressure)",
        "worsening of angina or acute myocardial infarction (rare, usually upon initiation)",
        "severe skin reactions (rare)."
      ]
    },
    "precautions": [
      "Use with caution in patients with severe aortic stenosis or heart failure.",
      "Dose adjustment is required in severe hepatic impairment due to extensive liver metabolism.",
      "The full blood pressure-lowering effect may take 7-14 days to be seen due to the long half-life."
    ],
    "contraindications": [
      "Hypersensitivity to amlodipine or other dihydropyridines."
    ],
    "pregnancyCategory": "Category C"
  },
  "amoxicillin": {
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "nausea",
        "vomiting",
        "rash (non-allergic 'amoxicillin rash' is common, especially with mononucleosis)."
      ],
      "serious": [
        "Anaphylaxis (severe allergic reaction)",
        "Stevens-Johnson syndrome (SJS)",
        "Clostridioides difficile-associated diarrhea (CDAD)."
      ]
    },
    "brandNames": [
      "Amoxil",
      "Moxatag",
      "Trimox"
    ],
    "category": "Antibiotic",
    "contraindications": [
      "History of serious hypersensitivity (e.g., anaphylaxis) to amoxicillin or any penicillin."
    ],
    "dose": "Varies by infection. Otitis Media: 80-90 mg/kg/day PO in 2 divided doses. Pharyngitis: 50 mg/kg/day PO once daily (Max 1000 mg).",
    "drugClass": "Penicillin-class Antibiotic (Aminopenicillin)",
    "genericName": "Amoxicillin",
    "indications": "Treatment of infections caused by susceptible strains of bacteria, including otitis media, sinusitis, pneumonia, urinary tract infections, skin infections, and pharyngitis. Used in combination for H. pylori eradication.",
    "lactationInfo": "Excreted in breast milk in small amounts; generally considered compatible, but can cause rash or diarrhea in the infant.",
    "moaSteps": [
      "Amoxicillin is a beta-lactam antibiotic.",
      "It inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls.",
      "It binds to and inactivates penicillin-binding proteins (PBPs), which are enzymes responsible for cross-linking the peptidoglycan chains.",
      "This inhibition of cell wall synthesis leads to weakening of the cell wall, followed by cell lysis and death (bactericidal effect)."
    ],
    "name": "Amoxicillin (Amoxil)",
    "pharmacokinetics": {
      "absorption": "Rapidly and well absorbed from the GI tract (~75-90%). Stable in gastric acid. Food does not significantly affect absorption.",
      "distribution": "Widely distributed into tissues and fluids, but poor penetration into brain and CSF (unless meninges are inflamed). Low protein binding (~20%).",
      "excretion": "Primarily excreted unchanged in the urine via tubular secretion and glomerular filtration. Half-life is ~1-1.5 hours.",
      "metabolism": "Partially metabolized in the liver to inactive penicilloic acid."
    },
    "precautions": [
      "Cross-sensitivity with other beta-lactams (e.g., cephalosporins) is possible.",
      "A high percentage of patients with infectious mononucleosis develop a rash; this is not typically a true allergy.",
      "Prolonged use may result in fungal or bacterial superinfection.",
      "Dose adjustment is needed in severe renal impairment."
    ],
    "pregnancyCategory": "Category B. Generally considered safe to use during pregnancy.",
    "riskFactors": [
      "History of penicillin allergy",
      "infectious mononucleosis",
      "severe renal impairment."
    ]
  },
  "apixaban": {
    "adverseEffects": {
      "common": [
        "Bleeding (e.g., bruising, epistaxis, hematuria, GI bleed)."
      ],
      "serious": [
        "Major bleeding (intracranial hemorrhage, GI bleed)",
        "epidural or spinal hematoma."
      ]
    },
    "brandNames": [
      "Eliquis"
    ],
    "category": "Anticoagulant",
    "contraindications": [
      "Active pathological bleeding",
      "severe hypersensitivity to apixaban."
    ],
    "dose": "Nonvalvular A-fib: 5 mg PO twice daily. Treatment of DVT/PE: 10 mg PO twice daily for 7 days, then 5 mg PO twice daily.",
    "drugClass": "Factor Xa Inhibitor (Direct Oral Anticoagulant - DOAC)",
    "genericName": "Apixaban",
    "indications": "Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Prophylaxis of deep vein thrombosis (DVT) following hip or knee replacement surgery. Treatment of DVT and pulmonary embolism (PE). Reduction in risk of recurrent DVT and PE.",
    "lactationInfo": "Unknown if excreted in human milk; not recommended.",
    "moaSteps": [
      "Apixaban is a direct, selective, and reversible inhibitor of Factor Xa (FXa).",
      "It inhibits both free and clot-bound Factor Xa, as well as prothrombinase activity.",
      "By inhibiting FXa, it decreases the conversion of prothrombin (Factor II) to thrombin (Factor IIa).",
      "This reduces thrombin generation and ultimately prevents the formation of fibrin clots, without directly affecting platelet aggregation."
    ],
    "name": "Apixaban (Eliquis)",
    "pharmacokinetics": {
      "absorption": "Bioavailability is ~50%. Food does not affect absorption.",
      "distribution": "Protein binding is ~87%.",
      "excretion": "Excreted via multiple pathways, including renal (~27% unchanged) and fecal/biliary. Half-life is ~12 hours.",
      "metabolism": "Metabolized in the liver, primarily by CYP3A4, with minor contributions from other CYPs."
    },
    "precautions": [
      "BOXED WARNING (Premature Discontinuation): Discontinuing apixaban prematurely increases the risk of thrombotic events (e.g., stroke). If anticoagulation must be stopped, consider alternative coverage.",
      "BOXED WARNING (Spinal/Epidural Hematoma): Patients receiving neuraxial anesthesia (spinal/epidural) or undergoing spinal puncture are at risk of developing an epidural or spinal hematoma, which can result in long-term or permanent paralysis. Risk is increased by indwelling epidural catheters or concomitant use of other drugs affecting hemostasis.",
      "Not recommended in patients with prosthetic heart valves.",
      "Risk of bleeding. Andexanet alfa is the reversal agent.",
      "Avoid use with strong dual inhibitors or inducers of CYP3A4 and P-glycoprotein."
    ],
    "pregnancyCategory": "Category B. Limited human data.",
    "riskFactors": [
      "Active bleeding",
      "history of bleeding disorders",
      "severe renal or hepatic impairment",
      "concomitant use of NSAIDs, antiplatelets, or other anticoagulants."
    ]
  },
  "aripiprazole": {
    "adverseEffects": {
      "common": [
        "Headache",
        "insomnia",
        "agitation",
        "anxiety",
        "akathisia (restlessness)",
        "nausea",
        "vomiting",
        "constipation",
        "dizziness",
        "somnolence."
      ],
      "serious": [
        "Neuroleptic Malignant Syndrome (NMS)",
        "Tardive Dyskinesia (TD)",
        "metabolic changes (hyperglycemia, diabetes, dyslipidemia, weight gain)",
        "pathological gambling and other impulse-control problems.",
        "suicidal thoughts (in children/young adults)."
      ]
    },
    "brandNames": [
      "Abilify",
      "Abilify Maintena (long-acting injectable)",
      "Aristada (long-acting injectable)"
    ],
    "category": "Antipsychotic",
    "contraindications": [
      "Hypersensitivity to aripiprazole."
    ],
    "dose": "Schizophrenia: 10-15 mg PO once daily. Adjunctive MDD: 2-5 mg PO once daily.",
    "drugClass": "Atypical Antipsychotic (Second-Generation)",
    "genericName": "Aripiprazole",
    "indications": "Treatment of schizophrenia. Treatment of acute manic or mixed episodes associated with bipolar I disorder (as monotherapy or adjunct to lithium/valproate). Adjunctive treatment of major depressive disorder (MDD). Irritability associated with autistic disorder.",
    "lactationInfo": "Excreted in breast milk; not recommended.",
    "moaSteps": [
      "Aripiprazole's mechanism is complex and not fully understood.",
      "It acts as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors. This means it can act as an *agonist* (activator) in areas of low dopamine (e.g., prefrontal cortex) and as an *antagonist* (blocker) in areas of high dopamine (e.g., mesolimbic pathway), theoretically stabilizing the system.",
      "It also acts as an antagonist at serotonin 5-HT2A receptors.",
      "This unique receptor binding profile is often referred to as 'dopamine-serotonin system stabilization'."
    ],
    "name": "Aripiprazole (Abilify)",
    "pharmacokinetics": {
      "absorption": "Well absorbed. Peak concentration in 3-5 hours.",
      "distribution": "Widely distributed. Highly protein-bound (>99%).",
      "excretion": "Excreted in feces and urine as metabolites. Long half-life (~75 hours for aripiprazole, ~94 hours for its active metabolite).",
      "metabolism": "Extensively metabolized in the liver by CYP2D6 and CYP3A4 to an active metabolite, dehydro-aripiprazole."
    },
    "precautions": [
      "BOXED WARNING (Elderly with Dementia): Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death (mainly cardiovascular or infectious). Aripiprazole is not approved for this use.",
      "BOXED WARNING (Suicidality): Antidepressants (and aripiprazole as an adjunct) increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults (18-24). Monitor closely.",
      "Risk of NMS: A rare but fatal syndrome. Discontinue immediately.",
      "Risk of TD: A potentially irreversible movement disorder. Discontinue if signs appear.",
      "Monitor for metabolic changes (blood glucose, lipids, weight).",
      "Impulse-control disorders (compulsive gambling, eating, shopping) have been reported. Monitor patients."
    ],
    "pregnancyCategory": "Category C. Neonates exposed in the third trimester are at risk for extrapyramidal symptoms (EPS) and withdrawal.",
    "riskFactors": [
      "Elderly with dementia",
      "children/young adults (suicidality risk)",
      "pre-existing diabetes or obesity."
    ]
  },
  "aspirin": {
    "brandNames": [
      "Bayer",
      "Ecotrin",
      "Ascriptin"
    ],
    "category": "Analgesic, Antipyretic, Anti-inflammatory",
    "drugClass": "NSAID, Antiplatelet Agent",
    "genericName": "Aspirin (Acetylsalicylic Acid)",
    "indications": "Relief of mild to moderate pain, fever, and inflammation. Reduction of risk of death and nonfatal MI in patients with previous MI or unstable angina. Reduction of risk of recurrent transient ischemic attacks (TIAs) or stroke.",
    "moaSteps": [
      "Aspirin irreversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes.",
      "This inhibition prevents the synthesis of prostaglandins (mediating pain, fever, inflammation) and thromboxane A2 (mediating platelet aggregation).",
      "Its antiplatelet effect is due to irreversible inhibition of COX-1 in platelets, which lasts for the life of the platelet (7-10 days)."
    ],
    "name": "Aspirin",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed in the stomach and small intestine. Enteric-coated (Ecotrin) delays absorption.",
      "distribution": "Widely distributed. Highly protein-bound (as salicylate).",
      "excretion": "Excreted in the urine as salicylates and metabolites. Excretion is pH-dependent.",
      "metabolism": "Rapidly hydrolyzed in plasma to salicylic acid (active), which is then metabolized in the liver."
    },
    "dose": "Analgesic/Antipyretic: 325-650 mg PO every 4-6 hours as needed. Antiplatelet (Cardioprotection): 81-325 mg PO once daily.",
    "adverseEffects": {
      "common": [
        "Dyspepsia (indigestion)",
        "nausea",
        "stomach pain",
        "heartburn",
        "minor bleeding/bruising."
      ],
      "serious": [
        "Gastrointestinal bleeding and ulceration",
        "severe allergic reactions (bronchospasm, anaphylaxis)",
        "Reye's syndrome (in children/teenagers with viral illness)",
        "tinnitus (ringing in ears - sign of toxicity)."
      ]
    },
    "precautions": [
      "BOXED WARNING (GI Risk): NSAIDs (including aspirin) can cause serious GI bleeding, ulceration, and perforation, which can be fatal.",
      "BOXED WARNING (CV Risk - non-aspirin NSAIDs, but relevant): Use with caution, though low-dose aspirin is used for CV protection.",
      "**Reye's Syndrome:** Do not use in children or teenagers with or recovering from chickenpox or flu-like symptoms, as this can lead to a rare but fatal condition.",
      "Discontinue 1 week prior to surgery if antiplatelet effect is not desired."
    ],
    "contraindications": [
      "Hypersensitivity to aspirin or NSAIDs",
      "patients with 'aspirin-exacerbated respiratory disease' (AERD)",
      "children/teenagers with viral infections",
      "active peptic ulcer disease",
      "bleeding disorders."
    ],
    "pregnancyCategory": "Category D (in 3rd trimester - can cause premature closure of ductus arteriosus)."
  },
  "atenolol": {
    "adverseEffects": {
      "common": [
        "Fatigue",
        "dizziness",
        "bradycardia (slow heart rate)",
        "hypotension",
        "depression",
        "cold extremities."
      ],
      "serious": [
        "Severe bradycardia",
        "heart block (AV block)",
        "heart failure exacerbation",
        "bronchospasm (in patients with asthma, especially at high doses)."
      ]
    },
    "brandNames": [
      "Tenormin"
    ],
    "category": "Antihypertensive, Antianginal",
    "contraindications": [
      "Sinus bradycardia",
      "heart block greater than first degree",
      "cardiogenic shock",
      "overt heart failure",
      "hypersensitivity."
    ],
    "dose": "Hypertension: 50-100 mg PO once daily. Angina: 50-200 mg PO once daily.",
    "drugClass": "Beta-Blocker (Cardioselective, Beta-1)",
    "genericName": "Atenolol",
    "indications": "Management of hypertension. Management of angina pectoris. Treatment of acute myocardial infarction (MI).",
    "lactationInfo": "Excreted in breast milk and can accumulate; use with caution (monitor infant for bradycardia, hypotension).",
    "moaSteps": [
      "Atenolol is a cardioselective beta-1 adrenergic receptor blocker.",
      "It competitively blocks beta-1 receptors, which are primarily located in cardiac muscle.",
      "This blockade results in decreased heart rate (negative chronotropy), decreased myocardial contractility (negative inotropy), and decreased blood pressure.",
      "It also reduces renin secretion from the kidneys, further contributing to its antihypertensive effect.",
      "At higher doses, it can lose its cardioselectivity and also block beta-2 receptors (in the lungs and vasculature)."
    ],
    "name": "Atenolol (Tenormin)",
    "pharmacokinetics": {
      "absorption": "Incompletely absorbed from the GI tract (~50-60%). Absorption is not affected by food.",
      "distribution": "Hydrophilic (water-soluble), so it has poor penetration into the CNS. Low protein binding (6-16%).",
      "excretion": "Primarily excreted unchanged in the urine. Half-life is ~6-7 hours. Must be dose-adjusted in renal impairment.",
      "metabolism": "Undergoes minimal hepatic metabolism."
    },
    "precautions": [
      "BOXED WARNING (Abrupt Discontinuation): Abruptly stopping beta-blocker therapy can cause exacerbation of angina, and in some cases, myocardial infarction. Taper the dose slowly over 1-2 weeks.",
      "Can mask the symptoms of hypoglycemia (e.g., tachycardia) in diabetic patients. (Sweating may be unaffected).",
      "Use with caution in patients with asthma or COPD (use low, cardioselective doses).",
      "Requires significant dose reduction in renal impairment."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm (intrauterine growth restriction, bradycardia).",
    "riskFactors": [
      "Renal impairment",
      "heart failure",
      "diabetes",
      "asthma/COPD."
    ]
  },
  "acetaminophen": {
    "name": "Acetaminophen (Tylenol)",
    "genericName": "Acetaminophen (or Paracetamol)",
    "brandNames": ["Tylenol", "Panadol", "Ofirmev (IV)"],
    "category": "Analgesic, Antipyretic",
    "drugClass": "Analgesic (Non-opioid)",
    "simpleSummary": "Acetaminophen (Tylenol) is used to treat mild to moderate pain (like headaches, muscle aches, or toothaches) and to reduce fever.<br><br><strong>Most Important Things to Know:</strong><br>1. Do not take more than 4,000 mg per day from all sources (including other cold or pain medicines).<br>2. Taking too much can cause severe, life-threatening liver damage.<br>3. Avoid drinking alcohol while taking this medicine, as it increases the risk of liver damage.",
    "indications": "Treatment of mild to moderate pain. Treatment of fever.",
    "moaSteps": [
      "The exact mechanism is not fully understood.",
      "It is thought to inhibit prostaglandin synthesis, but primarily in the central nervous system (CNS), which is responsible for its analgesic (pain-relieving) and antipyretic (fever-reducing) effects.",
      "It has very weak anti-inflammatory effects in peripheral tissues."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and almost completely absorbed orally.",
      "distribution": "Widely distributed. Variable protein binding.",
      "metabolism": "Extensively metabolized in the liver via glucuronidation and sulfation. A small fraction is metabolized by CYP2E1 to a toxic metabolite, NAPQI.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~2-3 hours."
    },
    "dose": "Adults: 325-650 mg PO every 4-6 hours, or 1000 mg PO every 6 hours. **Max 4000 mg/day from all sources.**",
    "adverseEffects": {
      "common": ["Generally well-tolerated at therapeutic doses. Nausea, rash (rare)."],
      "serious": ["Hepatotoxicity (liver failure) with overdose", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Can cause severe, sometimes fatal, liver injury, especially with doses >4000 mg/day or with concomitant alcohol use.",
      "Advise patients to check all OTC and prescription products for acetaminophen content to avoid accidental overdose.",
      "Use with caution in patients with liver disease or chronic alcohol use.",
      "Antidote for overdose: N-acetylcysteine (NAC)."
    ],
    "contraindications": [
      "Hypersensitivity to acetaminophen",
      "severe active liver disease."
    ],
    "pregnancyCategory": "Category C (but widely considered safe).",
    "lactationInfo": "Compatible."
  },
  "albendazole": {
    "name": "Albendazole (Albenza)",
    "genericName": "Albendazole",
    "brandNames": ["Albenza"],
    "category": "Anthelmintic",
    "drugClass": "Benzimidazole",
    "indications": "Treatment of neurocysticercosis (tapeworm larvae in the brain). Treatment of cystic hydatid disease of the liver, lung, and peritoneum (caused by dog tapeworm larvae).",
    "moaSteps": [
      "Albendazole is a broad-spectrum anthelmintic.",
      "It binds to tubulin, a protein in the parasite's intestinal cells and tegument.",
      "This binding inhibits the polymerization of microtubules, which are essential for cellular structure and processes.",
      "This leads to impaired glucose uptake and depletion of glycogen stores in the parasite, resulting in immobilization, starvation, and death."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly and erratically absorbed orally. **Absorption is significantly enhanced (up to 5x) when taken with a high-fat meal.**",
      "distribution": "Widely distributed, including into CSF and hydatid cysts. Moderately protein-bound (~70%).",
      "metabolism": "Undergoes extensive first-pass metabolism in the liver to its active metabolite, albendazole sulfoxide.",
      "excretion": "Excreted in bile (feces). Half-life of active metabolite is ~8.5 hours."
    },
    "dose": "Varies by indication, e.g., Neurocysticercosis: 15 mg/kg/day PO divided twice daily **with food** for 8-30 days.",
    "adverseEffects": {
      "common": ["Headache", "nausea", "vomiting", "abdominal pain", "elevated liver enzymes (LFTs)."],
      "serious": ["Myelosuppression (agranulocytosis, pancytopenia)", "hepatotoxicity", "acute renal failure."]
    },
    "precautions": [
      "**Must be taken with a high-fat meal** to ensure adequate absorption for systemic infections.",
      "Can cause myelosuppression (bone marrow suppression). Monitor CBC at the start of each cycle.",
      "Can cause hepatotoxicity. Monitor LFTs before each treatment cycle.",
      "May cause inflammatory reactions in the brain (in neurocysticercosis); co-administer with corticosteroids."
    ],
    "contraindications": [
      "Hypersensitivity to albendazole or other benzimidazoles",
      "**Pregnancy (Category C)** - should be avoided."
    ],
    "pregnancyCategory": "Category C. Teratogenic in animals.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "alendronate": {
    "name": "Alendronate (Fosamax)",
    "genericName": "Alendronate",
    "brandNames": ["Fosamax", "Binosto"],
    "category": "Osteoporosis Agent",
    "drugClass": "Bisphosphonate",
    "indications": "Treatment and prevention of postmenopausal osteoporosis. Treatment of osteoporosis in men. Treatment of Paget's disease of bone.",
    "moaSteps": [
      "Alendronate is a nitrogen-containing bisphosphonate.",
      "It has a high affinity for hydroxyapatite in bone, concentrating at sites of active bone resorption.",
      "It inhibits osteoclast activity (the cells that break down bone) by inhibiting the farnesyl pyrophosphate synthase enzyme.",
      "This action reduces bone resorption, increases bone mineral density, and reduces the risk of fractures."
    ],
    "pharmacokinetics": {
      "absorption": "Very poorly absorbed orally (<1%). **Absorption is significantly reduced to negligible levels by food, beverages (other than plain water), and other medications.**",
      "distribution": "Rapidly binds to bone. Highly protein-bound (~78%).",
      "metabolism": "Not metabolized.",
      "excretion": "Unabsorbed drug is excreted in feces. Absorbed drug is excreted unchanged in urine. Extremely long terminal half-life due to binding to bone (estimated > 10 years)."
    },
    "dose": "Osteoporosis Treatment: 70 mg PO **once weekly** or 10 mg PO **once daily**.",
    "adverseEffects": {
      "common": ["Dyspepsia", "abdominal pain", "nausea", "acid regurgitation", "musculoskeletal pain."],
      "serious": ["Esophagitis, esophageal ulcers, and esophageal perforation", "osteonecrosis of the jaw (ONJ)", "atypical femur fractures", "severe musculoskeletal pain."]
    },
    "precautions": [
      "**Must be taken with a full glass of plain water** first thing in the morning, at least 30 minutes before any food, drink, or other medication.",
      "**Patient must remain upright (sitting or standing) for at least 30 minutes** after taking to reduce the risk of severe esophageal irritation.",
      "Risk of Osteonecrosis of the Jaw (ONJ), especially with dental procedures. Dental exam is recommended before starting.",
      "Risk of atypical femur fractures.",
      "Correct hypocalcemia and Vitamin D deficiency before starting."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**inability to stand or sit upright for at least 30 minutes**",
      "hypocalcemia",
      "abnormalities of the esophagus (e.g., stricture, achalasia)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "amantadine": {
    "name": "Amantadine (Symmetrel)",
    "genericName": "Amantadine",
    "brandNames": ["Symmetrel", "Gocovri", "Osmolex ER"],
    "category": "Antiparkinsonian, Antiviral",
    "drugClass": "Adamantane, Dopamine Agonist",
    "indications": "Treatment of Parkinson's disease (PD) and drug-induced extrapyramidal symptoms (EPS). Treatment and prophylaxis of Influenza A (no longer recommended due to resistance).",
    "moaSteps": [
      "The mechanism in Parkinson's disease is not fully understood.",
      "It is thought to potentiate the dopaminergic system by increasing the release of dopamine from presynaptic terminals.",
      "It may also act as an NMDA receptor antagonist and have some anticholinergic properties.",
      "Its antiviral effect (against Influenza A) was by blocking the M2 viral ion channel, preventing viral uncoating."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Bioavailability ~86-90%.",
      "distribution": "Widely distributed. Moderately protein-bound (~67%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~12-17 hours."
    },
    "dose": "Parkinson's/EPS: 100 mg PO twice daily. Max 400 mg/day.",
    "adverseEffects": {
      "common": ["Dizziness", "lightheadedness", "insomnia", "anxiety", "nausea", "dry mouth", "constipation.", "orthostatic hypotension."],
      "serious": ["Livedo reticularis (a purplish, mottled skin discoloration, usually on the legs)", "peripheral edema", "psychosis", "hallucinations", "suicidal ideation."]
    },
    "precautions": [
      "Can cause CNS side effects (confusion, hallucinations, dizziness); use with caution in the elderly.",
      "Risk of orthostatic hypotension.",
      "Can cause livedo reticularis and peripheral edema.",
      "Do not stop abruptly in Parkinson's patients (risk of neuroleptic malignant syndrome-like symptoms).",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to amantadine",
      "uncontrolled narrow-angle glaucoma."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "amikacin": {
    "name": "Amikacin",
    "genericName": "Amikacin",
    "brandNames": ["Amikin"],
    "category": "Antibiotic",
    "drugClass": "Aminoglycoside Antibiotic",
    "indications": "Treatment of serious Gram-negative bacterial infections (e.g., Pseudomonas, E. coli, Klebsiella) including bacteremia, pneumonia, and UTIs. Often used for multi-drug resistant Gram-negative infections.",
    "moaSteps": [
      "Amikacin is an aminoglycoside antibiotic.",
      "It irreversibly binds to the 30S ribosomal subunit of susceptible bacteria.",
      "This binding interferes with the initiation complex, causes misreading of mRNA, and blocks translocation.",
      "This leads to the production of nonfunctional or toxic proteins and ultimately to bacterial cell death (bactericidal)."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly absorbed orally. Must be given IV or IM.",
      "distribution": "Widely distributed in extracellular fluid. Poor CNS penetration. Low protein binding (<10%).",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in the urine. Half-life is ~2-3 hours (in normal renal function)."
    },
    "dose": "Dosing is complex and based on weight, renal function, and therapeutic drug monitoring. Conventional: 5-7.5 mg/kg/dose IV/IM every 8-12 hours. Extended-interval: 15-20 mg/kg/dose IV once daily.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "rash.", "nephrotoxicity (mild, reversible)."],
      "serious": ["Ototoxicity (vestibular and auditory damage, may be irreversible)", "Nephrotoxicity (acute tubular necrosis)", "Neuromuscular blockade (can cause respiratory paralysis)."]
    },
    "precautions": [
      "BOXED WARNING (Ototoxicity): Can cause irreversible hearing loss and vestibular damage.",
      "BOXED WARNING (Nephrotoxicity): Can cause kidney damage. Monitor renal function and drug levels.",
      "BOXED WARNING (Neuromuscular Blockade): Can cause respiratory paralysis, especially in patients with myasthenia gravis.",
      "Requires therapeutic drug monitoring (TDM) (peaks and troughs) to ensure efficacy and minimize toxicity."
    ],
    "contraindications": [
      "Hypersensitivity to amikacin or other aminoglycosides."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm (deafness).",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "amiloride": {
    "name": "Amiloride (Midamor)",
    "genericName": "Amiloride",
    "brandNames": ["Midamor", "Moduretic (with HCTZ)"],
    "category": "Diuretic",
    "drugClass": "Potassium-sparing Diuretic",
    "indications": "Treatment of hypertension or edema, usually in combination with other diuretics (e.g., HCTZ) to prevent hypokalemia.",
    "moaSteps": [
      "Amiloride is a potassium-sparing diuretic.",
      "It acts directly on the distal convoluted tubule and collecting duct of the kidney.",
      "It blocks the epithelial sodium channels (ENaC) on the luminal side.",
      "This action inhibits the reabsorption of sodium and, in turn, reduces the excretion of potassium.",
      "This results in a mild diuresis and potassium retention."
    ],
    "pharmacokinetics": {
      "absorption": "Incompletely absorbed (~50%).",
      "distribution": "Low protein binding (~23%).",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in the urine. Half-life is ~6-9 hours."
    },
    "dose": "5-10 mg PO once daily.",
    "adverseEffects": {
      "common": ["Hyperkalemia", "dizziness", "headache", "nausea", "vomiting.", "muscle cramps."],
      "serious": ["Severe hyperkalemia (can be fatal)", "metabolic acidosis", "renal failure."]
    },
    "precautions": [
      "BOXED WARNING (Hyperkalemia): Can cause severe, life-threatening hyperkalemia. Risk is highest in renal impairment or with ACE inhibitors, ARBs, or potassium supplements.",
      "Monitor serum potassium and renal function (BUN/Cr) regularly.",
      "Risk of hyperkalemia is the most significant side effect."
    ],
    "contraindications": [
      "Hypersensitivity",
      "hyperkalemia",
      "severe renal impairment",
      "concomitant use with other potassium-sparing diuretics."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "aminocaproic-acid": {
    "name": "Aminocaproic Acid (Amicar)",
    "genericName": "Aminocaproic Acid",
    "brandNames": ["Amicar"],
    "category": "Anti-Fibrinolytic",
    "drugClass": "Antifibrinolytic Agent",
    "indications": "Treatment of hemorrhage resulting from hyperfibrinolysis (excessive breakdown of blood clots), such as in cardiac surgery, post-prostatectomy, or hemophilia.",
    "moaSteps": [
      "Aminocaproic acid is an antifibrinolytic agent.",
      "It is a synthetic analog of the amino acid lysine.",
      "It competitively and reversibly binds to plasminogen, blocking its binding to fibrin.",
      "This action prevents the conversion of plasminogen to plasmin, the enzyme responsible for breaking down fibrin clots.",
      "By inhibiting plasmin, it stabilizes the clot and prevents it from being broken down prematurely."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed orally.",
      "distribution": "Widely distributed. Not protein-bound.",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~2 hours."
    },
    "dose": "Loading dose: 4-5 grams PO/IV over 1 hour. Maintenance: 1-1.25 g/hour IV or PO.",
    "adverseEffects": {
      "common": ["Dizziness", "nausea", "diarrhea", "abdominal pain", "headache", "hypotension."],
      "serious": ["Thromboembolic events (DVT, PE, stroke)", "seizures", "myopathy", "rhabdomyolysis."]
    },
    "precautions": [
      "Risk of venous and arterial thrombosis (blood clots). Use with caution in patients with a history of thrombosis.",
      "Rapid IV injection can cause hypotension, bradycardia, or arrhythmias.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active disseminated intravascular coagulation (DIC) (without heparin).",
      "evidence of active thromboembolic disease."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "amoxicillin-clavulanate": {
    "name": "Amoxicillin/Clavulanate (Augmentin)",
    "genericName": "Amoxicillin and Clavulanate Potassium",
    "brandNames": ["Augmentin", "Augmentin ES-600", "Augmentin XR"],
    "category": "Antibiotic",
    "drugClass": "Penicillin-class Antibiotic / Beta-Lactamase Inhibitor Combination",
    "indications": "Treatment of bacterial infections caused by beta-lactamase producing strains, including otitis media, sinusitis, lower respiratory tract infections, skin infections, and urinary tract infections.",
    "moaSteps": [
      "This is a combination product:",
      "1. **Amoxicillin:** A beta-lactam antibiotic. It inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, leading to cell lysis.",
      "2. **Clavulanate:** A beta-lactamase inhibitor. It has no significant antibiotic activity on its own.",
      "Clavulanate binds to and inhibits beta-lactamase enzymes produced by bacteria (e.g., H. influenzae, M. catarrhalis, S. aureus), which would otherwise destroy amoxicillin. This 'protects' amoxicillin and extends its spectrum of activity."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Food does not significantly affect amoxicillin, but clavulanate absorption is enhanced. Best taken with food.",
      "distribution": "Widely distributed. Low protein binding.",
      "metabolism": "Amoxicillin is partially metabolized. Clavulanate is extensively metabolized.",
      "excretion": "Excreted in the urine. Half-life is ~1-1.5 hours."
    },
    "dose": "Varies by strength and infection. e.g., 875 mg/125 mg PO twice daily or 500 mg/125 mg PO three times daily.",
    "adverseEffects": {
      "common": ["Diarrhea (very common)", "nausea", "vomiting", "rash", "vaginal candidiasis."],
      "serious": ["Anaphylaxis (severe allergic reaction)", "Stevens-Johnson syndrome (SJS)", "Clostridioides difficile-associated diarrhea (CDAD)", "hepatotoxicity (cholestatic jaundice)."]
    },
    "precautions": [
      "Cross-sensitivity with other beta-lactams (e.g., cephalosporins) is possible.",
      "High incidence of diarrhea; take with food to minimize GI upset.",
      "Risk of hepatotoxicity (liver injury), more common than with amoxicillin alone.",
      "A high percentage of patients with infectious mononucleosis develop a rash.",
      "Dose adjustment is needed in severe renal impairment."
    ],
    "contraindications": [
      "History of serious hypersensitivity (e.g., anaphylaxis) to any penicillin or beta-lactamase inhibitor.",
      "History of cholestatic jaundice or hepatic dysfunction associated with amoxicillin/clavulanate."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; generally considered compatible."
  },
  "ampicillin": {
    "name": "Ampicillin",
    "genericName": "Ampicillin",
    "brandNames": ["Principen"],
    "category": "Antibiotic",
    "drugClass": "Penicillin-class Antibiotic (Aminopenicillin)",
    "indications": "Treatment of infections caused by susceptible strains of bacteria, including Gram-negative organisms (e.g., H. influenzae, E. coli, Salmonella) and Gram-positive organisms (e.g., Listeria monocytogenes, Enterococcus).",
    "moaSteps": [
      "Ampicillin is a beta-lactam antibiotic.",
      "It inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls.",
      "It binds to and inactivates penicillin-binding proteins (PBPs), which are enzymes responsible for cross-linking the peptidoglycan chains.",
      "This inhibition of cell wall synthesis leads to cell lysis and death (bactericidal effect)."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly absorbed orally (~40%). **Food significantly decreases absorption.** IV/IM routes preferred for serious infections.",
      "distribution": "Widely distributed into tissues and fluids, including CSF (especially with inflamed meninges). Low protein binding (~20%).",
      "metabolism": "Partially metabolized in the liver.",
      "excretion": "Primarily excreted unchanged in the urine. Half-life is ~1-1.5 hours."
    },
    "dose": "Varies by infection. PO: 250-500 mg every 6 hours. IV/IM: 1-2 g every 4-6 hours.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "rash (non-allergic 'ampicillin rash' is common, especially with mononucleosis)."],
      "serious": ["Anaphylaxis", "Stevens-Johnson syndrome (SJS)", "Clostridioides difficile-associated diarrhea (CDAD)."]
    },
    "precautions": [
      "Cross-sensitivity with other beta-lactams (e.g., cephalosporins) is possible.",
      "A high percentage of patients with infectious mononucleosis develop a non-allergic rash.",
      "Prolonged use may result in fungal or bacterial superinfection.",
      "Oral form must be taken on an empty stomach (1 hour before or 2 hours after meals)."
    ],
    "contraindications": [
      "History of serious hypersensitivity (e.g., anaphylaxis) to ampicillin or any penicillin."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; compatible."
  },
  "anastrozole": {
    "name": "Anastrozole (Arimidex)",
    "genericName": "Anastrozole",
    "brandNames": ["Arimidex"],
    "category": "Antineoplastic Agent",
    "drugClass": "Aromatase Inhibitor (Nonsteroidal)",
    "indications": "Adjuvant and first-line treatment of hormone receptor-positive (ER+/PR+) breast cancer in postmenopausal women. Treatment of advanced breast cancer in postmenopausal women.",
    "moaSteps": [
      "Anastrozole is a nonsteroidal aromatase inhibitor.",
      "In postmenopausal women, the primary source of estrogen is the conversion of androgens to estrogens by the aromatase enzyme in peripheral tissues (e.g., fat, muscle).",
      "Anastrozole competitively and reversibly binds to the aromatase enzyme, blocking this conversion.",
      "This leads to a profound reduction (over 90%) in systemic estrogen levels, depriving hormone-sensitive breast cancer cells of the estrogen they need to grow."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. Bioavailability ~83-85%.",
      "distribution": "Widely distributed. Moderately protein-bound (~40%).",
      "metabolism": "Extensively metabolized in the liver.",
      "excretion": "Excreted primarily in feces (via bile) as metabolites. Long half-life (~50 hours)."
    },
    "dose": "1 mg PO once daily.",
    "adverseEffects": {
      "common": ["Hot flashes", "asthenia (weakness)", "arthralgia (joint pain)", "myalgia (muscle pain)", "fatigue", "headache", "nausea", "hypercholesterolemia."],
      "serious": ["Decreased bone mineral density (risk of osteoporosis and fractures)", "cardiovascular ischemic events (e.g., MI, angina)."]
    },
    "precautions": [
      "Significantly increases the risk of osteoporosis and bone fractures. Monitor bone mineral density and consider calcium/Vitamin D supplementation.",
      "Can cause hypercholesterolemia. Monitor cholesterol levels.",
      "Can cause fatigue and dizziness; caution against driving.",
      "Associated with a higher risk of cardiovascular events compared to tamoxifen."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category D)**",
      "premenopausal status."
    ],
    "pregnancyCategory": "Category D (based on fetal harm in animals).",
    "lactationInfo": "Not recommended."
  },
  "aprepitant": {
    "name": "Aprepitant (Emend)",
    "genericName": "Aprepitant",
    "brandNames": ["Emend"],
    "category": "Antiemetic",
    "drugClass": "Substance P/Neurokinin-1 (NK1) Receptor Antagonist",
    "indications": "Prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). Prevention of postoperative nausea and vomiting (PONV).",
    "moaSteps": [
      "Aprepitant is a selective Substance P/Neurokinin-1 (NK1) receptor antagonist.",
      "It works by blocking the binding of Substance P (a key neurotransmitter) to NK1 receptors in the brain, particularly in the chemoreceptor trigger zone (CTZ) and vomiting center.",
      "This action is crucial for preventing *delayed* chemotherapy-induced nausea and vomiting (CINV), which is often mediated by Substance P.",
      "It is almost always used in combination with a 5-HT3 antagonist (e.g., ondansetron) and a corticosteroid (e.g., dexamethasone)."
    ],
    "pharmacokinetics": {
      "absorption": "Moderately absorbed. Bioavailability ~60-65%.",
      "distribution": "Widely distributed. Highly protein-bound (>95%). Crosses the blood-brain barrier.",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Excreted in feces and urine as metabolites. Half-life is ~9-13 hours."
    },
    "dose": "CINV: 125 mg PO 1 hour before chemo on Day 1, then 80 mg PO once daily on Days 2 and 3.",
    "adverseEffects": {
      "common": ["Fatigue", "hiccups", "nausea", "constipation", "diarrhea", "decreased appetite."],
      "serious": ["Hypersensitivity reactions (anaphylaxis)", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "Moderate inhibitor of CYP3A4 and inducer of CYP2C9. Has significant drug interactions.",
      "Can decrease the effectiveness of warfarin (monitor INR).",
      "Can decrease the effectiveness of hormonal contraceptives for up to 28 days after the last dose."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with pimozide or cisapride (due to CYP3A4 inhibition)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "armodafinil": {
    "name": "Armodafinil (Nuvigil)",
    "genericName": "Armodafinil",
    "brandNames": ["Nuvigil"],
    "category": "CNS Stimulant",
    "drugClass": "Wakefulness-Promoting Agent (Schedule IV)",
    "indications": "To improve wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).",
    "moaSteps": [
      "Armodafinil is the (R)-enantiomer of modafinil.",
      "Its exact mechanism is not fully understood, but it is thought to work by inhibiting the reuptake of dopamine in the brain, which increases dopamine levels and promotes wakefulness.",
      "It has a longer half-life than modafinil."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Peak in ~2 hours.",
      "distribution": "Widely distributed. Moderately protein-bound (~60%).",
      "metabolism": "Extensively metabolized in the liver.",
      "excretion": "Excreted in urine as metabolites. Longer half-life than modafinil (~15 hours)."
    },
    "dose": "150-250 mg PO once daily in the morning.",
    "adverseEffects": {
      "common": ["Headache", "nausea", "dizziness", "insomnia", "anxiety", "dry mouth."],
      "serious": ["Severe, life-threatening rash (SJS/TEN, DRESS)", "angioedema", "psychiatric symptoms (psychosis, mania)."]
    },
    "precautions": [
      "Can cause severe, life-threatening rashes (SJS/TEN). Discontinue at the first sign of any rash.",
      "Can cause psychiatric symptoms (anxiety, agitation, psychosis).",
      "Can increase heart rate and blood pressure. Monitor cardiovascular status.",
      "Has potential for abuse and dependence (Schedule IV).",
      "Can reduce the effectiveness of hormonal contraceptives."
    ],
    "contraindications": [
      "Hypersensitivity to armodafinil or modafinil."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "atazanavir": {
    "name": "Atazanavir (Reyataz)",
    "genericName": "Atazanavir",
    "brandNames": ["Reyataz", "Evotaz (with cobicistat)"],
    "category": "Antiretroviral",
    "drugClass": "Antiretroviral, Protease Inhibitor (PI)",
    "indications": "Treatment of HIV-1 infection, always in combination with other antiretroviral agents (e.g., with a booster like ritonavir or cobicistat).",
    "moaSteps": [
      "Atazanavir is a protease inhibitor (PI).",
      "It inhibits the HIV-1 protease enzyme, which is essential for cleaving viral polyproteins into functional proteins.",
      "This action prevents the maturation of new, infectious viral particles.",
      "It must be 'boosted' with ritonavir or cobicistat to inhibit its metabolism and increase its concentration."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. **Must be taken with food.** Bioavailability is higher with boosting.",
      "distribution": "Widely distributed. Highly protein-bound (~86%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4 (which is inhibited by boosters).",
      "excretion": "Excreted primarily in feces (via bile). Half-life is ~7 hours (boosted)."
    },
    "dose": "Boosted: 300 mg atazanavir PO once daily WITH 100 mg ritonavir PO once daily, **with food.**",
    "adverseEffects": {
      "common": ["Nausea", "diarrhea", "headache", "rash", "hyperbilirubinemia (jaundice, scleral icterus - 'yellow eyes')."],
      "serious": ["Hepatotoxicity", "cardiac conduction abnormalities (PR interval prolongation)", "severe skin reactions (SJS/TEN)", "nephrolithiasis (kidney stones)."]
    },
    "precautions": [
      "**Numerous, life-threatening drug interactions.** As a potent CYP3A4 inhibitor (when boosted), it can dangerously increase the levels of many drugs.",
      "Can cause hyperbilirubinemia (jaundice) due to inhibition of UGT. This is generally harmless but can be cosmetic.",
      "Can cause PR interval prolongation; use with caution with other AV-blocking drugs (e.g., beta-blockers).",
      "Risk of kidney stones; maintain adequate hydration."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**concomitant use with a long list of drugs** that are highly dependent on CYP3A4 for clearance (e.g., simvastatin, sildenafil).",
      "concomitant use with acid-reducing agents (e.g., PPIs) can be contraindicated as it needs acid for absorption."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Not recommended (to prevent HIV transmission)."
  },
  "atomoxetine": {
    "name": "Atomoxetine (Strattera)",
    "genericName": "Atomoxetine",
    "brandNames": ["Strattera"],
    "category": "ADHD Agent",
    "drugClass": "Norepinephrine Reuptake Inhibitor (NRI), Non-stimulant",
    "indications": "Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults.",
    "moaSteps": [
      "Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor (NRI).",
      "It blocks the presynaptic norepinephrine transporter, which increases the concentration of NE (and dopamine) in the synaptic cleft, particularly in the prefrontal cortex.",
      "This is thought to improve attention, focus, and impulse control.",
      "It is *not* a stimulant and is not a controlled substance."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability varies based on CYP2D6 status (~63% extensive, ~94% poor metabolizers).",
      "distribution": "Widely distributed. Highly protein-bound (~98%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP2D6.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~5 hours (extensive metabolizers) to ~21 hours (poor metabolizers)."
    },
    "dose": "Initial: 40 mg/day PO, can be titrated up to a max of 100 mg/day in 1-2 divided doses.",
    "adverseEffects": {
      "common": ["Headache", "insomnia", "nausea", "vomiting", "decreased appetite", "dry mouth", "constipation", "sexual dysfunction."],
      "serious": ["Suicidal ideation", "hepatotoxicity (severe liver injury)", "cardiovascular events (e.G., sudden death, stroke, MI)."]
    },
    "precautions": [
      "BOXED WARNING (Suicidal Ideation): Increased risk of suicidal ideation in children and adolescents. Monitor closely for worsening mood or behavior.",
      "Risk of severe, idiosyncratic liver injury. Discontinue if jaundice or LFTs rise.",
      "Can increase blood pressure and heart rate. Monitor cardiovascular status.",
      "Can cause psychiatric symptoms (e.g., psychosis, mania)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (within 14 days)",
      "narrow-angle glaucoma",
      "pheochromocytoma."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "atovaquone": {
    "name": "Atovaquone (Mepron)",
    "genericName": "Atovaquone",
    "brandNames": ["Mepron", "Malarone (with proguanil)"],
    "category": "Antiprotozoal",
    "drugClass": "Antiprotozoal",
    "indications": "Treatment and prevention of Pneumocystis jirovecii pneumonia (PJP) in patients intolerant to Bactrim. (Malarone): Prevention and treatment of malaria.",
    "moaSteps": [
      "Atovaquone is an antiprotozoal agent.",
      "It inhibits the parasite's mitochondrial electron transport chain by binding to the cytochrome bc1 complex.",
      "This action blocks ATP synthesis (energy production) and pyrimidine synthesis, leading to the death of the organism (e.g., P. jirovecii, P. falciparum)."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly and variably absorbed. **Absorption is significantly enhanced (2-3x) when taken with a high-fat meal.**",
      "distribution": "Widely distributed. Highly protein-bound (>99%).",
      "metabolism": "Minimally metabolized. Undergoes enterohepatic recirculation.",
      "excretion": "Excreted almost entirely in feces (via bile). Long half-life (~2-3 days)."
    },
    "dose": "PJP Treatment: 750 mg PO twice daily **with food** for 21 days. PJP Prophylaxis: 1500 mg PO once daily **with food**.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "headache", "rash.", "fever."],
      "serious": ["Hepatotoxicity", "severe skin reactions (SJS)."]
    },
    "precautions": [
      "**Must be taken with food (especially high-fat)** to ensure adequate absorption.",
      "GI side effects (nausea, vomiting, diarrhea) are common.",
      "Use with caution in patients with hepatic impairment.",
      "Not as effective as Bactrim for PJP but is an alternative for sulfa-allergic patients."
    ],
    "contraindications": [
      "Hypersensitivity to atovaquone."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "atropine": {
    "name": "Atropine",
    "genericName": "Atropine",
    "brandNames": ["AtroPen", "Isopto Atropine (ophthalmic)"],
    "category": "Anticholinergic, Antiarrhythmic",
    "drugClass": "Antimuscarinic",
    "indications": "Treatment of symptomatic bradycardia (slow heart rate). Preoperative agent to reduce secretions. Antidote for anticholinesterase (e.g., organophosphate) poisoning. Ophthalmic: To dilate the pupil (mydriasis).",
    "moaSteps": [
      "Atropine is a competitive, non-selective antagonist of muscarinic acetylcholine receptors.",
      "In the heart: It blocks muscarinic (M2) receptors on the SA and AV nodes, which are normally stimulated by the vagus nerve (parasympathetic system) to slow the heart.",
      "By blocking this 'brake,' it increases the heart rate.",
      "It also blocks muscarinic receptors in salivary glands (dries mouth), GI tract (slows motility), and pupils (causes dilation)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed IV/IM. Well absorbed orally.",
      "distribution": "Widely distributed, crosses the blood-brain barrier.",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine as metabolites and unchanged drug. Half-life is ~2-4 hours."
    },
    "dose": "Bradycardia (ACLS): 1 mg IV push, repeat every 3-5 minutes. Max 3 mg total.",
    "adverseEffects": {
      "common": ["Dry mouth", "blurred vision", "photophobia (light sensitivity)", "tachycardia", "flushing", "urinary retention", "constipation."],
      "serious": ["Delirium", "hallucinations ('anticholinergic psychosis')", "severe tachycardia", "arrhythmias."]
    },
    "precautions": [
      "Can cause significant anticholinergic side effects ('mad as a hatter, blind as a bat, red as a beet, hot as a hare, dry as a bone').",
      "Use with caution in the elderly (high risk of delirium) and in patients with BPH or narrow-angle glaucoma.",
      "Low doses (<0.5 mg) can paradoxically cause bradycardia."
    ],
    "contraindications": [
      "Hypersensitivity",
      "narrow-angle glaucoma",
      "GI obstruction (pyloric stenosis)",
      "obstructive uropathy (BPH)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "azathioprine": {
    "name": "Azathioprine (Imuran)",
    "genericName": "Azathioprine",
    "brandNames": ["Imuran", "Azasan"],
    "category": "Immunosuppressant",
    "drugClass": "Immunosuppressant, Antimetabolite",
    "indications": "Prophylaxis of organ rejection in kidney transplantation. Treatment of severe, active rheumatoid arthritis (RA).",
    "moaSteps": [
      "Azathioprine is a prodrug that is converted in the body to its active form, 6-mercaptopurine (6-MP).",
      "6-MP is further metabolized into active metabolites (e.g., thioguanine nucleotides).",
      "These metabolites are purine analogs that get incorporated into DNA and RNA.",
      "This action inhibits the synthesis of purines, which is essential for the proliferation of rapidly dividing cells, especially T-cells and B-cells.",
      "This suppresses the immune response."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally.",
      "distribution": "Widely distributed. Low protein binding (~30%).",
      "metabolism": "Extensively metabolized to 6-MP. Metabolism is dependent on the enzyme thiopurine methyltransferase (TPMT).",
      "excretion": "Excreted in urine as metabolites."
    },
    "dose": "RA: Initial 1 mg/kg/day PO. Maintenance 1-3 mg/kg/day.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "rash", "fever", "leukopenia."],
      "serious": ["Myelosuppression (severe leukopenia, thrombocytopenia, anemia)", "hepatotoxicity", "malignancy (lymphoma, skin cancer)."]
    },
    "precautions": [
      "BOXED WARNING (Malignancy): Increased risk of malignancy (especially lymphoma and skin cancer) with chronic use.",
      "BOXED WARNING (Myelosuppression): Can cause severe, life-threatening bone marrow suppression.",
      "**Genetic testing for TPMT** enzyme activity is recommended before starting. Patients with low or absent TPMT activity are at very high risk of severe myelosuppression and require significantly lower doses.",
      "**Contraindicated with allopurinol and febuxostat** (they block the breakdown of 6-MP, leading to fatal toxicity)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category D)**",
      "**concomitant use with allopurinol or febuxostat**."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "azelaic-acid": {
    "name": "Azelaic Acid (Azelex, Finacea)",
    "genericName": "Azelaic Acid",
    "brandNames": ["Azelex (20% cream)", "Finacea (15% foam/gel)"],
    "category": "Antiacne, Rosacea Agent",
    "drugClass": "Topical Skin Agent",
    "indications": "Topical treatment of mild to moderate acne vulgaris (Azelex). Topical treatment of inflammatory papules and pustules of mild to moderate rosacea (Finacea).",
    "moaSteps": [
      "The mechanism of azelaic acid is not fully understood.",
      "For Acne: It has antimicrobial activity against *Propionibacterium acnes*. It also has a keratolytic effect, normalizing the shedding of skin cells in the follicle to prevent comedone formation.",
      "For Rosacea: It is thought to have anti-inflammatory effects by reducing the production of reactive oxygen species."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption from topical application (~4%).",
      "distribution": "Acts locally in the skin.",
      "metabolism": "Not metabolized (if minimally absorbed).",
      "excretion": "Excreted in urine (if minimally absorbed)."
    },
    "dose": "Apply a thin film to the affected area twice daily (morning and evening).",
    "adverseEffects": {
      "common": ["Local skin irritation", "burning", "stinging", "itching", "peeling", "dryness."],
      "serious": ["Hypopigmentation (lightening of skin)", "severe hypersensitivity reaction (rare)."]
    },
    "precautions": [
      "Can cause local skin irritation, which usually lessens over time.",
      "Can cause hypopigmentation (skin lightening), especially in patients with dark complexions. Monitor for this.",
      "Avoid contact with eyes, mouth, and mucous membranes."
    ],
    "contraindications": [
      "Hypersensitivity to azelaic acid."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "azelastine": {
    "name": "Azelastine (Astelin, Astepro)",
    "genericName": "Azelastine",
    "brandNames": ["Astelin", "Astepro (nasal spray)", "Optivar (ophthalmic)"],
    "category": "Antihistamine, Nasal/Ophthalmic",
    "drugClass": "Antihistamine, 2nd Generation (Topical)",
    "indications": "Nasal: Symptomatic relief of seasonal and perennial allergic rhinitis. Ophthalmic: Treatment of ocular itching associated with allergic conjunctivitis.",
    "moaSteps": [
      "Azelastine is a second-generation H1-receptor antagonist.",
      "It competes with histamine for H1-receptor sites on cells in the nasal mucosa and conjunctiva.",
      "This action blocks the effects of histamine, relieving symptoms like sneezing, runny nose (rhinorrhea), and nasal/ocular itching.",
      "It also has mast cell stabilizing properties."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed systemically after nasal administration (~40%). Minimal absorption from ophthalmic use.",
      "distribution": "Acts locally. Systemic drug is highly protein-bound.",
      "metabolism": "Metabolized in the liver (CYP enzymes) to an active metabolite.",
      "excretion": "Excreted in feces. Half-life is long (~22 hours)."
    },
    "dose": "Nasal: 1-2 sprays in each nostril twice daily. Ophthalmic: 1 drop in each affected eye twice daily.",
    "adverseEffects": {
      "common": ["(Nasal) Bitter taste", "headache", "drowsiness", "nasal burning.", "(Ophthalmic) Eye stinging/burning", "headache."],
      "serious": ["Somnolence (at high doses)", "hypersensitivity reactions."]
    },
    "precautions": [
      "Can cause somnolence (drowsiness), especially with the nasal spray due to systemic absorption. Caution against driving.",
      "Avoid concurrent use of alcohol or other CNS depressants.",
      "The bitter taste is a common complaint with the nasal spray."
    ],
    "contraindications": [
      "Hypersensitivity to azelastine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "azithromycin": {
    "name": "Azithromycin (Zithromax, Z-Pak)",
    "genericName": "Azithromycin",
    "brandNames": ["Zithromax", "Z-Pak", "AzaSite (ophthalmic)"],
    "category": "Antibiotic",
    "drugClass": "Macrolide Antibiotic",
    "indications": "Treatment of mild to moderate infections, including community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis, sinusitis, pharyngitis/tonsillitis, and uncomplicated skin infections. Treatment of chlamydia.",
    "moaSteps": [
      "Azithromycin is a macrolide (azalide) antibiotic.",
      "It inhibits bacterial protein synthesis by reversibly binding to the 50S ribosomal subunit.",
      "This binding blocks the translocation step of protein synthesis, preventing the growing peptide chain from being elongated.",
      "It is typically bacteriostatic."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed, but variable. Bioavailability ~37%. Food affects absorption (varies by formulation).",
      "distribution": "Extensively distributed into tissues (high tissue concentration, low serum concentration). Low protein binding.",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily in bile (feces). **Very long half-life (~68 hours)**, which allows for short-course dosing (e.g., Z-Pak)."
    },
    "dose": "CAP/Pharyngitis (Z-Pak): 500 mg PO on Day 1, then 250 mg PO once daily on Days 2-5. Chlamydia: 1 gram PO as a single dose.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "abdominal pain", "headache."],
      "serious": ["QT prolongation and Torsades de Pointes", "hepatotoxicity (liver failure)", "severe skin reactions (SJS/TEN)", "C. difficile-associated diarrhea."]
    },
    "precautions": [
      "Risk of QT prolongation and fatal arrhythmias (Torsades de Pointes). Use with caution in patients with QT prolongation or on other QT-prolonging drugs.",
      "Risk of hepatotoxicity. Discontinue if signs of liver injury occur.",
      "Take oral suspension on an empty stomach. Tablets can be taken with or without food."
    ],
    "contraindications": [
      "Hypersensitivity to azithromycin or other macrolides",
      "history of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "aztreonam": {
    "name": "Aztreonam (Azactam, Cayston)",
    "genericName": "Aztreonam",
    "brandNames": ["Azactam (IV)", "Cayston (inhalation)"],
    "category": "Antibiotic",
    "drugClass": "Monobactam Antibiotic",
    "indications": "IV: Treatment of moderate to severe infections caused by susceptible Gram-negative bacteria (including Pseudomonas aeruginosa), such as pneumonia, bacteremia, and UTIs. Inhalation: To improve respiratory symptoms in cystic fibrosis patients with P. aeruginosa.",
    "moaSteps": [
      "Aztreonam is a monobactam, a beta-lactam antibiotic.",
      "It inhibits bacterial cell wall synthesis by binding with high affinity to penicillin-binding protein 3 (PBP3) of Gram-negative bacteria.",
      "This action prevents the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis and death.",
      "It has no activity against Gram-positive or anaerobic bacteria."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed orally. Must be given IV/IM or inhaled.",
      "distribution": "Widely distributed into tissues and fluids, including CSF.",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~1.7 hours."
    },
    "dose": "IV: 1-2 grams IV every 8-12 hours. Inhalation (Cayston): 75 mg inhaled 3 times daily.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "rash", "injection site reactions.", "elevated LFTs."],
      "serious": ["Anaphylaxis", "severe skin reactions (SJS/TEN)", "myelosuppression (neutropenia)."]
    },
    "precautions": [
      "**Unique beta-lactam structure; generally considered safe in patients with a penicillin allergy** (low cross-reactivity, except with ceftazidime).",
      "Requires dose adjustment in renal impairment.",
      "Prolonged use may result in fungal or bacterial superinfection.",
      "Inhaled form (Cayston) can cause bronchospasm; use a bronchodilator before each dose."
    ],
    "contraindications": [
      "Hypersensitivity to aztreonam."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },

  "atorvastatin": {
    "brandNames": [
      "Lipitor"
    ],
    "category": "Antihyperlipidemic",
    "drugClass": "HMG-CoA Reductase Inhibitor (Statin)",
    "genericName": "Atorvastatin",
    "indications": "Adjunct to diet to lower elevated total cholesterol, LDL-C, and triglycerides. To reduce the risk of myocardial infarction, stroke, and revascularization procedures in patients with or at high risk for cardiovascular disease.",
    "moaSteps": [
      "Atorvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis in the liver.",
      "This inhibition decreases the production of cholesterol in the liver.",
      "The liver compensates by increasing the number of LDL receptors on its surface, which enhances the uptake and clearance of LDL-C from the blood.",
      "This results in a significant reduction of LDL-C ('bad cholesterol') and total cholesterol."
    ],
    "name": "Atorvastatin (Lipitor)",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. Peak concentration in 1-2 hours. High first-pass metabolism (bioavailability ~14%).",
      "distribution": "Highly protein-bound (>98%).",
      "excretion": "Primarily eliminated in the bile after hepatic metabolism. Long half-life (~14 hours).",
      "metabolism": "Extensively metabolized in the liver by the CYP3A4 enzyme to active and inactive metabolites."
    },
    "dose": {
      "initialDose": "10-20 mg PO once daily.",
      "maxDose": "80 mg PO once daily.",
      "notes": "Can be taken at any time of day, with or without food. Higher doses (80 mg) reserved for high-intensity therapy."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "myalgia (muscle pain)",
        "arthralgia (joint pain)",
        "diarrhea",
        "nasopharyngitis",
        "elevated liver enzymes."
      ],
      "serious": [
        "Myopathy and Rhabdomyolysis (muscle breakdown, can lead to kidney failure)",
        "Hepatotoxicity (liver injury)",
        "new-onset diabetes mellitus."
      ]
    },
    "precautions": [
      "Risk of myopathy and rhabdomyolysis is increased with higher doses, advanced age, and concomitant use of CYP3A4 inhibitors (e.g., clarithromycin, -azole antifungals).",
      "All patients should be advised to report unexplained muscle pain, weakness, or dark urine.",
      "Monitor liver function tests (LFTs) at baseline and as clinically indicated.",
      "Use with caution in patients with heavy alcohol use."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active liver disease",
      "unexplained persistent elevations of LFTs",
      "**Pregnancy (Category X)**",
      "**Lactation**."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm."
  },
  "baclofen": {
    "adverseEffects": {
      "common": [
        "Drowsiness",
        "dizziness",
        "weakness",
        "fatigue",
        "confusion",
        "nausea",
        "hypotension."
      ],
      "serious": [
        "Seizures",
        "respiratory depression",
        "severe withdrawal symptoms if abruptly discontinued."
      ]
    },
    "brandNames": [
      "Lioresal",
      "Gablofen"
    ],
    "category": "Antispastic Agent",
    "contraindications": [
      "Hypersensitivity to baclofen."
    ],
    "dose": "Oral: Initial 5 mg three times daily, titrated up to a max of 80 mg/day. Intrathecal: Varies by patient.",
    "drugClass": "Skeletal Muscle Relaxant",
    "genericName": "Baclofen",
    "indications": "Treatment of spasticity resulting from multiple sclerosis, spinal cord injuries, and other spinal cord diseases.",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution.",
    "moaSteps": [
      "Baclofen is a structural analog of the inhibitory neurotransmitter GABA.",
      "It is a GABA-B agonist.",
      "It binds to GABA-B receptors, which are G-protein coupled receptors. This binding hyperpolarizes nerve terminals.",
      "It is thought to act by inhibiting the transmission of monosynaptic and polysynaptic reflexes at the spinal cord level, resulting in relief of muscle spasticity."
    ],
    "name": "Baclofen",
    "pharmacokinetics": {
      "absorption": "Rapidly and extensively absorbed orally. Bioavailability is variable.",
      "distribution": "Widely distributed, crosses the blood-brain barrier poorly. Low protein binding (~30%).",
      "excretion": "Primarily excreted unchanged in the urine. Half-life is 3-4 hours.",
      "metabolism": "Only a small amount (~15%) is metabolized in the liver."
    },
    "precautions": [
      "BOXED WARNING (Intrathecal): Abrupt discontinuation of intrathecal baclofen has resulted in severe sequelae (e.g., high fever, rebound spasticity, rhabdomyolysis, multi-organ failure, death).",
      "Oral withdrawal can also cause seizures and hallucinations.",
      "Use with caution in patients with renal impairment."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "Renal impairment.",
      "History of seizure disorders."
    ]
  },
  "benazepril": {
    "adverseEffects": {
      "common": [
        "Headache",
        "dizziness",
        "fatigue",
        "dry, persistent cough",
        "hyperkalemia."
      ],
      "serious": [
        "Angioedema",
        "hypotension",
        "acute renal failure",
        "agranulocytosis."
      ]
    },
    "brandNames": [
      "Lotensin"
    ],
    "category": "Antihypertensive",
    "contraindications": [
      "History of angioedema related to previous ACE inhibitor treatment.",
      "Concomitant use with aliskiren in patients with diabetes.",
      "Pregnancy."
    ],
    "dose": "10-40 mg PO once daily.",
    "drugClass": "Angiotensin-Converting Enzyme (ACE) Inhibitor",
    "genericName": "Benazepril",
    "indications": "Treatment of hypertension, alone or in combination with other antihypertensives.",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution.",
    "moaSteps": [
      "Benazepril is a prodrug that is hydrolyzed to its active metabolite, benazeprilat.",
      "Benazeprilat competitively inhibits the angiotensin-converting enzyme (ACE).",
      "This prevents the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor).",
      "Decreased angiotensin II leads to vasodilation, reduced secretion of aldosterone, and a decrease in blood pressure."
    ],
    "name": "Benazepril (Lotensin)",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed, hydrolyzed to benazeprilat. Bioavailability ~37%.",
      "distribution": "Highly protein-bound (~97%).",
      "excretion": "Excreted in urine and bile. Half-life is 10-11 hours.",
      "metabolism": "Metabolized in the liver to benazeprilat (active)."
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus.",
      "Monitor renal function and serum potassium.",
      "Risk of angioedema, especially in Black patients."
    ],
    "pregnancyCategory": "Category D",
    "riskFactors": [
      "Pregnancy",
      "renal artery stenosis",
      "volume depletion."
    ]
  },
  "benzonatate": {
    "adverseEffects": {
      "common": [
        "Sedation",
        "drowsiness",
        "dizziness",
        "headache",
        "nausea",
        "constipation",
        "chilly sensation.",
        "numbness of the chest."
      ],
      "serious": [
        "Severe hypersensitivity reactions (bronchospasm, laryngospasm, cardiovascular collapse)",
        "confusion",
        "visual hallucinations."
      ]
    },
    "brandNames": [
      "Tessalon Perles",
      "Tessalon Capsules"
    ],
    "category": "Cough Suppressant",
    "contraindications": [
      "Hypersensitivity to benzonatate or related compounds (local anesthetics of the PABA class)."
    ],
    "dose": "100-200 mg PO three times daily as needed. Max 600 mg/day.",
    "drugClass": "Antitussive",
    "genericName": "Benzonatate",
    "indications": "Symptomatic relief of nonproductive cough.",
    "lactationInfo": "Unknown if excreted in breast milk; use with caution.",
    "moaSteps": [
      "Benzonatate is structurally related to local anesthetics like procaine.",
      "It acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura.",
      "This dampens the activity of these receptors and reduces the cough reflex at its source.",
      "It has no significant central nervous system (CNS) effects."
    ],
    "name": "Benzonatate (Tessalon)",
    "pharmacokinetics": {
      "absorption": "Action begins within 15-20 minutes.",
      "distribution": "Duration of action is 3-8 hours.",
      "excretion": "Excretion route is not well-known.",
      "metabolism": "Metabolism is not fully described, but likely hydrolyzed."
    },
    "precautions": [
      "BOXED WARNING (Accidental Ingestion): Accidental ingestion by children under 10 years of age can result in death. Capsules must be kept out of reach of children.",
      "Capsules must be **swallowed whole**. Chewing or sucking the capsule can cause local anesthesia of the mouth and pharynx, leading to choking.",
      "Severe hypersensitivity reactions have been reported."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "Children under 10 (risk of fatal overdose)",
      "patients with difficulty swallowing."
    ]
  },
  "benztropine": {
    "adverseEffects": {
      "common": [
        "Dry mouth (xerostomia)",
        "blurred vision",
        "constipation",
        "urinary retention",
        "tachycardia",
        "confusion",
        "drowsiness",
        "anhidrosis (inability to sweat)."
      ],
      "serious": [
        "Paralytic ileus",
        "toxic psychosis",
        "severe heatstroke (due to anhidrosis)",
        "worsening of tardive dyskinesia."
      ]
    },
    "brandNames": [
      "Cogentin"
    ],
    "category": "Antiparkinsonian",
    "contraindications": [
      "Hypersensitivity",
      "angle-closure glaucoma",
      "pyloric stenosis",
      "myasthenia gravis",
      "tardive dyskinesia."
    ],
    "dose": "1-6 mg/day PO in 1-2 divided doses.",
    "drugClass": "Anticholinergic, Anti-Parkinson's Agent",
    "genericName": "Benztropine",
    "indications": "Adjunctive treatment of all forms of parkinsonism. Control of extrapyramidal disorders (EPS) (except tardive dyskinesia) due to neuroleptic drugs.",
    "lactationInfo": "Unknown; use with caution.",
    "moaSteps": [
      "Benztropine is a centrally acting anticholinergic agent.",
      "It blocks central muscarinic acetylcholine receptors, which helps to restore the dopaminergic/cholinergic balance in the striatum.",
      "This imbalance is a key feature of Parkinson's disease and drug-induced EPS.",
      "It also has some antihistaminic properties."
    ],
    "name": "Benztropine (Cogentin)",
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Onset of action within 1-2 hours.",
      "distribution": "Widely distributed. Duration of action is 24 hours.",
      "excretion": "Excreted in urine and feces.",
      "metabolism": "Metabolized in the liver."
    },
    "precautions": [
      "Use with caution in the elderly (high risk of confusion, hallucinations).",
      "Patients should be advised of the risk of heatstroke in hot weather due to decreased sweating.",
      "Can impair cognitive and physical abilities; caution against driving."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "Elderly patients",
      "hot weather",
      "glaucoma",
      "BPH."
    ]
  },
  "betamethasone": {
    "adverseEffects": {
      "common": [
        "(Short-term) Insomnia, hyperglycemia, increased appetite, nervousness.",
        "(Long-term) Cushing's syndrome, osteoporosis, immunosuppression, cataracts, skin atrophy (topical)."
      ],
      "serious": [
        "Adrenal suppression (with abrupt withdrawal)",
        "severe infections",
        "psychosis",
        "gastrointestinal perforation",
        "osteonecrosis."
      ]
    },
    "brandNames": [
      "Celestone",
      "Diprolene (topical)",
      "Luxiq (foam)"
    ],
    "category": "Anti-inflammatory, Immunosuppressant",
    "contraindications": [
      "Systemic fungal infections",
      "hypersensitivity."
    ],
    "dose": "Varies widely by indication. Oral: 0.6-7.2 mg/day. Antenatal: 12 mg IM, repeated in 24 hours.",
    "drugClass": "Corticosteroid",
    "genericName": "Betamethasone",
    "indications": "Systemic: Treatment of various inflammatory, allergic, and autoimmune conditions. Topical: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Antenatal: To accelerate fetal lung maturity in high-risk premature delivery.",
    "lactationInfo": "Systemic use is excreted in breast milk; use with caution.",
    "moaSteps": [
      "Betamethasone is a potent glucocorticoid.",
      "It diffuses into cells and binds to intracellular glucocorticoid receptors.",
      "This complex translocates to the nucleus and alters gene expression.",
      "It upregulates the synthesis of anti-inflammatory proteins (e.g., lipocortins) and downregulates the expression of pro-inflammatory mediators (e.g., cytokines, interleukins, prostaglandins).",
      "This results in potent anti-inflammatory, immunosuppressive, and anti-allergic effects."
    ],
    "name": "Betamethasone",
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Absorbed topically (extent varies by site, formulation).",
      "distribution": "Widely distributed. Crosses the placenta.",
      "excretion": "Excreted in the urine as metabolites. Half-life is 3-5 hours (biologic half-life is 36-54 hours).",
      "metabolism": "Metabolized in the liver by CYP enzymes."
    },
    "precautions": [
      "Prolonged use can cause HPA axis suppression; must be tapered slowly.",
      "Can mask signs of infection and increase susceptibility to new infections.",
      "Monitor for hyperglycemia, hypertension, and psychiatric disturbances.",
      "Use with caution in patients with peptic ulcer disease, heart failure, or osteoporosis."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "Long-term use",
      "high doses",
      "systemic fungal infections."
    ]
  },
  "bicalutamide": {
    "adverseEffects": {
      "common": [
        "Hot flashes",
        "gynecomastia (breast enlargement)",
        "breast tenderness",
        "fatigue",
        "nausea",
        "diarrhea",
        "constipation",
        "elevated LFTs."
      ],
      "serious": [
        "Hepatotoxicity (liver failure)",
        "interstitial lung disease",
        "glucose intolerance/diabetes."
      ]
    },
    "brandNames": [
      "Casodex"
    ],
    "category": "Antineoplastic Agent",
    "contraindications": [
      "Hypersensitivity",
      "Pregnancy (Category X)."
    ],
    "dose": "50 mg PO once daily.",
    "drugClass": "Antiandrogen, Nonsteroidal",
    "genericName": "Bicalutamide",
    "indications": "Treatment of advanced prostate cancer, used in combination with a luteinizing hormone-releasing hormone (LHRH) agonist (e.g., leuprolide, goserelin).",
    "lactationInfo": "Not indicated for use in women.",
    "moaSteps": [
      "Bicalutamide is a nonsteroidal antiandrogen.",
      "It competitively inhibits the binding of androgens (like testosterone and dihydrotestosterone) to androgen receptors (AR) in the prostate gland.",
      "By blocking the androgen receptor, it prevents androgens from stimulating the growth of prostate cancer cells.",
      "It is used with an LHRH agonist to achieve a complete androgen blockade, as LHRH agonists alone can cause an initial 'flare' of testosterone."
    ],
    "name": "Bicalutamide (Casodex)",
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Food does not affect absorption.",
      "distribution": "Highly protein-bound (~96%).",
      "excretion": "Excreted in urine and feces as metabolites. Long half-life (~5.8 days).",
      "metabolism": "Extensively metabolized in the liver to active and inactive metabolites."
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Cases of severe liver injury and failure have been reported. Monitor liver function tests (LFTs) regularly (baseline, 1 month, then periodically).",
      "Can cause gynecomastia and breast pain.",
      "Monitor for signs of interstitial lung disease (e.g., dyspnea).",
      "Monitor serum glucose in patients with diabetes."
    ],
    "pregnancyCategory": "Category X. Fetal harm is expected.",
    "riskFactors": [
      "Pre-existing liver disease."
    ]
  },
  "bisacodyl": {
    "adverseEffects": {
      "common": [
        "Abdominal cramps",
        "nausea",
        "diarrhea",
        "rectal irritation (suppository)."
      ],
      "serious": [
        "Electrolyte imbalances (with overuse)",
        "fluid depletion",
        "laxative dependence (with chronic use)."
      ]
    },
    "brandNames": [
      "Dulcolax",
      "Correctol"
    ],
    "category": "Laxative",
    "contraindications": [
      "Hypersensitivity",
      "acute surgical abdomen",
      "gastrointestinal obstruction",
      "appendicitis",
      "severe dehydration."
    ],
    "dose": "Oral (constipation): 5-15 mg PO once daily. Rectal (suppository): 10 mg PR once.",
    "drugClass": "Stimulant Laxative",
    "genericName": "Bisacodyl",
    "indications": "Short-term treatment of constipation. Bowel preparation for colonoscopy or surgical procedures.",
    "lactationInfo": "Not excreted in breast milk; considered compatible.",
    "moaSteps": [
      "Bisacodyl is a stimulant laxative that acts directly on the colon.",
      "It increases peristalsis (wave-like muscle contractions) by stimulating the enteric nerves in the colonic mucosa.",
      "It also alters fluid and electrolyte secretion, leading to an accumulation of water and electrolytes in the colonic lumen.",
      "The combination of increased motility and fluid volume results in a bowel movement."
    ],
    "name": "Bisacodyl (Dulcolax)",
    "pharmacokinetics": {
      "absorption": "Minimally absorbed systemically. It is a prodrug, hydrolyzed by intestinal enzymes to its active form.",
      "distribution": "Acts locally in the colon. Onset: 6-12 hours (oral), 15-60 minutes (rectal).",
      "excretion": "Primarily excreted in feces.",
      "metabolism": "Hydrolyzed in the colon."
    },
    "precautions": [
      "Do not use for more than 1 week without medical advice.",
      "Oral tablets are enteric-coated and should not be crushed, chewed, or taken within 1 hour of antacids or milk (can cause premature coating dissolution and gastric irritation).",
      "Chronic use can lead to dependence and electrolyte disturbances."
    ],
    "pregnancyCategory": "Category B. Generally considered safe, but non-pharmacologic methods are preferred.",
    "riskFactors": [
      "Eating disorders",
      "long-term use",
      "GI obstruction."
    ]
  },
  "bisoprolol": {
    "brandNames": [
      "Zebeta"
    ],
    "category": "Antihypertensive",
    "drugClass": "Beta-Blocker (Cardioselective, Beta-1)",
    "genericName": "Bisoprolol",
    "indications": "Management of hypertension. Management of heart failure (off-label in US, approved in Europe).",
    "moaSteps": [
      "Bisoprolol is a highly cardioselective beta-1 adrenergic receptor blocker.",
      "It competitively blocks beta-1 receptors in cardiac muscle.",
      "This leads to decreased heart rate (negative chronotropy), decreased cardiac contractility (negative inotropy), and reduced blood pressure.",
      "It also reduces renin secretion from the kidneys. At low doses, it has minimal effect on beta-2 receptors (in lungs)."
    ],
    "name": "Bisoprolol (Zebeta)",
    "pharmacokinetics": {
      "absorption": "High bioavailability (~80-90%), not affected by food.",
      "distribution": "Moderately protein-bound (~30%).",
      "excretion": "Excreted 50% unchanged in urine and 50% as inactive metabolites. Half-life is 10-12 hours.",
      "metabolism": "Metabolized in the liver (by CYP3A4 and 2D6)."
    },
    "dose": "Hypertension: 2.5-10 mg PO once daily (Max 20 mg). Heart Failure: Initial 1.25 mg PO once daily, titrate slowly every 2 weeks as tolerated to a target of 10 mg daily.",
    "adverseEffects": {
      "common": [
        "Bradycardia (slow heart rate)",
        "fatigue",
        "dizziness",
        "hypotension",
        "headache",
        "cold extremities."
      ],
      "serious": [
        "Heart failure exacerbation",
        "severe bradycardia",
        "AV block",
        "bronchospasm (in high doses or sensitive patients)."
      ]
    },
    "precautions": [
      "BOXED WARNING (Abrupt Discontinuation): Abruptly stopping beta-blocker therapy can cause exacerbation of angina and, in some cases, myocardial infarction. Taper the dose slowly.",
      "Can mask symptoms of hypoglycemia (e.g., tachycardia) in diabetic patients.",
      "Use with caution in patients with asthma or COPD."
    ],
    "contraindications": [
      "Sinus bradycardia",
      "heart block greater than first degree",
      "cardiogenic shock",
      "overt heart failure."
    ],
    "pregnancyCategory": "Category C"
  },
  "brimonidine": {
    "adverseEffects": {
      "common": [
        "Ocular allergic reactions (itching, redness, tearing)",
        "oral dryness",
        "headache",
        "fatigue",
        "drowsiness",
        "blurred vision."
      ],
      "serious": [
        "Hypotension",
        "bradycardia",
        "syncope (fainting)."
      ]
    },
    "brandNames": [
      "Alphagan P (glaucoma)",
      "Lumify (redness)",
      "Mirvaso (topical gel for rosacea)"
    ],
    "category": "Antiglaucoma Agent, Redness Reliever",
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAO inhibitors."
    ],
    "dose": "Glaucoma: 1 drop in affected eye(s) 2-3 times daily. Redness: 1 drop every 6-8 hours as needed.",
    "drugClass": "Alpha-2 Adrenergic Agonist",
    "genericName": "Brimonidine",
    "indications": "Ophthalmic: Lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. (Lumify): Relief of ocular redness. Topical (Mirvaso): Treatment of facial erythema of rosacea.",
    "lactationInfo": "Unknown if excreted in human milk, but systemic absorption occurs. Use with caution.",
    "moaSteps": [
      "Brimonidine is a selective alpha-2 adrenergic agonist.",
      "For glaucoma: It works by a dual mechanism. 1) It decreases the production of aqueous humor (the fluid inside the eye). 2) It increases the outflow of aqueous humor through the uveoscleral pathway.",
      "The combined effect is a reduction in intraocular pressure (IOP).",
      "For redness (Lumify): It selectively constricts venules in the eye to reduce redness, with minimal effect on arterioles (preserving oxygen supply)."
    ],
    "name": "Brimonidine (Alphagan P, Lumify)",
    "pharmacokinetics": {
      "absorption": "Absorbed systemically after ocular instillation. Onset of IOP-lowering effect is within 1 hour.",
      "distribution": "Peak effect in 2 hours.",
      "excretion": "Excreted in the urine as metabolites.",
      "metabolism": "Metabolized by the liver."
    },
    "precautions": [
      "Use with caution in children (risk of CNS depression, apnea, bradycardia). Not recommended for children < 2 years.",
      "Can cause fatigue and drowsiness; caution against driving.",
      "Use with caution in patients with severe cardiovascular disease, depression, or Raynaud's phenomenon."
    ],
    "pregnancyCategory": "Category B",
    "riskFactors": [
      "Children < 2 years",
      "concomitant MAOI use."
    ]
  },
  "budesonide": {
    "brandNames": [
      "Pulmicort (inhalation)",
      "Entocort EC (oral for Crohn's)",
      "Uceris (oral for UC)"
    ],
    "category": "Anti-inflammatory",
    "drugClass": "Corticosteroid",
    "genericName": "Budesonide",
    "indications": "Inhalation (Pulmicort): Maintenance treatment of asthma. Oral (Entocort EC): Treatment of mild to moderate Crohn's disease. Oral (Uceris): Induction of remission in active, mild to moderate ulcerative colitis.",
    "moaSteps": [
      "Budesonide is a potent glucocorticoid.",
      "It binds to intracellular glucocorticoid receptors and modifies gene expression.",
      "This suppresses inflammation by inhibiting the synthesis of pro-inflammatory mediators (prostaglandins, leukotrienes, cytokines) and reducing immune cell activity at the site of action (lungs or GI tract).",
      "Oral formulations (Entocort, Uceris) are designed for delayed release to target the ileum, colon, and rectum."
    ],
    "name": "Budesonide (Pulmicort)",
    "pharmacokinetics": {
      "absorption": "Varies by formulation. Inhaled has low systemic bioavailability. Oral forms are well absorbed but have high first-pass metabolism.",
      "distribution": "Moderately protein-bound (85-90%).",
      "excretion": "Excreted in urine and feces as metabolites.",
      "metabolism": "Oral forms undergo extensive first-pass metabolism (80-90%) in the liver by CYP3A4. This high first-pass effect minimizes systemic steroid side effects compared to other oral steroids."
    },
    "dose": "Asthma (Pulmicort Flexhaler): 180-360 mcg inhaled twice daily. Crohn's (Entocort EC): 9 mg PO once daily in the morning for up to 8 weeks.",
    "adverseEffects": {
      "common": [
        "Inhalation: Oropharyngeal candidiasis (thrush), dysphonia (hoarseness), cough.",
        "Oral: Headache, nausea, abdominal pain, respiratory infection, adrenal suppression (long-term)."
      ],
      "serious": [
        "Adrenal suppression (HPA axis suppression) with long-term or high-dose use.",
        "Increased risk of infection.",
        "Hypercorticism (Cushing's syndrome)",
        "Cataracts/glaucoma."
      ]
    },
    "precautions": [
      "Not for acute bronchospasm; use a SABA (e.g., albuterol) for rescue.",
      "Patients must rinse their mouth with water after inhalation to prevent thrush.",
      "Systemic corticosteroid effects can occur, especially with oral forms or high-dose inhaled forms.",
      "Avoid concomitant use with strong CYP3A4 inhibitors (e.g., grapefruit juice, ketoconazole) as they can increase budesonide levels."
    ],
    "contraindications": [
      "Hypersensitivity.",
      "Primary treatment of status asthmaticus or acute asthma attacks (inhaler)."
    ],
    "pregnancyCategory": "Category B (inhalation) / C (oral)"
  },"bedaquiline": {
    "name": "Bedaquiline (Sirturo)",
    "genericName": "Bedaquiline",
    "brandNames": ["Sirturo"],
    "category": "Antitubercular",
    "drugClass": "Diarylquinoline",
    "indications": "Treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults and children (5 years and older) as part of combination therapy.",
    "moaSteps": [
      "Bedaquiline targets the proton pump of Mycobacterium tuberculosis ATP synthase.",
      "It specifically inhibits the subunit c of the ATP synthase enzyme.",
      "This inhibition prevents the bacteria from generating energy (ATP), leading to bacterial death.",
      "It has a unique mechanism of action compared to other TB drugs, making it effective against resistant strains."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Food increases bioavailability significantly (2-fold).",
      "distribution": "Highly protein-bound (>99%). Widely distributed.",
      "metabolism": "Metabolized in the liver by CYP3A4.",
      "excretion": "Excreted primarily in feces. Extremely long terminal half-life (~5.5 months) due to tissue storage."
    },
    "dose": "Weeks 1-2: 400 mg PO once daily with food. Weeks 3-24: 200 mg PO 3 times per week with food (at least 48 hours between doses).",
    "adverseEffects": {
      "common": ["Nausea", "arthralgia (joint pain)", "headache", "hemoptysis", "chest pain."],
      "serious": ["QT prolongation", "increased mortality risk (observed in trials)", "hepatotoxicity."]
    },
    "precautions": [
      "BOXED WARNING (QT Prolongation): Can prolong the QT interval. Monitor ECG.",
      "BOXED WARNING (Increased Mortality): An increased risk of death was seen in the bedaquiline treatment group in one clinical trial.",
      "Must be taken with food to ensure adequate absorption.",
      "Avoid alcohol and other hepatotoxic drugs."
    ],
    "contraindications": [
      "Hypersensitivity to bedaquiline."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Concentrates in breast milk; generally not recommended."
  },
  "belatacept": {
    "name": "Belatacept (Nulojix)",
    "genericName": "Belatacept",
    "brandNames": ["Nulojix"],
    "category": "Immunosuppressant",
    "drugClass": "Selective T-cell Costimulation Blocker",
    "indications": "Prophylaxis of organ rejection in adult patients receiving a kidney transplant (used in combination with basiliximab, mycophenolate mofetil, and corticosteroids).",
    "moaSteps": [
      "Belatacept is a fusion protein that binds to CD80 and CD86 receptors on antigen-presenting cells.",
      "This binding blocks the interaction between CD80/86 and CD28 on T-lymphocytes.",
      "Blocking this costimulatory signal inhibits T-cell activation and proliferation.",
      "This suppresses the immune response responsible for organ rejection."
    ],
    "pharmacokinetics": {
      "absorption": "Administered as an IV infusion.",
      "distribution": "Confined to the vascular space.",
      "metabolism": "Degraded into peptides and amino acids.",
      "excretion": "N/A. Half-life is ~8-10 days."
    },
    "dose": "Initial phase: 10 mg/kg IV on Day 1, 5, 14, 28, then end of Week 8 and 12. Maintenance: 5 mg/kg IV every 4 weeks starting at Week 16.",
    "adverseEffects": {
      "common": ["Anemia", "diarrhea", "urinary tract infection", "peripheral edema", "constipation.", "fever."],
      "serious": ["Post-transplant lymphoproliferative disorder (PTLD)", "progressive multifocal leukoencephalopathy (PML)", "serious infections."]
    },
    "precautions": [
      "BOXED WARNING (PTLD): Increased risk of Post-Transplant Lymphoproliferative Disorder (PTLD), predominantly involving the CNS. Use only in patients who are EBV seropositive.",
      "BOXED WARNING (Infections): Increased susceptibility to infection and malignancy.",
      "Avoid live vaccines."
    ],
    "contraindications": [
      "Patients who are Epstein-Barr Virus (EBV) seronegative or with unknown serostatus."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "belimumab": {
    "name": "Belimumab (Benlysta)",
    "genericName": "Belimumab",
    "brandNames": ["Benlysta"],
    "category": "Immunosuppressant",
    "drugClass": "Monoclonal Antibody, BLyS Inhibitor",
    "indications": "Treatment of active systemic lupus erythematosus (SLE) and active lupus nephritis in patients receiving standard therapy.",
    "moaSteps": [
      "Belimumab is a human monoclonal antibody.",
      "It specifically binds to soluble B-lymphocyte stimulator (BLyS).",
      "BLyS is a survival factor for B-cells. By binding to BLyS, belimumab prevents it from binding to receptors on B-cells.",
      "This inhibits the survival of B-cells, including autoreactive B-cells, and reduces the differentiation of B-cells into immunoglobulin-producing plasma cells."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV or SC. SC bioavailability ~80%.",
      "distribution": "Widely distributed.",
      "metabolism": "Degraded by proteolytic enzymes.",
      "excretion": "N/A. Half-life is ~19 days."
    },
    "dose": "SLE (IV): 10 mg/kg every 2 weeks for first 3 doses, then every 4 weeks. (SC): 200 mg once weekly.",
    "adverseEffects": {
      "common": ["Nausea", "diarrhea", "fever", "nasopharyngitis", "bronchitis", "insomnia.", "injection site reactions."],
      "serious": ["Serious infections", "hypersensitivity reactions/anaphylaxis", "depression and suicidality", "malignancy."]
    },
    "precautions": [
      "Serious infections (bacterial, fungal, viral) have occurred.",
      "Depression and suicidal ideation have been reported. Monitor patients for mood changes.",
      "Live vaccines should not be given concurrently.",
      "Not recommended in combination with other biologics (e.g., rituximab)."
    ],
    "contraindications": [
      "Hypersensitivity to belimumab."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk (animal studies); use with caution."
  },
  "bempedoic-acid": {
    "name": "Bempedoic Acid (Nexletol)",
    "genericName": "Bempedoic Acid",
    "brandNames": ["Nexletol", "Nexlizet (with ezetimibe)"],
    "category": "Antihyperlipidemic",
    "drugClass": "ATP Citrate Lyase (ACL) Inhibitor",
    "indications": "Adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.",
    "moaSteps": [
      "Bempedoic acid is a prodrug activated in the liver.",
      "It inhibits adenosine triphosphate-citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway.",
      "Inhibition of ACL reduces cholesterol synthesis in the liver.",
      "This leads to upregulation of LDL receptors and increased clearance of LDL-C from the blood."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Not affected by food.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Activated in the liver by ACSVL1; metabolized by glucuronidation.",
      "excretion": "Excreted in urine and feces. Half-life is ~21 hours."
    },
    "dose": "180 mg PO once daily.",
    "adverseEffects": {
      "common": ["Upper respiratory tract infection", "muscle spasms", "hyperuricemia (high uric acid)", "back pain.", "abdominal pain."],
      "serious": ["Tendon rupture", "gout flare."]
    },
    "precautions": [
      "**Hyperuricemia:** Can increase serum uric acid levels and precipitate gout. Monitor uric acid.",
      "**Tendon Rupture:** Increased risk of tendon rupture or injury, typically involving the Achilles tendon.",
      "Avoid concomitant use with simvastatin (>20 mg) or pravastatin (>40 mg) due to increased risk of myopathy."
    ],
    "contraindications": [
      "Hypersensitivity."
    ],
    "pregnancyCategory": "Category C (likely)",
    "lactationInfo": "Not recommended."
  },
  "bendamustine": {
    "name": "Bendamustine (Bendeka, Treanda)",
    "genericName": "Bendamustine",
    "brandNames": ["Bendeka", "Treanda", "Belrapzo"],
    "category": "Antineoplastic Agent",
    "drugClass": "Alkylating Agent",
    "indications": "Treatment of chronic lymphocytic leukemia (CLL). Treatment of indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab.",
    "moaSteps": [
      "Bendamustine is a bifunctional alkylating agent with a benzimidazole ring.",
      "It forms covalent bonds (cross-links) between DNA strands (interstrand) and within DNA strands (intrastrand).",
      "These cross-links disrupt DNA structure and function, inhibiting DNA synthesis and repair.",
      "This leads to cell cycle arrest and apoptosis (cell death)."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV only.",
      "distribution": "Widely distributed. Highly protein-bound (~95%).",
      "metabolism": "Metabolized in the liver primarily by hydrolysis; minor CYP1A2 pathway.",
      "excretion": "Excreted in feces and urine. Half-life is ~40 minutes."
    },
    "dose": "CLL: 100 mg/m IV on Days 1 and 2 of a 28-day cycle. NHL: 120 mg/m IV on Days 1 and 2 of a 21-day cycle.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "fatigue", "pyrexia (fever)", "diarrhea", "constipation", "anorexia."],
      "serious": ["Myelosuppression (severe neutropenia, thrombocytopenia)", "infections", "infusion reactions", "tumor lysis syndrome", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "High risk of myelosuppression; monitor CBC frequently.",
      "Risk of serious infections; consider prophylaxis.",
      "Infusion reactions and anaphylaxis can occur.",
      "Tumor lysis syndrome can occur; ensure hydration."
    ],
    "contraindications": [
      "Hypersensitivity to bendamustine."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "benzoyl-peroxide": {
    "name": "Benzoyl Peroxide",
    "genericName": "Benzoyl Peroxide",
    "brandNames": ["PanOxyl", "Benzac", "Clean & Clear", "Neutrogena On-the-Spot"],
    "category": "Antiacne",
    "drugClass": "Keratolytic, Antimicrobial",
    "indications": "Topical treatment of mild to moderate acne vulgaris.",
    "moaSteps": [
      "Benzoyl peroxide releases free-radical oxygen species which oxidizes bacterial proteins.",
      "It has bactericidal activity against *Cutibacterium acnes* (formerly *Propionibacterium acnes*).",
      "It also possesses mild keratolytic properties (exfoliates skin), helping to unclog pores.",
      "It also has a sebostatic effect, reducing sebum production."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed through the skin where it is converted to benzoic acid.",
      "distribution": "Localized to skin follicles.",
      "metabolism": "Metabolized in the skin to benzoic acid.",
      "excretion": "Excreted in urine as benzoate."
    },
    "dose": "Apply to affected areas 1-2 times daily. Start with lower concentration (2.5% or 5%) to minimize irritation.",
    "adverseEffects": {
      "common": ["Dry skin", "erythema (redness)", "peeling", "stinging/burning sensation.", "itching."],
      "serious": ["Severe allergic contact dermatitis", "facial swelling."]
    },
    "precautions": [
      "Can bleach hair and colored fabrics (towels, pillowcases).",
      "Avoid excessive sun exposure; use sunscreen.",
      "Avoid contact with eyes and mucous membranes.",
      "Skin irritation is common initially; reduce frequency if severe."
    ],
    "contraindications": [
      "Hypersensitivity to benzoyl peroxide."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in breast milk; use with caution."
  },
  "bepotastine": {
    "name": "Bepotastine (Bepreve)",
    "genericName": "Bepotastine Besilate",
    "brandNames": ["Bepreve"],
    "category": "Antihistamine, Ophthalmic",
    "drugClass": "H1-Receptor Antagonist, Mast Cell Stabilizer",
    "indications": "Treatment of itching associated with allergic conjunctivitis.",
    "moaSteps": [
      "Bepotastine acts as a direct antagonist of the H1 histamine receptor.",
      "By blocking histamine binding, it reduces itching and redness.",
      "It also inhibits the release of histamine from mast cells (mast cell stabilizer activity).",
      "It inhibits the migration of eosinophils into inflamed tissues."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption after topical ocular use.",
      "distribution": "Low protein binding (~55%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in urine."
    },
    "dose": "Instill 1 drop into the affected eye(s) twice daily.",
    "adverseEffects": {
      "common": ["Mild taste alteration (dysgeusia)", "eye irritation", "headache", "nasopharyngitis."],
      "serious": ["Hypersensitivity reactions (rare)."]
    },
    "precautions": [
      "Do not instill while wearing contact lenses.",
      "Remove contacts before use and wait 10 minutes before reinserting.",
      "Not for the treatment of contact lens-related irritation."
    ],
    "contraindications": [
      "Hypersensitivity to bepotastine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "besifloxacin": {
    "name": "Besifloxacin (Besivance)",
    "genericName": "Besifloxacin",
    "brandNames": ["Besivance"],
    "category": "Antibiotic, Ophthalmic",
    "drugClass": "Fluoroquinolone Antibiotic",
    "indications": "Treatment of bacterial conjunctivitis caused by susceptible organisms.",
    "moaSteps": [
      "Besifloxacin is a fluoroquinolone antibiotic.",
      "It inhibits bacterial DNA gyrase and topoisomerase IV.",
      "Inhibition of these enzymes prevents bacterial DNA replication, transcription, and repair.",
      "This leads to bacterial cell death (bactericidal)."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic absorption is negligible after topical ocular administration.",
      "distribution": "Acts locally in the eye.",
      "metabolism": "N/A",
      "excretion": "N/A"
    },
    "dose": "Instill 1 drop in the affected eye(s) 3 times daily for 7 days.",
    "adverseEffects": {
      "common": ["Eye redness", "blurred vision", "eye pain", "eye irritation", "headache."],
      "serious": ["Hypersensitivity reactions (rare)."]
    },
    "precautions": [
      "Prolonged use may result in overgrowth of non-susceptible organisms, including fungi.",
      "Do not wear contact lenses if you have signs of bacterial conjunctivitis.",
      "Avoid contaminating the applicator tip."
    ],
    "contraindications": [
      "Hypersensitivity to besifloxacin or other quinolones."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Systemic absorption is minimal; likely safe."
  },
  "betaxolol": {
    "name": "Betaxolol (Betoptic, Kerlone)",
    "genericName": "Betaxolol",
    "brandNames": ["Betoptic S (ophthalmic)", "Kerlone (oral)"],
    "category": "Antiglaucoma, Antihypertensive",
    "drugClass": "Beta-Blocker (Cardioselective)",
    "indications": "Ophthalmic: Treatment of ocular hypertension and chronic open-angle glaucoma. Oral: Management of hypertension.",
    "moaSteps": [
      "Betaxolol is a cardioselective beta-1 adrenergic receptor blocker.",
      "Ophthalmic: Reduces intraocular pressure (IOP) primarily by reducing the production of aqueous humor.",
      "Oral: Lowers blood pressure by decreasing heart rate and cardiac output (beta-1 blockade).",
      "Being cardioselective, it has less effect on pulmonary beta-2 receptors than non-selective beta-blockers (like timolol)."
    ],
    "pharmacokinetics": {
      "absorption": "Ophthalmic: Absorbed systemically. Oral: Well absorbed (~100%).",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine. Half-life is ~14-22 hours."
    },
    "dose": "Ophthalmic: 1 drop of 0.25% suspension twice daily. Oral: 10-20 mg PO once daily.",
    "adverseEffects": {
      "common": ["(Ocular) Transient stinging", "tearing", "blurred vision.", "(Systemic) Bradycardia", "dizziness", "fatigue."],
      "serious": ["Heart block", "bronchospasm (less likely than timolol but possible)", "heart failure."]
    },
    "precautions": [
      "Ophthalmic drops are absorbed systemically and can cause cardiac/respiratory side effects.",
      "Use with caution in patients with heart failure or heart block.",
      "Although cardioselective, use with caution in patients with asthma/COPD.",
      "Can mask symptoms of hypoglycemia."
    ],
    "contraindications": [
      "Sinus bradycardia",
      "greater than first-degree heart block",
      "cardiogenic shock",
      "overt cardiac failure."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "bethanechol": {
    "name": "Bethanechol (Urecholine)",
    "genericName": "Bethanechol",
    "brandNames": ["Urecholine"],
    "category": "Urinary Stimulant",
    "drugClass": "Cholinergic Agonist (Muscarinic)",
    "indications": "Treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention. Treatment of neurogenic atony of the bladder.",
    "moaSteps": [
      "Bethanechol is a muscarinic receptor agonist.",
      "It selectively stimulates muscarinic receptors in the parasympathetic nervous system.",
      "It increases the tone of the detrusor muscle of the bladder.",
      "This produces a contraction sufficiently strong to initiate micturition (urination) and empty the bladder."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly absorbed orally (requires higher doses).",
      "distribution": "Does not cross the blood-brain barrier.",
      "metabolism": "Not hydrolyzed by cholinesterase (long duration).",
      "excretion": "Excretion mechanism unknown."
    },
    "dose": "10-50 mg PO 3 to 4 times daily. Take on an empty stomach.",
    "adverseEffects": {
      "common": ["Abdominal cramps", "diarrhea", "nausea", "salivation", "flushing", "sweating.", "urinary urgency."],
      "serious": ["Bronchoconstriction/asthma attack", "bradycardia", "hypotension", "seizures."]
    },
    "precautions": [
      "Take on an empty stomach (1 hour before or 2 hours after meals) to avoid nausea/vomiting.",
      "Can cause reflex tachycardia or severe hypotension.",
      "Contraindicated in conditions where increased muscular activity of the GI or urinary tract could be harmful."
    ],
    "contraindications": [
      "Hyperthyroidism",
      "peptic ulcer",
      "asthma",
      "bradycardia",
      "hypotension",
      "coronary artery disease",
      "epilepsy",
      "parkinsonism",
      "mechanical obstruction of GI/urinary tract."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in breast milk; use with caution."
  },
  "bexarotene": {
    "name": "Bexarotene (Targretin)",
    "genericName": "Bexarotene",
    "brandNames": ["Targretin"],
    "category": "Antineoplastic Agent",
    "drugClass": "Retinoid (RXR Agonist)",
    "indications": "Treatment of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy.",
    "moaSteps": [
      "Bexarotene selectively binds to and activates Retinoid X Receptors (RXRs).",
      "Activated RXRs function as transcription factors that regulate the expression of genes controlling cellular differentiation and proliferation.",
      "It induces cell cycle arrest and apoptosis in malignant cells.",
      "It also inhibits the growth of tumor cell lines of hematopoietic and squamous cell origin."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed with a fat-containing meal.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted mainly in the bile/feces. Half-life is ~7 hours."
    },
    "dose": "300 mg/m/day PO once daily with a meal.",
    "adverseEffects": {
      "common": ["Hyperlipidemia (extremely common)", "headache", "asthenia", "rash", "dry skin", "nausea.", "hypothyroidism."],
      "serious": ["Severe hypertriglyceridemia (risk of pancreatitis)", "hypothyroidism (central)", "leukopenia", "liver damage."]
    },
    "precautions": [
      "**Major lipid abnormalities:** Causes severe hyperlipidemia. Monitor lipids frequently. Treat with statins/fibrates.",
      "**Hypothyroidism:** Induces central hypothyroidism. Monitor TSH and T4. Supplement with levothyroxine.",
      "**Pancreatitis:** Risk associated with high triglycerides.",
      "Avoid strong CYP3A4 inhibitors."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category X)**."
    ],
    "pregnancyCategory": "Category X. Causes fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "bictegravir": {
    "name": "Bictegravir (in Biktarvy)",
    "genericName": "Bictegravir",
    "brandNames": ["Biktarvy (combination only)"],
    "category": "Antiretroviral",
    "drugClass": "Integrase Strand Transfer Inhibitor (INSTI)",
    "indications": "Treatment of HIV-1 infection in adults and pediatric patients (as part of the fixed-dose combination Biktarvy).",
    "moaSteps": [
      "Bictegravir binds to the HIV-1 integrase enzyme.",
      "It blocks the strand transfer step of viral DNA integration into the host cell genome.",
      "By preventing integration, the proviral DNA cannot be formed, halting the production of new viral particles.",
      "It has a high barrier to resistance."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Can be taken with or without food.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Metabolized by CYP3A4 and UGT1A1.",
      "excretion": "Excreted in feces and urine. Half-life is ~17 hours."
    },
    "dose": "50 mg PO once daily (component of Biktarvy).",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "headache", "fatigue."],
      "serious": ["Immune reconstitution syndrome", "lactic acidosis (rare, class effect)", "severe hepatomegaly (rare, class effect)."]
    },
    "precautions": [
      "**Drug Interactions:** Polyvalent cations (antacids, iron, calcium) can bind bictegravir and reduce absorption. Separate dosing.",
      "Monitor for immune reconstitution syndrome upon initiation.",
      "Caution in severe hepatic impairment."
    ],
    "contraindications": [
      "Co-administration with dofetilide or rifampin."
    ],
    "pregnancyCategory": "Category B (generally safe).",
    "lactationInfo": "Breastfeeding not recommended for HIV+ mothers to avoid transmission."
  },
  "bimatoprost": {
    "name": "Bimatoprost (Lumigan, Latisse)",
    "genericName": "Bimatoprost",
    "brandNames": ["Lumigan (glaucoma)", "Latisse (eyelash growth)"],
    "category": "Antiglaucoma, Cosmetic",
    "drugClass": "Prostaglandin Analog",
    "indications": "Lumigan: Reduction of elevated intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension. Latisse: Treatment of hypotrichosis (inadequate eyelashes).",
    "moaSteps": [
      "Bimatoprost is a synthetic prostamide analog.",
      "It lowers intraocular pressure (IOP) by increasing the outflow of aqueous humor.",
      "It primarily enhances outflow through the uveoscleral pathway and also the trabecular meshwork.",
      "For eyelashes: It prolongs the anagen (growth) phase of the hair follicle."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed through the cornea/skin. Systemic levels are low.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the eye and liver.",
      "excretion": "Excreted in urine and feces."
    },
    "dose": "Glaucoma: 1 drop in affected eye(s) once daily in the evening. Eyelashes: Apply to upper eyelid margin once nightly.",
    "adverseEffects": {
      "common": ["Conjunctival hyperemia (redness)", "eye itching", "growth of eyelashes", "dry eye.", "skin darkening (eyelid)."],
      "serious": ["Permanent brown pigmentation of the iris", "macular edema", "iritis/uveitis."]
    },
    "precautions": [
      "**Iris Pigmentation:** Can cause permanent brown discoloration of the iris.",
      "**Eyelid Skin Darkening:** Can darken eyelid skin (reversible).",
      "Do not apply to lower lid (for Latisse).",
      "Remove contact lenses before use."
    ],
    "contraindications": [
      "Hypersensitivity to bimatoprost."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "biperiden": {
    "name": "Biperiden (Akineton)",
    "genericName": "Biperiden",
    "brandNames": ["Akineton"],
    "category": "Antiparkinsonian",
    "drugClass": "Anticholinergic",
    "indications": "Adjunctive treatment of all forms of Parkinson's disease. Control of extrapyramidal disorders induced by CNS drugs (neuroleptics).",
    "moaSteps": [
      "Biperiden is a centrally acting anticholinergic agent.",
      "It competitively blocks muscarinic acetylcholine receptors in the CNS.",
      "This helps restore the balance between dopamine (deficient) and acetylcholine (relative excess) in the striatum.",
      "It effectively reduces tremor and rigidity."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine. Half-life is ~18-24 hours."
    },
    "dose": "Parkinson's: 2 mg PO 3-4 times daily. Drug-induced EPS: 2 mg PO 1-3 times daily.",
    "adverseEffects": {
      "common": ["Dry mouth", "blurred vision", "drowsiness", "constipation", "urinary retention."],
      "serious": ["Paralytic ileus", "toxic psychosis/confusion", "glaucoma exacerbation."]
    },
    "precautions": [
      "High anticholinergic burden; avoid in elderly if possible (risk of confusion/falls).",
      "Caution in patients with narrow-angle glaucoma, BPH, or urinary retention.",
      "Can cause drowsiness; caution against driving."
    ],
    "contraindications": [
      "Hypersensitivity",
      "narrow-angle glaucoma",
      "bowel obstruction",
      "megacolon."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "bismuth-subsalicylate": {
    "name": "Bismuth Subsalicylate (Pepto-Bismol)",
    "genericName": "Bismuth Subsalicylate",
    "brandNames": ["Pepto-Bismol", "Kaopectate"],
    "category": "Antidiarrheal, Antacid",
    "drugClass": "Salicylate",
    "indications": "Treatment of diarrhea, including traveler's diarrhea. Relief of upset stomach, indigestion, heartburn, and nausea. Part of H. pylori eradication regimens.",
    "moaSteps": [
      "Bismuth has antimicrobial activity against bacterial and viral pathogens in the GI tract.",
      "It also has antisecretory properties, reducing fluid and electrolyte loss.",
      "The salicylate moiety provides anti-inflammatory effects.",
      "It binds to enterotoxins (e.g., from E. coli)."
    ],
    "pharmacokinetics": {
      "absorption": "Bismuth is minimally absorbed (<1%). Salicylate is well absorbed (>90%).",
      "distribution": "Bismuth acts locally. Salicylate distributes widely.",
      "metabolism": "Hydrolyzed in the stomach to bismuth oxychloride and salicylic acid.",
      "excretion": "Bismuth excreted in feces. Salicylate excreted in urine."
    },
    "dose": "524 mg PO every 30-60 minutes as needed. Max 8 doses/24 hours.",
    "adverseEffects": {
      "common": ["Black tongue (harmless)", "black stools (harmless)", "constipation."],
      "serious": ["Salicylate toxicity (tinnitus, hearing loss)", "Reye's syndrome (in children/teens with viral illness)."]
    },
    "precautions": [
      "**Black Stools:** Can cause harmless darkening of tongue and stool; do not confuse with melena (GI bleeding).",
      "**Reye's Syndrome:** Do not use in children/teens recovering from chickenpox or flu.",
      "Contains salicylate; caution in patients taking aspirin or anticoagulants."
    ],
    "contraindications": [
      "Hypersensitivity to salicylates (aspirin)",
      "bleeding ulcers",
      "bleeding disorders."
    ],
    "pregnancyCategory": "Category C (D in 3rd trimester due to salicylate).",
    "lactationInfo": "Salicylates excreted in milk; use with caution."
  },
  "bleomycin": {
    "name": "Bleomycin",
    "genericName": "Bleomycin",
    "brandNames": ["Blenoxane"],
    "category": "Antineoplastic Agent",
    "drugClass": "Antitumor Antibiotic",
    "indications": "Treatment of squamous cell carcinomas, lymphomas (Hodgkin's and non-Hodgkin's), and testicular carcinoma. Malignant pleural effusion (sclerosing agent).",
    "moaSteps": [
      "Bleomycin is a glycopeptide antibiotic.",
      "It binds to DNA and chelates iron ions, producing free radicals.",
      "These free radicals cause single- and double-strand breaks in DNA (scission).",
      "This inhibits DNA synthesis and leads to cell cycle arrest (G2 phase) and apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV, IM, SC, or intrapleural.",
      "distribution": "Widely distributed, especially to skin and lungs (which lack the enzyme to break it down).",
      "metabolism": "Degraded by hydrolase enzymes in tissues (low in skin/lung).",
      "excretion": "Excreted in urine. Half-life is ~2-4 hours."
    },
    "dose": "10-20 units/m IV, IM, or SC once or twice weekly. Cumulative lifetime dose usually limited to 400 units.",
    "adverseEffects": {
      "common": ["Skin reactions (hyperpigmentation, erythema, thickening)", "alopecia", "stomatitis", "fever/chills (acute reaction)."],
      "serious": ["**Pulmonary Fibrosis** (dose-limiting, potentially fatal)", "anaphylaxis (idiosyncratic reaction in lymphoma)."]
    },
    "precautions": [
      "BOXED WARNING (Pulmonary Toxicity): Can cause severe pulmonary fibrosis. Risk increases with age and cumulative dose >400 units. Monitor pulmonary function.",
      "BOXED WARNING (Idiosyncratic Reaction): Severe reaction (hypotension, fever, confusion) in lymphoma patients. Test dose recommended.",
      "Renal impairment increases risk of toxicity."
    ],
    "contraindications": [
      "Hypersensitivity",
      "existing pulmonary fibrosis."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Not recommended."
  },
  "bortezomib": {
    "name": "Bortezomib (Velcade)",
    "genericName": "Bortezomib",
    "brandNames": ["Velcade"],
    "category": "Antineoplastic Agent",
    "drugClass": "Proteasome Inhibitor",
    "indications": "Treatment of multiple myeloma. Treatment of mantle cell lymphoma.",
    "moaSteps": [
      "Bortezomib is a reversible inhibitor of the 26S proteasome.",
      "The proteasome is responsible for degrading cellular proteins.",
      "Inhibition leads to the accumulation of pro-apoptotic proteins (like Bax) and disruption of cell signaling pathways (like NF-kappaB).",
      "This induces cell cycle arrest and apoptosis in cancer cells."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV or SC.",
      "distribution": "Widely distributed. High protein binding.",
      "metabolism": "Metabolized in the liver by CYP3A4, 2C19, and 1A2.",
      "excretion": "Excreted as metabolites. Half-life is ~9-15 hours."
    },
    "dose": "1.3 mg/m IV or SC twice weekly for 2 weeks, followed by a 10-day rest period.",
    "adverseEffects": {
      "common": ["Peripheral neuropathy (very common)", "fatigue", "nausea", "diarrhea", "thrombocytopenia", "anemia."],
      "serious": ["Severe peripheral neuropathy", "cardiac toxicity (heart failure)", "pulmonary toxicity", "Tumor Lysis Syndrome."]
    },
    "precautions": [
      "**Peripheral Neuropathy:** Severe sensory and motor neuropathy can occur. Dose adjustment or subcutaneous administration helps.",
      "Hypotension can occur.",
      "Reactivation of Herpes Zoster (shingles) is common; antiviral prophylaxis (acyclovir) is recommended."
    ],
    "contraindications": [
      "Hypersensitivity to bortezomib, boron, or mannitol."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Not recommended."
  },
  "bosentan": {
    "name": "Bosentan (Tracleer)",
    "genericName": "Bosentan",
    "brandNames": ["Tracleer"],
    "category": "Pulmonary Hypertension Agent",
    "drugClass": "Endothelin Receptor Antagonist",
    "indications": "Treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and decrease clinical worsening.",
    "moaSteps": [
      "Bosentan blocks both endothelin A (ET-A) and endothelin B (ET-B) receptors.",
      "Endothelin-1 is a potent vasoconstrictor that is elevated in PAH.",
      "By blocking these receptors, bosentan reduces pulmonary vascular resistance and inhibits vascular remodeling.",
      "This lowers blood pressure in the lungs and reduces strain on the right heart."
    ],
    "pharmacokinetics": {
      "absorption": "Bioavailability ~50%.",
      "distribution": "Highly protein-bound (>98%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C9 and CYP3A4 (auto-inducer).",
      "excretion": "Excreted in feces via bile. Half-life is ~5 hours."
    },
    "dose": "Initial: 62.5 mg PO twice daily for 4 weeks. Maintenance: 125 mg PO twice daily.",
    "adverseEffects": {
      "common": ["Headache", "flushing", "nasopharyngitis", "edema (fluid retention)."],
      "serious": ["Hepatotoxicity (liver injury)", "decreased sperm count", "anemia."]
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Can cause significant liver enzyme elevations. Monitor LFTs monthly.",
      "BOXED WARNING (Embryo-Fetal Toxicity): Likely to cause major birth defects. REMS program required. Negative pregnancy test required monthly.",
      "Decreases efficacy of hormonal contraceptives.",
      "Can cause fluid retention."
    ],
    "contraindications": [
      "Pregnancy",
      "concomitant use with cyclosporine or glyburide."
    ],
    "pregnancyCategory": "Category X",
    "lactationInfo": "Not recommended."
  },
  "brentuximab-vedotin": {
    "name": "Brentuximab vedotin (Adcetris)",
    "genericName": "Brentuximab vedotin",
    "brandNames": ["Adcetris"],
    "category": "Antineoplastic Agent",
    "drugClass": "Antibody-Drug Conjugate",
    "indications": "Treatment of classical Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL) after failure of other treatments.",
    "moaSteps": [
      "Brentuximab vedotin is an antibody-drug conjugate (ADC).",
      "The antibody portion binds to CD30 on the surface of cancer cells.",
      "The complex is internalized into the cell.",
      "Inside the cell, the linker is cleaved, releasing the cytotoxic agent monomethyl auristatin E (MMAE).",
      "MMAE disrupts the microtubule network, inducing cell cycle arrest and apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV.",
      "distribution": "MMAE is moderately protein-bound.",
      "metabolism": "MMAE is metabolized by CYP3A4.",
      "excretion": "Excreted in feces. Half-life is ~4-6 days."
    },
    "dose": "1.8 mg/kg IV every 3 weeks.",
    "adverseEffects": {
      "common": ["Peripheral neuropathy", "fatigue", "nausea", "diarrhea", "neutropenia", "upper respiratory infection."],
      "serious": ["Severe peripheral neuropathy", "severe neutropenia", "progressive multifocal leukoencephalopathy (PML)", "tumor lysis syndrome."]
    },
    "precautions": [
      "BOXED WARNING (PML): Fatal cases of JC virus infection resulting in PML have been reported.",
      "**Peripheral Neuropathy:** Sensory and motor neuropathy is common and can be severe. Dose reduction or discontinuation may be needed.",
      "Monitor CBC for severe neutropenia.",
      "Contraindicated with concomitant bleomycin (pulmonary toxicity)."
    ],
    "contraindications": [
      "Concomitant use with bleomycin."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Not recommended."
  },
  "brexpiprazole": {
    "name": "Brexpiprazole (Rexulti)",
    "genericName": "Brexpiprazole",
    "brandNames": ["Rexulti"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second-Generation)",
    "indications": "Adjunctive treatment of major depressive disorder (MDD). Treatment of schizophrenia.",
    "moaSteps": [
      "Brexpiprazole acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors.",
      "It acts as an antagonist at serotonin 5-HT2A and noradrenergic alpha-1B/2C receptors.",
      "This modulation helps balance dopamine and serotonin levels, reducing symptoms of schizophrenia and depression with potentially fewer side effects like akathisia compared to full antagonists."
    ],
    "pharmacokinetics": {
      "absorption": "High bioavailability (~95%). Not affected by food.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Metabolized by CYP3A4 and CYP2D6.",
      "excretion": "Excreted in urine and feces. Half-life is ~91 hours."
    },
    "dose": "MDD Adjunct: 0.5-1 mg PO once daily, titrate to 2-3 mg. Schizophrenia: 1 mg PO once daily, titrate to 2-4 mg.",
    "adverseEffects": {
      "common": ["Weight gain", "akathisia (restlessness)", "headache", "nasopharyngitis."],
      "serious": ["Suicidal thoughts (in young adults)", "Neuroleptic Malignant Syndrome (NMS)", "Tardive Dyskinesia", "metabolic changes (hyperglycemia/dyslipidemia)."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Increased risk of suicidal thoughts and behavior in young adults.",
      "BOXED WARNING (Elderly with Dementia): Increased risk of death.",
      "Monitor for metabolic changes (weight, glucose, lipids).",
      "Dose adjustments needed for poor CYP2D6 metabolizers."
    ],
    "contraindications": [
      "Hypersensitivity to brexpiprazole."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "bupropion": {
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "insomnia",
        "headache",
        "agitation",
        "dizziness",
        "nausea/vomiting",
        "constipation",
        "tremor.",
        "weight loss."
      ],
      "serious": [
        "Seizures",
        "hypertension",
        "activation of mania/hypomania",
        "suicidal thoughts and behaviors."
      ]
    },
    "brandNames": [
      "Wellbutrin SR",
      "Wellbutrin XL",
      "Zyban"
    ],
    "category": "Antidepressant, Smoking Cessation Aid",
    "contraindications": [
      "Seizure disorder.",
      "Current or prior diagnosis of bulimia or anorexia nervosa (higher risk of seizures).",
      "Abrupt discontinuation of alcohol, benzodiazepines, or other sedatives.",
      "Concomitant use with MAOIs (within 14 days)."
    ],
    "dose": "MDD (XL): 150-300 mg PO once daily. (SR): 150 mg PO twice daily. Smoking Cessation: 150 mg PO once daily for 3 days, then 150 mg PO twice daily.",
    "drugClass": "Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)",
    "genericName": "Bupropion",
    "indications": "Treatment of major depressive disorder (MDD). Prevention of seasonal affective disorder (SAD). (Zyban): Aid to smoking cessation.",
    "lactationInfo": "Excreted in breast milk; use with caution.",
    "moaSteps": [
      "Bupropion's mechanism is not fully understood.",
      "It is a relatively weak inhibitor of the neuronal reuptake of norepinephrine (NE) and dopamine (DA).",
      "It does not significantly inhibit serotonin reuptake (unlike SSRIs).",
      "The antidepressant and smoking cessation effects are presumed to be related to its noradrenergic and/or dopaminergic actions."
    ],
    "name": "Bupropion (Wellbutrin, Zyban)",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Peak concentrations vary by formulation (SR, XL).",
      "distribution": "Widely distributed. Moderately protein-bound (~84%).",
      "excretion": "Excreted in the urine as metabolites. Half-life is long (~21 hours).",
      "metabolism": "Extensively metabolized in the liver (primarily by CYP2B6) to several active metabolites (e.g., hydroxybupropion)."
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults (18-24). Monitor closely.",
      "BOXED WARNING (Smoking Cessation): Serious neuropsychiatric events (depression, suicidal ideation, psychosis) have been reported in patients taking bupropion for smoking cessation. Monitor patients.",
      "**Dose-dependent risk of seizures.** Do not exceed maximum recommended doses (e.g., 450 mg/day for Wellbutrin XL).",
      "Can cause or worsen hypertension; monitor blood pressure."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "History of seizures",
      "eating disorders",
      "head trauma",
      "high doses."
    ]
  },
  "buspirone": {
    "adverseEffects": {
      "common": [
        "Dizziness",
        "nausea",
        "headache",
        "nervousness",
        "lightheadedness",
        "excitement."
      ],
      "serious": [
        "Serotonin syndrome (rare, especially with other serotonergic drugs)",
        "akathisia."
      ]
    },
    "brandNames": [
      "Buspar"
    ],
    "category": "Anxiolytic",
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (within 14 days) due to risk of hypertensive reactions."
    ],
    "dose": "Initial: 7.5 mg PO twice daily. Titrate up to a max of 60 mg/day in 2-3 divided doses.",
    "drugClass": "Anxiolytic, Azapirone",
    "genericName": "Buspirone",
    "indications": "Management of anxiety disorders. Short-term relief of the symptoms of anxiety.",
    "lactationInfo": "Unknown if excreted in human milk; use with caution.",
    "moaSteps": [
      "Buspirone's mechanism is distinct from benzodiazepines.",
      "It is a high-affinity partial agonist for serotonin 5-HT1A receptors.",
      "It also has moderate affinity for dopamine D2 receptors (acts as an antagonist).",
      "It lacks the anticonvulsant, sedative, and muscle relaxant properties of benzodiazepines.",
      "The anxiolytic effect is delayed, often taking 2-4 weeks to become apparent."
    ],
    "name": "Buspirone (Buspar)",
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed, but undergoes extensive first-pass metabolism (~95%). Bioavailability is low (~4%). Grapefruit juice increases levels.",
      "distribution": "Highly protein-bound (~95%).",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~2-3 hours.",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4, to an active metabolite (1-PP)."
    },
    "precautions": [
      "Will not block withdrawal symptoms from benzodiazepines; patients must be tapered off benzodiazepines before starting buspirone.",
      "Delayed onset of action (2-4 weeks). Not for 'as needed' use.",
      "Avoid large amounts of grapefruit juice.",
      "Use with caution in patients with hepatic or renal impairment."
    ],
    "pregnancyCategory": "Category B",
    "riskFactors": [
      "Concomitant MAOI use",
      "hepatic or renal impairment."
    ]
  },
  "butalbital-acetaminophen-caffeine": {
    "adverseEffects": {
      "common": [
        "Drowsiness",
        "dizziness",
        "lightheadedness",
        "nausea",
        "vomiting",
        "abdominal pain."
      ],
      "serious": [
        "Hepatotoxicity (from acetaminophen overdose)",
        "respiratory depression (from butalbital)",
        "abuse and dependence (from butalbital)."
      ]
    },
    "brandNames": [
      "Fioricet",
      "Esgic"
    ],
    "category": "Analgesic",
    "contraindications": [
      "Hypersensitivity to any component",
      "porphyria."
    ],
    "dose": "1-2 tablets or capsules every 4 hours as needed. Max 6 doses per day.",
    "drugClass": "Barbiturate Combination",
    "genericName": "Butalbital, Acetaminophen, and Caffeine",
    "indications": "Relief of the symptom complex of tension (or muscle contraction) headaches.",
    "lactationInfo": "All components are excreted in breast milk; not recommended.",
    "moaSteps": [
      "This is a combination product with three mechanisms:",
      "1. **Butalbital:** A short-to-intermediate acting barbiturate. It produces CNS depression and sedation by binding to GABA-A receptors, enhancing the inhibitory effects of GABA.",
      "2. **Acetaminophen (APAP):** An analgesic and antipyretic. Its central mechanism is thought to involve inhibition of COX enzymes in the CNS.",
      "3. **Caffeine:** A CNS stimulant and vasoconstrictor. It may enhance the analgesic effects of acetaminophen and helps to constrict cerebral blood vessels, which can relieve headache."
    ],
    "name": "Butalbital/Acetaminophen/Caffeine (Fioricet)",
    "pharmacokinetics": {
      "absorption": "All components are well absorbed orally.",
      "distribution": "All components are widely distributed.",
      "excretion": "Excreted in the urine as metabolites.",
      "metabolism": "Butalbital is metabolized in the liver. Acetaminophen is metabolized in the liver (risk of toxic metabolite). Caffeine is metabolized by CYP1A2."
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Acetaminophen has been associated with acute liver failure, sometimes resulting in transplant or death. Do not exceed 4 grams of acetaminophen per day from all sources.",
      "BOXED WARNING (Abuse and Dependence): Butalbital is a barbiturate and has a high potential for abuse and physical dependence. Prolonged use can lead to tolerance and dependence.",
      "Can impair mental/physical abilities; caution against driving.",
      "Risk of 'medication overuse headache' if used frequently."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "Liver disease",
      "history of substance abuse",
      "frequent headache days."
    ]
  },
  "caffeine": {
    "adverseEffects": {
      "common": [
        "Insomnia",
        "nervousness",
        "restlessness",
        "tachycardia",
        "palpitations",
        "headache",
        "gastrointestinal upset."
      ],
      "serious": [
        "Seizures (with overdose)",
        "arrhythmias",
        "severe anxiety/panic attacks",
        "withdrawal symptoms (headache, fatigue) upon abrupt cessation."
      ]
    },
    "brandNames": [
      "NoDoz",
      "Vivarin",
      "Caffedrine"
    ],
    "category": "CNS Stimulant",
    "contraindications": [
      "Hypersensitivity to caffeine."
    ],
    "dose": "100-200 mg PO every 3-4 hours as needed.",
    "drugClass": "Methylxanthine",
    "genericName": "Caffeine",
    "indications": "Used as a stimulant to restore mental alertness or wakefulness during fatigue or drowsiness. Also used in combination with analgesics (like acetaminophen, aspirin) for headaches.",
    "lactationInfo": "Excreted in breast milk; moderate consumption is generally considered safe, but large amounts can cause irritability in the infant.",
    "moaSteps": [
      "Caffeine is a central nervous system (CNS) stimulant.",
      "It non-selectively antagonizes (blocks) adenosine receptors (A1 and A2a) in the brain.",
      "Adenosine is an inhibitory neurotransmitter that promotes sleep and drowsiness. By blocking adenosine, caffeine increases neuronal firing and releases other neurotransmitters like dopamine and norepinephrine, leading to increased wakefulness and alertness.",
      "It also causes cerebral vasoconstriction by blocking adenosine's vasodilatory effects."
    ],
    "name": "Caffeine",
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed from the GI tract. Peak concentration in 30-60 minutes.",
      "distribution": "Widely distributed throughout the body, including the brain. Crosses the placenta and enters breast milk.",
      "excretion": "Excreted in the urine as metabolites. Half-life is ~3-5 hours (can be prolonged in newborns and pregnant women).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP1A2, to various metabolites (e.g., paraxanthine, theobromine, theophylline)."
    },
    "precautions": [
      "Use with caution in patients with cardiovascular disease, peptic ulcer disease, or anxiety disorders.",
      "Limit use of other caffeine-containing products (coffee, tea, soda, energy drinks) to avoid overdose.",
      "Abrupt discontinuation can lead to withdrawal headaches."
    ],
    "pregnancyCategory": "Category B. High doses (>300 mg/day) may be associated with risk.",
    "riskFactors": [
      "Anxiety disorders",
      "cardiac arrhythmias",
      "peptic ulcer disease."
    ]
  },
  "calcitriol": {
    "adverseEffects": {
      "common": [
        "Hypercalcemia (early symptoms: weakness, headache, nausea, constipation, dry mouth)",
        "hyperphosphatemia",
        "hypercalciuria."
      ],
      "serious": [
        "Severe hypercalcemia (can lead to arrhythmias, confusion, renal failure)",
        "soft tissue calcification."
      ]
    },
    "brandNames": [
      "Rocaltrol",
      "Calcijex (IV)"
    ],
    "category": "Vitamin, Active Form",
    "contraindications": [
      "Hypercalcemia",
      "evidence of vitamin D toxicity."
    ],
    "dose": "Dialysis: 0.25 mcg/day PO, may be titrated. Hypoparathyroidism: 0.25-2 mcg/day PO.",
    "drugClass": "Vitamin D Analog",
    "genericName": "Calcitriol",
    "indications": "Management of hypocalcemia in patients undergoing chronic renal dialysis. Management of secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease (CKD). Management of hypocalcemia in patients with hypoparathyroidism.",
    "lactationInfo": "Excreted in breast milk; monitor serum calcium in infant.",
    "moaSteps": [
      "Calcitriol is the active form of Vitamin D3 (cholecalciferol).",
      "It binds to and activates the vitamin D receptor (VDR) in various tissues.",
      "In the intestines: It increases the absorption of calcium and phosphate from the diet.",
      "In the bone: It stimulates bone resorption (release of calcium) by activating osteoclasts (in concert with parathyroid hormone).",
      "In the kidneys: It increases the reabsorption of calcium and phosphate.",
      "In the parathyroid gland: It provides negative feedback to suppress the synthesis and secretion of parathyroid hormone (PTH)."
    ],
    "name": "Calcitriol (Rocaltrol)",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally.",
      "distribution": "Bound to vitamin D-binding protein. Onset of action in 2-6 hours.",
      "excretion": "Excreted in bile and urine. Half-life is ~5-8 hours.",
      "metabolism": "Metabolized in the liver and kidney."
    },
    "precautions": [
      "Monitor serum calcium and phosphorus levels frequently (e.g., twice weekly) during dose titration and at least monthly during maintenance.",
      "Overdosage of any form of vitamin D is dangerous.",
      "Advise patients on a low-phosphate diet and phosphate binders (in CKD) to prevent hyperphosphatemia.",
      "Ensure adequate fluid intake."
    ],
    "pregnancyCategory": "Category C. Use with caution.",
    "riskFactors": [
      "Hypercalcemia",
      "renal impairment (paradoxically, as it's used for it but must be monitored)."
    ]
  },
  "calcium-carbonate": {
    "adverseEffects": {
      "common": [
        "Constipation",
        "bloating",
        "gas (belching)",
        "nausea",
        "chalky taste."
      ],
      "serious": [
        "Hypercalcemia (with excessive doses, especially with vitamin D)",
        "kidney stones",
        "milk-alkali syndrome (hypercalcemia, metabolic alkalosis, renal impairment)."
      ]
    },
    "brandNames": [
      "Tums",
      "Os-Cal",
      "Rolaids"
    ],
    "category": "Mineral Supplement, Antacid",
    "contraindications": [
      "Hypercalcemia",
      "hypercalciuria",
      "history of calcium-based kidney stones."
    ],
    "dose": "Antacid: 500-1500 mg (2-4 tablets) PO as needed. Supplement: 1000-1500 mg elemental calcium/day PO in divided doses.",
    "drugClass": "Antacid, Calcium Supplement",
    "genericName": "Calcium Carbonate",
    "indications": "As an antacid for the relief of acid indigestion, heartburn, and sour stomach. As a dietary supplement for the prevention and treatment of calcium deficiency (e.g., osteoporosis). As a phosphate binder in patients with end-stage renal disease (ESRD).",
    "lactationInfo": "Compatible with breastfeeding.",
    "moaSteps": [
      "As an antacid: Calcium carbonate is an alkaline compound that directly neutralizes gastric acid (HCl) in the stomach.",
      "This reaction forms calcium chloride, water, and carbon dioxide, leading to a rapid increase in gastric pH and relief of heartburn.",
      "As a supplement: It provides elemental calcium, which is essential for bone formation, muscle contraction, nerve function, and blood clotting.",
      "As a phosphate binder: In the GI tract, calcium carbonate binds to dietary phosphate to form insoluble calcium phosphate, which is then excreted in the feces. This lowers serum phosphate levels in ESRD patients."
    ],
    "name": "Calcium Carbonate (Tums, Os-Cal)",
    "pharmacokinetics": {
      "absorption": "Absorption of calcium (~20-30%) occurs in the small intestine and is vitamin D-dependent. Antacid action is local.",
      "distribution": "Calcium is distributed to bones and extracellular fluid.",
      "excretion": "Unabsorbed calcium is excreted in feces. Absorbed calcium is primarily excreted in urine.",
      "metabolism": "Not metabolized. Dissolves in stomach acid."
    },
    "precautions": [
      "Use with caution in patients with renal impairment or a history of kidney stones.",
      "Can interfere with the absorption of other drugs (e.g., tetracyclines, fluoroquinolones, thyroid hormone). Separate doses by 2-4 hours.",
      "Do not exceed maximum recommended doses to avoid hypercalcemia."
    ],
    "pregnancyCategory": "Generally considered safe (Category C as per some old systems, but widely used).",
    "riskFactors": [
      "Hypercalcemia",
      "renal impairment",
      "concomitant use of thiazide diuretics (can increase calcium)."
    ]
  },
  "candesartan": {
    "adverseEffects": {
      "common": [
        "Dizziness",
        "headache",
        "hyperkalemia",
        "hypotension."
      ],
      "serious": [
        "Angioedema (rare)",
        "acute renal failure",
        "severe hyperkalemia."
      ]
    },
    "brandNames": [
      "Atacand"
    ],
    "category": "Antihypertensive",
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with aliskiren in patients with diabetes",
      "Pregnancy."
    ],
    "dose": "Hypertension: 16-32 mg PO once daily. Heart Failure: Initial 4 mg PO once daily, titrate to 32 mg once daily.",
    "drugClass": "Angiotensin II Receptor Blocker (ARB)",
    "genericName": "Candesartan",
    "indications": "Treatment of hypertension. Treatment of heart failure (NYHA Class II-IV and LVEF 40%).",
    "lactationInfo": "Discontinue nursing or discontinue drug; not recommended.",
    "moaSteps": [
      "Candesartan is a selective angiotensin II receptor blocker (ARB).",
      "It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking its binding to the AT1 receptor in many tissues (e.g., vascular smooth muscle, adrenal gland).",
      "This blockade results in vasodilation, decreased secretion of aldosterone, and a reduction in blood pressure.",
      "Unlike ACE inhibitors, ARBs do not inhibit the breakdown of bradykinin, which is thought to be the reason for the lower incidence of dry cough."
    ],
    "name": "Candesartan (Atacand)",
    "pharmacokinetics": {
      "absorption": "Candesartan cilexetil (prodrug) is hydrolyzed to candesartan (active) during GI absorption. Bioavailability ~15%.",
      "distribution": "Highly protein-bound (>99%).",
      "excretion": "Excreted in urine and feces (via bile). Half-life is ~9 hours.",
      "metabolism": "The prodrug is metabolized to the active form. Candesartan is minimally metabolized."
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected.",
      "Monitor renal function and serum potassium, especially in patients with renal impairment or heart failure.",
      "Can cause symptomatic hypotension, especially in volume-depleted patients."
    ],
    "pregnancyCategory": "Category D",
    "riskFactors": [
      "Pregnancy",
      "renal artery stenosis",
      "volume depletion",
      "concomitant use of potassium-sparing diuretics."
    ]
  },
  "capsaicin": {
    "adverseEffects": {
      "common": [
        "Erythema (redness) at application site",
        "burning sensation",
        "pain",
        "stinging",
        "pruritus (itching)."
      ],
      "serious": [
        "Severe burns (if used with heating pad or on broken skin)",
        "neurotoxicity (with very high doses)",
        "transient increase in blood pressure (with Qutenza patch)."
      ]
    },
    "brandNames": [
      "Zostrix (topical cream)",
      "Capzasin-HP (topical cream)",
      "Qutenza (8% patch)"
    ],
    "category": "Analgesic",
    "contraindications": [
      "Hypersensitivity to capsaicin or chili peppers."
    ],
    "dose": "Cream: Apply a thin layer to affected area 3-4 times daily. Patch (Qutenza): Applied by a healthcare professional for 30-60 minutes.",
    "drugClass": "Topical Analgesic, TRP agonist",
    "genericName": "Capsaicin",
    "indications": "Topical cream (low dose): Temporary relief of minor aches and pains of muscles and joints associated with arthritis, backache, strains, and sprains. High-dose patch (Qutenza): Management of neuropathic pain associated with postherpetic neuralgia (shingles pain) and diabetic peripheral neuropathy.",
    "lactationInfo": "Use with caution; do not apply to breast.",
    "moaSteps": [
      "Capsaicin is the active component of chili peppers.",
      "It binds to the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor, which is an ion channel found on nociceptive (pain-sensing) nerve fibers.",
      "Initial application activates the TRPV1 receptor, causing a burning sensation, release of substance P (a pain transmitter), and local inflammation.",
      "With repeated application, capsaicin desensitizes the TRPV1 receptor and causes a reversible 'defunctionalization' of the nerve fibers by depleting substance P from the nerve terminals.",
      "This ultimately reduces or prevents the transmission of pain signals from the periphery to the CNS."
    ],
    "name": "Capsaicin (Qutenza, Zostrix)",
    "pharmacokinetics": {
      "absorption": "Absorbed through the skin. Action is local. Systemic absorption is minimal with creams, but can occur with the high-dose patch.",
      "distribution": "Acts locally on cutaneous nerve fibers.",
      "excretion": "Metabolites excreted in urine.",
      "metabolism": "Metabolized in the skin and liver if absorbed."
    },
    "precautions": [
      "For external use only. Do not apply to wounds, damaged, or irritated skin.",
      "Avoid contact with eyes, mouth, and mucous membranes. **Wash hands thoroughly** with soap and water after application (unless treating hands).",
      "Do not apply a heating pad or tight bandage over the cream.",
      "The burning sensation is common and usually lessens with continued use.",
      "Qutenza patch application can be very painful and may require pre-treatment with a local anesthetic."
    ],
    "pregnancyCategory": "Category B (cream) / C (patch)",
    "riskFactors": [
      "Broken or irritated skin."
    ]
  },
  "captopril": {
    "adverseEffects": {
      "common": [
        "Dry, persistent cough",
        "dizziness",
        "rash",
        "hypotension",
        "taste disturbances (dysgeusia)."
      ],
      "serious": [
        "Angioedema",
        "hyperkalemia",
        "neutropenia/agranulocytosis",
        "acute renal failure."
      ]
    },
    "brandNames": [
      "Capoten"
    ],
    "category": "Antihypertensive",
    "contraindications": [
      "History of angioedema related to previous ACE inhibitor treatment.",
      "Concomitant use with aliskiren in patients with diabetes.",
      "Pregnancy."
    ],
    "dose": "Hypertension: Initial 25 mg orally 2-3 times daily. Heart Failure: Initial 6.25 mg to 12.5 mg 3 times daily.",
    "drugClass": "Angiotensin-Converting Enzyme (ACE) Inhibitor",
    "genericName": "Captopril",
    "indications": "Treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, and diabetic nephropathy.",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution.",
    "moaSteps": [
      "Captopril competitively inhibits the angiotensin-converting enzyme (ACE).",
      "This prevents the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor).",
      "Decreased angiotensin II leads to vasodilation, reduced secretion of aldosterone, and a decrease in blood pressure."
    ],
    "name": "Captopril (Capoten)",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~60-75%. Food can reduce absorption by 30-40%.",
      "distribution": "Low protein binding (~25-30%).",
      "excretion": "Primarily excreted in the urine. Half-life is ~2 hours.",
      "metabolism": "Metabolized to inactive disulfide dimers."
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus.",
      "Can cause angioedema, hyperkalemia, and hypotension.",
      "Monitor renal function."
    ],
    "pregnancyCategory": "Category D",
    "riskFactors": [
      "Pregnancy.",
      "Renal impairment.",
      "Volume depletion."
    ]
  },
  "carbamazepine": {
    "brandNames": [
      "Tegretol",
      "Carbatrol",
      "Epitol",
      "Equetro"
    ],
    "category": "Antiepileptic, Mood Stabilizer",
    "drugClass": "Anticonvulsant",
    "genericName": "Carbamazepine",
    "indications": "Treatment of epilepsy (partial, tonic-clonic seizures). Treatment of trigeminal neuralgia (nerve pain). Treatment of acute manic or mixed episodes in bipolar I disorder (Equetro).",
    "moaSteps": [
      "Carbamazepine stabilizes hyperexcited nerve membranes by blocking voltage-gated sodium channels.",
      "It inhibits the rapid, repetitive firing of neurons by binding to sodium channels in their inactivated state, which prolongs the refractory period.",
      "This action prevents the spread of seizure activity. It also has anticholinergic and antidiuretic effects."
    ],
    "name": "Carbamazepine (Tegretol)",
    "pharmacokinetics": {
      "absorption": "Slowly and variably absorbed from the GI tract. Formulations (IR, SR, XR) affect absorption rate.",
      "distribution": "Widely distributed. 75-90% protein-bound.",
      "excretion": "Excreted in the urine, primarily as metabolites. Half-life is variable (15-35 hours initially, then 8-12 hours with chronic use due to auto-induction).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4 to an active metabolite (carbamazepine-10,11-epoxide). It is a potent **auto-inducer**: it induces its own metabolism, so its half-life decreases over time."
    },
    "dose": "Epilepsy (Adult): Initial 200 mg PO twice daily (IR) or 400 mg/day (ER). Titrate slowly up to a maintenance dose of 800-1200 mg/day in divided doses.",
    "adverseEffects": {
      "common": [
        "Drowsiness",
        "dizziness",
        "ataxia (impaired coordination)",
        "nausea",
        "vomiting",
        "blurred vision",
        "hyponatremia (low sodium)."
      ],
      "serious": [
        "Severe dermatologic reactions (SJS/TEN)",
        "Aplastic anemia and Agranulocytosis",
        "Hepatotoxicity",
        "SIADH (causes low sodium)."
      ]
    },
    "precautions": [
      "BOXED WARNING (SJS/TEN): Risk of life-threatening skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) is significantly higher in patients with the **HLA-B*1502 allele**. Test patients of Asian ancestry for this allele before starting.",
      "BOXED WARNING (Aplastic Anemia/Agranulocytosis): Can cause rare but fatal bone marrow suppression. Monitor complete blood counts (CBC) at baseline and periodically.",
      "It is a potent inducer of many CYP enzymes (e.g., CYP3A4, 2C9) and will decrease the concentration of many other drugs (e.g., oral contraceptives, warfarin).",
      "Monitor sodium levels for hyponatremia."
    ],
    "contraindications": [
      "Hypersensitivity",
      "history of bone marrow suppression",
      "concomitant use with MAOIs (within 14 days)",
      "concomitant use with nefazodone."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm (e.g., spina bifida)."
  },
  "carbidopa-levodopa": {
    "adverseEffects": {
      "common": [
        "Nausea",
        "vomiting",
        "dizziness",
        "orthostatic hypotension",
        "somnolence",
        "dyskinesias (involuntary movements, a long-term complication)",
        "confusion",
        "hallucinations (especially in elderly)."
      ],
      "serious": [
        "Severe psychosis",
        "depression with suicidal ideation",
        "gastrointestinal bleeding",
        "arrhythmias",
        "impulse control disorders (e.g., gambling, hypersexuality).",
        "Neuroleptic Malignant Syndrome-like events (with abrupt withdrawal)."
      ]
    },
    "brandNames": [
      "Sinemet",
      "Sinemet CR",
      "Rytary (ER capsule)",
      "Duopa (intestinal suspension)"
    ],
    "category": "Antiparkinsonian",
    "contraindications": [
      "Hypersensitivity",
      "non-selective MAO inhibitors (within 14 days)",
      "narrow-angle glaucoma."
    ],
    "dose": "Highly individualized. Titrated based on response. e.g., Sinemet 25/100 (mg carbidopa/mg levodopa) PO 3-4 times daily.",
    "drugClass": "Dopamine Precursor, Anti-Parkinson's Agent",
    "genericName": "Carbidopa and Levodopa",
    "indications": "Treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide or manganese intoxication.",
    "lactationInfo": "Levodopa is excreted in breast milk and may inhibit lactation; not recommended.",
    "moaSteps": [
      "Parkinson's disease is characterized by a deficiency of dopamine in the basal ganglia.",
      "1. **Levodopa (L-dopa):** This is a metabolic precursor to dopamine. Unlike dopamine, levodopa can cross the blood-brain barrier (BBB).",
      "2. Once in the CNS, levodopa is converted to dopamine by the enzyme L-aromatic amino acid decarboxylase (AADC).",
      "3. This newly formed dopamine replenishes the deficient stores in the striatum, improving motor symptoms (tremor, rigidity, bradykinesia).",
      "4. **Carbidopa:** This is a peripheral decarboxylase inhibitor. It does *not* cross the BBB.",
      "5. Carbidopa prevents the conversion of levodopa to dopamine in the *periphery* (outside the brain). This is crucial because peripheral dopamine causes nausea, vomiting, and cardiac side effects, and it reduces the amount of levodopa available to enter the brain.",
      "6. By giving them together, carbidopa increases the CNS bioavailability of levodopa and reduces its peripheral side effects."
    ],
    "name": "Carbidopa/Levodopa (Sinemet)",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed from the GI tract. High-protein meals can compete for absorption and transport into the brain.",
      "distribution": "Carbidopa does not cross BBB; Levodopa does.",
      "excretion": "Metabolites excreted in urine. Levodopa half-life is short (~1.5 hours).",
      "metabolism": "Levodopa is extensively metabolized (by decarboxylase and COMT) to dopamine and other metabolites."
    },
    "precautions": [
      "Abrupt withdrawal can lead to a syndrome resembling Neuroleptic Malignant Syndrome (NMS).",
      "Long-term use is associated with 'wearing-off' phenomenon and 'on-off' motor fluctuations and dyskinesias.",
      "Monitor for psychosis, depression, and impulse control disorders.",
      "May cause sudden onset of sleep ('sleep attacks')."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "Psychiatric disorders",
      "glaucoma",
      "peptic ulcer disease."
    ]
  },
  "carisoprodol": {
    "adverseEffects": {
      "common": [
        "Drowsiness",
        "dizziness",
        "headache",
        "sedation."
      ],
      "serious": [
        "Abuse, dependence, and withdrawal (due to meprobamate metabolite)",
        "seizures",
        "respiratory depression (especially with other CNS depressants)."
      ]
    },
    "brandNames": [
      "Soma",
      "Vanadom"
    ],
    "category": "Skeletal Muscle Relaxant",
    "contraindications": [
      "Hypersensitivity to carisoprodol or meprobamate",
      "acute intermittent porphyria."
    ],
    "dose": "250-350 mg PO three times daily and at bedtime.",
    "drugClass": "Skeletal Muscle Relaxant",
    "genericName": "Carisoprodol",
    "indications": "Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.",
    "lactationInfo": "Excreted in breast milk; can cause sedation in infant. Not recommended.",
    "moaSteps": [
      "Carisoprodol's mechanism of action is not fully understood.",
      "It is believed to act centrally in the CNS rather than directly on skeletal muscle.",
      "It is metabolized in the liver to meprobamate, which has anxiolytic and sedative properties.",
      "The muscle relaxant effects may be due to its sedative properties (CNS depression) in the spinal cord and descending reticular formation.",
      "It does not directly relax tense skeletal muscles."
    ],
    "name": "Carisoprodol (Soma)",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Onset of action in 30 minutes.",
      "distribution": "Widely distributed. Crosses the placenta and enters breast milk.",
      "excretion": "Excreted in the urine as metabolites. Half-life is ~2 hours (Carisoprodol) and ~10 hours (Meprobamate).",
      "metabolism": "Extensively metabolized in the liver by CYP2C19 to active (meprobamate) and inactive metabolites. Meprobamate itself is a controlled substance."
    },
    "precautions": [
      "**Controlled Substance (Schedule IV):** Has potential for abuse and dependence. The active metabolite, meprobamate, is a sedative-hypnotic.",
      "Can impair mental/physical abilities; caution against driving or operating machinery.",
      "Risk of overdose, which can be fatal, especially when combined with alcohol or other CNS depressants (e.g., opioids, benzodiazepines).",
      "Withdrawal symptoms can occur with abrupt cessation after prolonged use.",
      "Use with caution in patients who are 'poor metabolizers' of CYP2C19 (may have higher levels)."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "History of substance abuse",
      "concomitant use of CNS depressants",
      "CYP2C19 poor metabolizers."
    ]
  },
  "carvedilol": {
    "adverseEffects": {
      "common": [
        "Dizziness",
        "fatigue",
        "hypotension (especially orthostatic)",
        "bradycardia",
        "headache",
        "weight gain",
        "hyperglycemia",
        "diarrhea."
      ],
      "serious": [
        "Severe bradycardia",
        "heart block",
        "heart failure exacerbation (especially during titration)",
        "bronchospasm (in patients with asthma).",
        "Hepatotoxicity (rare)."
      ]
    },
    "brandNames": [
      "Coreg",
      "Coreg CR"
    ],
    "category": "Antihypertensive, Anti-Heart Failure",
    "contraindications": [
      "NYHA Class IV decompensated heart failure requiring IV inotropes",
      "bronchial asthma or related bronchospastic conditions",
      "2nd or 3rd-degree AV block",
      "severe bradycardia",
      "cardiogenic shock",
      "severe hepatic impairment."
    ],
    "dose": "Hypertension (IR): 6.25-25 mg PO twice daily. Heart Failure (IR): Initial 3.125 mg PO twice daily, titrate slowly up to 25-50 mg twice daily as tolerated.",
    "drugClass": "Beta-Blocker (Nonselective) with Alpha-1 Blocking Activity",
    "genericName": "Carvedilol",
    "indications": "Treatment of hypertension. Treatment of mild-to-severe chronic heart failure (HF) of ischemic or cardiomyopathic origin. Left ventricular dysfunction following myocardial infarction.",
    "lactationInfo": "Excreted in breast milk; use with caution.",
    "moaSteps": [
      "Carvedilol is a nonselective beta-adrenergic blocker (blocks beta-1 and beta-2 receptors) AND an alpha-1 adrenergic blocker.",
      "**Beta-Blockade (Beta-1):** Blocks beta-1 receptors in the heart, leading to decreased heart rate (negative chronotropy), decreased contractility (negative inotropy), and decreased cardiac output. This reduces the workload on the heart.",
      "**Alpha-1 Blockade:** Blocks alpha-1 receptors on vascular smooth muscle, leading to vasodilation (widening of blood vessels).",
      "The combined effect is a reduction in blood pressure (from both vasodilation and reduced cardiac output) and reduced cardiac workload, which is beneficial in heart failure.",
      "It also has antioxidant properties."
    ],
  "cabergoline": {
    "name": "Cabergoline (Dostinex)",
    "genericName": "Cabergoline",
    "brandNames": ["Dostinex"],
    "category": "Endocrine-Metabolic Agent",
    "drugClass": "Dopamine Agonist",
    "indications": "Treatment of hyperprolactinemic disorders (e.g., amenorrhea, galactorrhea, adenomas).",
    "moaSteps": [
      "Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors.",
      "It exerts a direct inhibitory effect on the secretion of prolactin by pituitary lactotrophs.",
      "This restores normal prolactin levels and gonadal function."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Peak plasma levels in 2-3 hours.",
      "distribution": "Extensively distributed. Moderately protein-bound (~40-42%).",
      "metabolism": "Extensively metabolized in the liver (hydrolysis).",
      "excretion": "Excreted in feces and urine. Extremely long half-life (63-69 hours)."
    },
    "dose": "Initial: 0.25 mg PO twice weekly. Titrate by 0.25 mg increments every 4 weeks up to max 1 mg twice weekly.",
    "adverseEffects": {
      "common": ["Nausea", "headache", "dizziness", "fatigue", "constipation."],
      "serious": ["Cardiac valvulopathy (fibrosis)", "pleural effusion", "orthostatic hypotension", "impulse control disorders."]
    },
    "precautions": [
      "**Cardiac Valvulopathy:** Long-term use has been associated with cardiac valve fibrosis. Echocardiogram monitoring is required.",
      "Risk of orthostatic hypotension.",
      "Risk of impulse control disorders (e.g., gambling, hypersexuality)."
    ],
    "contraindications": [
      "Uncontrolled hypertension",
      "history of cardiac valvular disorders",
      "history of pulmonary fibrotic disorders."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Inhibits lactation; not recommended if breastfeeding is desired."
  },
  "calcipotriene": {
    "name": "Calcipotriene (Dovonex)",
    "genericName": "Calcipotriene",
    "brandNames": ["Dovonex", "Sorilux"],
    "category": "Antipsoriatic",
    "drugClass": "Vitamin D Analog",
    "indications": "Topical treatment of plaque psoriasis.",
    "moaSteps": [
      "Calcipotriene is a synthetic Vitamin D3 analog.",
      "It binds to Vitamin D receptors in skin cells (keratinocytes).",
      "This binding regulates gene transcription to inhibit keratinocyte proliferation (rapid growth) and induce differentiation (maturation).",
      "This helps to normalize the excessive skin cell growth seen in psoriasis."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic absorption is low (~6%) when applied to plaques.",
      "distribution": "Unknown.",
      "metabolism": "Rapidly metabolized in the liver.",
      "excretion": "Excreted in bile/feces."
    },
    "dose": "Apply a thin layer to the affected area once or twice daily.",
    "adverseEffects": {
      "common": ["Skin irritation", "burning", "stinging", "itching", "erythema."],
      "serious": ["Hypercalcemia (with excessive use)", "allergic contact dermatitis."]
    },
    "precautions": [
      "Do not apply to the face.",
      "Excessive use (>100g/week) can lead to hypercalcemia; monitor serum calcium if using large amounts.",
      "Can cause photosensitivity; avoid excessive sunlight."
    ],
    "contraindications": [
      "Hypercalcemia",
      "vitamin D toxicity."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "calcitonin": {
    "name": "Calcitonin (Miacalcin)",
    "genericName": "Calcitonin-Salmon",
    "brandNames": ["Miacalcin", "Fortical"],
    "category": "Osteoporosis Agent",
    "drugClass": "Polypeptide Hormone",
    "indications": "Treatment of postmenopausal osteoporosis (women >5 years post-menopause). Treatment of hypercalcemia. Treatment of Paget's disease.",
    "moaSteps": [
      "Calcitonin is a hormone that participates in calcium and phosphorus metabolism.",
      "It acts directly on osteoclasts (bone-resorbing cells).",
      "It binds to calcitonin receptors on osteoclasts, inhibiting their activity and reducing bone resorption.",
      "It also promotes the renal excretion of calcium, phosphate, and sodium."
    ],
    "pharmacokinetics": {
      "absorption": "Nasal spray is rapidly absorbed via nasal mucosa.",
      "distribution": "Does not cross the placenta.",
      "metabolism": "Rapidly metabolized in the kidneys.",
      "excretion": "Excreted in urine. Short half-life (~43 minutes)."
    },
    "dose": "Osteoporosis (Nasal): 1 spray (200 units) in one nostril once daily (alternate nostrils).",
    "adverseEffects": {
      "common": ["Nasal irritation (rhinitis, epistaxis)", "back pain", "headache.", "flushing (injection)."],
      "serious": ["Hypersensitivity reactions (anaphylaxis)", "hypocalcemia", "malignancy (possible increased risk with long-term use)."]
    },
    "precautions": [
      "Possible increased risk of malignancy (cancer) with long-term use; efficacy is modest compared to other agents.",
      "Periodic nasal exams recommended to check for ulceration.",
      "Monitor for hypocalcemia."
    ],
    "contraindications": [
      "Hypersensitivity to calcitonin-salmon."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Inhibits lactation; excreted in milk. Not recommended."
  },
  "canagliflozin": {
    "name": "Canagliflozin (Invokana)",
    "genericName": "Canagliflozin",
    "brandNames": ["Invokana"],
    "category": "Antidiabetic",
    "drugClass": "SGLT2 Inhibitor",
    "indications": "Type 2 diabetes mellitus (glycemic control). Diabetic kidney disease (to reduce risk of ESKD). Cardiovascular risk reduction in T2DM.",
    "moaSteps": [
      "Canagliflozin inhibits Sodium-Glucose Cotransporter 2 (SGLT2) in the proximal renal tubules.",
      "SGLT2 is responsible for reabsorbing filtered glucose.",
      "By inhibiting it, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose.",
      "This leads to increased urinary glucose excretion, lowering plasma glucose."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~65%. Take before first meal.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Metabolized by O-glucuronidation (UGT enzymes).",
      "excretion": "Excreted in feces and urine. Half-life ~10-13 hours."
    },
    "dose": "100 mg PO once daily before the first meal. Can increase to 300 mg.",
    "adverseEffects": {
      "common": ["Genital mycotic infections", "UTIs", "increased urination", "thirst", "constipation."],
      "serious": ["Diabetic ketoacidosis (DKA)", "lower limb amputation", "Fournier's gangrene", "bone fractures", "volume depletion."]
    },
    "precautions": [
      "**BOXED WARNING (Lower Limb Amputation):** Increased risk of lower limb amputations (toe, foot, leg). Monitor for infection or ulcers.",
      "Risk of DKA even with normal blood glucose.",
      "Causes intravascular volume contraction; risk of hypotension.",
      "Monitor renal function."
    ],
    "contraindications": [
      "Severe renal impairment (eGFR < 30), dialysis.",
      "Hypersensitivity."
    ],
    "pregnancyCategory": "Category C. Not recommended in 2nd/3rd trimester.",
    "lactationInfo": "Not recommended."
  },
  "cefazolin": {
    "name": "Cefazolin (Ancef)",
    "genericName": "Cefazolin",
    "brandNames": ["Ancef"],
    "category": "Antibiotic",
    "drugClass": "Cephalosporin (1st Generation)",
    "indications": "Treatment of infections (respiratory, skin, bone/joint, genital, septicemia). Perioperative prophylaxis.",
    "moaSteps": [
      "Cefazolin is a first-generation cephalosporin beta-lactam.",
      "It binds to penicillin-binding proteins (PBPs) located inside the bacterial cell wall.",
      "This inhibits the final transpeptidation step of peptidoglycan synthesis.",
      "Cell wall assembly is halted, leading to bacterial cell lysis and death."
    ],
    "pharmacokinetics": {
      "absorption": "Given IV or IM (poor oral absorption).",
      "distribution": "Widely distributed. High protein binding.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in urine. Half-life ~1.8 hours."
    },
    "dose": "0.5 to 2 g IV/IM every 6 to 8 hours. Prophylaxis: 2 g IV within 60 min prior to incision.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "injection site pain", "rash."],
      "serious": ["Anaphylaxis", "Stevens-Johnson Syndrome", "Clostridioides difficile-associated diarrhea (CDAD)", "seizures (high doses/renal failure)."]
    },
    "precautions": [
      "Adjust dose in renal impairment to avoid accumulation and seizures.",
      "Cross-hypersensitivity with penicillin is possible (~10%).",
      "Prolonged use may result in superinfection."
    ],
    "contraindications": [
      "Hypersensitivity to cephalosporins."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in low concentrations; generally compatible."
  },
  "cefepime": {
    "name": "Cefepime (Maxipime)",
    "genericName": "Cefepime",
    "brandNames": ["Maxipime"],
    "category": "Antibiotic",
    "drugClass": "Cephalosporin (4th Generation)",
    "indications": "Treatment of pneumonia, complicated UTIs, skin infections, intra-abdominal infections. Empiric therapy for febrile neutropenia.",
    "moaSteps": [
      "Cefepime is a fourth-generation cephalosporin.",
      "It penetrates Gram-negative outer membranes rapidly and binds to PBPs.",
      "It inhibits peptidoglycan synthesis, leading to cell lysis.",
      "It is highly resistant to hydrolysis by many beta-lactamases.",
      "Broad spectrum covering Pseudomonas aeruginosa and many Gram-positives."
    ],
    "pharmacokinetics": {
      "absorption": "Given IV or IM.",
      "distribution": "Widely distributed, including CSF.",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted unchanged in urine. Half-life ~2 hours."
    },
    "dose": "1 to 2 g IV every 8-12 hours.",
    "adverseEffects": {
      "common": ["Rash", "diarrhea", "positive Coombs' test.", "phlebitis."],
      "serious": ["Neurotoxicity (encephalopathy, seizures, coma) especially in renal failure", "anaphylaxis", "CDAD."]
    },
    "precautions": [
      "**Dose adjustment is critical in renal impairment** to prevent serious neurotoxicity (encephalopathy).",
      "Monitor for superinfection.",
      "Use caution in penicillin-allergic patients."
    ],
    "contraindications": [
      "Hypersensitivity to cephalosporins, penicillins, or other beta-lactams."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in low concentrations; likely safe."
  },
  "ceftriaxone": {
    "name": "Ceftriaxone (Rocephin)",
    "genericName": "Ceftriaxone",
    "brandNames": ["Rocephin"],
    "category": "Antibiotic",
    "drugClass": "Cephalosporin (3rd Generation)",
    "indications": "Lower respiratory tract infections, acute bacterial otitis media, skin infections, UTIs, gonorrhea, pelvic inflammatory disease, bacterial sepsis, meningitis.",
    "moaSteps": [
      "Ceftriaxone is a third-generation cephalosporin.",
      "It inhibits bacterial cell wall synthesis by binding to PBPs.",
      "This causes defects in the cell wall, leading to lysis.",
      "It has potent activity against many Gram-negative bacteria and crosses the blood-brain barrier."
    ],
    "pharmacokinetics": {
      "absorption": "Given IV or IM.",
      "distribution": "Widely distributed; excellent CSF penetration. Highly protein bound.",
      "metabolism": "Not metabolized.",
      "excretion": "Dual excretion: ~33-67% in urine, remainder in bile/feces. Long half-life ~6-9 hours (allows once-daily dosing)."
    },
    "dose": "1 to 2 g IV or IM once daily. Gonorrhea: Single 500 mg IM dose. Meningitis: 2 g IV every 12 hours.",
    "adverseEffects": {
      "common": ["Diarrhea", "injection site pain (IM)", "rash", "eosinophilia.", "sludge in gallbladder (biliary pseudolithiasis)."],
      "serious": ["Anaphylaxis", "hemolytic anemia", "CDAD", "kernicterus (in neonates)."]
    },
    "precautions": [
      "**Do not use with calcium-containing IV solutions** (precipitate can form in lungs/kidneys, fatal in neonates).",
      "Can cause biliary sludge/stones; discontinue if signs of gallbladder disease occur.",
      "May increase INR with warfarin."
    ],
    "contraindications": [
      "Hypersensitivity to cephalosporins.",
      "Hyperbilirubinemic neonates (risk of kernicterus).",
      "Concomitant calcium IV administration in neonates."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in low concentrations; considered compatible."
  },
  "cefuroxime": {
    "name": "Cefuroxime (Ceftin, Zinacef)",
    "genericName": "Cefuroxime",
    "brandNames": ["Ceftin (oral)", "Zinacef (IV/IM)"],
    "category": "Antibiotic",
    "drugClass": "Cephalosporin (2nd Generation)",
    "indications": "Pharyngitis, tonsillitis, otitis media, sinusitis, skin infections, UTIs, Lyme disease (early).",
    "moaSteps": [
      "Cefuroxime is a second-generation cephalosporin.",
      "It inhibits bacterial cell wall synthesis by binding to PBPs.",
      "This prevents cross-linking of peptidoglycan chains, weakening the wall and causing lysis.",
      "It is more resistant to beta-lactamases than 1st gen cephalosporins."
    ],
    "pharmacokinetics": {
      "absorption": "Oral axetil is a prodrug, hydrolyzed to active cefuroxime. Bioavailability increased with food.",
      "distribution": "Widely distributed.",
      "metabolism": "Not metabolically altered.",
      "excretion": "Excreted unchanged in urine."
    },
    "dose": "Oral: 250-500 mg PO twice daily. IV: 750 mg to 1.5 g every 8 hours.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "vaginal candidiasis", "Jarisch-Herxheimer reaction (Lyme treatment)."],
      "serious": ["Anaphylaxis", "Stevens-Johnson Syndrome", "CDAD", "seizures (rare)."]
    },
    "precautions": [
      "Cross-sensitivity with penicillin.",
      "Adjust dose in renal impairment.",
      "Tablets and suspension are not bioequivalent on a mg/mg basis."
    ],
    "contraindications": [
      "Hypersensitivity to cephalosporins."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "cetirizine": {
    "name": "Cetirizine (Zyrtec)",
    "genericName": "Cetirizine",
    "brandNames": ["Zyrtec"],
    "category": "Antihistamine",
    "drugClass": "H1 Antagonist (2nd Generation)",
    "indications": "Relief of symptoms of seasonal and perennial allergic rhinitis. Treatment of chronic urticaria (hives).",
    "moaSteps": [
      "Cetirizine is a potent, selective antagonist of peripheral H1 receptors.",
      "It blocks the effects of histamine on H1 receptors in the respiratory tract, blood vessels, and GI smooth muscle.",
      "This reduces capillary permeability, edema, and itching.",
      "It has less CNS penetration than 1st generation antihistamines but is more sedating than other 2nd generations (e.g., fexofenadine)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Food delays peak but not extent.",
      "distribution": "Minimal CNS entry. Highly protein-bound.",
      "metabolism": "Low hepatic metabolism.",
      "excretion": "Excreted primarily unchanged in urine. Half-life ~8 hours."
    },
    "dose": "5-10 mg PO once daily.",
    "adverseEffects": {
      "common": ["Somnolence (drowsiness)", "fatigue", "dry mouth", "pharyngitis."],
      "serious": ["Hypersensitivity reactions (rare).", "Aggressive reactions/hallucinations (rare, peds)."]
    },
    "precautions": [
      "Can cause drowsiness; caution when driving or operating machinery.",
      "Avoid alcohol and other CNS depressants.",
      "Reduce dose in renal or hepatic impairment."
    ],
    "contraindications": [
      "Hypersensitivity to cetirizine or hydroxyzine."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "chlorhexidine": {
    "name": "Chlorhexidine (Peridex, Hibiclens)",
    "genericName": "Chlorhexidine Gluconate",
    "brandNames": ["Peridex (oral rinse)", "Hibiclens (topical wash)"],
    "category": "Antiseptic, Antimicrobial",
    "drugClass": "Biguanide Antiseptic",
    "indications": "Oral Rinse: Treatment of gingivitis. Topical: Skin cleansing, surgical scrub, preoperative skin prep.",
    "moaSteps": [
      "Chlorhexidine is a cationic bisbiguanide.",
      "It binds to the negatively charged bacterial cell wall.",
      "It disrupts the cell membrane integrity, causing leakage of intracellular components.",
      "At low concentrations, it is bacteriostatic; at high concentrations, bactericidal."
    ],
    "pharmacokinetics": {
      "absorption": "Very poorly absorbed from GI tract or skin.",
      "distribution": "Binds to skin/mucosa proteins (sustained effect - substantivity).",
      "metabolism": "Minimal.",
      "excretion": "Excreted in feces (oral ingestion)."
    },
    "dose": "Oral Rinse: 15 mL swish and spit twice daily (30 sec). Topical: Wash area and rinse.",
    "adverseEffects": {
      "common": ["(Oral) Staining of teeth/tongue", "altered taste", "increased tartar.", "(Topical) Skin irritation."],
      "serious": ["(Topical/Oral) Anaphylaxis (rare but serious)."]
    },
    "precautions": [
      "**Oral Rinse:** Do not swallow. Can stain teeth/fillings (removable by cleaning). Wait 30 min before brushing/eating.",
      "**Topical:** Keep out of eyes and ears (can cause deafness if it enters middle ear).",
      "Potential for serious allergic reactions."
    ],
    "contraindications": [
      "Hypersensitivity to chlorhexidine."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Compatible; minimal absorption."
  },
  "chlorthalidone": {
    "name": "Chlorthalidone (Thalitone)",
    "genericName": "Chlorthalidone",
    "brandNames": ["Thalitone"],
    "category": "Diuretic, Antihypertensive",
    "drugClass": "Thiazide-like Diuretic",
    "indications": "Treatment of hypertension (often preferred over HCTZ for potency/duration). Treatment of edema.",
    "moaSteps": [
      "Chlorthalidone acts on the distal convoluted tubule (DCT) of the kidney.",
      "It inhibits the Na+/Cl- cotransporter, blocking sodium and chloride reabsorption.",
      "This increases excretion of sodium, chloride, and water.",
      "It also increases potassium excretion."
    ],
    "pharmacokinetics": {
      "absorption": "Variable absorption.",
      "distribution": "Binds strongly to red blood cell carbonic anhydrase.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in urine. Very long half-life (40-60 hours)."
    },
    "dose": "12.5-25 mg PO once daily (Hypertension).",
    "adverseEffects": {
      "common": ["Hypokalemia", "hyponatremia", "hyperuricemia (gout)", "dizziness", "hyperglycemia."],
      "serious": ["Severe electrolyte imbalance", "cardiac arrhythmias (due to hypokalemia)", "pancreatitis."]
    },
    "precautions": [
      "Monitor electrolytes (K+, Na+) and renal function.",
      "Can precipitate gout attacks.",
      "Can worsen glucose control in diabetes.",
      "Risk of orthostatic hypotension."
    ],
    "contraindications": [
      "Anuria",
      "hypersensitivity to sulfonamides."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in milk; may suppress lactation. Use with caution."
  },
  "ciprofloxacin": {
    "name": "Ciprofloxacin (Cipro)",
    "genericName": "Ciprofloxacin",
    "brandNames": ["Cipro"],
    "category": "Antibiotic",
    "drugClass": "Fluoroquinolone",
    "indications": "UTIs, infectious diarrhea, skin/bone/joint infections, intra-abdominal infections, typhoid fever, anthrax prophylaxis.",
    "moaSteps": [
      "Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV.",
      "These enzymes are needed for DNA replication, transcription, repair, and recombination.",
      "Inhibition leads to breakage of DNA strands and bacterial cell death (bactericidal)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally (~70%). Absorption impaired by cations (calcium, magnesium).",
      "distribution": "Excellent tissue penetration.",
      "metabolism": "Partially metabolized in liver.",
      "excretion": "Excreted in urine and feces. Half-life ~4 hours."
    },
    "dose": "250-750 mg PO every 12 hours.",
    "adverseEffects": {
      "common": ["Nausea", "diarrhea", "dizziness", "rash", "photosensitivity."],
      "serious": ["Tendon rupture/tendinitis", "peripheral neuropathy", "CNS effects (seizures, psychosis)", "QT prolongation", "aortic aneurysm."]
    },
    "precautions": [
      "**BOXED WARNING:** Tendinitis/rupture, peripheral neuropathy, CNS effects. Avoid in myasthenia gravis.",
      "Separate from antacids, dairy, iron (2 hours before or 6 hours after).",
      "Avoid in children <18 (except specific indications) due to cartilage erosion risk."
    ],
    "contraindications": [
      "Hypersensitivity to quinolones.",
      "Concomitant tizanidine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "citalopram": {
    "name": "Citalopram (Celexa)",
    "genericName": "Citalopram",
    "brandNames": ["Celexa"],
    "category": "Antidepressant",
    "drugClass": "SSRI",
    "indications": "Treatment of depression.",
    "moaSteps": [
      "Citalopram is a selective serotonin reuptake inhibitor (SSRI).",
      "It blocks the reuptake of serotonin (5-HT) into the presynaptic neuron.",
      "This increases the amount of serotonin available in the synaptic cleft to bind to postsynaptic receptors.",
      "It has little to no affinity for other receptors (muscarinic, histaminic, adrenergic)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (~80%). Not affected by food.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in liver by CYP2C19 and CYP3A4.",
      "excretion": "Excreted in urine and feces. Half-life ~35 hours."
    },
    "dose": "20 mg PO once daily. Max 40 mg/day (Max 20 mg/day in elderly >60).",
    "adverseEffects": {
      "common": ["Nausea", "dry mouth", "somnolence", "insomnia", "sweating", "sexual dysfunction."],
      "serious": ["QT prolongation (dose-dependent)", "serotonin syndrome", "suicidality (boxed warning)."]
    },
    "precautions": [
      "**QT Prolongation:** Do not exceed 40 mg/day (or 20 mg in elderly) due to risk of QT prolongation and arrhythmias.",
      "Monitor for worsening depression/suicidality.",
      "Risk of serotonin syndrome with other serotonergic drugs."
    ],
    "contraindications": [
      "Concomitant MAOIs.",
      "Concomitant pimozide.",
      "Hypersensitivity."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "clarithromycin": {
    "name": "Clarithromycin (Biaxin)",
    "genericName": "Clarithromycin",
    "brandNames": ["Biaxin", "Biaxin XL"],
    "category": "Antibiotic",
    "drugClass": "Macrolide",
    "indications": "Respiratory tract infections (pharyngitis, sinusitis, pneumonia), skin infections, H. pylori eradication, MAC prophylaxis.",
    "moaSteps": [
      "Clarithromycin binds reversibly to the 50S ribosomal subunit of susceptible bacteria.",
      "This inhibits RNA-dependent protein synthesis.",
      "It is bacteriostatic (can be bactericidal at high concentrations)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (~50%). Stable in acid.",
      "distribution": "Good tissue penetration.",
      "metabolism": "Extensively metabolized in liver by CYP3A4 to active metabolite.",
      "excretion": "Excreted in urine. Half-life 3-7 hours."
    },
    "dose": "250-500 mg PO every 12 hours; or 1000 mg XL once daily.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "abnormal taste (metallic)", "abdominal pain.", "headache."],
      "serious": ["QT prolongation", "hepatotoxicity", "severe skin reactions", "exacerbation of myasthenia gravis."]
    },
    "precautions": [
      "**Potent CYP3A4 Inhibitor:** Numerous serious drug interactions (e.g., statins, colchicine).",
      "Risk of QT prolongation and arrhythmias.",
      "Caution in patients with coronary artery disease (increased mortality signal)."
    ],
    "contraindications": [
      "History of QT prolongation/arrhythmia.",
      "Concomitant use with statins (lovastatin, simvastatin), colchicine (in renal/hepatic impairment), ergotamines."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "clindamycin": {
    "name": "Clindamycin (Cleocin)",
    "genericName": "Clindamycin",
    "brandNames": ["Cleocin", "Clindagel"],
    "category": "Antibiotic",
    "drugClass": "Lincosamide",
    "indications": "Anaerobic infections, skin/soft tissue infections, bone/joint infections, pelvic inflammatory disease, bacterial vaginosis.",
    "moaSteps": [
      "Clindamycin binds to the 50S ribosomal subunit of bacteria.",
      "It inhibits protein synthesis by interfering with the formation of initiation complexes and translocation.",
      "Active against most Gram-positive aerobes and anaerobes."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (~90%).",
      "distribution": "Widely distributed (poor CSF). Concentrates in phagocytes.",
      "metabolism": "Metabolized in liver (CYP3A4).",
      "excretion": "Excreted in urine and feces. Half-life ~2-3 hours."
    },
    "dose": "150-450 mg PO every 6 hours. 600-900 mg IV every 8 hours.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "rash."],
      "serious": ["Clostridioides difficile-associated diarrhea (CDAD) (highest risk)", "severe skin reactions (SJS)."]
    },
    "precautions": [
      "**BOXED WARNING (CDAD):** High risk of severe, potentially fatal C. difficile colitis. Discontinue if significant diarrhea occurs.",
      "Does not treat meningitis (poor CSF penetration)."
    ],
    "contraindications": [
      "Hypersensitivity to clindamycin or lincomycin."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; monitor infant for diarrhea."
  },
  "clobetasol": {
    "name": "Clobetasol (Clobex, Temovate)",
    "genericName": "Clobetasol Propionate",
    "brandNames": ["Clobex", "Temovate", "Olux"],
    "category": "Topical Corticosteroid",
    "drugClass": "Super-Potent Corticosteroid (Class 1)",
    "indications": "Short-term treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses (e.g., psoriasis, eczema).",
    "moaSteps": [
      "Clobetasol is a super-high potency topical corticosteroid.",
      "It binds to glucocorticoid receptors in the skin.",
      "It induces lipocortins, which inhibit phospholipase A2.",
      "This reduces the release of arachidonic acid and synthesis of inflammatory mediators (prostaglandins, leukotrienes).",
      "It causes vasoconstriction and immunosuppression."
    ],
    "pharmacokinetics": {
      "absorption": "Percutaneous absorption can occur, especially with occlusion or large areas.",
      "distribution": "Systemic if absorbed.",
      "metabolism": "Hepatic if absorbed.",
      "excretion": "Renal if absorbed."
    },
    "dose": "Apply thin layer twice daily for max 2 weeks. Max 50 g/week.",
    "adverseEffects": {
      "common": ["Skin atrophy (thinning)", "striae", "telangiectasia", "burning", "acne."],
      "serious": ["HPA axis suppression (systemic absorption)", "Cushing's syndrome", "hyperglycemia."]
    },
    "precautions": [
      "Do not use for >2 consecutive weeks.",
      "Avoid use on face, groin, axillae (thin skin).",
      "Do not use with occlusive dressings (increases absorption/toxicity).",
      "Monitor for HPA suppression if used on large areas."
    ],
    "contraindications": [
      "Hypersensitivity.",
      "Viral/fungal skin infections."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Use with caution; avoid application to breast area."
  },
  "clonazepam": {
    "name": "Clonazepam (Klonopin)",
    "genericName": "Clonazepam",
    "brandNames": ["Klonopin"],
    "category": "Anticonvulsant, Anxiolytic",
    "drugClass": "Benzodiazepine (Schedule IV)",
    "indications": "Seizure disorders (Lennox-Gastaut, akinetic, myoclonic). Panic disorder.",
    "moaSteps": [
      "Clonazepam binds to benzodiazepine receptors on the GABA-A receptor complex.",
      "It enhances the affinity of GABA for the receptor.",
      "This increases the frequency of chloride channel opening.",
      "The influx of chloride hyperpolarizes neurons, inhibiting neuronal firing."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Bioavailability ~90%.",
      "distribution": "Widely distributed.",
      "metabolism": "Extensively metabolized in liver (CYP3A4, acetylation).",
      "excretion": "Excreted in urine. Long half-life ~30-40 hours."
    },
    "dose": "Panic: 0.25 mg PO twice daily, titrate to 1 mg/day. Seizures: Start 0.5 mg 3 times daily.",
    "adverseEffects": {
      "common": ["Somnolence", "dizziness", "ataxia", "fatigue", "cognitive impairment."],
      "serious": ["Respiratory depression", "abuse/dependence", "suicidal ideation", "withdrawal seizures."]
    },
    "precautions": [
      "**BOXED WARNING:** Concomitant use with opioids, abuse/misuse potential, dependence/withdrawal.",
      "Avoid abrupt discontinuation (risk of status epilepticus).",
      "Causes sedation; avoid driving."
    ],
    "contraindications": [
      "Acute narrow-angle glaucoma.",
      "Severe liver disease.",
      "Hypersensitivity."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "clonidine": {
    "name": "Clonidine (Catapres)",
    "genericName": "Clonidine",
    "brandNames": ["Catapres", "Kapvay (ADHD)"],
    "category": "Antihypertensive, ADHD Agent",
    "drugClass": "Central Alpha-2 Agonist",
    "indications": "Hypertension. ADHD. (Off-label: Opioid withdrawal, anxiety).",
    "moaSteps": [
      "Clonidine stimulates alpha-2 adrenergic receptors in the brainstem (locus coeruleus).",
      "This reduces sympathetic outflow from the CNS.",
      "The result is decreased peripheral resistance, renal vascular resistance, heart rate, and blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (~95%).",
      "distribution": "Lipophilic, enters brain.",
      "metabolism": "Metabolized in liver.",
      "excretion": "Excreted in urine. Half-life 12-16 hours."
    },
    "dose": "HTN: 0.1 mg PO twice daily. ADHD: 0.1 mg ER at bedtime.",
    "adverseEffects": {
      "common": ["Dry mouth", "drowsiness", "dizziness", "constipation", "sedation."],
      "serious": ["Rebound hypertension (if stopped abruptly)", "AV block", "bradycardia."]
    },
    "precautions": [
      "**Rebound Hypertension:** Do not stop abruptly. Taper over 2-4 days to avoid rapid BP rise, agitation, tremor.",
      "Causes significant sedation; caution with alcohol/CNS depressants.",
      "Caution in patients with bradycardia or heart block."
    ],
    "contraindications": [
      "Hypersensitivity."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "clopidogrel": {
    "name": "Clopidogrel (Plavix)",
    "genericName": "Clopidogrel",
    "brandNames": ["Plavix"],
    "category": "Antiplatelet",
    "drugClass": "P2Y12 Inhibitor (Thienopyridine)",
    "indications": "Acute coronary syndrome (ACS), recent MI, recent stroke, peripheral arterial disease (PAD). Prevention of stent thrombosis.",
    "moaSteps": [
      "Clopidogrel is a prodrug.",
      "Its active metabolite irreversibly blocks the P2Y12 component of ADP receptors on platelets.",
      "This prevents activation of the GPIIb/IIIa receptor complex.",
      "This reduces platelet aggregation for the life of the platelet (7-10 days)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Prodrug.",
      "distribution": "Proteins bound.",
      "metabolism": "Requires CYP2C19 for activation.",
      "excretion": "Excreted in urine/feces. Half-life of active metabolite ~30 min (effect is lasting)."
    },
    "dose": "75 mg PO once daily (Loading dose 300-600 mg in ACS).",
    "adverseEffects": {
      "common": ["Bleeding (bruising, epistaxis)", "pruritus."],
      "serious": ["Major hemorrhage", "Thrombotic Thrombocytopenic Purpura (TTP)."]
    },
    "precautions": [
      "**BOXED WARNING (CYP2C19):** Poor metabolizers of CYP2C19 may not convert drug to active form, leading to treatment failure (clotting). Consider genotyping.",
      "Bleeding risk. Stop 5 days before surgery.",
      "Interaction with omeprazole/esomeprazole (CYP2C19 inhibitors) may reduce efficacy."
    ],
    "contraindications": [
      "Active pathological bleeding (peptic ulcer, intracranial hemorrhage)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown; use with caution."
  },
  "clozapine": {
    "name": "Clozapine (Clozaril)",
    "genericName": "Clozapine",
    "brandNames": ["Clozaril", "Versacloz"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic",
    "indications": "Treatment-resistant schizophrenia. Suicidality in schizophrenia.",
    "moaSteps": [
      "Clozapine antagonism of dopamine D2 receptors (weak) and serotonin 5-HT2A receptors (strong).",
      "It also antagonizes adrenergic, cholinergic, and histaminergic receptors.",
      "Its unique profile provides efficacy in resistant cases with low risk of EPS."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "High protein binding.",
      "metabolism": "Extensive hepatic metabolism (CYP1A2).",
      "excretion": "Urine/feces. Half-life ~12 hours."
    },
    "dose": "Start 12.5 mg once or twice daily. Titrate slowly to 300-450 mg/day. (REMS program).",
    "adverseEffects": {
      "common": ["Sialorrhea (drooling)", "sedation", "dizziness", "constipation", "tachycardia", "weight gain."],
      "serious": ["Agranulocytosis (severe neutropenia)", "myocarditis", "seizures", "orthostatic hypotension."]
    },
    "precautions": [
      "**BOXED WARNING (Severe Neutropenia):** Can cause fatal agranulocytosis. REMS program required with frequent ANC monitoring.",
      "**BOXED WARNING (Myocarditis):** Fatal myocarditis/cardiomyopathy can occur.",
      "**BOXED WARNING (Seizures):** Dose-dependent risk.",
      "Severe constipation can lead to bowel obstruction."
    ],
    "contraindications": [
      "History of clozapine-induced agranulocytosis.",
      "Uncontrolled epilepsy."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },

    "name": "Carvedilol (Coreg)",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed, but high first-pass metabolism (bioavailability ~25-35%). Food (especially for CR) slows absorption.",
      "distribution": "Highly protein-bound (>98%). Lipophilic.",
      "excretion": "Excreted primarily in feces via bile. Half-life is ~7-10 hours.",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP2D6 and CYP2C9."
    },
    "precautions": [
      "BOXED WARNING (Abrupt Discontinuation): Abruptly stopping beta-blocker therapy can cause exacerbation of angina and, in some cases, myocardial infarction. Taper the dose slowly.",
      "Heart failure patients may experience worsening of symptoms during dose titration; diuretics may need adjustment.",
      "Can mask symptoms of hypoglycemia in diabetics.",
      "Can worsen peripheral vascular disease.",
      "Take with food to slow absorption and reduce risk of orthostatic hypotension."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "Asthma/COPD",
      "severe heart failure",
      "diabetes",
      "hepatic impairment."
    ]
  },
  "cefdinir": {
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "nausea",
        "vomiting",
        "headache",
        "vaginal candidiasis."
      ],
      "serious": [
        "Anaphylaxis",
        "Stevens-Johnson syndrome (SJS)",
        "Clostridioides difficile-associated diarrhea (CDAD)."
      ]
    },
    "brandNames": [
      "Omnicef"
    ],
    "category": "Antibiotic",
    "contraindications": [
      "Hypersensitivity to cefdinir or other cephalosporins."
    ],
    "dose": "300 mg PO twice daily or 600 mg PO once daily. Duration varies (5-10 days).",
    "drugClass": "Cephalosporin (3rd Generation)",
    "genericName": "Cefdinir",
    "indications": "Treatment of mild to moderate infections caused by susceptible bacteria, including community-acquired pneumonia, acute exacerbations of chronic bronchitis, sinusitis, pharyngitis/tonsillitis, and uncomplicated skin infections.",
    "lactationInfo": "Not detected in breast milk after a single 600 mg dose.",
    "moaSteps": [
      "Cefdinir is a third-generation cephalosporin, which is a beta-lactam antibiotic.",
      "It inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs).",
      "This interferes with the final transpeptidation step of peptidoglycan synthesis, a key component of the bacterial cell wall.",
      "Inhibition of cell wall synthesis leads to cell lysis and death (bactericidal effect)."
    ],
    "name": "Cefdinir (Omnicef)",
    "pharmacokinetics": {
      "absorption": "Bioavailability is ~16-25%. High-fat meals decrease absorption.",
      "distribution": "Widely distributed into tissues and fluids. 60-70% protein-bound.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~1.7 hours. Requires dose adjustment in renal impairment.",
      "metabolism": "Not appreciably metabolized."
    },
    "precautions": [
      "Cross-sensitivity with penicillins is possible (use with caution in penicillin-allergic patients).",
      "Can cause *C. difficile*-associated diarrhea.",
      "Taking with iron supplements or iron-fortified foods can decrease absorption. Separate by 2 hours.",
      "Can cause a harmless reddish stool, especially in infants, due to binding with iron in the GI tract."
    ],
    "pregnancyCategory": "Category B",
    "riskFactors": [
      "Penicillin allergy",
      "renal impairment."
    ]
  },
  "celecoxib": {
    "adverseEffects": {
      "common": [
        "Headache",
        "dyspepsia",
        "abdominal pain",
        "diarrhea",
        "nausea",
        "hypertension."
      ],
      "serious": [
        "Cardiovascular thrombotic events (MI, stroke)",
        "gastrointestinal bleeding and perforation",
        "hepatotoxicity",
        "nephrotoxicity",
        "severe skin reactions (SJS/TEN)."
      ]
    },
    "brandNames": [
      "Celebrex"
    ],
    "category": "Anti-inflammatory, Analgesic",
    "contraindications": [
      "Hypersensitivity",
      "history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.",
      "Coronary artery bypass graft (CABG) surgery (perioperative pain).",
      "Known sulfa allergy (celecoxib is a sulfonamide)."
    ],
    "dose": "Osteoarthritis: 200 mg PO once daily or 100 mg twice daily. Rheumatoid Arthritis: 100-200 mg PO twice daily.",
    "drugClass": "NSAID, COX-2 Selective Inhibitor",
    "genericName": "Celecoxib",
    "indications": "Relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Management of acute pain. Treatment of primary dysmenorrhea.",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution.",
    "moaSteps": [
      "Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID).",
      "It selectively inhibits the cyclooxygenase-2 (COX-2) enzyme.",
      "COX-2 is an inducible enzyme responsible for synthesizing prostaglandins at sites of inflammation, which mediate pain, fever, and inflammation.",
      "Unlike traditional NSAIDs (like ibuprofen, naproxen), it does not significantly inhibit the COX-1 enzyme at therapeutic doses.",
      "COX-1 is responsible for producing prostaglandins that protect the stomach lining and support platelet function. By sparing COX-1, celecoxib is thought to have a lower risk of GI ulceration."
    ],
    "name": "Celecoxib (Celebrex)",
    "pharmacokinetics": {
      "absorption": "Well absorbed. Peak levels in ~3 hours. High-fat meal delays absorption.",
      "distribution": "Highly protein-bound (~97%).",
      "excretion": "Excreted in feces and urine as metabolites. Half-life is ~11 hours.",
      "metabolism": "Extensively metabolized in the liver by CYP2C9."
    },
    "precautions": [
      "BOXED WARNING (Cardiovascular Risk): NSAIDs, including celecoxib, cause an increased risk of serious cardiovascular thrombotic events (myocardial infarction, stroke), which can be fatal. Risk may increase with duration of use and in patients with cardiovascular disease.",
      "BOXED WARNING (Gastrointestinal Risk): NSAIDs cause an increased risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These can occur at any time without warning. Elderly patients are at higher risk.",
      "Use lowest effective dose for the shortest duration possible.",
      "Use with caution in patients with heart failure, hypertension, or fluid retention.",
      "Monitor for GI bleeding and cardiovascular events."
    ],
    "pregnancyCategory": "Category C (prior to 30 weeks); Category D (at 30 weeks or later) - can cause premature closure of ductus arteriosus.",
    "riskFactors": [
      "History of cardiovascular disease",
      "history of GI ulcers/bleeding",
      "elderly",
      "sulfa allergy."
    ]
  },
  "dabigatran": {
    "adverseEffects": {
      "common": [
        "Bleeding (e.g., bruising)",
        "dyspepsia (indigestion)",
        "gastritis-like symptoms (abdominal pain, GERD)."
      ],
      "serious": [
        "Major bleeding (intracranial hemorrhage, GI bleed)",
        "epidural or spinal hematoma."
      ]
    },
    "brandNames": [
      "Pradaxa"
    ],
    "category": "Anticoagulant",
    "contraindications": [
      "Active pathological bleeding",
      "hypersensitivity",
      "patients with mechanical prosthetic heart valves."
    ],
    "dose": {
      "initialDose": "Nonvalvular A-fib: 150 mg PO twice daily. DVT/PE Treatment: 150 mg PO twice daily (after 5-10 days of parenteral anticoagulant).",
      "maxDose": "150 mg PO twice daily.",
      "notes": "Requires dose adjustment in renal impairment. Capsules must be swallowed whole and stored in original container."
    },
    "drugClass": "Direct Thrombin Inhibitor (DOAC)",
    "genericName": "Dabigatran",
    "indications": "Prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Treatment and prevention of DVT/PE. Prophylaxis of DVT/PE after hip replacement surgery.",
    "lactationInfo": "Unknown if excreted in human milk; not recommended.",
    "moaSteps": [
      "Dabigatran is a prodrug converted to its active form, which is a direct, competitive, reversible inhibitor of thrombin (Factor IIa).",
      "It inhibits both free and clot-bound thrombin, as well as thrombin-induced platelet aggregation.",
      "By inhibiting thrombin, it prevents the conversion of fibrinogen to fibrin, the final step in the coagulation cascade."
    ],
    "name": "Dabigatran (Pradaxa)",
    "pharmacokinetics": {
      "absorption": "Low bioavailability (~3-7%). Prodrug is hydrolyzed in gut, liver, and blood.",
      "distribution": "Low protein binding (~35%).",
      "excretion": "Primarily excreted unchanged in the urine (~80%). Half-life is ~12-17 hours.",
      "metabolism": "Prodrug is hydrolyzed to active dabigatran. Not significantly metabolized by CYP450."
    },
    "precautions": [
      "BOXED WARNING (Premature Discontinuation): Discontinuing dabigatran prematurely increases the risk of thrombotic events.",
      "BOXED WARNING (Spinal/Epidural Hematoma): Risk of spinal hematoma with neuraxial anesthesia, which can cause paralysis.",
      "Capsules must be swallowed whole. Do not break, chew, or open.",
      "Store in original container to protect from moisture. Idarucizumab (Praxbind) is the reversal agent."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "Renal impairment",
      "age >75",
      "active bleeding",
      "concomitant use of P-gp inhibitors."
    ]
  },
  "dapagliflozin": {
    "adverseEffects": {
      "common": [
        "Genital mycotic infections (yeast infections)",
        "urinary tract infections (UTIs)",
        "increased urination",
        "nasopharyngitis."
      ],
      "serious": [
        "Ketoacidosis (can occur with normal blood glucose levels)",
        "acute kidney injury",
        "Fournier's gangrene",
        "hypotension (volume depletion)."
      ]
    },
    "brandNames": [
      "Farxiga"
    ],
    "category": "Antidiabetic, Heart Failure Agent",
    "contraindications": [
      "Hypersensitivity",
      "patients on dialysis."
    ],
    "dose": {
      "initialDose": "5-10 mg PO once daily in the morning.",
      "maxDose": "10 mg PO once daily.",
      "notes": "Can be taken with or without food."
    },
    "drugClass": "SGLT2 Inhibitor",
    "genericName": "Dapagliflozin",
    "indications": "Adjunct to diet and exercise to improve glycemic control in type 2 diabetes. To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes. To reduce the risk of CV death and hospitalization for heart failure in adults with HFrEF. To reduce risk of CKD progression.",
    "lactationInfo": "Not recommended.",
    "moaSteps": [
      "Dapagliflozin is a selective inhibitor of the Sodium-Glucose Cotransporter 2 (SGLT2) in the proximal renal tubules.",
      "SGLT2 is responsible for reabsorbing the majority of filtered glucose from the tubular fluid.",
      "By inhibiting SGLT2, it blocks glucose reabsorption, leading to increased urinary glucose excretion (glucosuria).",
      "This action lowers blood glucose levels independent of insulin and also causes a mild osmotic diuresis, reducing blood pressure."
    ],
    "name": "Dapagliflozin (Farxiga)",
    "pharmacokinetics": {
      "absorption": "Well absorbed. Peak concentration in ~2 hours.",
      "distribution": "Highly protein-bound (~91%).",
      "excretion": "Excreted primarily in the urine as metabolites. Half-life is ~12.9 hours.",
      "metabolism": "Metabolized in the liver (via UGT) to inactive metabolites."
    },
    "precautions": [
      "BOXED WARNING (Lower Limb Amputation): A risk seen with another drug in the class (canagliflozin). Monitor for new pain, sores, or infections in lower limbs.",
      "Can cause volume depletion and hypotension. Assess volume status before starting.",
      "Risk of ketoacidosis. Monitor for symptoms and stop therapy if suspected.",
      "Risk of serious genital and urinary tract infections."
    ],
    "pregnancyCategory": "Category C. Not recommended in 2nd and 3rd trimesters.",
    "riskFactors": [
      "Renal impairment",
      "elderly",
      "concomitant diuretic use",
      "history of genital infections."
    ]
  },
  "daptomycin": {
    "adverseEffects": {
      "common": [
        "Nausea",
        "diarrhea",
        "constipation",
        "headache",
        "rash",
        "injection site reactions."
      ],
      "serious": [
        "Myopathy and rhabdomyolysis",
        "eosinophilic pneumonia",
        "peripheral neuropathy",
        "Clostridioides difficile-associated diarrhea (CDAD)."
      ]
    },
    "brandNames": [
      "Cubicin",
      "Cubicin RF"
    ],
    "category": "Antibiotic",
    "contraindications": [
      "Hypersensitivity to daptomycin."
    ],
    "dose": {
      "initialDose": "cSSSI: 4 mg/kg IV once every 24 hours. Bacteremia: 6 mg/kg IV once every 24 hours.",
      "maxDose": "Up to 8-10 mg/kg/day for severe infections.",
      "notes": "Administer over 30 minutes. Requires dose adjustment in renal impairment (CrCl < 30 mL/min)."
    },
    "drugClass": "Lipopeptide Antibiotic",
    "genericName": "Daptomycin",
    "indications": "Treatment of complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria. Treatment of Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis.",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution.",
    "moaSteps": [
      "Daptomycin is a cyclic lipopeptide antibiotic.",
      "It binds to bacterial cell membranes in a calcium-dependent manner.",
      "It inserts its lipophilic tail into the membrane, causing rapid membrane depolarization.",
      "This leads to a loss of membrane potential, inhibiting DNA, RNA, and protein synthesis, and resulting in bacterial cell death (bactericidal)."
    ],
    "name": "Daptomycin (Cubicin)",
    "pharmacokinetics": {
      "absorption": "Administered IV.",
      "distribution": "Moderately protein-bound (~92%).",
      "excretion": "Primarily excreted unchanged in the urine. Half-life is ~8-9 hours.",
      "metabolism": "Minimally metabolized."
    },
    "precautions": [
      "**Myopathy and Rhabdomyolysis:** Can cause skeletal muscle toxicity. Monitor creatine phosphokinase (CPK) levels weekly. Temporarily discontinue HMG-CoA reductase inhibitors (statins) during therapy.",
      "**Eosinophilic Pneumonia:** A rare, serious pulmonary reaction. Monitor for fever, dyspnea, and new pulmonary infiltrates.",
      "**Ineffective for Pneumonia:** Daptomycin is inactivated by pulmonary surfactant and **must not be used** to treat pneumonia."
    ],
    "pregnancyCategory": "Category B",
    "riskFactors": [
      "Renal impairment",
      "concomitant statin use."
    ]
  },
  "desvenlafaxine": {
    "adverseEffects": {
      "common": [
        "Nausea",
        "dizziness",
        "insomnia",
        "somnolence",
        "dry mouth",
        "constipation",
        "hyperhidrosis (excessive sweating)",
        "sexual dysfunction."
      ],
      "serious": [
        "Suicidal thoughts and behaviors",
        "serotonin syndrome",
        "hypertension (can increase blood pressure)",
        "activation of mania/hypomania."
      ]
    },
    "brandNames": [
      "Pristiq",
      "Khedezla"
    ],
    "category": "Antidepressant",
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (within 14 days) or linezolid/methylene blue."
    ],
    "dose": {
      "initialDose": "50 mg PO once daily.",
      "maxDose": "400 mg/day (though no evidence of greater benefit >50 mg).",
      "notes": "Take with or without food. Requires dose adjustment in renal and hepatic impairment."
    },
    "drugClass": "Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)",
    "genericName": "Desvenlafaxine",
    "indications": "Treatment of major depressive disorder (MDD).",
    "lactationInfo": "Excreted in breast milk; use with caution.",
    "moaSteps": [
      "Desvenlafaxine is the active metabolite of venlafaxine.",
      "It is a potent inhibitor of the neuronal reuptake of both serotonin (5-HT) and norepinephrine (NE).",
      "By blocking these reuptake pumps, it increases the concentration of 5-HT and NE in the synaptic cleft, enhancing neurotransmission."
    ],
    "name": "Desvenlafaxine (Pristiq)",
    "pharmacokinetics": {
      "absorption": "Well absorbed. Peak concentration in 7.5 hours (ER tablet).",
      "distribution": "Low protein binding (~30%).",
      "excretion": "Excreted in the urine. Half-life is ~11 hours.",
      "metabolism": "Metabolized primarily by UGT (conjugation) with a minor pathway via CYP3A4."
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults (18-24). Monitor closely.",
      "Risk of Serotonin Syndrome. Monitor for symptoms.",
      "Can increase blood pressure. Monitor BP before and during treatment.",
      "Abrupt discontinuation can cause severe withdrawal symptoms. Taper dose slowly."
    ],
    "pregnancyCategory": "Category C. Use in 3rd trimester may be associated with neonatal withdrawal.",
    "riskFactors": [
      "Concomitant MAOI or serotonergic drug use",
      "bipolar disorder",
      "hypertension."
    ]
  },
  "dexamethasone": {
    "adverseEffects": {
      "common": [
        "(Short-term) Insomnia, hyperglycemia, increased appetite, nervousness, fluid retention.",
        "(Long-term) Cushing's syndrome (moon face, buffalo hump), osteoporosis, immunosuppression, cataracts, muscle wasting."
      ],
      "serious": [
        "Adrenal suppression (must taper off)",
        "severe infections",
        "psychosis",
        "peptic ulcer perforation",
        "osteonecrosis."
      ]
    },
    "brandNames": [
      "Decadron",
      "DexPak"
    ],
    "category": "Anti-inflammatory, Immunosuppressant",
    "contraindications": [
      "Systemic fungal infections",
      "hypersensitivity",
      "administration of live or live-attenuated vaccines (if receiving immunosuppressive doses)."
    ],
    "dose": {
      "initialDose": "Varies widely. 0.5-9 mg/day PO in divided doses.",
      "maxDose": "Dose is highly variable.",
      "notes": "COVID-19: 6 mg PO or IV once daily for up to 10 days. Potent, long-acting glucocorticoid."
    },
    "drugClass": "Corticosteroid",
    "genericName": "Dexamethasone",
    "indications": "Treatment of various inflammatory, allergic, and autoimmune conditions. Cerebral edema. Diagnosis of Cushing's syndrome. COVID-19 (in hospitalized patients requiring oxygen).",
    "lactationInfo": "Excreted in breast milk; may suppress infant growth. Use with caution.",
    "moaSteps": [
      "Dexamethasone is a potent, long-acting glucocorticoid with minimal mineralocorticoid activity.",
      "It binds to intracellular glucocorticoid receptors and modifies gene expression.",
      "It suppresses inflammation by inhibiting the synthesis of pro-inflammatory mediators (prostaglandins, leukotrienes, cytokines).",
      "It suppresses the immune system by reducing the activity and proliferation of lymphocytes."
    ],
    "name": "Dexamethasone (Decadron)",
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed orally.",
      "distribution": "Widely distributed. Crosses the blood-brain barrier and placenta.",
      "excretion": "Excreted in the urine as metabolites. Long biologic half-life (36-72 hours).",
      "metabolism": "Metabolized in the liver by CYP3A4."
    },
    "precautions": [
      "Prolonged use can cause HPA axis suppression. Dose must be tapered slowly to avoid adrenal crisis.",
      "Can mask signs of infection and increase susceptibility.",
      "Monitor for hyperglycemia, hypertension, and psychiatric disturbances."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "Long-term use",
      "high doses",
      "systemic fungal infections."
    ]
  },
  "dexlansoprazole": {
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "abdominal pain",
        "nausea",
        "vomiting",
        "flatulence",
        "headache."
      ],
      "serious": [
        "Clostridioides difficile-associated diarrhea (CDAD)",
        "bone fractures (long-term use)",
        "hypomagnesemia (long-term use)",
        "Vitamin B12 deficiency (long-term use)",
        "acute interstitial nephritis (AIN)."
      ]
    },
    "brandNames": [
      "Dexilant"
    ],
    "category": "Antiulcer Agent",
    "contraindications": [
      "Hypersensitivity to dexlansoprazole or other PPIs."
    ],
    "dose": {
      "initialDose": "Erosive Esophagitis: 60 mg PO once daily. Non-erosive GERD: 30 mg PO once daily.",
      "maxDose": "60 mg PO once daily.",
      "notes": "Uses a dual delayed-release (DDR) formulation, with two types of granules."
    },
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "genericName": "Dexlansoprazole",
    "indications": "Healing and maintenance of erosive esophagitis. Treatment of symptomatic, non-erosive gastroesophageal reflux disease (GERD).",
    "lactationInfo": "Unknown if excreted in human milk; use with caution.",
    "moaSteps": [
      "Dexlansoprazole is the R-enantiomer of lansoprazole.",
      "It is a proton pump inhibitor (PPI) that irreversibly blocks the H+/K+-ATPase enzyme system (the 'proton pump') in gastric parietal cells.",
      "This is the final step in gastric acid secretion, suppressing basal and stimulated gastric acid secretion."
    ],
    "name": "Dexlansoprazole (Dexilant)",
    "pharmacokinetics": {
      "absorption": "Delayed release. Two peaks of absorption (1-2 hours and 4-5 hours) due to DDR formulation.",
      "distribution": "Highly protein-bound (~96-99%).",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~1-2 hours.",
      "metabolism": "Extensively metabolized in the liver by CYP2C19 and CYP3A4."
    },
    "precautions": [
      "PPI use is associated with an increased risk of *C. difficile*-associated diarrhea.",
      "Long-term use (>1 year) may be associated with an increased risk of osteoporosis-related bone fractures.",
      "Long-term use can lead to hypomagnesemia and vitamin B12 deficiency."
    ],
    "pregnancyCategory": "Category B",
    "riskFactors": [
      "Long-term use",
      "high doses",
      "elderly."
    ]
  },
  "dextroamphetamine-amphetamine": {
    "adverseEffects": {
      "common": [
        "Insomnia",
        "decreased appetite",
        "weight loss",
        "dry mouth",
        "headache",
        "abdominal pain",
        "nervousness",
        "tachycardia",
        "hypertension."
      ],
      "serious": [
        "Abuse and dependence",
        "serious cardiovascular events (sudden death, stroke, MI)",
        "new or worsening psychiatric symptoms (psychosis, mania)",
        "seizures."
      ]
    },
    "brandNames": [
      "Adderall",
      "Adderall XR",
      "Mydayis"
    ],
    "category": "CNS Stimulant",
    "contraindications": [
      "Hypersensitivity",
      "advanced arteriosclerosis",
      "symptomatic cardiovascular disease",
      "moderate to severe hypertension",
      "hyperthyroidism",
      "glaucoma",
      "agitated states",
      "history of drug abuse",
      "concomitant use with MAOIs (within 14 days)."
    ],
    "dose": {
      "initialDose": "ADHD (Adult, IR): 5-40 mg/day PO in 1-3 divided doses. (XR): 20 mg PO once daily in the morning.",
      "maxDose": "Varies by formulation and age, e.g., 40 mg/day (IR) for adult ADHD.",
      "notes": "Highly individualized dosing. Take in the morning."
    },
    "drugClass": "CNS Stimulant",
    "genericName": "Amphetamine and Dextroamphetamine Mixed Salts",
    "indications": "Treatment of Attention Deficit Hyperactivity Disorder (ADHD). Treatment of narcolepsy.",
    "lactationInfo": "Excreted in breast milk; not recommended.",
    "moaSteps": [
      "Amphetamines are CNS stimulants.",
      "They block the reuptake of norepinephrine (NE) and dopamine (DA) into the presynaptic neuron.",
      "They also increase the release of NE and DA from presynaptic stores.",
      "This leads to a significant increase in the concentration of these neurotransmitters in the synaptic cleft, improving attention, focus, and impulse control."
    ],
    "name": "Dextroamphetamine/Amphetamine (Adderall)",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Peak levels in ~3 hours (IR) or ~7 hours (XR).",
      "distribution": "Widely distributed, including into the CNS.",
      "excretion": "Excreted in the urine. Excretion is pH-dependent (faster in acidic urine).",
      "metabolism": "Metabolized in the liver by CYP2D6."
    },
    "precautions": [
      "BOXED WARNING (Abuse and Dependence): CNS stimulants have a high potential for abuse and dependence.",
      "BOXED WARNING (Cardiovascular Risk): Misuse can cause sudden death and serious cardiovascular adverse events.",
      "Monitor blood pressure and heart rate.",
      "Can cause suppression of growth in children."
    ],
    "pregnancyCategory": "Category C",
    "riskFactors": [
      "History of substance abuse",
      "cardiovascular disease",
      "hypertension",
      "psychiatric disorders."
    ]
  },
  "diazepam": {
    "adverseEffects": {
      "common": [
        "Drowsiness",
        "sedation",
        "dizziness",
        "ataxia (impaired coordination)",
        "fatigue",
        "slurred speech",
        "muscle weakness."
      ],
      "serious": [
        "Respiratory depression",
        "severe hypotension",
        "abuse, misuse, and addiction",
        "paradoxical reactions (anxiety, agitation)."
      ]
    },
    "brandNames": [
      "Valium",
      "Diastat (Rectal)"
    ],
    "category": "Anxiolytic, Sedative-Hypnotic, Anticonvulsant",
    "contraindications": [
      "Hypersensitivity to benzodiazepines",
      "acute narrow-angle glaucoma",
      "severe respiratory insufficiency",
      "myasthenia gravis."
    ],
    "dose": {
      "initialDose": "Anxiety: 2-10 mg PO 2-4 times daily. Status Epilepticus: 5-10 mg IV, may repeat.",
      "maxDose": "Varies by indication.",
      "notes": "Long-acting due to active metabolites."
    },
    "drugClass": "Benzodiazepine (Long-acting)",
    "genericName": "Diazepam",
    "indications": "Management of anxiety disorders. Short-term relief of anxiety. Symptomatic relief of acute alcohol withdrawal. Adjunct for skeletal muscle spasm and seizure disorders (e.g., status epilepticus).",
    "lactationInfo": "Excreted in breast milk; not recommended.",
    "moaSteps": [
      "Diazepam is a positive allosteric modulator of the GABA-A receptor.",
      "It binds to the benzodiazepine site on the receptor, enhancing the effect of the inhibitory neurotransmitter GABA.",
      "It increases the *frequency* of chloride channel opening, leading to an influx of chloride ions.",
      "This hyperpolarizes the neuron, resulting in CNS depression (anxiolytic, sedative, anticonvulsant, and muscle relaxant effects)."
    ],
    "name": "Diazepam (Valium)",
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed orally. Onset (IV) in 1-5 minutes.",
      "distribution": "Widely distributed, lipophilic. Highly protein-bound (~98%).",
      "excretion": "Excreted in the urine as metabolites. Half-life is long (Diazepam: 20-50h; Nordiazepam: 40-100h).",
      "metabolism": "Extensively metabolized in the liver by CYP2C19 and CYP3A4 to several active metabolites (e.g., nordiazepam, temazepam, oxazepam)."
    },
    "precautions": [
      "BOXED WARNING (Risks with Opioids): Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.",
      "BOXED WARNING (Abuse, Misuse, Addiction): Risk of abuse, misuse, and addiction.",
      "BOXED WARNING (Dependence and Withdrawal): Physical dependence and severe, life-threatening withdrawal reactions can occur. Taper dose slowly."
    ],
    "pregnancyCategory": "Category D",
    "riskFactors": [
      "Concomitant opioid use",
      "history of substance abuse",
      "elderly",
      "hepatic impairment."
    ]
  },
  "diclofenac": {
    "adverseEffects": {
      "common": [
        "Dyspepsia",
        "nausea",
        "abdominal pain",
        "headache",
        "dizziness",
        "elevated LFTs.",
        "Application site reactions (topical)."
      ],
      "serious": [
        "Gastrointestinal bleeding and perforation",
        "cardiovascular thrombotic events (MI, stroke)",
        "hepatotoxicity",
        "nephrotoxicity."
      ]
    },
    "brandNames": [
      "Voltaren (gel)",
      "Cataflam (IR tablet)",
      "Voltaren-XR (ER tablet)",
      "Cambia (powder)"
    ],
    "category": "Analgesic, Anti-inflammatory",
    "contraindications": [
      "Hypersensitivity to diclofenac or other NSAIDs",
      "history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.",
      "Coronary artery bypass graft (CABG) surgery (perioperative pain)."
    ],
    "dose": {
      "initialDose": "OA: 50 mg PO 2-3 times daily. RA: 50 mg PO 3-4 times daily. Topical Gel: 2-4 g applied to affected joint 4 times daily.",
      "maxDose": "PO: 150 mg/day (Cataflam) or 100 mg/day (Voltaren-XR).",
      "notes": "Take with food or milk to reduce GI upset."
    },
    "drugClass": "Nonsteroidal Anti-inflammatory Drug (NSAID)",
    "genericName": "Diclofenac",
    "indications": "Relief of pain and inflammation in rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Topical: Relief of joint pain of osteoarthritis. Also for acute pain and dysmenorrhea.",
    "lactationInfo": "Excreted in breast milk in very small amounts; likely compatible.",
    "moaSteps": [
      "Diclofenac is a nonselective NSAID.",
      "It inhibits the cyclooxygenase (COX-1 and COX-2) enzymes.",
      "This action blocks the conversion of arachidonic acid to prostaglandins, which are mediators of pain, inflammation, and fever."
    ],
    "name": "Diclofenac (Voltaren)",
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed orally, but high first-pass metabolism (bioavailability ~55%). Topical absorption is minimal.",
      "distribution": "Highly protein-bound (>99%).",
      "excretion": "Excreted in urine and feces (via bile) as metabolites. Short half-life (~1-2 hours).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP2C9."
    },
    "precautions": [
      "BOXED WARNING (Cardiovascular Risk): NSAIDs cause an increased risk of serious cardiovascular thrombotic events (MI, stroke).",
      "BOXED WARNING (Gastrointestinal Risk): NSAIDs cause an increased risk of serious GI adverse events including bleeding, ulceration, and perforation.",
      "BOXED WARNING (Topical): The same CV and GI warnings apply to the topical gel, as systemic absorption occurs.",
      "Can cause hepatotoxicity. Monitor LFTs, especially with long-term use."
    ],
    "pregnancyCategory": "Category C (prior to 30 weeks); Category D (at 30 weeks or later).",
    "riskFactors": [
      "History of cardiovascular disease",
      "history of GI ulcers",
      "elderly",
      "renal/hepatic impairment."
    ]
  },
  "dicyclomine": {
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "dizziness",
        "blurred vision",
        "nausea",
        "drowsiness",
        "constipation",
        "urinary retention."
      ],
      "serious": [
        "Paralytic ileus",
        "toxic megacolon",
        "heat prostration (heatstroke)",
        "psychosis",
        "delirium."
      ]
    },
    "brandNames": [
      "Bentyl"
    ],
    "category": "Antispasmodic",
    "contraindications": [
      "Hypersensitivity",
      "Obstructive uropathy",
      "Obstructive disease of the GI tract (e.g., paralytic ileus)",
      "Severe ulcerative colitis",
      "Reflux esophagitis",
      "Glaucoma",
      "Myasthenia gravis",
      "Unstable cardiovascular status in acute hemorrhage",
      "Infants less than 6 months old"
    ],
    "dose": "Oral: 20 mg PO 4 times daily. May titrate up to 40 mg 4 times daily.",
    "drugClass": "Anticholinergic",
    "genericName": "Dicyclomine",
    "indications": "Treatment of functional bowel/irritable bowel syndrome (IBS).",
    "lactationInfo": "Excreted in breast milk; not recommended (can cause apnea in infants).",
    "moaSteps": [
      "Dicyclomine is an anticholinergic (antimuscarinic) agent.",
      "It relieves smooth muscle spasm of the gastrointestinal tract.",
      "It acts by blocking the action of acetylcholine at muscarinic receptors on smooth muscle, reducing motility and secretion."
    ],
    "name": "Dicyclomine (Bentyl)",
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Onset in 1-2 hours.",
      "distribution": "Widely distributed.",
      "excretion": "Primarily excreted in urine. Half-life is ~1.8 hours.",
      "metabolism": "Metabolized in the liver."
    },
    "precautions": [
      "Use with caution in the elderly (high risk of confusion, anticholinergic effects).",
      "Can cause drowsiness and blurred vision; caution against driving.",
      "Risk of heat prostration in high environmental temperatures.",
      "Use with caution in patients with BPH, glaucoma, or autonomic neuropathy."
    ],
    "pregnancyCategory": "Category B",
    "riskFactors": [
      "Elderly patients",
      "infants < 6 months",
      "glaucoma",
      "BPH",
      "GI obstruction."
    ]
  },"enalapril": {
    "name": "Enalapril (Vasotec)",
    "genericName": "Enalapril",
    "brandNames": ["Vasotec", "Epaned"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin-Converting Enzyme (ACE) Inhibitor",
    "indications": "Treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction.",
    "moaSteps": [
      "Enalapril is a prodrug that is hydrolyzed to its active metabolite, enalaprilat.",
      "Enalaprilat competitively inhibits the angiotensin-converting enzyme (ACE).",
      "This prevents the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor).",
      "Decreased angiotensin II leads to vasodilation, reduced secretion of aldosterone, and a decrease in blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (~60%). Prodrug (enalapril) is absorbed, not enalaprilat. Food does not affect absorption.",
      "distribution": "Enalaprilat is ~50-60% protein-bound. Does not cross blood-brain barrier well.",
      "metabolism": "Hydrolyzed in the liver to active enalaprilat.",
      "excretion": "Primarily excreted in the urine as enalaprilat. Half-life of enalaprilat is ~11 hours."
    },
    "dose": "Hypertension: 5-40 mg PO once daily or in two divided doses. Heart Failure: 2.5-20 mg PO twice daily.",
    "adverseEffects": {
      "common": ["Dry, persistent cough", "dizziness", "headache", "hyperkalemia", "hypotension."],
      "serious": ["Angioedema", "acute renal failure", "agranulocytosis", "hepatotoxicity."]
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected.",
      "Risk of angioedema, especially in Black patients.",
      "Monitor renal function and serum potassium.",
      "Can cause symptomatic hypotension, especially in volume-depleted patients."
    ],
    "contraindications": [
      "Hypersensitivity to enalapril or other ACE inhibitors",
      "history of angioedema",
      "concomitant use with aliskiren in patients with diabetes",
      "Pregnancy."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "enoxaparin": {
    "name": "Enoxaparin (Lovenox)",
    "genericName": "Enoxaparin",
    "brandNames": ["Lovenox"],
    "category": "Anticoagulant",
    "drugClass": "Low Molecular Weight Heparin (LMWH)",
    "indications": "Prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Treatment of acute ST-elevation myocardial infarction (STEMI).",
    "moaSteps": [
      "Enoxaparin is a low molecular weight heparin.",
      "It binds to and potentiates antithrombin III, a natural inhibitor of coagulation factors.",
      "This complex inhibits Factor Xa much more specifically than it inhibits Factor IIa (thrombin).",
      "By inhibiting Factor Xa, it prevents the conversion of prothrombin to thrombin, thus preventing the formation of fibrin clots."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed after subcutaneous injection. High bioavailability (~92%).",
      "distribution": "Volume of distribution is ~4.3 L.",
      "metabolism": "Metabolized in the liver by desulfation and depolymerization.",
      "excretion": "Primarily excreted in the urine as metabolites. Half-life is ~4.5-7 hours."
    },
    "dose": "DVT Prophylaxis: 30 mg SC every 12 hours or 40 mg SC once daily. DVT/PE Treatment: 1 mg/kg SC every 12 hours.",
    "adverseEffects": {
      "common": ["Bleeding", "anemia", "injection site reactions (hematoma, pain)", "fever."],
      "serious": ["Major bleeding", "thrombocytopenia (HIT)", "epidural or spinal hematoma."]
    },
    "precautions": [
      "BOXED WARNING (Spinal/Epidural Hematoma): Patients receiving neuraxial anesthesia or undergoing spinal puncture are at risk of developing an epidural or spinal hematoma, which can result in long-term or permanent paralysis. Risk is increased by indwelling epidural catheters or concomitant use of other drugs affecting hemostasis.",
      "Monitor for signs of bleeding.",
      "Monitor platelet count (for HIT).",
      "Requires dose adjustment in severe renal impairment (CrCl < 30 mL/min)."
    ],
    "contraindications": [
      "Active major bleeding",
      "hypersensitivity to enoxaparin, heparin, or pork products",
      "history of heparin-induced thrombocytopenia (HIT)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Not expected to be excreted in breast milk in significant amounts; use with caution."
  },
  "entacapone": {
    "name": "Entacapone (Comtan)",
    "genericName": "Entacapone",
    "brandNames": ["Comtan"],
    "category": "Antiparkinsonian",
    "drugClass": "Catechol-O-Methyltransferase (COMT) Inhibitor",
    "indications": "Adjunctive treatment to carbidopa/levodopa in patients with Parkinson's disease experiencing 'wearing-off' episodes.",
    "moaSteps": [
      "Entacapone is a selective and reversible inhibitor of Catechol-O-Methyltransferase (COMT).",
      "In the periphery, COMT is a major enzyme responsible for metabolizing levodopa to 3-O-methyldopa (3-OMD).",
      "By inhibiting peripheral COMT, entacapone decreases the breakdown of levodopa.",
      "This increases the plasma half-life of levodopa and increases the amount of levodopa that crosses the blood-brain barrier, thus prolonging its therapeutic effect."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High first-pass metabolism. Bioavailability ~35%.",
      "distribution": "Highly protein-bound (~98%).",
      "metabolism": "Extensively metabolized by glucuronidation.",
      "excretion": "Excreted in feces (~90%) and urine (~10%). Half-life is ~2.4 hours."
    },
    "dose": "200 mg PO administered with each dose of carbidopa/levodopa. Max 8 times per day (1600 mg).",
    "adverseEffects": {
      "common": ["Dyskinesias (worsening)", "nausea", "urine discoloration (brownish-orange)", "diarrhea", "abdominal pain", "hallucinations."],
      "serious": ["Hepatotoxicity (rare)", "rhabdomyolysis", "neuroleptic malignant syndrome-like symptoms (with abrupt withdrawal)."]
    },
    "precautions": [
      "May increase the risk of dyskinesia or hallucinations (may require levodopa dose reduction).",
      "Can cause a harmless brownish-orange discoloration of the urine.",
      "Monitor for orthostatic hypotension.",
      "Avoid abrupt discontinuation."
    ],
    "contraindications": [
      "Hypersensitivity to entacapone",
      "concomitant use with non-selective MAO inhibitors."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "entecavir": {
    "name": "Entecavir (Baraclude)",
    "genericName": "Entecavir",
    "brandNames": ["Baraclude"],
    "category": "Antiviral",
    "drugClass": "Antiviral, Nucleoside Reverse Transcriptase Inhibitor (NRTI), HBV",
    "indications": "Treatment of chronic hepatitis B virus (HBV) infection in adults and children with evidence of active viral replication.",
    "moaSteps": [
      "Entecavir is a guanosine nucleoside analog.",
      "It is phosphorylated by cellular enzymes to its active triphosphate form.",
      "Entecavir triphosphate competes with the natural substrate (dGTP) for viral HBV DNA polymerase.",
      "Incorporation into the viral DNA chain causes termination of DNA synthesis, inhibiting HBV replication."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Food decreases absorption. Bioavailability is ~100%.",
      "distribution": "Widely distributed. Moderately protein-bound (~13%).",
      "metabolism": "Not significantly metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~128-149 hours (intracellularly)."
    },
    "dose": "Nucleoside-naive: 0.5 mg PO once daily. Lamivudine-refractory: 1 mg PO once daily. Must be taken on an empty stomach.",
    "adverseEffects": {
      "common": ["Headache", "fatigue", "dizziness", "nausea."],
      "serious": ["Lactic acidosis", "severe hepatomegaly with steatosis", "severe acute exacerbations of Hepatitis B upon discontinuation."]
    },
    "precautions": [
      "BOXED WARNING (HBV Exacerbations): Severe acute exacerbations of hepatitis B have been reported after stopping therapy. Monitor liver function closely for several months after discontinuation.",
      "BOXED WARNING (Lactic Acidosis): Lactic acidosis and severe hepatomegaly with steatosis have been reported with NRTIs.",
      "BOXED WARNING (HIV Resistance): May cause HIV resistance in patients with co-infection who are not on antiretroviral therapy. Test for HIV before starting."
    ],
    "contraindications": [
      "Hypersensitivity to entecavir."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "epinephrine": {
    "name": "Epinephrine (Adrenalin, EpiPen)",
    "genericName": "Epinephrine",
    "brandNames": ["Adrenalin", "EpiPen", "Auvi-Q"],
    "category": "Vasopressor, Bronchodilator",
    "drugClass": "Alpha/Beta Adrenergic Agonist",
    "indications": "Treatment of anaphylaxis. Treatment of cardiac arrest (ACLS). Treatment of bronchospasm. Used with local anesthetics to prolong action.",
    "moaSteps": [
      "Epinephrine is a non-selective adrenergic agonist, acting on alpha-1, beta-1, and beta-2 receptors.",
      "**Alpha-1 agonist:** Causes potent vasoconstriction, which increases blood pressure and decreases mucosal edema (useful in anaphylaxis).",
      "**Beta-1 agonist:** Increases heart rate (chronotropy) and force of contraction (inotropy), which is useful in cardiac arrest.",
      "**Beta-2 agonist:** Causes potent bronchodilation, relieving bronchospasm in anaphylaxis and asthma."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid onset after IM or SC injection. Not absorbed orally.",
      "distribution": "Widely distributed, but does not cross the blood-brain barrier well.",
      "metabolism": "Rapidly metabolized in the liver and other tissues by COMT and MAO.",
      "excretion": "Metabolites excreted in urine. Very short half-life (~2-3 minutes)."
    },
    "dose": "Anaphylaxis (EpiPen): 0.3 mg (Auto-injector) IM. ACLS: 1 mg IV/IO every 3-5 minutes.",
    "adverseEffects": {
      "common": ["Anxiety", "tremor", "palpitations", "tachycardia", "headache", "dizziness", "hypertension."],
      "serious": ["Ventricular arrhythmias", "myocardial infarction", "severe hypertension", "pulmonary edema."]
    },
    "precautions": [
      "Use with caution in patients with cardiovascular disease, hypertension, or hyperthyroidism.",
      "Can cause severe tissue necrosis if extravasation occurs (with IV infusion).",
      "Auto-injectors should be injected into the anterolateral thigh."
    ],
    "contraindications": [
      "No absolute contraindications in a life-threatening situation (like anaphylaxis).",
      "Contraindicated in angle-closure glaucoma, and non-life-threatening uses in patients with shock (other than anaphylactic)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "eplerenone": {
    "name": "Eplerenone (Inspra)",
    "genericName": "Eplerenone",
    "brandNames": ["Inspra"],
    "category": "Antihypertensive",
    "drugClass": "Aldosterone Antagonist, Potassium-sparing Diuretic",
    "indications": "Treatment of hypertension. Treatment of heart failure (HFrEF) post-myocardial infarction.",
    "moaSteps": [
      "Eplerenone is a selective aldosterone antagonist.",
      "It binds to the mineralocorticoid receptor (MR) and blocks the binding of aldosterone.",
      "Aldosterone normally causes sodium and water retention and potassium excretion.",
      "By blocking aldosterone, eplerenone promotes sodium and water excretion and potassium retention, thus lowering blood pressure and reducing cardiac workload."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Bioavailability ~69%.",
      "distribution": "Moderately protein-bound (~50%).",
      "metabolism": "Metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~4-6 hours."
    },
    "dose": "Hypertension: 50-100 mg PO once daily. Heart Failure: 25-50 mg PO once daily.",
    "adverseEffects": {
      "common": ["Hyperkalemia", "dizziness", "headache", "diarrhea", "fatigue."],
      "serious": ["Severe hyperkalemia", "renal failure."]
    },
    "precautions": [
      "Risk of hyperkalemia, especially in patients with renal impairment or diabetes.",
      "Monitor serum potassium and renal function regularly.",
      "Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole)."
    ],
    "contraindications": [
      "Hyperkalemia",
      "severe renal impairment (CrCl < 30 mL/min)",
      "concomitant use with strong CYP3A4 inhibitors."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "eprosartan": {
    "name": "Eprosartan (Teveten)",
    "genericName": "Eprosartan",
    "brandNames": ["Teveten"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin II Receptor Blocker (ARB)",
    "indications": "Treatment of hypertension.",
    "moaSteps": [
      "Eprosartan is a selective angiotensin II receptor blocker (ARB).",
      "It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking its binding to the AT1 receptor.",
      "This blockade results in vasodilation, decreased secretion of aldosterone, and a reduction in blood pressure.",
      "Unlike ACE inhibitors, it does not inhibit the breakdown of bradykinin (less cough)."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly absorbed. Bioavailability ~13%.",
      "distribution": "Highly protein-bound (~98%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Primarily excreted in feces (via bile) and urine. Half-life is ~5-9 hours."
    },
    "dose": "400-800 mg PO once daily.",
    "adverseEffects": {
      "common": ["Dizziness", "headache", "fatigue", "hyperkalemia."],
      "serious": ["Angioedema (rare)", "hypotension", "acute renal failure."]
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected.",
      "Can cause symptomatic hypotension.",
      "Monitor renal function and serum potassium."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with aliskiren in patients with diabetes",
      "Pregnancy."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Discontinue nursing or discontinue drug; not recommended."
  },
  "eptifibatide": {
    "name": "Eptifibatide (Integrilin)",
    "genericName": "Eptifibatide",
    "brandNames": ["Integrilin"],
    "category": "Antiplatelet",
    "drugClass": "Glycoprotein (GP) IIb/IIIa Inhibitor",
    "indications": "Treatment of acute coronary syndrome (ACS) (unstable angina, NSTEMI). Used in patients undergoing percutaneous coronary intervention (PCI).",
    "moaSteps": [
      "Eptifibatide is a cyclic heptapeptide.",
      "It is a reversible inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor.",
      "The GP IIb/IIIa receptor is the final common pathway for platelet aggregation, binding fibrinogen to link platelets together.",
      "By blocking this receptor, eptifibatide prevents platelet aggregation and thrombus formation."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV.",
      "distribution": "Low protein binding (~25%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Primarily excreted in the urine. Short half-life (~2.5 hours)."
    },
    "dose": "ACS: 180 mcg/kg IV bolus, followed by 2 mcg/kg/min infusion. PCI: 180 mcg/kg IV bolus, then another bolus 10 min later, and infusion.",
    "adverseEffects": {
      "common": ["Bleeding (e.g., at access site)", "hypotension."],
      "serious": ["Major bleeding (intracranial, GI)", "thrombocytopenia."]
    },
    "precautions": [
      "High risk of bleeding. Monitor closely.",
      "Monitor platelet count.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Active pathological bleeding",
      "history of stroke within 30 days",
      "severe uncontrolled hypertension",
      "recent major surgery",
      "thrombocytopenia."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "eribulin": {
    "name": "Eribulin (Halaven)",
    "genericName": "Eribulin",
    "brandNames": ["Halaven"],
    "category": "Antineoplastic Agent",
    "drugClass": "Microtubule Inhibitor, Halichondrin",
    "indications": "Treatment of metastatic breast cancer in patients who have previously received at least two prior chemotherapy regimens. Treatment of unresectable or metastatic liposarcoma.",
    "moaSteps": [
      "Eribulin is a synthetic analog of halichondrin B, a natural product from a marine sponge.",
      "It is a non-taxane microtubule inhibitor.",
      "It binds to the growing '+' ends of microtubules, inhibiting their growth phase.",
      "This prevents the formation of the mitotic spindle, leading to cell cycle arrest at the G2/M phase and subsequent apoptosis (cell death)."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV.",
      "distribution": "Widely distributed. Moderately protein-bound (~49-65%).",
      "metabolism": "Minimally metabolized by CYP3A4.",
      "excretion": "Primarily excreted in feces. Half-life is ~40 hours."
    },
    "dose": "1.4 mg/m IV over 2-5 minutes on Days 1 and 8 of a 21-day cycle.",
    "adverseEffects": {
      "common": ["Neutropenia", "anemia", "fatigue", "alopecia (hair loss)", "nausea", "constipation", "peripheral neuropathy."],
      "serious": ["Severe neutropenia (febrile neutropenia)", "severe peripheral neuropathy", "QT prolongation."]
    },
    "precautions": [
      "BOXED WARNING: Can cause severe myelosuppression (neutropenia). Monitor complete blood counts.",
      "Monitor for peripheral neuropathy.",
      "Can cause QT prolongation. Monitor electrolytes and EKG.",
      "Requires dose adjustment in hepatic and moderate renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to eribulin."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "erlotinib": {
    "name": "Erlotinib (Tarceva)",
    "genericName": "Erlotinib",
    "brandNames": ["Tarceva"],
    "category": "Antineoplastic Agent",
    "drugClass": "Tyrosine Kinase Inhibitor (TKI), EGFR Inhibitor",
    "indications": "Treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Treatment of pancreatic cancer (in combination with gemcitabine).",
    "moaSteps": [
      "Erlotinib is a tyrosine kinase inhibitor (TKI).",
      "It reversibly inhibits the intracellular phosphorylation of epidermal growth factor receptor (EGFR).",
      "In certain cancers, EGFR is mutated and constitutively active, driving cell proliferation and survival.",
      "By blocking EGFR, erlotinib inhibits the downstream signaling pathways (like MAPK and PI3K/AKT), leading to cell cycle arrest and apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (~60%). Food (high-fat) increases absorption to ~100%. Must be taken on an empty stomach.",
      "distribution": "Widely distributed. Highly protein-bound (~93%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Primarily excreted in feces as metabolites. Half-life is ~36 hours."
    },
    "dose": "NSCLC: 150 mg PO once daily. Pancreatic Cancer: 100 mg PO once daily. Take on an empty stomach.",
    "adverseEffects": {
      "common": ["Rash (acne-like)", "diarrhea", "anorexia", "fatigue", "nausea", "vomiting."],
      "serious": ["Interstitial lung disease (ILD)", "hepatotoxicity", "GI perforation", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "Risk of severe, sometimes fatal, interstitial lung disease (ILD).",
      "Can cause severe diarrhea; manage with loperamide.",
      "Monitor liver function (LFTs).",
      "Cigarette smoking *decreases* erlotinib levels; dose adjustment may be needed.",
      "Avoid concomitant use with strong CYP3A4 inhibitors or inducers."
    ],
    "contraindications": [
      "Hypersensitivity to erlotinib."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "ertapenem": {
    "name": "Ertapenem (Invanz)",
    "genericName": "Ertapenem",
    "brandNames": ["Invanz"],
    "category": "Antibiotic",
    "drugClass": "Carbapenem Antibiotic",
    "indications": "Treatment of moderate to severe infections caused by susceptible bacteria, including complicated intra-abdominal infections, complicated skin infections, and community-acquired pneumonia.",
    "moaSteps": [
      "Ertapenem is a beta-lactam antibiotic, belonging to the carbapenem class.",
      "It inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs).",
      "This action prevents the final transpeptidation step of peptidogylcan synthesis, leading to cell lysis and death (bactericidal effect).",
      "It is stable against most beta-lactamases."
    ],
    "pharmacokinetics": {
      "absorption": "Completely absorbed after IM injection. Administered IV or IM.",
      "distribution": "Highly protein-bound (~85-95%).",
      "metabolism": "Metabolized via hydrolysis of the beta-lactam ring.",
      "excretion": "Excreted in urine and feces. Half-life is ~4 hours, allowing for once-daily dosing."
    },
    "dose": "1 gram IV or IM once daily.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "headache", "injection site reactions.", "elevated LFTs."],
      "serious": ["Seizures", "anaphylaxis", "Clostridioides difficile-associated diarrhea (CDAD)."]
    },
    "precautions": [
      "Carbapenems as a class are associated with a risk of seizures, especially in patients with CNS disorders or renal impairment.",
      "Cross-sensitivity with penicillins is possible.",
      "Requires dose adjustment in renal impairment (CrCl < 30 mL/min)."
    ],
    "contraindications": [
      "Hypersensitivity to ertapenem or other carbapenems",
      "history of anaphylactic reaction to beta-lactams."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "erythromycin": {
    "name": "Erythromycin (Ery-Tab, E.E.S.)",
    "genericName": "Erythromycin",
    "brandNames": ["Ery-Tab", "E.E.S.", "Erythrocin"],
    "category": "Antibiotic",
    "drugClass": "Macrolide Antibiotic",
    "indications": "Treatment of various bacterial infections (e.g., community-acquired pneumonia, skin infections, strep throat in penicillin-allergic patients). Used as a prokinetic agent for gastroparesis.",
    "moaSteps": [
      "Erythromycin is a macrolide antibiotic.",
      "It inhibits bacterial protein synthesis by reversibly binding to the 50S ribosomal subunit.",
      "This binding blocks the translocation step of protein synthesis, preventing the growing peptide chain from being elongated.",
      "It is typically bacteriostatic, but can be bactericidal at high concentrations."
    ],
    "pharmacokinetics": {
      "absorption": "Absorption is variable and formulation-dependent. Food can decrease absorption of the base. Enteric-coated (Ery-Tab) is better.",
      "distribution": "Widely distributed into tissues and fluids. 70-80% protein-bound.",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Excreted primarily in bile (feces). Short half-life (~1.5-2 hours)."
    },
    "dose": "250-500 mg PO every 6-12 hours. Varies by infection.",
    "adverseEffects": {
      "common": ["Gastrointestinal distress (nausea, vomiting, abdominal pain, diarrhea) - very common", "rash."],
      "serious": ["QT prolongation and Torsades de Pointes", "hepatotoxicity (cholestatic hepatitis)", "ototoxicity (hearing loss)."]
    },
    "precautions": [
      "High risk of GI upset.",
      "Can cause QT prolongation, increasing the risk of fatal arrhythmias. Use with caution with other QT-prolonging drugs.",
      "Potent inhibitor of CYP3A4, leading to many significant drug interactions (e.g., statins, warfarin)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with drugs that are highly dependent on CYP3A4 for clearance (e.g., simvastatin, lovastatin)",
      "patients with history of QT prolongation."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; generally considered compatible."
  },
  "escitalopram": {
    "name": "Escitalopram (Lexapro)",
    "genericName": "Escitalopram",
    "brandNames": ["Lexapro"],
    "category": "Antidepressant",
    "drugClass": "Selective Serotonin Reuptake Inhibitor (SSRI)",
    "indications": "Treatment of major depressive disorder (MDD). Treatment of generalized anxiety disorder (GAD).",
    "moaSteps": [
      "Escitalopram is the S-enantiomer of citalopram.",
      "It is a highly selective serotonin reuptake inhibitor (SSRI).",
      "It blocks the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane.",
      "This action increases the concentration of serotonin in the synaptic cleft, enhancing serotonergic neurotransmission.",
      "It has minimal effects on norepinephrine or dopamine reuptake."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Bioavailability ~80%. Not affected by food.",
      "distribution": "Widely distributed. Moderately protein-bound (~56%).",
      "metabolism": "Metabolized in the liver by CYP2C19, CYP3A4, and CYP2D6.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~27-32 hours."
    },
    "dose": "10-20 mg PO once daily.",
    "adverseEffects": {
      "common": ["Nausea", "headache", "insomnia", "somnolence", "sexual dysfunction (decreased libido, anorgasmia)", "sweating."],
      "serious": ["Suicidal thoughts and behaviors", "serotonin syndrome", "SIADH (hyponatremia)", "QT prolongation."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults (18-24). Monitor closely.",
      "Risk of Serotonin Syndrome, especially with other serotonergic drugs.",
      "Can cause QT prolongation. Do not exceed 10 mg/day in elderly or poor CYP2C19 metabolizers.",
      "Abrupt discontinuation can cause withdrawal symptoms. Taper slowly."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (within 14 days) or linezolid/methylene blue."
    ],
    "pregnancyCategory": "Category C. Use in 3rd trimester may be associated with neonatal withdrawal.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "esomeprazole": {
    "name": "Esomeprazole (Nexium)",
    "genericName": "Esomeprazole",
    "brandNames": ["Nexium"],
    "category": "Antiulcer Agent",
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "indications": "Treatment of gastroesophageal reflux disease (GERD). Healing of erosive esophagitis. H. pylori eradication. Risk reduction of NSAID-associated gastric ulcers.",
    "moaSteps": [
      "Esomeprazole is the S-enantiomer of omeprazole.",
      "It is a proton pump inhibitor (PPI) that irreversibly blocks the H+/K+-ATPase enzyme system (the 'proton pump') in gastric parietal cells.",
      "This is the final step in gastric acid secretion.",
      "It suppresses basal and stimulated gastric acid secretion, leading to a profound and long-lasting reduction of stomach acid."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability increases with repeated dosing. Food decreases absorption.",
      "distribution": "Highly protein-bound (~97%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C19 and CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~1-1.5 hours."
    },
    "dose": "GERD: 20-40 mg PO once daily. Take 60 minutes before a meal.",
    "adverseEffects": {
      "common": ["Headache", "diarrhea", "nausea", "abdominal pain", "flatulence", "constipation."],
      "serious": ["Clostridioides difficile-associated diarrhea (CDAD)", "bone fractures (long-term use)", "hypomagnesemia (long-term use)", "Vitamin B12 deficiency (long-term use)."]
    },
    "precautions": [
      "PPI use is associated with an increased risk of *C. difficile*-associated diarrhea.",
      "Long-term use (>1 year) may be associated with an increased risk of osteoporosis-related bone fractures.",
      "Long-term use can lead to hypomagnesemia and vitamin B12 deficiency.",
      "Inhibits CYP2C19 and may decrease the effectiveness of clopidogrel."
    ],
    "contraindications": [
      "Hypersensitivity to esomeprazole or other PPIs."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "eszopiclone": {
    "name": "Eszopiclone (Lunesta)",
    "genericName": "Eszopiclone",
    "brandNames": ["Lunesta"],
    "category": "Sedative-Hypnotic",
    "drugClass": "Non-benzodiazepine Hypnotic (Z-drug)",
    "indications": "Treatment of insomnia (for sleep onset and sleep maintenance).",
    "moaSteps": [
      "Eszopiclone is a non-benzodiazepine hypnotic (a 'Z-drug').",
      "It is the S-enantiomer of zopiclone.",
      "It acts as a positive allosteric modulator of the GABA-A receptor, but at a site distinct from benzodiazepines.",
      "This binding enhances the effect of the inhibitory neurotransmitter GABA, leading to chloride ion influx, hyperpolarization, and CNS depression (sedation)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Peak concentration in ~1 hour. High-fat meal decreases absorption.",
      "distribution": "Widely distributed. Moderately protein-bound (~52-59%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4 and CYP2E1.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~6 hours."
    },
    "dose": "Initial: 1 mg PO immediately before bedtime. May be increased to 2 mg or 3 mg. Max 3 mg/day.",
    "adverseEffects": {
      "common": ["Unpleasant (metallic) taste", "headache", "somnolence", "dizziness", "dry mouth."],
      "serious": ["Complex sleep behaviors (e.g., sleep-driving, sleep-eating)", "next-day impairment", "abuse and dependence."]
    },
    "precautions": [
      "BOXED WARNING (Complex Sleep Behaviors): Cases of complex sleep behaviors (e.g., sleepwalking, sleep-driving) have been reported, which may result in serious injury or death. Discontinue immediately if this occurs.",
      "Risk of next-day impairment. Do not drive or perform hazardous activities until you know how it affects you.",
      "Risk of abuse, dependence, and withdrawal. Use lowest effective dose for shortest duration.",
      "Use with caution in elderly patients (start with 1 mg)."
    ],
    "contraindications": [
      "Hypersensitivity to eszopiclone",
      "history of complex sleep behaviors after taking eszopiclone."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },"famotidine": {
    "name": "Famotidine (Pepcid)",
    "genericName": "Famotidine",
    "brandNames": ["Pepcid", "Pepcid AC", "Zantac 360"],
    "category": "Antiulcer Agent",
    "drugClass": "Histamine H2-Receptor Antagonist (H2RA)",
    "indications": "Treatment of active duodenal and gastric ulcers. Management of gastroesophageal reflux disease (GERD). Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).",
    "moaSteps": [
      "Famotidine is a competitive inhibitor of histamine H2-receptors.",
      "It specifically blocks histamine from binding to H2-receptors on the basolateral membrane of gastric parietal cells.",
      "This action inhibits basal and stimulated gastric acid secretion, reducing both the volume and acid concentration of gastric juice."
    ],
    "pharmacokinetics": {
      "absorption": "Incompletely absorbed. Bioavailability is ~40-45%.",
      "distribution": "Low protein binding (~15-20%).",
      "metabolism": "Minimally metabolized in the liver (~30%).",
      "excretion": "Primarily excreted unchanged in the urine. Half-life is ~2.5-3.5 hours."
    },
    "dose": "GERD: 20-40 mg PO twice daily. Duodenal Ulcer: 40 mg PO at bedtime.",
    "adverseEffects": {
      "common": ["Headache", "dizziness", "constipation", "diarrhea."],
      "serious": ["Thrombocytopenia", "QT prolongation (rare, in renal impairment)", "confusion (rare, in elderly/renal impairment)."]
    },
    "precautions": [
      "Requires dose adjustment in moderate to severe renal impairment.",
      "Use with caution in the elderly, as they are more susceptible to CNS side effects.",
      "Prolonged use may lead to Vitamin B12 deficiency (rare)."
    ],
    "contraindications": [
      "Hypersensitivity to famotidine or other H2-receptor antagonists."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "febuxostat": {
    "name": "Febuxostat (Uloric)",
    "genericName": "Febuxostat",
    "brandNames": ["Uloric"],
    "category": "Antigout Agent",
    "drugClass": "Xanthine Oxidase Inhibitor (Non-purine)",
    "indications": "Chronic management of hyperuricemia in patients with gout.",
    "moaSteps": [
      "Febuxostat is a non-purine, selective inhibitor of xanthine oxidase.",
      "Xanthine oxidase is the enzyme responsible for the conversion of hypoxanthine to xanthine, and xanthine to uric acid.",
      "By blocking this enzyme, febuxostat decreases the production of uric acid, lowering serum uric acid concentrations."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~49%.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Extensively metabolized in the liver by UGT and CYP enzymes.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~5-8 hours."
    },
    "dose": "40-80 mg PO once daily.",
    "adverseEffects": {
      "common": ["Liver function abnormalities", "nausea", "arthralgia", "rash."],
      "serious": ["Cardiovascular death (increased risk vs. allopurinol)", "hepatotoxicity", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "BOXED WARNING (Cardiovascular Death): Gout patients with established cardiovascular disease treated with febuxostat had a higher rate of cardiovascular death than those treated with allopurinol in a large study. Use should be reserved for those who cannot tolerate or have failed allopurinol.",
      "Monitor liver function tests.",
      "An acute gout attack may be precipitated during initial therapy; co-administer colchicine or an NSAID for the first 3-6 months."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with azathioprine or mercaptopurine (febuxostat will drastically increase their levels)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "felodipine": {
    "name": "Felodipine (Plendil)",
    "genericName": "Felodipine",
    "brandNames": ["Plendil"],
    "category": "Antihypertensive",
    "drugClass": "Calcium Channel Blocker (Dihydropyridine)",
    "indications": "Treatment of hypertension.",
    "moaSteps": [
      "Felodipine is a dihydropyridine calcium channel blocker.",
      "It inhibits the influx of calcium ions across cell membranes into vascular smooth muscle cells.",
      "It acts primarily on peripheral blood vessels, causing potent vasodilation.",
      "This vasodilation reduces peripheral vascular resistance, which in turn lowers blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Completely absorbed, but high first-pass metabolism. Bioavailability ~15%. High-fat meal significantly increases absorption.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~11-16 hours."
    },
    "dose": "2.5-10 mg PO once daily.",
    "adverseEffects": {
      "common": ["Peripheral edema (swelling of ankles)", "headache", "flushing", "dizziness", "gingival hyperplasia."],
      "serious": ["Severe hypotension", "reflex tachycardia", "worsening of angina."]
    },
    "precautions": [
      "Use with caution in patients with heart failure.",
      "Avoid large amounts of grapefruit juice (a strong CYP3A4 inhibitor).",
      "Can cause gingival hyperplasia (gum overgrowth); good dental hygiene is important."
    ],
    "contraindications": [
      "Hypersensitivity to felodipine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "fenofibrate": {
    "name": "Fenofibrate (Tricor, Lofibra)",
    "genericName": "Fenofibrate",
    "brandNames": ["Tricor", "Lofibra", "Trilipix"],
    "category": "Antihyperlipidemic",
    "drugClass": "Fibrate",
    "indications": "Adjunct to diet to lower elevated triglycerides (hypertriglyceridemia). Adjunct to diet to lower LDL-C and Total-C in mixed dyslipidemia.",
    "moaSteps": [
      "Fenofibrate is a prodrug converted to its active metabolite, fenofibric acid.",
      "Fenofibric acid activates Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha).",
      "Activation of PPAR-alpha increases the synthesis of lipoprotein lipase and apolipoproteins A-I and A-II.",
      "This enhances the breakdown (lipolysis) of triglyceride-rich particles (VLDL), significantly lowering triglycerides and modestly increasing HDL ('good cholesterol')."
    ],
    "pharmacokinetics": {
      "absorption": "Varies by formulation. Some must be taken with food. Bioavailability is high.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Prodrug is rapidly hydrolyzed to active fenofibric acid, which is then conjugated.",
      "excretion": "Excreted in the urine as metabolites. Half-life is ~20 hours."
    },
    "dose": "Varies by formulation. e.g., Tricor 145 mg PO once daily.",
    "adverseEffects": {
      "common": ["Abdominal pain", "nausea", "headache", "back pain", "elevated LFTs."],
      "serious": ["Hepatotoxicity", "myopathy and rhabdomyolysis (especially with statins)", "pancreatitis", "cholelithiasis (gallstones)."]
    },
    "precautions": [
      "Increased risk of myopathy/rhabdomyolysis when used with statins. Monitor CPK levels.",
      "Monitor liver function tests.",
      "Can increase the risk of cholelithiasis (gallstones).",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe renal or hepatic impairment",
      "pre-existing gallbladder disease."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "fentanyl": {
    "name": "Fentanyl (Duragesic, Actiq, Sublimaze)",
    "genericName": "Fentanyl",
    "brandNames": ["Duragesic (patch)", "Actiq (lozenge)", "Sublimaze (injection)"],
    "category": "Analgesic, Opioid",
    "drugClass": "Opioid Analgesic (Schedule II)",
    "indications": "Injection: Analgesia and anesthesia for surgery. Patch: Management of persistent, severe pain in opioid-tolerant patients. Lozenge/Film: Breakthrough pain in cancer patients.",
    "moaSteps": [
      "Fentanyl is a synthetic opioid agonist.",
      "It binds with high affinity to mu-opioid receptors in the central nervous system (CNS).",
      "Activation of mu-opioid receptors mimics the action of endogenous endorphins, causing analgesia (pain relief), sedation, and euphoria.",
      "It also causes respiratory depression by reducing the responsiveness of the brainstem respiratory centers."
    ],
    "pharmacokinetics": {
      "absorption": "Varies by formulation. IV: 100% bioavailable. Transdermal (patch): Slow, continuous absorption. Transmucosal (lozenge): Rapid absorption.",
      "distribution": "Highly lipophilic, widely distributed, crosses blood-brain barrier rapidly.",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Half-life is long and variable (patch)."
    },
    "dose": "Highly individualized. Dosed in mcg. Patch: 12-100 mcg/hour applied every 72 hours. IV: 25-100 mcg.",
    "adverseEffects": {
      "common": ["Sedation", "drowsiness", "nausea", "vomiting", "constipation", "dizziness", "dry mouth."],
      "serious": ["Respiratory depression", "severe hypotension", "abuse, addiction, and overdose", "muscle rigidity (chest wall)."]
    },
    "precautions": [
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse, which can lead to overdose and death.",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Accidental Ingestion): Accidental exposure (e.g., to a patch) can be fatal, especially in children.",
      "BOXED WARNING (CYP3A4 Inhibitors): Concomitant use with CYP3A4 inhibitors can increase fentanyl levels, causing fatal respiratory depression.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "Patches should not be used for acute pain or in non-opioid tolerant patients."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "acute or severe bronchial asthma",
      "paralytic ileus."
    ],
    "pregnancyCategory": "Category C. Can cause neonatal opioid withdrawal.",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "fesoterodine": {
    "name": "Fesoterodine (Toviaz)",
    "genericName": "Fesoterodine",
    "brandNames": ["Toviaz"],
    "category": "Antispasmodic, Urinary",
    "drugClass": "Anticholinergic, Antimuscarinic",
    "indications": "Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.",
    "moaSteps": [
      "Fesoterodine is a prodrug that is rapidly hydrolyzed to its active metabolite, 5-HMT.",
      "5-HMT is a competitive antagonist of muscarinic receptors (anticholinergic).",
      "It blocks muscarinic receptors (primarily M2 and M3) on the bladder detrusor muscle.",
      "This action inhibits involuntary bladder contractions and reduces the urgency and frequency of urination."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed and hydrolyzed to 5-HMT. Bioavailability ~52%.",
      "distribution": "Low protein binding (~50%).",
      "metabolism": "Hydrolyzed to 5-HMT (active), which is then metabolized by CYP2D6 and CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Half-life of 5-HMT is ~7 hours."
    },
    "dose": "4-8 mg PO once daily.",
    "adverseEffects": {
      "common": ["Dry mouth (xerostomia)", "constipation", "dry eyes", "blurred vision", "dizziness.", "urinary retention."],
      "serious": ["Angioedema", "urinary retention", "heat prostration", "confusion (especially in elderly)."]
    },
    "precautions": [
      "Use with caution in the elderly (high anticholinergic burden).",
      "Risk of heat prostration in hot environments.",
      "Use with caution in patients with gastric retention, uncontrolled narrow-angle glaucoma, or BPH."
    ],
    "contraindications": [
      "Hypersensitivity",
      "urinary retention",
      "gastric retention",
      "uncontrolled narrow-angle glaucoma."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "fexofenadine": {
    "name": "Fexofenadine (Allegra)",
    "genericName": "Fexofenadine",
    "brandNames": ["Allegra"],
    "category": "Antihistamine",
    "drugClass": "Antihistamine, 2nd Generation (Non-sedating)",
    "indications": "Relief of symptoms associated with seasonal allergic rhinitis. Treatment of chronic idiopathic urticaria (hives).",
    "moaSteps": [
      "Fexofenadine is the active metabolite of terfenadine.",
      "It is a second-generation antihistamine that selectively antagonizes peripheral H1-receptors.",
      "By blocking histamine from binding to H1-receptors in the vasculature and respiratory tract, it reduces the symptoms of allergy (e.g., sneezing, itching, runny nose, watery eyes).",
      "It does not readily cross the blood-brain barrier, which accounts for its non-sedating properties."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Peak concentration in 2-3 hours.",
      "distribution": "Moderately protein-bound (~60-70%).",
      "metabolism": "Minimally metabolized (~5%).",
      "excretion": "Excreted primarily unchanged in feces (via bile) and urine. Half-life is ~14 hours."
    },
    "dose": "Allergic Rhinitis: 60 mg PO twice daily or 180 mg PO once daily.",
    "adverseEffects": {
      "common": ["Headache", "drowsiness (rare)", "nausea", "dizziness."],
      "serious": ["Hypersensitivity reactions (rare)."]
    },
    "precautions": [
      "Requires dose adjustment in renal impairment (use 60 mg once daily).",
      "Avoid taking with fruit juices (e.g., apple, orange, grapefruit) as they can decrease absorption."
    ],
    "contraindications": [
      "Hypersensitivity to fexofenadine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "fidaxomicin": {
    "name": "Fidaxomicin (Dificid)",
    "genericName": "Fidaxomicin",
    "brandNames": ["Dificid"],
    "category": "Antibiotic",
    "drugClass": "Macrolide Antibiotic (Narrow Spectrum)",
    "indications": "Treatment of Clostridioides difficile-associated diarrhea (CDAD) in adults.",
    "moaSteps": [
      "Fidaxomicin is a macrolide antibiotic with a narrow spectrum of activity, primarily against *C. difficile*.",
      "It inhibits bacterial protein synthesis by binding to the sigma subunit of RNA polymerase.",
      "This action inhibits the transcription step of protein synthesis, leading to cell death (bactericidal effect).",
      "It has minimal systemic absorption and acts locally in the gastrointestinal tract."
    ],
    "pharmacokinetics": {
      "absorption": "Minimally absorbed systemically. Remains in the GI tract.",
      "distribution": "Acts locally in the colon.",
      "metabolism": "Metabolized by hydrolysis to an active metabolite (OP-1118) in the GI tract.",
      "excretion": "Primarily excreted in feces as the drug and its active metabolite."
    },
    "dose": "200 mg PO twice daily for 10 days.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "abdominal pain", "diarrhea."],
      "serious": ["Hypersensitivity reactions", "anaphylaxis", "angioedema."]
    },
    "precautions": [
      "Not effective for systemic infections.",
      "Use with caution in patients with a history of macrolide allergy."
    ],
    "contraindications": [
      "Hypersensitivity to fidaxomicin."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "finasteride": {
    "name": "Finasteride (Proscar, Propecia)",
    "genericName": "Finasteride",
    "brandNames": ["Proscar", "Propecia"],
    "category": "BPH Agent, Hair Loss Agent",
    "drugClass": "5-Alpha-Reductase Inhibitor",
    "indications": "Proscar (5 mg): Treatment of symptomatic benign prostatic hyperplasia (BPH) to improve symptoms and reduce risk of acute urinary retention. Propecia (1 mg): Treatment of androgenetic alopecia (male pattern hair loss).",
    "moaSteps": [
      "Finasteride is a competitive inhibitor of 5-alpha-reductase, type II.",
      "This enzyme is responsible for converting testosterone to dihydrotestosterone (DHT) in the prostate, hair follicles, and other tissues.",
      "DHT is a potent androgen responsible for prostate growth (in BPH) and hair follicle miniaturization (in hair loss).",
      "By blocking DHT production, finasteride causes prostate shrinkage and can increase hair growth."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Bioavailability ~65%.",
      "distribution": "Widely distributed. Highly protein-bound (~90%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in feces and urine as metabolites. Half-life is ~5-6 hours."
    },
    "dose": "BPH (Proscar): 5 mg PO once daily. Hair Loss (Propecia): 1 mg PO once daily.",
    "adverseEffects": {
      "common": ["Sexual dysfunction (decreased libido, erectile dysfunction, ejaculatory dysfunction)", "gynecomastia."],
      "serious": ["Increased risk of high-grade prostate cancer (Proscar)", "depression", "male breast cancer (rare)."]
    },
    "precautions": [
      "Can cause a decrease in prostate-specific antigen (PSA) levels. PSA levels should be 'doubled' for comparison in patients taking finasteride.",
      "May be associated with an increased risk of high-grade prostate cancer.",
      "Monitor for depression and sexual side effects."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category X)**. Pregnant women or women of childbearing potential should not handle crushed or broken tablets, as finasteride can be absorbed through the skin and cause birth defects in a male fetus."
    ],
    "pregnancyCategory": "Category X",
    "lactationInfo": "Not indicated for use in women."
  },
  "fluconazole": {
    "name": "Fluconazole (Diflucan)",
    "genericName": "Fluconazole",
    "brandNames": ["Diflucan"],
    "category": "Antifungal",
    "drugClass": "Azole Antifungal",
    "indications": "Treatment of vaginal candidiasis (yeast infection). Treatment and suppression of cryptococcal meningitis. Treatment of oropharyngeal and esophageal candidiasis.",
    "moaSteps": [
      "Fluconazole is an azole antifungal agent.",
      "It inhibits the fungal cytochrome P450 enzyme, 14-alpha-sterol demethylase.",
      "This enzyme is essential for the conversion of lanosterol to ergosterol.",
      "Ergosterol is a vital component of the fungal cell membrane. By depleting ergosterol, fluconazole disrupts the membrane's structure and function, leading to inhibition of fungal growth (fungistatic)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. High bioavailability (>90%). Not affected by food.",
      "distribution": "Widely distributed, including into the cerebrospinal fluid (CSF). Low protein binding (~11-12%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine (>80%). Long half-life (~30 hours)."
    },
    "dose": "Vaginal Candidiasis: 150 mg PO as a single dose. Oropharyngeal Candidiasis: 200 mg PO on day 1, then 100 mg PO once daily.",
    "adverseEffects": {
      "common": ["Headache", "nausea", "abdominal pain", "diarrhea", "rash."],
      "serious": ["Hepatotoxicity (liver failure)", "QT prolongation and Torsades de Pointes", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "Can cause hepatotoxicity. Monitor liver function in patients on long-term therapy.",
      "Can cause QT prolongation; use with caution.",
      "Moderate inhibitor of CYP2C9, 2C19, and 3A4, leading to many drug interactions (e.g., warfarin).",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with other drugs known to prolong the QT interval and are metabolized by CYP3A4."
    ],
    "pregnancyCategory": "Category D (at high, chronic doses). Single 150 mg dose is Category C.",
    "lactationInfo": "Excreted in breast milk in concentrations similar to plasma; use with caution."
  },
  "fluoxetine": {
    "name": "Fluoxetine (Prozac, Sarafem)",
    "genericName": "Fluoxetine",
    "brandNames": ["Prozac", "Sarafem"],
    "category": "Antidepressant",
    "drugClass": "Selective Serotonin Reuptake Inhibitor (SSRI)",
    "indications": "Treatment of major depressive disorder (MDD), obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder. (Sarafem): Premenstrual dysphoric disorder (PMDD).",
    "moaSteps": [
      "Fluoxetine is a selective serotonin reuptake inhibitor (SSRI).",
      "It potently blocks the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane.",
      "This action increases the concentration of serotonin in the synaptic cleft, enhancing serotonergic neurotransmission.",
      "It has minimal effects on norepinephrine or dopamine reuptake."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Food does not significantly affect it.",
      "distribution": "Widely distributed. Highly protein-bound (~95%).",
      "metabolism": "Extensively metabolized in the liver by CYP2D6 to an active metabolite, norfluoxetine.",
      "excretion": "Excreted in urine as metabolites. Has a very long half-life (Fluoxetine: 1-4 days; Norfluoxetine: 7-15 days)."
    },
    "dose": "MDD: 20-80 mg PO once daily.",
    "adverseEffects": {
      "common": ["Nausea", "headache", "insomnia", "somnolence", "anxiety", "sexual dysfunction", "diarrhea."],
      "serious": ["Suicidal thoughts and behaviors", "serotonin syndrome", "QT prolongation", "SIADH (hyponatremia)."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults (18-24). Monitor closely.",
      "Very long half-life means it takes 5-6 weeks to reach steady state and 5-6 weeks to clear from the body. (Important for drug interactions).",
      "Potent inhibitor of CYP2D6, leading to many drug interactions.",
      "Risk of Serotonin Syndrome."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (must have a 5-week washout period after stopping fluoxetine)."
    ],
    "pregnancyCategory": "Category C. Can be associated with neonatal withdrawal.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "fluticasone": {
    "name": "Fluticasone (Flonase, Flovent, Arnuity)",
    "genericName": "Fluticasone",
    "brandNames": ["Flonase (nasal)", "Flovent (inhalation)", "Arnuity (inhalation)"],
    "category": "Anti-inflammatory",
    "drugClass": "Corticosteroid",
    "indications": "Nasal (Flonase): Management of allergic rhinitis. Inhalation (Flovent, Arnuity): Maintenance treatment of asthma.",
    "moaSteps": [
      "Fluticasone is a potent synthetic corticosteroid.",
      "It binds to intracellular glucocorticoid receptors and modifies gene expression.",
      "This suppresses inflammation by inhibiting the synthesis of pro-inflammatory mediators (prostaglandins, leukotrienes, cytokines).",
      "In the airways, this reduces inflammation, hyper-responsiveness, and mucus production."
    ],
    "pharmacokinetics": {
      "absorption": "Low systemic bioavailability due to high first-pass metabolism. Nasal: <2%. Inhaled: ~1-18% (varies by device).",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in feces. Short half-life."
    },
    "dose": "Nasal: 2 sprays per nostril once daily. Inhaled: Varies by device, e.g., 88-440 mcg twice daily.",
    "adverseEffects": {
      "common": ["Nasal: Headache, nasal irritation/burning, nosebleed.", "Inhaled: Oropharyngeal candidiasis (thrush), dysphonia (hoarseness), cough."],
      "serious": ["Adrenal suppression (HPA axis suppression) with high doses", "immunosuppression", "cataracts/glaucoma."]
    },
    "precautions": [
      "Inhaled forms are not for acute bronchospasm.",
      "Patients must rinse their mouth with water after inhalation to prevent thrush.",
      "Use with caution with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) as they can significantly increase fluticasone levels."
    ],
    "contraindications": [
      "Hypersensitivity",
      "primary treatment of status asthmaticus (inhaler)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "folic-acid": {
    "name": "Folic Acid (Vitamin B9)",
    "genericName": "Folic Acid",
    "brandNames": ["Folacin", "Folvite"],
    "category": "Vitamin",
    "drugClass": "Water-soluble Vitamin",
    "indications": "Treatment of folic acid deficiency anemia (megaloblastic anemia). Prevention of neural tube defects during pregnancy.",
    "moaSteps": [
      "Folic acid is a water-soluble B-vitamin.",
      "It is converted in the body to its active metabolite, tetrahydrofolic acid (THFA).",
      "THFA is a crucial coenzyme in one-carbon transfer reactions.",
      "These reactions are essential for the synthesis of purines and pyrimidines (DNA synthesis), and for the metabolism of amino acids (e.g., homocysteine to methionine)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed from the GI tract (jejunum).",
      "distribution": "Widely distributed, stored in the liver.",
      "metabolism": "Metabolized in the liver to active THFA.",
      "excretion": "Excreted in the urine."
    },
    "dose": "Deficiency: 1-5 mg PO once daily. Pregnancy Prophylaxis: 0.4-0.8 mg (400-800 mcg) PO once daily.",
    "adverseEffects": {
      "common": ["Generally well-tolerated. Rash (rare)."],
      "serious": ["Can mask the hematological signs of Vitamin B12 deficiency (pernicious anemia), while allowing neurological damage to progress."]
    },
    "precautions": [
      "Must rule out Vitamin B12 deficiency before treating megaloblastic anemia, as folic acid alone can worsen neurological symptoms."
    ],
    "contraindications": [
      "Hypersensitivity",
      "treatment of pernicious anemia (unless B12 is also given)."
    ],
    "pregnancyCategory": "Category A",
    "lactationInfo": "Excreted in breast milk; compatible."
  },
  "fosinopril": {
    "name": "Fosinopril (Monopril)",
    "genericName": "Fosinopril",
    "brandNames": ["Monopril"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin-Converting Enzyme (ACE) Inhibitor",
    "indications": "Treatment of hypertension. Treatment of heart failure.",
    "moaSteps": [
      "Fosinopril is a prodrug hydrolyzed to its active metabolite, fosinoprilat.",
      "Fosinoprilat competitively inhibits the angiotensin-converting enzyme (ACE).",
      "This prevents the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor).",
      "Decreased angiotensin II leads to vasodilation, reduced secretion of aldosterone, and a decrease in blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Prodrug is well absorbed. Bioavailability ~36%.",
      "distribution": "Highly protein-bound (~95%).",
      "metabolism": "Hydrolyzed in the liver to active fosinoprilat.",
      "excretion": "Unique dual excretion: eliminated by both the kidneys (urine) and the liver (feces/bile) in roughly equal proportions."
    },
    "dose": "Hypertension: 10-80 mg PO once daily. Heart Failure: 10-40 mg PO once daily.",
    "adverseEffects": {
      "common": ["Dry, persistent cough", "dizziness", "headache", "hyperkalemia."],
      "serious": ["Angioedema", "hypotension", "acute renal failure", "hepatotoxicity."]
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus.",
      "Risk of angioedema.",
      "Monitor renal function and serum potassium.",
      "Dual excretion pathway means dose adjustment is generally not needed in mild-moderate renal or hepatic impairment (unlike other ACEs)."
    ],
    "contraindications": [
      "Hypersensitivity to fosinopril or other ACE inhibitors",
      "history of angioedema",
      "Pregnancy."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "furosemide": {
    "name": "Furosemide (Lasix)",
    "genericName": "Furosemide",
    "brandNames": ["Lasix"],
    "category": "Diuretic",
    "drugClass": "Loop Diuretic",
    "indications": "Treatment of edema associated with congestive heart failure (CHF), cirrhosis of the liver, and renal disease (e.g., nephrotic syndrome). Treatment of hypertension.",
    "moaSteps": [
      "Furosemide is a potent loop diuretic.",
      "It inhibits the reabsorption of sodium, chloride, and water by blocking the Na+/K+/2Cl- cotransporter in the thick ascending limb of the Loop of Henle.",
      "This action leads to a significant increase in the excretion of sodium, chloride, potassium, magnesium, calcium, and water.",
      "This results in profound diuresis and a reduction in fluid volume (preload)."
    ],
    "pharmacokinetics": {
      "absorption": "Variable oral absorption (bioavailability ~10-90%). Onset (IV): 5 min. Onset (PO): 30-60 min.",
      "distribution": "Highly protein-bound (~91-99%).",
      "metabolism": "Minimally metabolized in the liver.",
      "excretion": "Primarily excreted unchanged in the urine. Half-life is ~2 hours."
    },
    "dose": "Edema (PO): 20-80 mg PO once or twice daily. (IV): 20-40 mg IV push.",
    "adverseEffects": {
      "common": ["Hypokalemia", "hypomagnesemia", "hyponatremia", "hypovolemia", "hypotension", "hyperuricemia (can precipitate gout)."],
      "serious": ["Severe electrolyte imbalances", "ototoxicity (hearing loss, especially with rapid IV push)", "renal failure", "sulfa allergy reactions (SJS/TEN)."]
    },
    "precautions": [
      "BOXED WARNING (Fluid/Electrolyte Loss): Furosemide is a potent diuretic that can lead to profound diuresis with water and electrolyte depletion. Strict medical supervision is required.",
      "Risk of ototoxicity, especially with high doses or rapid IV infusion.",
      "Can cause a sulfa allergic reaction in patients with a history of sulfa allergy.",
      "Monitor electrolytes (especially potassium), renal function, and fluid status."
    ],
    "contraindications": [
      "Hypersensitivity to furosemide or sulfonamides (potential cross-reactivity)",
      "anuria (inability to produce urine)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk and may inhibit lactation; use with caution."
  },"gabapentin": {
    "name": "Gabapentin (Neurontin)",
    "genericName": "Gabapentin",
    "brandNames": ["Neurontin", "Gralise", "Horizant"],
    "category": "Anticonvulsant, Analgesic",
    "drugClass": "GABA Analog",
    "indications": "Adjunctive therapy in the treatment of partial onset seizures. Management of postherpetic neuralgia. (Gralise): Postherpetic neuralgia. (Horizant): Restless legs syndrome, postherpetic neuralgia.",
    "moaSteps": [
      "Gabapentin is a structural analog of the neurotransmitter GABA.",
      "Its mechanism is not fully understood. It does not bind to GABA receptors or affect GABA reuptake.",
      "It is thought to bind to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS.",
      "This binding may modulate the release of excitatory neurotransmitters (like glutamate and substance P), leading to anticonvulsant and analgesic effects."
    ],
    "pharmacokinetics": {
      "absorption": "Absorption is variable and saturable (bioavailability decreases with increasing dose). Not affected by food (Neurontin).",
      "distribution": "Low protein binding (<3%). Widely distributed.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted entirely unchanged in the urine. Half-life is ~5-7 hours."
    },
    "dose": "Seizures: 300-1200 mg PO three times daily. Max 3600 mg/day. Neuralgia: 300-3600 mg/day PO in 3 divided doses. Titrate slowly.",
    "adverseEffects": {
      "common": ["Drowsiness", "dizziness", "ataxia (impaired coordination)", "fatigue", "peripheral edema.", "nystagmus."],
      "serious": ["Suicidal thoughts and behaviors", "respiratory depression (especially with opioids)", "anaphylaxis", "angioedema.", "abuse and dependence."]
    },
    "precautions": [
      "Can cause significant drowsiness and dizziness; caution against driving.",
      "Risk of suicidal thoughts and behaviors.",
      "Risk of serious, life-threatening respiratory depression when co-administered with CNS depressants like opioids.",
      "Abrupt discontinuation can precipitate seizures. Taper dose slowly.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to gabapentin."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "galantamine": {
    "name": "Galantamine (Razadyne)",
    "genericName": "Galantamine",
    "brandNames": ["Razadyne", "Razadyne ER"],
    "category": "Alzheimer's Agent",
    "drugClass": "Cholinesterase Inhibitor",
    "indications": "Treatment of mild to moderate dementia of the Alzheimer's type.",
    "moaSteps": [
      "Galantamine is a reversible, competitive cholinesterase inhibitor.",
      "It inhibits the enzyme acetylcholinesterase from breaking down acetylcholine in the synaptic cleft.",
      "This increases the concentration of acetylcholine, a neurotransmitter in the brain that is deficient in Alzheimer's disease.",
      "It also modulates nicotinic receptors, which may further enhance cholinergic neurotransmission."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. Bioavailability ~90%.",
      "distribution": "Low protein binding (~18%).",
      "metabolism": "Metabolized in the liver by CYP2D6 and CYP3A4.",
      "excretion": "Excreted in urine. Half-life is ~7 hours."
    },
    "dose": "Initial: 4 mg PO twice daily (IR) or 8 mg PO once daily (ER). Titrate slowly to 16-24 mg/day.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "anorexia", "weight loss", "dizziness", "headache."],
      "serious": ["Bradycardia", "syncope", "GI bleeding", "severe skin reactions (SJS)."]
    },
    "precautions": [
      "Can cause significant nausea and vomiting, especially during dose titration.",
      "Can cause bradycardia and heart block; use with caution in patients with cardiac conduction abnormalities.",
      "Can increase gastric acid secretion; monitor for GI bleeding.",
      "Risk of serious skin reactions (SJS/AGEP). Discontinue if rash appears."
    ],
    "contraindications": [
      "Hypersensitivity to galantamine."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "ganciclovir": {
    "name": "Ganciclovir (Cytovene)",
    "genericName": "Ganciclovir",
    "brandNames": ["Cytovene (IV)", "Zirgan (ophthalmic gel)"],
    "category": "Antiviral",
    "drugClass": "Antiviral, Guanosine Analog",
    "indications": "Treatment and prevention of cytomegalovirus (CMV) retinitis in immunocompromised patients. Prevention of CMV disease in transplant recipients.",
    "moaSteps": [
      "Ganciclovir is a synthetic nucleoside analog of guanosine.",
      "It is first phosphorylated by a viral protein kinase (in CMV-infected cells) to ganciclovir monophosphate.",
      "Cellular enzymes then convert it to the active triphosphate form.",
      "Ganciclovir triphosphate competitively inhibits viral DNA polymerase and can be incorporated into the viral DNA chain, terminating elongation."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral bioavailability (~5-9%). Typically given IV or as valganciclovir (prodrug) orally.",
      "distribution": "Widely distributed, including into CSF.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in the urine. Half-life is ~3-4 hours."
    },
    "dose": "IV: 5 mg/kg IV every 12 hours (induction), then 5 mg/kg IV once daily (maintenance).",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "fever", "anemia", "neutropenia.", "thrombocytopenia."],
      "serious": ["Severe neutropenia, anemia, and thrombocytopenia (myelosuppression)", "carcinogenicity", "teratogenicity."]
    },
    "precautions": [
      "BOXED WARNING (Myelosuppression): Can cause severe leukopenia, neutropenia, anemia, and thrombocytopenia. Monitor complete blood counts.",
      "BOXED WARNING (Fetal Toxicity): Can cause birth defects. Use effective contraception during and after treatment.",
      "BOXED WARNING (Impaired Fertility): May cause temporary or permanent infertility in males and females.",
      "BOXED WARNING (Carcinogenicity): Has caused tumors in animal studies.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe neutropenia (ANC < 500) or thrombocytopenia (platelets < 25,000)."
    ],
    "pregnancyCategory": "Category C (but with boxed warnings for teratogenicity).",
    "lactationInfo": "Not recommended."
  },
  "gemfibrozil": {
    "name": "Gemfibrozil (Lopid)",
    "genericName": "Gemfibrozil",
    "brandNames": ["Lopid"],
    "category": "Antihyperlipidemic",
    "drugClass": "Fibrate",
    "indications": "Treatment of severe hypertriglyceridemia (Type IV and V hyperlipidemia) at risk of pancreatitis. Reduction of coronary heart disease risk in Type IIb patients (low HDL, high LDL, high triglycerides).",
    "moaSteps": [
      "Gemfibrozil is a fibrate.",
      "It activates Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha).",
      "This increases lipoprotein lipase activity, enhancing the clearance of triglyceride-rich particles (VLDL).",
      "It also increases HDL synthesis by increasing apolipoproteins A-I and A-II.",
      "The primary effect is a significant reduction in triglycerides and a modest increase in HDL."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. Bioavailability ~100%.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Metabolized in the liver (CYP2C8, 2C9, 2C19).",
      "excretion": "Excreted in urine as metabolites. Half-life is ~1.5 hours."
    },
    "dose": "600 mg PO twice daily, 30 minutes before the morning and evening meals.",
    "adverseEffects": {
      "common": ["Dyspepsia (indigestion)", "abdominal pain", "diarrhea", "nausea."],
      "serious": ["Myopathy and rhabdomyolysis (especially with statins)", "cholelithiasis (gallstones)", "hepatotoxicity."]
    },
    "precautions": [
      "Increased risk of myopathy/rhabdomyolysis, especially when co-administered with statins. **Contraindicated with simvastatin.**",
      "Can increase the risk of cholelithiasis (gallstones).",
      "Monitor liver function tests.",
      "Potent inhibitor of CYP2C8."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe renal or hepatic impairment",
      "pre-existing gallbladder disease",
      "concomitant use with simvastatin, repaglinide, or dasabuvir."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "gentamicin": {
    "name": "Gentamicin (Garamycin)",
    "genericName": "Gentamicin",
    "brandNames": ["Garamycin (injection)", "Gentak (ophthalmic)"],
    "category": "Antibiotic",
    "drugClass": "Aminoglycoside Antibiotic",
    "indications": "Treatment of serious Gram-negative bacterial infections (e.g., pseudomonas, E. coli, Klebsiella) including bacteremia, pneumonia, and UTIs. Used in combination with beta-lactams for synergistic Gram-positive coverage (e.g., endocarditis).",
    "moaSteps": [
      "Gentamicin is an aminoglycoside antibiotic.",
      "It irreversibly binds to the 30S ribosomal subunit of susceptible bacteria.",
      "This binding interferes with the initiation complex, causes misreading of mRNA, and blocks translocation.",
      "This leads to the production of nonfunctional or toxic proteins and ultimately to bacterial cell death (bactericidal)."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly absorbed orally. Must be given IV or IM for systemic infections.",
      "distribution": "Widely distributed in extracellular fluid. Poor CNS penetration. Low protein binding (<10%).",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in the urine. Half-life is ~2-3 hours (in normal renal function)."
    },
    "dose": "Dosing is complex and based on weight, renal function, and therapeutic drug monitoring (peaks and troughs). Conventional: 1-2.5 mg/kg/dose IV/IM every 8-12 hours. Extended-interval: 5-7 mg/kg/dose IV once daily.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "rash.", "nephrotoxicity (mild, reversible)."],
      "serious": ["Ototoxicity (vestibular and auditory damage, may be irreversible)", "Nephrotoxicity (acute tubular necrosis)", "Neuromuscular blockade (can cause respiratory paralysis)."]
    },
    "precautions": [
      "BOXED WARNING (Ototoxicity): Can cause irreversible hearing loss and vestibular damage. Risk increases with high doses, prolonged therapy, and renal impairment.",
      "BOXED WARNING (Nephrotoxicity): Can cause kidney damage. Risk is higher in elderly and those with renal impairment. Monitor renal function and drug levels.",
      "BOXED WARNING (Neuromuscular Blockade): Can cause respiratory paralysis, especially in patients with myasthenia gravis or those receiving anesthetics.",
      "Requires therapeutic drug monitoring (TDM) to ensure efficacy and minimize toxicity."
    ],
    "contraindications": [
      "Hypersensitivity to gentamicin or other aminoglycosides."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm (deafness).",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "glimepiride": {
    "name": "Glimepiride (Amaryl)",
    "genericName": "Glimepiride",
    "brandNames": ["Amaryl"],
    "category": "Antidiabetic",
    "drugClass": "Sulfonylurea (2nd Generation)",
    "indications": "Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.",
    "moaSteps": [
      "Glimepiride is a sulfonylurea.",
      "It stimulates insulin release from the pancreatic beta cells.",
      "It binds to and blocks the ATP-sensitive potassium channels (K-ATP) on the beta cell membrane.",
      "This blockage leads to membrane depolarization, which opens voltage-gated calcium channels.",
      "The influx of calcium triggers the exocytosis (release) of insulin-containing granules."
    ],
    "pharmacokinetics": {
      "absorption": "Completely absorbed. Bioavailability ~100%.",
      "distribution": "Highly protein-bound (~99.5%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C9.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~5-9 hours."
    },
    "dose": "1-4 mg PO once daily with the first main meal. Max 8 mg/day.",
    "adverseEffects": {
      "common": ["Hypoglycemia", "dizziness", "headache", "nausea", "weight gain."],
      "serious": ["Severe hypoglycemia", "hemolytic anemia", "hyponatremia."]
    },
    "precautions": [
      "High risk of hypoglycemia, especially in the elderly, debilitated, or malnourished, or those with renal/hepatic impairment.",
      "Can cause sulfa allergic reactions in patients with a history of sulfa allergy.",
      "May be associated with increased cardiovascular mortality (class effect)."
    ],
    "contraindications": [
      "Hypersensitivity to glimepiride or sulfonamides",
      "diabetic ketoacidosis."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "glipizide": {
    "name": "Glipizide (Glucotrol, Glucotrol XL)",
    "genericName": "Glipizide",
    "brandNames": ["Glucotrol", "Glucotrol XL"],
    "category": "Antidiabetic",
    "drugClass": "Sulfonylurea (2nd Generation)",
    "indications": "Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.",
    "moaSteps": [
      "Glipizide is a sulfonylurea.",
      "It stimulates insulin release from the pancreatic beta cells by binding to and blocking ATP-sensitive potassium channels.",
      "This leads to membrane depolarization, calcium influx, and insulin exocytosis.",
      "It also has some effect on increasing peripheral insulin sensitivity."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed (IR). XL formulation has extended release.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Extensively metabolized in the liver (CYP2C9).",
      "excretion": "Excreted in urine as metabolites. Half-life is ~2-4 hours (IR)."
    },
    "dose": "IR: 2.5-20 mg PO once daily or in 2 divided doses, 30 min before meals. XL: 5-20 mg PO once daily with breakfast.",
    "adverseEffects": {
      "common": ["Hypoglycemia", "dizziness", "headache", "nausea", "weight gain.", "diarrhea."],
      "serious": ["Severe hypoglycemia", "hemolytic anemia", "hepatotoxicity."]
    },
    "precautions": [
      "High risk of hypoglycemia, especially in the elderly and those with renal/hepatic impairment.",
      "Can cause sulfa allergic reactions.",
      "May be associated with increased cardiovascular mortality (class effect).",
      "Take IR formulation 30 minutes before a meal."
    ],
    "contraindications": [
      "Hypersensitivity to glipizide or sulfonamides",
      "diabetic ketoacidosis."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "glyburide": {
    "name": "Glyburide (Glynase, Diabeta)",
    "genericName": "Glyburide (also Glibenclamide)",
    "brandNames": ["Glynase PresTab", "Diabeta"],
    "category": "Antidiabetic",
    "drugClass": "Sulfonylurea (2nd Generation)",
    "indications": "Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.",
    "moaSteps": [
      "Glyburide is a sulfonylurea.",
      "It stimulates insulin release from the pancreatic beta cells by binding to and blocking ATP-sensitive potassium channels.",
      "This leads to membrane depolarization, calcium influx, and insulin exocytosis."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Micronized (Glynase) has better bioavailability.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Extensively metabolized in the liver (CYP2C9).",
      "excretion": "Excreted in urine and feces (bile) as metabolites. Half-life is ~10 hours."
    },
    "dose": "Conventional: 2.5-20 mg/day PO. Glynase: 1.5-12 mg/day PO. Give with first main meal.",
    "adverseEffects": {
      "common": ["Hypoglycemia", "weight gain", "nausea", "heartburn."],
      "serious": ["Severe and prolonged hypoglycemia", "hemolytic anemia."]
    },
    "precautions": [
      "**Highest risk of severe, prolonged hypoglycemia among all sulfonylureas**, especially in the elderly. Avoid use in elderly or those with renal impairment.",
      "Can cause sulfa allergic reactions.",
      "May be associated with increased cardiovascular mortality (class effect)."
    ],
    "contraindications": [
      "Hypersensitivity to glyburide or sulfonamides",
      "diabetic ketoacidosis."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution (hypoglycemia risk in infant)."
  },
  "griseofulvin": {
    "name": "Griseofulvin (Gris-PEG)",
    "genericName": "Griseofulvin",
    "brandNames": ["Gris-PEG"],
    "category": "Antifungal",
    "drugClass": "Antifungal",
    "indications": "Treatment of fungal infections of the skin, hair, and nails (dermatophytoses) (e.g., tinea capitis, tinea pedis, onychomycosis) that are not responsive to topical therapy.",
    "moaSteps": [
      "Griseofulvin is a fungistatic antibiotic.",
      "It is deposited in keratin precursor cells in the skin, hair, and nails.",
      "As these new, resistant cells grow, they replace the infected, older keratin.",
      "Its mechanism is to inhibit fungal cell mitosis by disrupting the mitotic spindle structure.",
      "This prevents the fungal cells from dividing and spreading."
    ],
    "pharmacokinetics": {
      "absorption": "Absorption is variable and significantly enhanced by a high-fat meal. Microsize and ultramicrosize (Gris-PEG) formulations exist to improve absorption.",
      "distribution": "Binds to and concentrates in keratin.",
      "metabolism": "Extensively metabolized in the liver.",
      "excretion": "Excreted in feces and urine as metabolites. Half-life is ~9-24 hours."
    },
    "dose": "Varies by formulation and infection. e.g., Ultramicrosize: 375-750 mg/day PO in 1-2 divided doses. **Must be taken with a fatty meal.**",
    "adverseEffects": {
      "common": ["Headache", "rash", "nausea", "vomiting", "diarrhea.", "photosensitivity."],
      "serious": ["Hepatotoxicity", "severe skin reactions (SJS/TEN)", "leukopenia."]
    },
    "precautions": [
      "**Must be taken with a high-fat meal** to ensure adequate absorption.",
      "Can cause photosensitivity; advise sun protection.",
      "Monitor liver function and CBC with long-term therapy.",
      "Can cause a disulfiram-like reaction with alcohol.",
      "Potent inducer of CYP enzymes (e.g., 3A4), can decrease levels of other drugs (e.g., oral contraceptives)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe liver disease",
      "porphyria",
      "**Pregnancy (Category X)**."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "guaifenesin": {
    "name": "Guaifenesin (Mucinex, Robitussin)",
    "genericName": "Guaifenesin",
    "brandNames": ["Mucinex", "Robitussin (plain)", "Tussin"],
    "category": "Expectorant",
    "drugClass": "Expectorant",
    "indications": "Helps loosen phlegm (mucus) and thin bronchial secretions to make coughs more productive.",
    "moaSteps": [
      "Guaifenesin is an expectorant.",
      "Its mechanism is thought to involve increasing the volume and reducing the viscosity of secretions in the trachea and bronchi.",
      "This thins the mucus, making it easier to cough up and clear from the airways."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed from the GI tract.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine as metabolites. Short half-life (~1 hour)."
    },
    "dose": "IR: 200-400 mg PO every 4 hours. ER (Mucinex): 600-1200 mg PO every 12 hours.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "dizziness", "headache", "rash."],
      "serious": ["Kidney stones (with very large doses)."]
    },
    "precautions": [
      "Does not stop the cough itself, only helps make it productive.",
      "Patients should be advised to drink plenty of water to help thin mucus.",
      "Not for chronic cough (e.g., from smoking or asthma)."
    ],
    "contraindications": [
      "Hypersensitivity to guaifenesin."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "guanfacine": {
    "name": "Guanfacine (Tenex, Intuniv)",
    "genericName": "Guanfacine",
    "brandNames": ["Tenex (IR for hypertension)", "Intuniv (ER for ADHD)"],
    "category": "Antihypertensive, ADHD Agent",
    "drugClass": "Alpha-2 Adrenergic Agonist (Central)",
    "indications": "Tenex (IR): Treatment of hypertension. Intuniv (ER): Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.",
    "moaSteps": [
      "Guanfacine is a selective, central alpha-2A adrenergic agonist.",
      "For Hypertension: It stimulates alpha-2 receptors in the brainstem, which reduces sympathetic outflow from the CNS. This leads to decreased heart rate, vasodilation, and reduced blood pressure.",
      "For ADHD: The mechanism is not fully understood, but it is thought to modulate signaling in the prefrontal cortex, enhancing working memory and attention."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (IR), slowly absorbed (ER).",
      "distribution": "Moderately protein-bound (~70%).",
      "metabolism": "Metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Excreted in urine. Half-life is long (~17 hours)."
    },
    "dose": "Hypertension (Tenex): 1-2 mg PO at bedtime. ADHD (Intuniv): 1-4 mg PO once daily.",
    "adverseEffects": {
      "common": ["Sedation", "somnolence", "drowsiness", "dry mouth", "dizziness", "constipation", "hypotension.", "bradycardia."],
      "serious": ["Severe hypotension", "bradycardia", "syncope", "rebound hypertension (if abruptly stopped)."]
    },
    "precautions": [
      "Can cause significant sedation and hypotension; caution against driving.",
      "Do not stop abruptly, as this can cause severe rebound hypertension. Taper dose slowly.",
      "Use with caution with other CNS depressants or antihypertensives."
    ],
    "contraindications": [
      "Hypersensitivity to guanfacine."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "gatifloxacin": {
    "name": "Gatifloxacin (Zymar, Zymaxid)",
    "genericName": "Gatifloxacin",
    "brandNames": ["Zymar", "Zymaxid"],
    "category": "Antibiotic",
    "drugClass": "Fluoroquinolone Antibiotic",
    "indications": "Ophthalmic: Treatment of bacterial conjunctivitis.",
    "moaSteps": [
      "Gatifloxacin is a fluoroquinolone antibiotic.",
      "It inhibits two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV.",
      "Inhibition of these enzymes prevents the replication, transcription, and repair of bacterial DNA, leading to cell death (bactericidal)."
    ],
    "pharmacokinetics": {
      "absorption": "Ophthalmic use results in minimal systemic absorption.",
      "distribution": "Acts locally in the eye.",
      "metabolism": "N/A (topical).",
      "excretion": "N/A (topical)."
    },
    "dose": "1 drop in affected eye(s) every 2 hours while awake (Day 1), then 1 drop 2-4 times daily (Days 2-7).",
    "adverseEffects": {
      "common": ["Ocular irritation", "blurred vision", "eye pain", "chemosis (swelling)."],
      "serious": ["Hypersensitivity reaction", "corneal ulcer."]
    },
    "precautions": [
      "Systemic use of gatifloxacin was withdrawn due to severe dysglycemia (hypo- and hyperglycemia). This is not a significant risk with ophthalmic use.",
      "Prolonged use may result in fungal superinfection.",
      "Avoid wearing contact lenses."
    ],
    "contraindications": [
      "Hypersensitivity to gatifloxacin or other quinolones."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "gavilan": {
    "name": "Gavilan (Prototype)",
    "genericName": "Gavilan",
    "brandNames": ["N/A - Example"],
    "category": "Prototype",
    "drugClass": "Prototype",
    "indications": "This is a placeholder entry for demonstration.",
    "moaSteps": ["N/A"],
    "pharmacokinetics": {},
    "dose": "N/A",
    "adverseEffects": {},
    "precautions": ["This is not a real drug. It is a placeholder for 'G'."],
    "contraindications": ["N/A"],
    "pregnancyCategory": "N/A",
    "lactationInfo": "N/A"
  },
  "gefitinib": {
    "name": "Gefitinib (Iressa)",
    "genericName": "Gefitinib",
    "brandNames": ["Iressa"],
    "category": "Antineoplastic Agent",
    "drugClass": "Tyrosine Kinase Inhibitor (TKI), EGFR Inhibitor",
    "indications": "First-line treatment of non-small cell lung cancer (NSCLC) in patients with specific EGFR mutations (exon 19 deletions or L858R).",
    "moaSteps": [
      "Gefitinib is a tyrosine kinase inhibitor (TKI).",
      "It selectively inhibits the intracellular phosphorylation of epidermal growth factor receptor (EGFR).",
      "By blocking the EGFR signaling pathway, it inhibits tumor cell growth, proliferation, and survival."
    ],
    "pharmacokinetics": {
      "absorption": "Slowly absorbed. Bioavailability ~60%. Food has a variable effect.",
      "distribution": "Widely distributed. Highly protein-bound (~90%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted primarily in feces as metabolites. Long half-life (~41 hours)."
    },
    "dose": "250 mg PO once daily.",
    "adverseEffects": {
      "common": ["Rash (acne-like)", "diarrhea", "nausea", "vomiting", "anorexia", "elevated LFTs."],
      "serious": ["Interstitial lung disease (ILD)", "hepatotoxicity", "GI perforation", "severe skin reactions."]
    },
    "precautions": [
      "Risk of severe, sometimes fatal, interstitial lung disease (ILD). Discontinue immediately if symptoms (dyspnea, cough, fever) occur.",
      "Monitor liver function tests.",
      "Can cause severe diarrhea; manage with loperamide.",
      "Avoid concomitant use with strong CYP3A4 inhibitors or inducers."
    ],
    "contraindications": [
      "Hypersensitivity to gefitinib."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "gemcitabine": {
    "name": "Gemcitabine (Gemzar)",
    "genericName": "Gemcitabine",
    "brandNames": ["Gemzar"],
    "category": "Antineoplastic Agent",
    "drugClass": "Antimetabolite (Nucleoside Analog)",
    "indications": "Treatment of various cancers, including pancreatic, non-small cell lung, breast, and ovarian cancer.",
    "moaSteps": [
      "Gemcitabine is a nucleoside analog (a prodrug).",
      "It is converted intracellularly to its active di- and triphosphate forms.",
      "The triphosphate form competes with dCTP for incorporation into DNA, leading to chain termination.",
      "The diphosphate form inhibits ribonucleotide reductase, the enzyme that generates the deoxynucleotides needed for DNA synthesis.",
      "This dual action arrests the cell cycle (S-phase) and induces apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized intracellularly to active forms and systemically by cytidine deaminase (inactive).",
      "excretion": "Excreted in urine. Short plasma half-life (~10-20 min), but long intracellular half-life of active forms."
    },
    "dose": "Varies by cancer type, e.g., 1000-1250 mg/m IV infusion over 30 minutes, repeated weekly.",
    "adverseEffects": {
      "common": ["Myelosuppression (neutropenia, anemia, thrombocytopenia)", "nausea", "vomiting", "flu-like symptoms", "rash.", "elevated LFTs."],
      "serious": ["Severe myelosuppression", "pulmonary toxicity (ARDS)", "hemolytic-uremic syndrome (HUS)", "hepatotoxicity."]
    },
    "precautions": [
      "Can cause severe myelosuppression (dose-limiting toxicity). Monitor complete blood counts.",
      "Can cause pulmonary toxicity (dyspnea, interstitial pneumonitis).",
      "Monitor renal and hepatic function."
    ],
    "contraindications": [
      "Hypersensitivity to gemcitabine."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },"haloperidol": {
    "name": "Haloperidol (Haldol)",
    "genericName": "Haloperidol",
    "brandNames": ["Haldol"],
    "category": "Antipsychotic",
    "drugClass": "Typical Antipsychotic (1st Generation)",
    "indications": "Treatment of schizophrenia. Control of tics and vocal utterances of Tourette's syndrome. Management of severe behavioral problems in children.",
    "moaSteps": [
      "Haloperidol is a typical antipsychotic of the butyrophenone class.",
      "It primarily works by non-selectively blocking postsynaptic dopamine D2 receptors in the mesolimbic pathway of the brain.",
      "This blockade of dopamine receptors is believed to reduce the positive symptoms of psychosis (e.g., hallucinations, delusions).",
      "It also has some alpha-1 adrenergic and anticholinergic blocking effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally (~60-70%).",
      "distribution": "Widely distributed, highly protein-bound (~92%).",
      "metabolism": "Extensively metabolized in the liver (CYP2D6, CYP3A4).",
      "excretion": "Excreted in urine and feces. Long half-life (~24 hours)."
    },
    "dose": "Schizophrenia: 0.5-5 mg PO 2-3 times daily. Dose is highly individualized.",
    "adverseEffects": {
      "common": ["Extrapyramidal symptoms (EPS) (e.g., parkinsonism, dystonia, akathisia)", "drowsiness", "dizziness", "dry mouth", "constipation."],
      "serious": ["Tardive Dyskinesia (TD)", "Neuroleptic Malignant Syndrome (NMS)", "QT prolongation and Torsades de Pointes", "seizures."]
    },
    "precautions": [
      "BOXED WARNING (Elderly with Dementia): Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death. Haloperidol is not approved for this use.",
      "High risk of Extrapyramidal Symptoms (EPS).",
      "Risk of Tardive Dyskinesia (TD), which may be irreversible.",
      "Risk of QT prolongation and Torsades de Pointes, especially with high doses or IV administration.",
      "Risk of Neuroleptic Malignant Syndrome (NMS)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe CNS depression",
      "coma",
      "Parkinson's disease",
      "dementia with Lewy bodies."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "hydralazine": {
    "name": "Hydralazine (Apresoline)",
    "genericName": "Hydralazine",
    "brandNames": ["Apresoline"],
    "category": "Antihypertensive",
    "drugClass": "Direct Vasodilator",
    "indications": "Treatment of essential hypertension, usually in combination with other antihypertensives. Used in combination with nitrates (BiDil) for heart failure in self-identified Black patients.",
    "moaSteps": [
      "Hydralazine is a direct-acting peripheral vasodilator.",
      "It acts primarily on arterioles (resistance vessels), causing them to relax.",
      "The exact mechanism is not fully known but may involve inhibiting the release of calcium from the sarcoplasmic reticulum in arterial smooth muscle.",
      "This vasodilation reduces peripheral resistance, leading to a decrease in blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability is variable (~25-50%) due to high first-pass metabolism, which is dependent on 'acetylator status'.",
      "distribution": "Widely distributed. Moderately protein-bound (~87%).",
      "metabolism": "Extensively metabolized in the liver by acetylation (N-acetyltransferase).",
      "excretion": "Excreted in urine as metabolites. Short half-life (~1 hour, but effects last longer)."
    },
    "dose": "Hypertension: 10-50 mg PO 4 times daily. Start low, titrate up.",
    "adverseEffects": {
      "common": ["Headache", "tachycardia (reflex)", "palpitations", "flushing", "anorexia", "nausea", "dizziness."],
      "serious": ["Drug-induced lupus erythematosus (DILE)", "severe hypotension", "peripheral neuritis."]
    },
    "precautions": [
      "Can cause a reflex tachycardia (increased heart rate) and palpitations, which can provoke angina in patients with coronary artery disease. Often co-prescribed with a beta-blocker to prevent this.",
      "Risk of Drug-Induced Lupus Erythematosus (DILE) with long-term, high-dose therapy. Monitor for symptoms (fever, arthralgia, rash) and ANA titers.",
      "Use with caution in 'slow acetylators' (higher risk of DILE)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "coronary artery disease",
      "mitral valvular rheumatic heart disease."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "hydrochlorothiazide": {
    "name": "Hydrochlorothiazide (Microzide)",
    "genericName": "Hydrochlorothiazide (HCTZ)",
    "brandNames": ["Microzide", "Hydrodiuril"],
    "category": "Antihypertensive, Diuretic",
    "drugClass": "Thiazide Diuretic",
    "indications": "Treatment of hypertension. Adjunctive therapy in edema associated with congestive heart failure, cirrhosis, or renal dysfunction.",
    "moaSteps": [
      "Hydrochlorothiazide is a thiazide diuretic.",
      "It inhibits the reabsorption of sodium and chloride in the distal convoluted tubule (DCT) of the kidney.",
      "It blocks the Na+/Cl- cotransporter in the DCT.",
      "This action increases the excretion of sodium, chloride, and water.",
      "It also increases the excretion of potassium and magnesium, but decreases the excretion of calcium."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Bioavailability ~60-80%.",
      "distribution": "Widely distributed. Moderately protein-bound (~40-68%).",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in the urine. Half-life is ~6-15 hours."
    },
    "dose": "Hypertension: 12.5-50 mg PO once daily. Edema: 25-100 mg PO once daily or in divided doses.",
    "adverseEffects": {
      "common": ["Hypokalemia", "hyponatremia", "hypomagnesemia", "hypercalcemia", "hyperuricemia (can precipitate gout)", "hyperglycemia", "dizziness.", "headache."],
      "serious": ["Severe electrolyte imbalances", "pancreatitis", "photosensitivity", "sulfa allergy reactions (SJS/TEN)."]
    },
    "precautions": [
      "Can cause electrolyte disturbances. Monitor serum electrolytes (especially potassium) periodically.",
      "Can cause sulfa allergic reactions in patients with a history of sulfa allergy.",
      "Use with caution in patients with renal impairment, liver disease, or diabetes.",
      "Risk of photosensitivity; advise sun protection."
    ],
    "contraindications": [
      "Hypersensitivity to hydrochlorothiazide or other sulfonamides",
      "anuria."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution (may inhibit lactation)."
  },
  "hydrocodone-acetaminophen": {
    "name": "Hydrocodone/Acetaminophen (Norco, Vicodin)",
    "genericName": "Hydrocodone and Acetaminophen",
    "brandNames": ["Norco", "Vicodin", "Lortab"],
    "category": "Analgesic, Opioid",
    "drugClass": "Opioid Analgesic Combination (Schedule II)",
    "indications": "For the management of severe pain, acute pain, or moderate pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.",
    "moaSteps": [
      "This is a combination product:",
      "1. **Hydrocodone:** A semi-synthetic opioid agonist. It binds to mu-opioid receptors in the CNS, mimicking endogenous endorphins and causing analgesia, sedation, and euphoria.",
      "2. **Acetaminophen (APAP):** An analgesic and antipyretic. Its central mechanism is thought to involve inhibition of COX enzymes in the CNS."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally.",
      "distribution": "Widely distributed. Hydrocodone crosses the blood-brain barrier.",
      "metabolism": "Hydrocodone is metabolized by CYP2D6 and CYP3A4. Acetaminophen is metabolized in the liver.",
      "excretion": "Excreted in urine as metabolites."
    },
    "dose": "Varies by strength, e.g., 1-2 tablets (5 mg/325 mg) PO every 4-6 hours as needed. Do not exceed 4000 mg of acetaminophen per day.",
    "adverseEffects": {
      "common": ["Drowsiness", "dizziness", "sedation", "nausea", "vomiting", "constipation."],
      "serious": ["Respiratory depression", "hepatotoxicity (from acetaminophen overdose)", "abuse, addiction, and overdose", "severe hypotension."]
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Acetaminophen has been associated with acute liver failure. Do not exceed 4 grams of acetaminophen per day from all sources.",
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse, which can lead to overdose and death.",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "BOXED WARNING (Neonatal Opioid Withdrawal): Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "acute or severe bronchial asthma",
      "paralytic ileus."
    ],
    "pregnancyCategory": "Category C. Can cause neonatal opioid withdrawal.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "hydrocortisone": {
    "name": "Hydrocortisone (Cortef, Solu-Cortef)",
    "genericName": "Hydrocortisone",
    "brandNames": ["Cortef (oral)", "Solu-Cortef (injection)", "Anusol-HC (topical)"],
    "category": "Anti-inflammatory, Immunosuppressant",
    "drugClass": "Corticosteroid",
    "indications": "Systemic: Adrenal insufficiency (physiologic replacement), various inflammatory and autoimmune conditions. Topical: Inflammatory and pruritic manifestations of skin disorders.",
    "moaSteps": [
      "Hydrocortisone is a glucocorticoid (and the pharmaceutical form of cortisol).",
      "It binds to intracellular glucocorticoid receptors and modifies gene expression.",
      "It upregulates anti-inflammatory proteins and downregulates pro-inflammatory mediators.",
      "This results in anti-inflammatory, immunosuppressive, and anti-allergic effects.",
      "It also has significant mineralocorticoid activity (sodium/water retention)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally and systemically from topical application (if skin is broken).",
      "distribution": "Widely distributed. Highly protein-bound (>90%).",
      "metabolism": "Metabolized in the liver (by CYP3A4) and other tissues.",
      "excretion": "Excreted in urine as metabolites. Short biologic half-life (8-12 hours)."
    },
    "dose": "Varies widely. Adrenal Insufficiency: 20-30 mg/day PO in divided doses. Anti-inflammatory: 20-240 mg/day PO.",
    "adverseEffects": {
      "common": ["(Short-term) Insomnia, hyperglycemia, increased appetite, fluid retention.", "(Long-term) Cushing's syndrome, osteoporosis, immunosuppression."],
      "serious": ["Adrenal suppression (must taper off)", "severe infections", "psychosis", "peptic ulcer perforation."]
    },
    "precautions": [
      "Prolonged use can cause HPA axis suppression. Dose must be tapered slowly.",
      "Can mask signs of infection and increase susceptibility.",
      "Monitor for hyperglycemia, hypertension, and psychiatric disturbances.",
      "Use with caution in patients with peptic ulcer disease or osteoporosis."
    ],
    "contraindications": [
      "Systemic fungal infections",
      "hypersensitivity",
      "administration of live vaccines (if receiving immunosuppressive doses)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "hydromorphone": {
    "name": "Hydromorphone (Dilaudid)",
    "genericName": "Hydromorphone",
    "brandNames": ["Dilaudid", "Exalgo (ER)"],
    "category": "Analgesic, Opioid",
    "drugClass": "Opioid Analgesic (Schedule II)",
    "indications": "Management of severe pain. Used for acute, severe pain and chronic pain (ER formulations).",
    "moaSteps": [
      "Hydromorphone is a semi-synthetic, potent opioid agonist.",
      "It binds with high affinity to mu-opioid receptors in the CNS.",
      "This activation mimics endorphins, causing potent analgesia, sedation, and euphoria.",
      "It also causes respiratory depression."
    ],
    "pharmacokinetics": {
      "absorption": "Oral bioavailability is low and variable (~30-40%) due to high first-pass metabolism. IV/IM is 100%.",
      "distribution": "Widely distributed. Low protein binding.",
      "metabolism": "Metabolized in the liver primarily by glucuronidation.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~2-3 hours (IR)."
    },
    "dose": "Highly individualized and for opioid-tolerant patients. Oral (IR): 2-4 mg PO every 4-6 hours. IV: 0.2-1 mg IV every 2-3 hours. **Note: Hydromorphone is ~5-7 times more potent than oral morphine.**",
    "adverseEffects": {
      "common": ["Sedation", "drowsiness", "dizziness", "nausea", "vomiting", "constipation", "hypotension."],
      "serious": ["Respiratory depression", "abuse, addiction, and overdose", "severe hypotension", "syncope."]
    },
    "precautions": [
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse, which can lead to overdose and death.",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "BOXED WARNING (Medication Errors): High potency drug. Dosing errors can be fatal. Ensure correct dose/concentration.",
      "BOXED WARNING (Neonatal Opioid Withdrawal): Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "acute or severe bronchial asthma",
      "paralytic ileus."
    ],
    "pregnancyCategory": "Category C. Can cause neonatal opioid withdrawal.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "hydroxychloroquine": {
    "name": "Hydroxychloroquine (Plaquenil)",
    "genericName": "Hydroxychloroquine",
    "brandNames": ["Plaquenil"],
    "category": "Antirheumatic, Antimalarial",
    "drugClass": "Antimalarial, DMARD",
    "indications": "Treatment of malaria. Treatment of rheumatoid arthritis (RA). Treatment of systemic lupus erythematosus (SLE).",
    "moaSteps": [
      "The mechanism of action in RA and SLE is not fully understood.",
      "It is thought to have immunomodulatory effects by inhibiting pro-inflammatory cytokine production.",
      "It may also inhibit antigen processing in antigen-presenting cells by increasing the pH of intracellular vacuoles.",
      "For malaria, it is thought to interfere with the parasite's ability to digest hemoglobin in the red blood cell."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and almost completely absorbed.",
      "distribution": "Widely distributed and concentrates in tissues (e.g., eyes, liver). Moderately protein-bound.",
      "metabolism": "Metabolized in the liver to active metabolites.",
      "excretion": "Excreted very slowly in the urine. Extremely long half-life (up to 40-50 days)."
    },
    "dose": "RA: 200-400 mg/day PO. SLE: 200-400 mg/day PO.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "abdominal pain", "headache", "rash."],
      "serious": ["Irreversible retinopathy (retinal damage)", "cardiomyopathy", "QT prolongation", "agranulocytosis.", "neuromyopathy."]
    },
    "precautions": [
      "**Irreversible retinopathy** leading to blindness is a major risk, related to cumulative dose. Regular (annual) eye exams, including visual field testing, are mandatory.",
      "Can cause cardiomyopathy and QT prolongation. Monitor EKG.",
      "Can cause hypoglycemia. Monitor blood glucose.",
      "Monitor CBC for rare but serious blood dyscrasias."
    ],
    "contraindications": [
      "Hypersensitivity",
      "pre-existing retinopathy or visual field changes."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "hydroxyzine": {
    "name": "Hydroxyzine (Vistaril, Atarax)",
    "genericName": "Hydroxyzine",
    "brandNames": ["Vistaril", "Atarax"],
    "category": "Antihistamine, Anxiolytic",
    "drugClass": "Antihistamine, 1st Generation",
    "indications": "Symptomatic relief of anxiety and tension. Management of pruritus (itching) due to allergic conditions. Sedation (pre/post-operative).",
    "moaSteps": [
      "Hydroxyzine is a first-generation antihistamine.",
      "It is a potent H1-receptor antagonist, blocking histamine's effects (sedation, anti-itching).",
      "It also has significant anticholinergic, antiemetic, and anxiolytic properties, likely due to its activity in the subcortical areas of the CNS."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Onset in 15-30 minutes.",
      "distribution": "Widely distributed. Crosses the blood-brain barrier.",
      "metabolism": "Metabolized in the liver to cetirizine (an active, 2nd-gen antihistamine).",
      "excretion": "Excreted in urine as metabolites. Half-life is ~14-20 hours."
    },
    "dose": "Anxiety: 50-100 mg PO 4 times daily. Pruritus: 25-50 mg PO 3-4 times daily.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "dry mouth (xerostomia)", "dizziness", "blurred vision.", "constipation."],
      "serious": ["QT prolongation and Torsades de Pointes", "severe anticholinergic effects (in elderly)", "skin reactions (SJS/AGEP)."]
    },
    "precautions": [
      "Can cause significant drowsiness and sedation; caution against driving.",
      "High anticholinergic burden; use with caution in the elderly.",
      "Risk of QT prolongation and Torsades de Pointes. Avoid use in patients with known QT prolongation or risk factors.",
      "Not recommended for long-term use as an anxiolytic."
    ],
    "contraindications": [
      "Hypersensitivity",
      "known QT prolongation",
      "concomitant use with other QT-prolonging drugs",
      "early pregnancy (Category X per some sources, C per others - generally avoided)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk (via cetirizine); not recommended."
  },
  "heparin": {
    "name": "Heparin",
    "genericName": "Heparin Sodium",
    "brandNames": ["Hep-Lock"],
    "category": "Anticoagulant",
    "drugClass": "Anticoagulant",
    "indications": "Prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Treatment of acute coronary syndromes (ACS). Used in anticoagulation for bypass surgery, dialysis, and blood transfusions.",
    "moaSteps": [
      "Heparin is a heterogeneous mixture of sulfated mucopolysaccharides.",
      "It binds to and potentiates the activity of antithrombin III (ATIII).",
      "This heparin-ATIII complex is a potent inhibitor of coagulation factors, primarily Factor Xa and Factor IIa (thrombin).",
      "By inhibiting thrombin and Factor Xa, it prevents the conversion of fibrinogen to fibrin, thus preventing clot formation."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed orally. Must be given IV or SC.",
      "distribution": "Highly protein-bound (to many proteins, not just ATIII).",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine as metabolites. Short, dose-dependent half-life (~1.5 hours)."
    },
    "dose": "Varies widely. DVT/PE Treatment: 80 units/kg IV bolus, then ~18 units/kg/hour IV infusion, adjusted based on aPTT. Prophylaxis: 5000 units SC every 8-12 hours.",
    "adverseEffects": {
      "common": ["Bleeding", "thrombocytopenia (mild, transient)", "injection site reaction."],
      "serious": ["Major bleeding", "Heparin-Induced Thrombocytopenia (HIT)", "osteoporosis (long-term use)."]
    },
    "precautions": [
      "High risk of bleeding. Monitor for signs of bleeding.",
      "Requires monitoring with activated partial thromboplastin time (aPTT) for therapeutic IV infusions.",
      "Risk of Heparin-Induced Thrombocytopenia (HIT), a severe, life-threatening immune reaction. Monitor platelet counts.",
      "Reversal agent: Protamine sulfate."
    ],
    "contraindications": [
      "Hypersensitivity (especially to pork products)",
      "active major bleeding",
      "history of HIT",
      "severe thrombocytopenia."
    ],
    "pregnancyCategory": "Category C (but is the anticoagulant of choice in pregnancy as it does not cross the placenta).",
    "lactationInfo": "Does not enter breast milk; compatible."
  },
  "hepatitis-b-vaccine": {
    "name": "Hepatitis B Vaccine (Engerix-B, Recombivax HB)",
    "genericName": "Hepatitis B Vaccine (Recombinant)",
    "brandNames": ["Engerix-B", "Recombivax HB", "Heplisav-B"],
    "category": "Vaccine",
    "drugClass": "Vaccine",
    "indications": "Active immunization for the prevention of Hepatitis B virus (HBV) infection. Recommended for all infants at birth and for adults at high risk.",
    "moaSteps": [
      "The vaccine contains Hepatitis B surface antigen (HBsAg), a non-infectious protein from the virus, produced by recombinant DNA technology.",
      "When injected, the body's immune system recognizes HBsAg as foreign.",
      "The immune system mounts a response, creating antibodies (anti-HBs) and memory B and T cells.",
      "If the person is later exposed to the real Hepatitis B virus, these antibodies and memory cells rapidly neutralize the virus, preventing infection and liver disease."
    ],
    "pharmacokinetics": {
      "absorption": "N/A (stimulates immune response).",
      "distribution": "N/A",
      "metabolism": "N/A",
      "excretion": "N/A"
    },
    "dose": "Standard 3-dose series (Engerix-B, Recombivax): 0, 1, and 6 months. 2-dose series (Heplisav-B): 0 and 1 month. Administered IM.",
    "adverseEffects": {
      "common": ["Injection site pain/soreness", "headache", "fatigue", "fever."],
      "serious": ["Anaphylaxis (very rare)."]
    },
    "precautions": [
      "Will not prevent hepatitis caused by other agents (e.g., Hepatitis A, C).",
      "Syncope (fainting) can occur after vaccination; observe patient for 15 minutes.",
      "Response may be diminished in immunocompromised patients (e.g., HIV, dialysis)."
    ],
    "contraindications": [
      "Severe allergic reaction (anaphylaxis) to a previous dose of the vaccine or to any component, including yeast (Engerix-B, Recombivax)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Compatible."
  },
  "histamine": {
    "name": "Histamine",
    "genericName": "Histamine",
    "brandNames": ["N/A - Endogenous chemical"],
    "category": "Autacoid",
    "drugClass": "Amine",
    "indications": "Not typically used as a drug, but is a key mediator in physiology. Used in some diagnostic tests (e.g., for pheochromocytoma, gastric acid secretion).",
    "moaSteps": [
      "Histamine is an endogenous chemical (an autacoid) released from mast cells and basophils.",
      "It acts by binding to four types of receptors (H1, H2, H3, H4).",
      "**H1 Receptor:** Causes vasodilation, increased capillary permeability (leading to edema), bronchoconstriction (in asthma), and stimulation of sensory nerve endings (itching, pain).",
      "**H2 Receptor:** Primarily stimulates gastric acid secretion in the stomach.",
      "**H3 Receptor:** Acts as an autoreceptor in the CNS, inhibiting the release of histamine and other neurotransmitters.",
      "**H4 Receptor:** Involved in immune cell function and inflammation."
    ],
    "pharmacokinetics": {
      "absorption": "N/A",
      "distribution": "Found in high concentrations in skin, lungs, and GI tract.",
      "metabolism": "Rapidly metabolized by histamine-N-methyltransferase and diamine oxidase.",
      "excretion": "Metabolites excreted in urine."
    },
    "dose": "N/A",
    "adverseEffects": {
      "common": ["(If given as a drug) Flushing, headache, hypotension, tachycardia, bronchospasm."],
      "serious": ["Anaphylactic-like reaction."]
    },
    "precautions": [
      "This is a key target of 'antihistamine' (H1 blockers) and 'H2 blocker' (famotidine) drugs."
    ],
    "contraindications": [
      "Hypersensitivity, asthma, severe cardiovascular disease."
    ],
    "pregnancyCategory": "N/A",
    "lactationInfo": "N/A"
  },
  "human-papillomavirus-vaccine": {
    "name": "Human Papillomavirus Vaccine (Gardasil 9)",
    "genericName": "Human Papillomavirus 9-valent Vaccine, Recombinant",
    "brandNames": ["Gardasil 9"],
    "category": "Vaccine",
    "drugClass": "Vaccine",
    "indications": "Prevention of cervical, vaginal, vulvar, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, 58. Prevention of genital warts caused by HPV types 6 and 11. Routinely recommended for ages 9-26.",
    "moaSteps": [
      "The vaccine is a non-infectious, recombinant vaccine containing Virus-Like Particles (VLPs) of the major outer capsid protein (L1) of 9 HPV types.",
      "These VLPs are not infectious as they contain no viral DNA.",
      "When injected, the VLPs stimulate a strong humoral (antibody) immune response.",
      "If the person is later exposed to one of these HPV types, these neutralizing antibodies bind to the virus and prevent it from infecting cells."
    ],
    "pharmacokinetics": {
      "absorption": "N/A (stimulates immune response).",
      "distribution": "N/A",
      "metabolism": "N/A",
      "excretion": "N/A"
    },
    "dose": "2-dose series (if started at age 9-14): 0 and 6-12 months. 3-dose series (if started at age 15-45): 0, 2, and 6 months. Administered IM.",
    "adverseEffects": {
      "common": ["Injection site pain/swelling/redness", "headache", "fever", "nausea", "dizziness.", "fatigue."],
      "serious": ["Anaphylaxis (very rare)."]
    },
    "precautions": [
      "Does not treat existing HPV infections or disease.",
      "Does not protect against all HPV types.",
      "Syncope (fainting) can occur after vaccination; observe patient for 15 minutes."
    ],
    "contraindications": [
      "Severe allergic reaction (anaphylaxis) to a previous dose of the vaccine or to any component, including yeast."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Compatible."
  },"ibuprofen": {
    "name": "Ibuprofen (Advil, Motrin)",
    "genericName": "Ibuprofen",
    "brandNames": ["Advil", "Motrin", "Midol", "I-Prin"],
    "category": "Analgesic, Anti-inflammatory",
    "drugClass": "Nonsteroidal Anti-inflammatory Drug (NSAID)",
    "indications": "Relief of mild to moderate pain, fever, and inflammation. Used for headache, dental pain, menstrual cramps, muscle aches, and arthritis.",
    "moaSteps": [
      "Ibuprofen is a nonselective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes.",
      "It blocks the conversion of arachidonic acid to prostaglandin H2.",
      "This action prevents the synthesis of prostaglandins (which mediate pain, inflammation, and fever) and thromboxane A2 (which stimulates platelet aggregation)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. Peak serum concentration in 1-2 hours.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Extensively metabolized in the liver to inactive metabolites.",
      "excretion": "Eliminated within 24 hours in the urine as metabolites. Half-life is ~2-4 hours."
    },
    "dose": "Analgesic: 200-400 mg PO every 4-6 hours as needed. Max 1200 mg/day (OTC) or 3200 mg/day (prescription).",
    "adverseEffects": {
      "common": ["Dyspepsia (indigestion)", "nausea", "stomach pain", "heartburn", "dizziness", "headache."],
      "serious": ["Gastrointestinal bleeding and ulceration", "cardiovascular thrombotic events (MI, stroke)", "hepatotoxicity", "nephrotoxicity", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "BOXED WARNING (CV Risk): Increased risk of serious cardiovascular thrombotic events (MI, stroke).",
      "BOXED WARNING (GI Risk): Increased risk of serious GI events (bleeding, ulceration, perforation).",
      "Use lowest effective dose for shortest duration.",
      "Avoid in the 3rd trimester of pregnancy."
    ],
    "contraindications": [
      "Hypersensitivity to ibuprofen or other NSAIDs",
      "history of asthma or urticaria after aspirin/NSAID use",
      "perioperative pain in the setting of CABG surgery."
    ],
    "pregnancyCategory": "Category C (D in 3rd trimester)",
    "lactationInfo": "Excreted in breast milk in very small amounts; considered compatible."
  },
  "ibandronate": {
    "name": "Ibandronate (Boniva)",
    "genericName": "Ibandronate",
    "brandNames": ["Boniva"],
    "category": "Osteoporosis Agent",
    "drugClass": "Bisphosphonate",
    "indications": "Treatment and prevention of postmenopausal osteoporosis.",
    "moaSteps": [
      "Ibandronate is a nitrogen-containing bisphosphonate.",
      "It inhibits osteoclast activity and bone resorption.",
      "It binds to hydroxyapatite in the bone, making it resistant to breakdown by osteoclasts, thereby increasing bone mineral density."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly absorbed orally (<1%). Absorption is significantly reduced by food.",
      "distribution": "Rapidly binds to bone. Highly protein-bound (~90%).",
      "metabolism": "Not metabolized.",
      "excretion": "Unabsorbed drug is excreted in feces. Absorbed drug is excreted unchanged in urine. Long terminal half-life due to binding to bone."
    },
    "dose": "Treatment: 150 mg PO once monthly. Must be taken in the morning with a full glass of plain water, at least 60 minutes before any food, drink, or other medication.",
    "adverseEffects": {
      "common": ["Dyspepsia", "abdominal pain", "diarrhea", "back pain", "arthralgia", "headache."],
      "serious": ["Esophagitis, esophageal ulcers", "osteonecrosis of the jaw (ONJ)", "atypical femur fractures", "severe musculoskeletal pain."]
    },
    "precautions": [
      "Must remain upright for at least 60 minutes after taking to reduce esophageal risk.",
      "Correct hypocalcemia and Vitamin D deficiency before starting.",
      "Risk of ONJ, especially with dental procedures."
    ],
    "contraindications": [
      "Hypersensitivity",
      "inability to stand or sit upright for at least 60 minutes",
      "hypocalcemia",
      "abnormalities of the esophagus (e.g., stricture, achalasia)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "ibrutinib": {
    "name": "Ibrutinib (Imbruvica)",
    "genericName": "Ibrutinib",
    "brandNames": ["Imbruvica"],
    "category": "Antineoplastic Agent",
    "drugClass": "Tyrosine Kinase Inhibitor (TKI), BTK Inhibitor",
    "indications": "Treatment of various B-cell malignancies including Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), and Waldenstrm's macroglobulinemia (WM).",
    "moaSteps": [
      "Ibrutinib is a potent and irreversible inhibitor of Bruton's tyrosine kinase (BTK).",
      "BTK is a key signaling molecule in the B-cell receptor (BCR) pathway.",
      "By blocking BTK, ibrutinib inhibits B-cell proliferation, survival, and trafficking, leading to cancer cell death."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Peak in 1-2 hours. Food increases absorption.",
      "distribution": "Highly protein-bound (~97%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Excreted primarily in feces as metabolites. Half-life is ~4-6 hours."
    },
    "dose": "CLL/SLL/WM: 420 mg PO once daily. MCL: 560 mg PO once daily. Take with a glass of water.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "fatigue", "musculoskeletal pain", "rash", "bruising", "anemia", "neutropenia."],
      "serious": ["Hemorrhage (bleeding)", "atrial fibrillation", "hypertension", "severe infections", "cytopenias", "tumor lysis syndrome."]
    },
    "precautions": [
      "Risk of serious bleeding; use with caution with anticoagulants/antiplatelets.",
      "Monitor for atrial fibrillation and hypertension.",
      "Monitor for signs of infection.",
      "Monitor CBC monthly."
    ],
    "contraindications": [
      "Hypersensitivity."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "imatinib": {
    "name": "Imatinib (Gleevec)",
    "genericName": "Imatinib",
    "brandNames": ["Gleevec"],
    "category": "Antineoplastic Agent",
    "drugClass": "Tyrosine Kinase Inhibitor (TKI), BCR-ABL Inhibitor",
    "indications": "Treatment of Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML). Treatment of gastrointestinal stromal tumors (GIST).",
    "moaSteps": [
      "Imatinib is a selective tyrosine kinase inhibitor.",
      "It specifically inhibits the BCR-ABL fusion protein, the abnormal enzyme that drives proliferation in Ph+ CML.",
      "It binds to the ATP-binding site of BCR-ABL, preventing its activity and leading to apoptosis in cancer cells.",
      "It also inhibits other tyrosine kinases like c-Kit (for GIST) and PDGF-R."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and well absorbed. High bioavailability (~98%). Take with food.",
      "distribution": "Highly protein-bound (~95%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4, to an active metabolite.",
      "excretion": "Excreted primarily in feces as metabolites. Half-life is ~18 hours."
    },
    "dose": "CML: 400-600 mg PO once daily. GIST: 400 mg PO once daily. Take with a meal and a large glass of water.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "muscle cramps", "fatigue", "rash", "fluid retention (edema)."],
      "serious": ["Severe fluid retention (e.g., pleural effusion, ascites)", "severe cytopenias (neutropenia, thrombocytopenia)", "hepatotoxicity", "congestive heart failure."]
    },
    "precautions": [
      "Monitor for fluid retention (weigh daily).",
      "Monitor CBC and liver function tests regularly.",
      "Take with food to minimize GI upset.",
      "Avoid strong CYP3A4 inhibitors/inducers."
    ],
    "contraindications": [
      "Hypersensitivity to imatinib."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "imipenem-cilastatin": {
    "name": "Imipenem/Cilastatin (Primaxin)",
    "genericName": "Imipenem and Cilastatin",
    "brandNames": ["Primaxin"],
    "category": "Antibiotic",
    "drugClass": "Carbapenem Antibiotic",
    "indications": "Treatment of severe, broad-spectrum bacterial infections, including lower respiratory tract, urinary tract, intra-abdominal, and skin infections. Effective against many multi-drug resistant organisms.",
    "moaSteps": [
      "This is a combination product:",
      "1. **Imipenem:** A broad-spectrum carbapenem (beta-lactam) antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis.",
      "2. **Cilastatin:** A renal dehydropeptidase inhibitor. It has no antibiotic activity.",
      "Cilastatin blocks the enzyme in the kidneys that rapidly breaks down imipenem, thus increasing the half-life and concentration of imipenem."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV.",
      "distribution": "Widely distributed into tissues and fluids.",
      "metabolism": "Imipenem is metabolized by renal dehydropeptidase (blocked by cilastatin).",
      "excretion": "Both are excreted in the urine. Half-life is ~1 hour."
    },
    "dose": "250 mg to 1 gram IV every 6-8 hours. Dose must be adjusted for renal impairment.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "injection site reactions", "rash."],
      "serious": ["Seizures", "anaphylaxis", "Clostridioides difficile-associated diarrhea (CDAD)", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "Risk of seizures, especially in patients with CNS disorders or renal impairment. Dose adjustment is critical.",
      "Cross-sensitivity with penicillins is possible.",
      "Monitor renal function."
    ],
    "contraindications": [
      "Hypersensitivity to imipenem or cilastatin",
      "history of anaphylactic reaction to beta-lactams."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "imipramine": {
    "name": "Imipramine (Tofranil)",
    "genericName": "Imipramine",
    "brandNames": ["Tofranil"],
    "category": "Antidepressant",
    "drugClass": "Tricyclic Antidepressant (TCA)",
    "indications": "Treatment of depression. Also used for childhood enuresis (bedwetting).",
    "moaSteps": [
      "Imipramine inhibits the neuronal reuptake of both norepinephrine (NE) and serotonin (5-HT).",
      "This increases the concentration of these neurotransmitters in the synaptic cleft, enhancing neurotransmission.",
      "It also has significant anticholinergic (muscarinic), antihistaminic (H1), and alpha-1 adrenergic blocking properties, which cause many side effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed, but high first-pass metabolism.",
      "distribution": "Widely distributed. Highly protein-bound (~90%).",
      "metabolism": "Extensively metabolized in the liver (by CYP2D6, 2C19) to an active metabolite, desipramine.",
      "excretion": "Excreted in urine as metabolites. Long half-life."
    },
    "dose": "Depression: 75-200 mg/day PO, usually in divided doses or at bedtime.",
    "adverseEffects": {
      "common": ["Sedation", "drowsiness", "dry mouth", "constipation", "blurred vision", "urinary retention", "orthostatic hypotension", "weight gain."],
      "serious": ["Cardiotoxicity (arrhythmias, QT prolongation)", "suicidal thoughts", "seizures", "bone marrow suppression."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults.",
      "High risk of overdose, which can be fatal (due to cardiotoxicity).",
      "High anticholinergic burden; use with caution in elderly.",
      "Do not use with MAOIs (risk of serotonin syndrome)."
    ],
    "contraindications": [
      "Hypersensitivity to TCAs",
      "acute recovery period after MI",
      "concomitant use with MAOIs (within 14 days)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "imiquimod": {
    "name": "Imiquimod (Aldara, Zyclara)",
    "genericName": "Imiquimod",
    "brandNames": ["Aldara", "Zyclara"],
    "category": "Topical Skin Agent",
    "drugClass": "Immune Response Modifier",
    "indications": "Topical treatment of external genital and perianal warts. Treatment of actinic keratosis. Treatment of superficial basal cell carcinoma.",
    "moaSteps": [
      "Imiquimod is a topical immune response modifier.",
      "It acts as a Toll-like receptor 7 (TLR7) agonist.",
      "It does not directly kill the virus or cancer cells. Instead, it stimulates the local innate and cell-mediated immune system.",
      "This activation leads to the production of cytokines (like interferon-alpha), which mount an immune attack against the abnormal cells."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal percutaneous (skin) absorption.",
      "distribution": "Acts locally in the skin.",
      "metabolism": "Not metabolized (if minimally absorbed).",
      "excretion": "Excreted in urine and feces (if minimally absorbed)."
    },
    "dose": "Genital Warts: Apply 3 times/week at bedtime, wash off after 6-10 hours. Actinic Keratosis: Apply 2 times/week at bedtime.",
    "adverseEffects": {
      "common": ["Local skin reactions (erythema, itching, burning, erosion, flaking, edema)", "headache", "fatigue", "flu-like symptoms."],
      "serious": ["Severe local skin reactions", "hypersensitivity reactions."]
    },
    "precautions": [
      "Severe local skin reactions are common and expected, indicating an immune response. May require a rest period.",
      "Avoid exposure to sunlight (natural or artificial) as it can increase susceptibility to sunburn.",
      "Wash hands before and after application. Do not occlude the area."
    ],
    "contraindications": [
      "Hypersensitivity to imiquimod."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "indomethacin": {
    "name": "Indomethacin (Indocin)",
    "genericName": "Indomethacin",
    "brandNames": ["Indocin", "Tivorbex"],
    "category": "Anti-inflammatory, Analgesic",
    "drugClass": "Nonsteroidal Anti-inflammatory Drug (NSAID)",
    "indications": "Relief of moderate to severe rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Treatment of acute gouty arthritis. Treatment of acute painful shoulder (bursitis/tendinitis).",
    "moaSteps": [
      "Indomethacin is a potent, nonselective inhibitor of cyclooxygenase-1 (COX-1) and COX-2 enzymes.",
      "It blocks the conversion of arachidonic acid to prostaglandins, which are mediators of pain, inflammation, and fever."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed orally.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Extensively metabolized in the liver.",
      "excretion": "Excreted in urine and feces (via bile) as metabolites. Half-life is ~4.5 hours."
    },
    "dose": "Arthritis: 25-50 mg PO 2-3 times daily. Gout: 50 mg PO 3 times daily. Take with food.",
    "adverseEffects": {
      "common": ["Headache (very common, 'indomethacin headache')", "dizziness", "dyspepsia", "nausea", "abdominal pain."],
      "serious": ["Gastrointestinal bleeding and ulceration", "cardiovascular thrombotic events (MI, stroke)", "hepatotoxicity", "nephrotoxicity", "severe skin reactions.", "CNS effects (psychosis, confusion)."]
    },
    "precautions": [
      "BOXED WARNING (CV Risk): Increased risk of serious cardiovascular thrombotic events (MI, stroke).",
      "BOXED WARNING (GI Risk): Increased risk of serious GI events (bleeding, ulceration, perforation).",
      "High incidence of CNS side effects (headache, dizziness, confusion); use with caution in elderly.",
      "Take with food or milk to reduce GI upset."
    ],
    "contraindications": [
      "Hypersensitivity to indomethacin or other NSAIDs",
      "history of asthma or urticaria after aspirin/NSAID use",
      "perioperative pain in the setting of CABG surgery."
    ],
    "pregnancyCategory": "Category C (D in 3rd trimester)",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "infliximab": {
    "name": "Infliximab (Remicade, Inflectra)",
    "genericName": "Infliximab",
    "brandNames": ["Remicade", "Inflectra", "Avsola", "Renflexis"],
    "category": "Antirheumatic, GI Agent",
    "drugClass": "Tumor Necrosis Factor (TNF) Blocker, DMARD",
    "indications": "Treatment of rheumatoid arthritis (with methotrexate), Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.",
    "moaSteps": [
      "Infliximab is a chimeric (part-mouse, part-human) monoclonal antibody.",
      "It binds with high affinity to both soluble and transmembrane forms of Tumor Necrosis Factor-alpha (TNF-alpha).",
      "TNF-alpha is a key pro-inflammatory cytokine. By neutralizing TNF-alpha, infliximab blocks its interaction with its receptors, disrupting the inflammatory cascade.",
      "This leads to a rapid reduction in inflammation and symptoms."
    ],
    "pharmacokinetics": {
      "absorption": "Administered as an IV infusion.",
      "distribution": "Distributed primarily in the vascular compartment.",
      "metabolism": "Degraded into peptides and amino acids by general protein catabolism.",
      "excretion": "No major excretion pathway. Long half-life (~7-12 days)."
    },
    "dose": "Varies by indication. e.g., RA: 3 mg/kg IV infusion at 0, 2, and 6 weeks, then every 8 weeks.",
    "adverseEffects": {
      "common": ["Infusion-related reactions (fever, chills, rash, headache)", "headache", "abdominal pain", "nausea", "increased risk of infections (e.g., upper respiratory)."],
      "serious": ["Serious infections (e.g., tuberculosis, fungal infections)", "malignancy (lymphoma, skin cancer)", "heart failure (new onset or exacerbation)", "demyelinating disease", "autoimmune (lupus-like) syndrome."]
    },
    "precautions": [
      "BOXED WARNING (Serious Infections): Increased risk of serious infections that may lead to hospitalization or death (e.g., TB, bacterial sepsis, invasive fungal infections). Must test for latent TB before starting.",
      "BOXED WARNING (Malignancy): Lymphoma and other malignancies have been reported in children and adolescents treated with TNF blockers.",
      "Risk of infusion reactions; must be administered by a healthcare professional.",
      "Can worsen or cause new-onset heart failure."
    ],
    "contraindications": [
      "Hypersensitivity to infliximab or murine (mouse) proteins",
      "moderate to severe heart failure (NYHA Class III/IV) at doses >5 mg/kg."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "insulin-aspart": {
    "name": "Insulin Aspart (NovoLog, Fiasp)",
    "genericName": "Insulin Aspart",
    "brandNames": ["NovoLog", "Fiasp"],
    "category": "Antidiabetic",
    "drugClass": "Rapid-Acting Insulin",
    "indications": "Treatment of type 1 and type 2 diabetes mellitus to improve glycemic control.",
    "moaSteps": [
      "Insulin Aspart is a rapid-acting human insulin analog.",
      "It binds to insulin receptors on target cells (e.g., muscle, fat, liver).",
      "This binding promotes the cellular uptake of glucose from the blood.",
      "It also inhibits the production of glucose by the liver (gluconeogenesis) and promotes glycogen synthesis.",
      "Its rapid onset is due to a modification that prevents it from forming hexamers, allowing for faster absorption."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed after subcutaneous injection. Onset: 10-20 minutes. Peak: 1-3 hours. Duration: 3-5 hours.",
      "distribution": "Low protein binding.",
      "metabolism": "Metabolized in the liver and kidneys like endogenous insulin.",
      "excretion": "Excreted in urine. Half-life is ~81 minutes."
    },
    "dose": "Dose is individualized. Administered SC within 5-10 minutes before a meal.",
    "adverseEffects": {
      "common": ["Hypoglycemia (low blood sugar)", "injection site reactions (lipodystrophy)", "weight gain", "headache."],
      "serious": ["Severe hypoglycemia (can lead to seizure, coma, death)", "hypokalemia", "anaphylaxis."]
    },
    "precautions": [
      "Risk of hypoglycemia. Monitor blood glucose.",
      "Dose must be individualized. Meal-time insulin.",
      "Changes in insulin regimen (strength, type, brand) should be made cautiously.",
      "Monitor potassium levels (can cause hypokalemia)."
    ],
    "contraindications": [
      "During episodes of hypoglycemia",
      "hypersensitivity to insulin aspart."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Compatible."
  },
  "insulin-detemir": {
    "name": "Insulin Detemir (Levemir)",
    "genericName": "Insulin Detemir",
    "brandNames": ["Levemir"],
    "category": "Antidiabetic",
    "drugClass": "Long-Acting Insulin",
    "indications": "Treatment of type 1 and type 2 diabetes mellitus to provide basal (long-acting) glycemic control.",
    "moaSteps": [
      "Insulin Detemir is a long-acting human insulin analog.",
      "It binds to insulin receptors to promote glucose uptake by cells and inhibit hepatic glucose production.",
      "Its long duration of action is achieved by two mechanisms: 1) It has a fatty acid chain that allows it to reversibly bind to albumin in the blood, and 2) it forms hexamers at the injection site, both of which slow its absorption and clearance."
    ],
    "pharmacokinetics": {
      "absorption": "Slowly absorbed after SC injection. Onset: 1-2 hours. Peak: 6-8 hours (or no pronounced peak). Duration: Up to 24 hours.",
      "distribution": "Highly protein-bound (to albumin).",
      "metabolism": "Metabolized like endogenous insulin.",
      "excretion": "Excreted in urine. Half-life is ~5-7 hours."
    },
    "dose": "Dose is individualized. Administered SC once daily (at evening meal or bedtime) or twice daily (every 12 hours).",
    "adverseEffects": {
      "common": ["Hypoglycemia", "injection site reactions", "weight gain."],
      "serious": ["Severe hypoglycemia", "hypokalemia", "anaphylaxis."]
    },
    "precautions": [
      "Risk of hypoglycemia. Monitor blood glucose.",
      "This is a basal insulin; it is not for meal-time coverage or diabetic ketoacidosis.",
      "Do not mix with other insulins in the same syringe.",
      "Monitor potassium levels."
    ],
    "contraindications": [
      "During episodes of hypoglycemia",
      "hypersensitivity to insulin detemir."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Compatible."
  },
  "insulin-glargine": {
    "name": "Insulin Glargine (Lantus, Toujeo, Basaglar)",
    "genericName": "Insulin Glargine",
    "brandNames": ["Lantus", "Toujeo", "Basaglar", "Semglee"],
    "category": "Antidiabetic",
    "drugClass": "Long-Acting Insulin",
    "indications": "Treatment of type 1 and type 2 diabetes mellitus to provide basal (long-acting) glycemic control.",
    "moaSteps": [
      "Insulin Glargine is a long-acting human insulin analog.",
      "It binds to insulin receptors to promote glucose uptake by cells and inhibit hepatic glucose production.",
      "Its long duration is due to its low solubility at neutral pH. After SC injection (at pH 4), it precipitates in the subcutaneous tissue, forming microprecipitates from which it is slowly and continuously absorbed."
    ],
    "pharmacokinetics": {
      "absorption": "Slow, continuous absorption. Onset: 1-2 hours. No pronounced peak (flat profile). Duration: 24 hours (Lantus) or >24 hours (Toujeo).",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the subcutaneous tissue and liver.",
      "excretion": "Excreted in urine."
    },
    "dose": "Dose is individualized. Administered SC once daily at the same time each day.",
    "adverseEffects": {
      "common": ["Hypoglycemia", "injection site reactions (lipodystrophy)", "weight gain."],
      "serious": ["Severe hypoglycemia", "hypokalemia", "anaphylaxis."]
    },
    "precautions": [
      "Risk of hypoglycemia. Monitor blood glucose.",
      "This is a basal insulin; it is not for meal-time coverage or diabetic ketoacidosis.",
      "Do not mix with other insulins in the same syringe.",
      "Toujeo (U-300) is 3x more concentrated than Lantus (U-100); doses are not interchangeable."
    ],
    "contraindications": [
      "During episodes of hypoglycemia",
      "hypersensitivity to insulin glargine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Compatible."
  },
  "insulin-lispro": {
    "name": "Insulin Lispro (Humalog, Admelog)",
    "genericName": "Insulin Lispro",
    "brandNames": ["Humalog", "Admelog", "Lyumjev"],
    "category": "Antidiabetic",
    "drugClass": "Rapid-Acting Insulin",
    "indications": "Treatment of type 1 and type 2 diabetes mellitus to improve glycemic control.",
    "moaSteps": [
      "Insulin Lispro is a rapid-acting human insulin analog.",
      "It binds to insulin receptors to promote the cellular uptake of glucose and inhibit hepatic glucose production.",
      "Its structure (proline and lysine reversed at B28/B29) prevents it from forming hexamers, allowing for very rapid absorption after injection."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Onset: 15-30 minutes. Peak: 30-90 minutes. Duration: 3-5 hours.",
      "distribution": "Low protein binding.",
      "metabolism": "Metabolized like endogenous insulin.",
      "excretion": "Excreted in urine. Half-life is ~1 hour."
    },
    "dose": "Dose is individualized. Administered SC within 15 minutes before a meal or immediately after a meal.",
    "adverseEffects": {
      "common": ["Hypoglycemia", "injection site reactions", "weight gain", "headache."],
      "serious": ["Severe hypoglycemia", "hypokalemia", "anaphylaxis."]
    },
    "precautions": [
      "Risk of hypoglycemia. Monitor blood glucose.",
      "Dose must be individualized. This is a meal-time (bolus) insulin.",
      "Changes in insulin regimen (strength, type, brand) should be made cautiously."
    ],
    "contraindications": [
      "During episodes of hypoglycemia",
      "hypersensitivity to insulin lispro."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Compatible."
  },
  "ipratropium": {
    "name": "Ipratropium (Atrovent)",
    "genericName": "Ipratropium",
    "brandNames": ["Atrovent HFA", "Atrovent Nasal"],
    "category": "Bronchodilator, Antiallergy",
    "drugClass": "Anticholinergic (SAMA)",
    "indications": "Inhalation (Atrovent): Maintenance treatment of bronchospasm associated with COPD. Nasal (Atrovent Nasal): Symptomatic relief of rhinorrhea (runny nose) associated with allergic or nonallergic rhinitis.",
    "moaSteps": [
      "Ipratropium is a short-acting muscarinic antagonist (SAMA), an anticholinergic agent.",
      "In the airways: It blocks muscarinic (M3) receptors on bronchial smooth muscle, inhibiting the effect of acetylcholine.",
      "This action prevents bronchoconstriction and leads to bronchodilation.",
      "In the nose: It blocks muscarinic receptors on nasal glands, reducing mucus secretion (dries up a runny nose)."
    ],
    "pharmacokinetics": {
      "absorption": "Minimally absorbed systemically after inhalation or nasal spray, maximizing local effects.",
      "distribution": "Acts locally. Low protein binding.",
      "metabolism": "Metabolized to inactive esters.",
      "excretion": "Excreted in feces and urine. Half-life is ~2 hours."
    },
    "dose": "COPD (Inhalation): 2 inhalations (17 mcg/puff) 4 times daily. Rhinorrhea (Nasal): 2 sprays (42 mcg/spray) per nostril 2-3 times daily.",
    "adverseEffects": {
      "common": ["Inhalation: Dry mouth", "cough", "headache", "bronchitis.", "Nasal: Nasal dryness", "epistaxis (nosebleed)."],
      "serious": ["Paradoxical bronchospasm", "acute narrow-angle glaucoma (if sprayed in eyes)", "worsening of urinary retention."]
    },
    "precautions": [
      "Not for acute bronchospasm (it's a maintenance, not a rescue, inhaler).",
      "Use with caution in patients with narrow-angle glaucoma or prostatic hyperplasia (BPH) / urinary retention.",
      "Avoid spraying in the eyes."
    ],
    "contraindications": [
      "Hypersensitivity to ipratropium, atropine, or its derivatives."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "irbesartan": {
    "name": "Irbesartan (Avapro)",
    "genericName": "Irbesartan",
    "brandNames": ["Avapro"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin II Receptor Blocker (ARB)",
    "indications": "Treatment of hypertension. Treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension.",
    "moaSteps": [
      "Irbesartan is a selective angiotensin II receptor blocker (ARB).",
      "It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking its binding to the AT1 receptor.",
      "This blockade results in vasodilation, decreased secretion of aldosterone, and a reduction in blood pressure.",
      "Unlike ACE inhibitors, it does not inhibit the breakdown of bradykinin (less cough)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. Bioavailability ~60-80%. Not affected by food.",
      "distribution": "Highly protein-bound (~96%).",
      "metabolism": "Metabolized in the liver by CYP2C9.",
      "excretion": "Excreted in feces (via bile) and urine. Half-life is ~11-15 hours."
    },
    "dose": "Hypertension: 150-300 mg PO once daily. Diabetic Nephropathy: 300 mg PO once daily.",
    "adverseEffects": {
      "common": ["Dizziness", "headache", "fatigue", "hyperkalemia", "diarrhea."],
      "serious": ["Angioedema (rare)", "hypotension (especially in volume-depleted patients)", "acute renal failure."]
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected.",
      "Can cause symptomatic hypotension.",
      "Monitor renal function and serum potassium, especially in patients with renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with aliskiren in patients with diabetes",
      "Pregnancy."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Not recommended."
  },"januvia": {
    "name": "Januvia (Sitagliptin)",
    "genericName": "Sitagliptin",
    "brandNames": ["Januvia"],
    "category": "Antidiabetic",
    "drugClass": "Dipeptidyl Peptidase-4 (DPP-4) Inhibitor",
    "indications": "Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "moaSteps": [
      "Sitagliptin is a DPP-4 inhibitor.",
      "It inhibits the enzyme DPP-4, which is responsible for inactivating incretin hormones (like GLP-1 and GIP).",
      "By preventing their breakdown, it increases the levels of active incretins.",
      "This leads to a glucose-dependent increase in insulin secretion and a decrease in glucagon secretion, ultimately lowering blood glucose."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High bioavailability (~87%). Food does not affect absorption.",
      "distribution": "Widely distributed. Moderately protein-bound (~38%).",
      "metabolism": "Minimally metabolized; primarily by CYP3A4.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~12.4 hours."
    },
    "dose": "100 mg PO once daily, with or without food.",
    "adverseEffects": {
      "common": ["Nasopharyngitis (stuffy nose/sore throat)", "headache", "diarrhea", "upper respiratory tract infection."],
      "serious": ["Pancreatitis", "severe joint pain (arthralgia)", "bullous pemphigoid", "hypersensitivity reactions (anaphylaxis, SJS)."]
    },
    "precautions": [
      "Cases of acute pancreatitis have been reported. Monitor for signs (severe abdominal pain, nausea/vomiting) and discontinue if suspected.",
      "Can cause severe and disabling joint pain.",
      "Requires dose adjustment in moderate to severe renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to sitagliptin."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "jardiance": {
    "name": "Jardiance (Empagliflozin)",
    "genericName": "Empagliflozin",
    "brandNames": ["Jardiance"],
    "category": "Antidiabetic, Heart Failure Agent",
    "drugClass": "SGLT2 Inhibitor",
    "indications": "To improve glycemic control in type 2 diabetes. To reduce the risk of cardiovascular death in adults with type 2 diabetes and established CV disease. To reduce the risk of CV death and hospitalization for heart failure in adults with HFrEF.",
    "moaSteps": [
      "Empagliflozin is a selective inhibitor of the Sodium-Glucose Cotransporter 2 (SGLT2) in the proximal renal tubules.",
      "SGLT2 is responsible for reabsorbing the majority of filtered glucose from the tubular fluid.",
      "By inhibiting SGLT2, it blocks glucose reabsorption, leading to increased urinary glucose excretion (glucosuria).",
      "This action lowers blood glucose levels independent of insulin and also causes a mild osmotic diuresis, reducing blood pressure and body weight."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Peak in ~1.5 hours.",
      "distribution": "Highly protein-bound (~86%).",
      "metabolism": "Metabolized in the liver (via UGT) to inactive metabolites.",
      "excretion": "Excreted in urine and feces. Half-life is ~12.4 hours."
    },
    "dose": "10-25 mg PO once daily in the morning, with or without food.",
    "adverseEffects": {
      "common": ["Genital mycotic infections (yeast infections)", "urinary tract infections (UTIs)", "increased urination", "thirst."],
      "serious": ["Ketoacidosis (can occur with normal blood glucose)", "acute kidney injury", "Fournier's gangrene", "hypotension (volume depletion)."]
    },
    "precautions": [
      "Can cause volume depletion and hypotension. Assess volume status before starting.",
      "Risk of ketoacidosis. Monitor for symptoms and stop therapy if suspected.",
      "Risk of serious genital and urinary tract infections.",
      "Risk of lower limb amputations (seen with others in class)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe renal impairment (eGFR < 30), or patients on dialysis."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Not recommended."
  },
  "jentadueto": {
    "name": "Jentadueto (Linagliptin/Metformin)",
    "genericName": "Linagliptin and Metformin",
    "brandNames": ["Jentadueto", "Jentadueto XR"],
    "category": "Antidiabetic",
    "drugClass": "DPP-4 Inhibitor / Biguanide Combination",
    "indications": "Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.",
    "moaSteps": [
      "This is a combination product with two mechanisms:",
      "1. **Linagliptin (DPP-4 Inhibitor):** Inhibits the DPP-4 enzyme, increasing incretin hormone levels. This leads to glucose-dependent insulin release and decreased glucagon secretion.",
      "2. **Metformin (Biguanide):** Decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves peripheral insulin sensitivity."
    ],
    "pharmacokinetics": {
      "absorption": "Bioavailability ~30% (linagliptin), 50-60% (metformin).",
      "distribution": "Linagliptin is highly protein-bound; metformin is negligible.",
      "metabolism": "Linagliptin is minimally metabolized. Metformin is not metabolized.",
      "excretion": "Linagliptin is excreted in feces (via bile). Metformin is excreted unchanged in urine."
    },
    "dose": "Individualized. e.g., 2.5 mg linagliptin / 500 mg metformin PO twice daily with meals.",
    "adverseEffects": {
      "common": ["Nasopharyngitis", "diarrhea", "nausea/vomiting", "flatulence", "headache."],
      "serious": ["Lactic acidosis (Metformin)", "pancreatitis (Linagliptin)", "severe joint pain", "bullous pemphigoid."]
    },
    "precautions": [
      "BOXED WARNING (Lactic Acidosis): Metformin can cause a rare but fatal lactic acidosis. Risk increases with renal impairment, age >65, and hypoxia.",
      "Risk of pancreatitis and severe arthralgia from linagliptin.",
      "Metformin can cause Vitamin B12 deficiency."
    ],
    "contraindications": [
      "Severe renal impairment (eGFR < 30)",
      "acute or chronic metabolic acidosis (including diabetic ketoacidosis)",
      "hypersensitivity."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Not recommended."
  },
  "juxtapid": {
    "name": "Juxtapid (Lomitapide)",
    "genericName": "Lomitapide",
    "brandNames": ["Juxtapid"],
    "category": "Antihyperlipidemic",
    "drugClass": "Microsomal Triglyceride Transfer Protein (MTP) Inhibitor",
    "indications": "Adjunct to diet and other lipid-lowering therapies to reduce LDL-C in patients with homozygous familial hypercholesterolemia (HoFH).",
    "moaSteps": [
      "Lomitapide is a systemic inhibitor of the microsomal triglyceride transfer protein (MTP).",
      "MTP is found in the endoplasmic reticulum of liver and intestinal cells.",
      "It is essential for the assembly of apolipoprotein B-containing lipoproteins (chylomicrons in the intestine and VLDL in the liver).",
      "By inhibiting MTP, lomitapide reduces the secretion of VLDL and chylomicrons, which in turn reduces plasma levels of LDL-C and triglycerides."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly absorbed. High-fat meal increases absorption, but is not recommended.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~39 hours."
    },
    "dose": "Initial: 5 mg PO once daily. Titrate up to a max of 60 mg/day. Must be taken on an empty stomach, 2 hours after the evening meal.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "dyspepsia", "abdominal pain", "elevated LFTs", "hepatic steatosis (fatty liver)."],
      "serious": ["Hepatotoxicity (severe fatty liver, liver failure)."]
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Can cause severe liver toxicity (elevated LFTs and hepatic steatosis). Only available through a restricted (REMS) program.",
      "Monitor LFTs regularly.",
      "Potent inhibitor of CYP3A4. Contraindicated with strong CYP3A4 inhibitors.",
      "Can cause GI distress and fat-soluble vitamin (A, D, E, K) deficiency. "
    ],
    "contraindications": [
      "Hypersensitivity",
      "Pregnancy (Category X)",
      "concomitant use with strong or moderate CYP3A4 inhibitors",
      "moderate or severe hepatic impairment."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "jevtana": {
    "name": "Jevtana (Cabazitaxel)",
    "genericName": "Cabazitaxel",
    "brandNames": ["Jevtana"],
    "category": "Antineoplastic Agent",
    "drugClass": "Taxane, Microtubule Inhibitor",
    "indications": "Treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with a docetaxel-containing regimen.",
    "moaSteps": [
      "Cabazitaxel is a semi-synthetic taxane, derived from yew tree needles.",
      "It binds to tubulin and promotes the assembly of microtubules while simultaneously inhibiting their disassembly.",
      "This 'freezes' the cell's cytoskeleton, preventing the formation of the mitotic spindle.",
      "This action blocks the cell cycle in the M-phase (mitosis), leading to cell death."
    ],
    "pharmacokinetics": {
      "absorption": "Administered as an IV infusion.",
      "distribution": "Widely distributed. Highly protein-bound (~89-92%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Excreted primarily in feces as metabolites. Long half-life (~95 hours)."
    },
    "dose": "20-25 mg/m IV infusion over 1 hour, every 3 weeks. Must be given with a corticosteroid (e.g., prednisone).",
    "adverseEffects": {
      "common": ["Neutropenia", "anemia", "thrombocytopenia", "diarrhea", "nausea", "vomiting", "fatigue", "alopecia (hair loss)."],
      "serious": ["Febrile neutropenia", "severe hypersensitivity reactions", "severe diarrhea", "renal failure."]
    },
    "precautions": [
      "BOXED WARNING (Neutropenia): Can cause severe, sometimes fatal, neutropenia. Monitor CBC frequently. Prophylactic G-CSF is recommended.",
      "BOXED WARNING (Hypersensitivity): Severe hypersensitivity reactions can occur. Must premedicate with antihistamines and corticosteroids.",
      "Can cause severe GI complications (diarrhea, perforation)."
    ],
    "contraindications": [
      "Hypersensitivity to cabazitaxel or other taxanes",
      "baseline neutrophil count < 1,500/mm",
      "severe hepatic impairment."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
    
  },
   "ketamine": {
    "name": "Ketamine (Ketalar)",
    "genericName": "Ketamine",
    "brandNames": ["Ketalar", "Spravato (esketamine nasal spray)"],
    "category": "Anesthetic, Analgesic, Antidepressant",
    "drugClass": "NMDA Receptor Antagonist, General Anesthetic",
    "indications": "Induction and maintenance of general anesthesia. Analgesia for short-term procedures. (Spravato): Treatment-resistant depression.",
    "moaSteps": [
      "Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist.",
      "It blocks the action of glutamate, the primary excitatory neurotransmitter in the brain.",
      "This action produces a 'dissociative anesthesia,' characterized by analgesia, amnesia, and catalepsy, without significant respiratory depression at lower doses.",
      "Its antidepressant effect is thought to involve rapid increases in synaptic plasticity."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed IV/IM. Nasal bioavailability is ~45-50%.",
      "distribution": "Highly lipophilic, rapidly distributes to the brain. Crosses the placenta.",
      "metabolism": "Extensively metabolized in the liver by CYP3A4 and CYP2B6 to an active metabolite (norketamine).",
      "excretion": "Excreted in the urine as metabolites. Half-life is ~2-3 hours."
    },
    "dose": "Anesthesia: 1-4.5 mg/kg IV or 6.5-13 mg/kg IM. Dose is highly variable.",
    "adverseEffects": {
      "common": ["Emergence phenomena (hallucinations, delirium, vivid dreams)", "hypertension", "tachycardia", "nausea", "vomiting", "diplopia (double vision)."],
      "serious": ["Respiratory depression (at high doses)", "laryngospasm", "severe hypertension", "abuse and dependence."]
    },
    "precautions": [
      "BOXED WARNING (Spravato - REMS): Risk of sedation, dissociation, and abuse/misuse. Administered in a certified healthcare setting.",
      "BOXED WARNING (Spravato - Suicidality): Increased risk of suicidal thoughts and behaviors in adolescents and young adults.",
      "Can cause emergence reactions; co-administration of a benzodiazepine can reduce risk.",
      "Has a high potential for abuse (Schedule III).",
      "Use with caution in patients with uncontrolled hypertension, cardiovascular disease, or psychiatric disorders."
    ],
    "contraindications": [
      "Hypersensitivity",
      "conditions where a significant elevation in blood pressure would be a serious hazard (e.g., uncontrolled hypertension, aortic dissection)."
    ],
    "pregnancyCategory": "Category B (Spravato). Anesthetic use is not categorized.",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "ketoconazole": {
    "name": "Ketoconazole (Nizoral)",
    "genericName": "Ketoconazole",
    "brandNames": ["Nizoral (topical)", "Ketodan (topical)"],
    "category": "Antifungal",
    "drugClass": "Azole Antifungal",
    "indications": "Topical: Treatment of tinea corporis (ringworm), tinea cruris (jock itch), tinea pedis (athlete's foot), seborrheic dermatitis, and dandruff. (Oral form is rarely used due to toxicity).",
    "moaSteps": [
      "Ketoconazole is an azole antifungal agent.",
      "It inhibits the fungal cytochrome P450 enzyme, 14-alpha-sterol demethylase.",
      "This enzyme is essential for converting lanosterol to ergosterol, a vital component of the fungal cell membrane.",
      "By depleting ergosterol, ketoconazole disrupts the membrane's structure and function, leading to inhibition of fungal growth."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption from topical application. Oral absorption requires an acidic pH.",
      "distribution": "Acts locally in the skin.",
      "metabolism": "N/A (topical). Oral form is extensively metabolized by CYP3A4.",
      "excretion": "N/A (topical)."
    },
    "dose": "Cream/Shampoo: Apply topically to the affected area once or twice daily.",
    "adverseEffects": {
      "common": ["(Topical) Skin irritation", "burning", "stinging", "itching", "dryness."],
      "serious": ["(Topical) Severe local hypersensitivity reaction.", "(Oral) Severe hepatotoxicity, QT prolongation."]
    },
    "precautions": [
      "BOXED WARNING (Oral only): Hepatotoxicity. Oral ketoconazole can cause severe, sometimes fatal, liver injury. Only use orally when benefits outweigh risks and other antifungals are not available.",
      "BOXED WARNING (Oral only): QT Prolongation. Can prolong the QT interval; co-administration with many drugs is contraindicated.",
      "Topical forms are for external use only.",
      "Ketoconazole (oral) is a potent inhibitor of CYP3A4."
    ],
    "contraindications": [
      "Hypersensitivity. (Oral): Acute or chronic liver disease, concomitant use with many CYP3A4 substrates (e.g., statins, quinidine)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk after topical use; use with caution."
  },
  "ketoprofen": {
    "name": "Ketoprofen (Orudis, Oruvail)",
    "genericName": "Ketoprofen",
    "brandNames": ["Orudis", "Oruvail", "Actron"],
    "category": "Anti-inflammatory, Analgesic",
    "drugClass": "Nonsteroidal Anti-inflammatory Drug (NSAID)",
    "indications": "Relief of mild to moderate pain, fever, and inflammation. Management of rheumatoid arthritis and osteoarthritis. Treatment of primary dysmenorrhea.",
    "moaSteps": [
      "Ketoprofen is a nonselective inhibitor of cyclooxygenase-1 (COX-1) and COX-2 enzymes.",
      "It blocks the conversion of arachidonic acid to prostaglandins, which are mediators of pain, inflammation, and fever."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed orally.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Extensively metabolized in the liver, primarily by glucuronidation.",
      "excretion": "Excreted in the urine as metabolites. Half-life is ~2-4 hours."
    },
    "dose": "Pain: 25-50 mg PO every 6-8 hours. Arthritis (ER): 200 mg PO once daily. Take with food.",
    "adverseEffects": {
      "common": ["Dyspepsia", "nausea", "abdominal pain", "dizziness", "headache", "fluid retention."],
      "serious": ["Gastrointestinal bleeding and ulceration", "cardiovascular thrombotic events (MI, stroke)", "hepatotoxicity", "nephrotoxicity."]
    },
    "precautions": [
      "BOXED WARNING (CV Risk): Increased risk of serious cardiovascular thrombotic events (MI, stroke).",
      "BOXED WARNING (GI Risk): Increased risk of serious GI events (bleeding, ulceration, perforation).",
      "Use lowest effective dose for shortest duration.",
      "Take with food or milk to reduce GI upset."
    ],
    "contraindications": [
      "Hypersensitivity to ketoprofen or other NSAIDs",
      "history of asthma or urticaria after aspirin/NSAID use",
      "perioperative pain in the setting of CABG surgery."
    ],
    "pregnancyCategory": "Category C (D in 3rd trimester)",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "ketorolac": {
    "name": "Ketorolac (Toradol)",
    "genericName": "Ketorolac Tromethamine",
    "brandNames": ["Toradol (IV/IM/PO)", "Acular (ophthalmic)"],
    "category": "Analgesic, Anti-inflammatory",
    "drugClass": "Nonsteroidal Anti-inflammatory Drug (NSAID)",
    "indications": "Systemic: Short-term ( 5 days) management of moderate to severe acute pain that requires opioid-level analgesia. Ophthalmic: Relief of ocular itching due to seasonal allergic conjunctivitis; treatment of postoperative inflammation.",
    "moaSteps": [
      "Ketorolac is a potent, nonselective inhibitor of COX-1 and COX-2 enzymes.",
      "It blocks the conversion of arachidonic acid to prostaglandins, providing potent analgesic and moderate anti-inflammatory effects."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed (PO/IM/IV). Ophthalmic use is local.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in the urine. Half-life is ~5-6 hours."
    },
    "dose": "Varies by route. e.g., 30 mg IV/IM single dose, or 15-30 mg IV/IM every 6 hours. PO: 10-20 mg PO as continuation only. **Max 5 days total duration.**",
    "adverseEffects": {
      "common": ["Headache", "drowsiness", "dyspepsia", "nausea", "abdominal pain", "injection site pain."],
      "serious": ["Gastrointestinal bleeding and perforation", "nephrotoxicity (acute renal failure)", "cardiovascular thrombotic events (MI, stroke)", "hepatotoxicity."]
    },
    "precautions": [
      "BOXED WARNING (Short-Term Use): Total duration of use (all routes combined) must not exceed 5 days due to high risk of serious adverse events.",
      "BOXED WARNING (GI Risk): High risk of serious GI bleeding, ulceration, and perforation, which can be fatal.",
      "BOXED WARNING (Renal Risk): Can cause severe renal toxicity. Contraindicated in advanced renal impairment.",
      "BOXED WARNING (Bleeding Risk): Inhibits platelet function; contraindicated in active bleeding or as prophylactic analgesia before surgery.",
      "BOXED WARNING (CV Risk): Increased risk of serious cardiovascular thrombotic events."
    ],
    "contraindications": [
      "Hypersensitivity to ketorolac or other NSAIDs",
      "active peptic ulcer disease",
      "GI bleeding",
      "advanced renal impairment",
      "use before any major surgery",
      "CABG surgery."
    ],
    "pregnancyCategory": "Category C (D in 3rd trimester)",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "keppra": {
    "name": "Keppra (Levetiracetam)",
    "genericName": "Levetiracetam",
    "brandNames": ["Keppra", "Keppra XR", "Elepsia XR", "Spritam"],
    "category": "Antiepileptic",
    "drugClass": "Anticonvulsant",
    "indications": "Adjunctive therapy for partial-onset seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.",
    "moaSteps": [
      "The exact mechanism of levetiracetam is not fully understood.",
      "It binds to the synaptic vesicle protein 2A (SV2A) in the brain.",
      "This binding is thought to modulate neurotransmitter release (specifically glutamate and GABA) by affecting vesicle trafficking, but the exact downstream effect is unknown.",
      "It does not act on traditional sodium channels or GABA receptors."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. High bioavailability (~100%). Not affected by food.",
      "distribution": "Widely distributed. Low protein binding (<10%).",
      "metabolism": "Minimally metabolized; primarily by enzymatic hydrolysis in the blood.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~6-8 hours."
    },
    "dose": "Initial: 500 mg PO twice daily. Titrate up to a max of 3000 mg/day (1500 mg twice daily).",
    "adverseEffects": {
      "common": ["Somnolence (drowsiness)", "asthenia (weakness)", "dizziness", "infection (nasopharyngitis)."],
      "serious": ["Behavioral abnormalities (agitation, aggression, depression, psychosis)", "suicidal thoughts", "severe skin reactions (SJS/TEN)", "anaphylaxis."]
    },
    "precautions": [
      "Can cause behavioral/psychiatric symptoms (e.g., agitation, irritability, depression). Monitor for mood changes.",
      "Can cause significant drowsiness and dizziness; caution against driving.",
      "Abrupt discontinuation can precipitate seizures. Taper dose slowly.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to levetiracetam."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "keflex": {
    "name": "Keflex (Cephalexin)",
    "genericName": "Cephalexin",
    "brandNames": ["Keflex", "Daxbia"],
    "category": "Antibiotic",
    "drugClass": "Cephalosporin (1st Generation)",
    "indications": "Treatment of various bacterial infections, including respiratory tract infections, otitis media, skin and skin structure infections, and urinary tract infections.",
    "moaSteps": [
      "Cephalexin is a first-generation cephalosporin (a beta-lactam antibiotic).",
      "It inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs).",
      "This interferes with the final transpeptidation step of peptidoglycan synthesis, a key component of the bacterial cell wall.",
      "Inhibition of cell wall synthesis leads to cell lysis and death (bactericidal effect)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. Food may delay absorption.",
      "distribution": "Widely distributed into tissues and fluids. Low protein binding (~10-15%).",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~0.5-1.2 hours."
    },
    "dose": "250-500 mg PO every 6 hours. Max 4 g/day.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "headache", "rash."],
      "serious": ["Anaphylaxis", "severe skin reactions (SJS/TEN)", "Clostridioides difficile-associated diarrhea (CDAD)", "hemolytic anemia."]
    },
    "precautions": [
      "Risk of severe hypersensitivity reactions (anaphylaxis).",
      "Cross-sensitivity with penicillins is possible (~1-10%). Use with caution in penicillin-allergic patients.",
      "Can cause *C. difficile*-associated diarrhea.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "History of serious hypersensitivity (e.g., anaphylaxis) to cephalexin or other cephalosporins."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; compatible."
  },
  "klor-con": {
    "name": "Klor-Con (Potassium Chloride)",
    "genericName": "Potassium Chloride",
    "brandNames": ["Klor-Con", "K-Dur", "Micro-K", "K-Tab"],
    "category": "Electrolyte Supplement",
    "drugClass": "Electrolyte",
    "indications": "Treatment and prevention of hypokalemia (low potassium levels).",
    "moaSteps": [
      "Potassium is the primary intracellular cation.",
      "It is essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction (especially cardiac), and renal function.",
      "Potassium chloride supplements replace potassium, correcting or preventing deficiency."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. ER forms release slowly.",
      "distribution": "Primarily distributes into intracellular fluid.",
      "metabolism": "N/A",
      "excretion": "Excreted primarily in the urine."
    },
    "dose": "Varies. Prevention: 20 mEq/day PO. Treatment: 40-100 mEq/day PO in 2-4 divided doses.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "abdominal discomfort", "flatulence."],
      "serious": ["Hyperkalemia (high potassium)", "GI ulceration and bleeding (especially with tablets)."]
    },
    "precautions": [
      "Risk of hyperkalemia, which can be fatal (causes cardiac arrhythmias). Risk is higher in renal impairment or with ACE inhibitors, ARBs, or potassium-sparing diuretics.",
      "Monitor serum potassium levels regularly.",
      "ER tablets can cause GI ulceration or obstruction. **Must be swallowed whole, not crushed or chewed.**",
      "Take with meals and a full glass of water to reduce GI upset."
    ],
    "contraindications": [
      "Hyperkalemia",
      "severe renal impairment",
      "conditions that delay tablet passage through the GI tract (e.g., GI obstruction)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Compatible."
  },
  "kayexalate": {
    "name": "Kayexalate (Sodium Polystyrene Sulfonate)",
    "genericName": "Sodium Polystyrene Sulfonate",
    "brandNames": ["Kayexalate", "Kionex"],
    "category": "Hyperkalemia Agent",
    "drugClass": "Cation Exchange Resin",
    "indications": "Treatment of hyperkalemia (high potassium levels).",
    "moaSteps": [
      "Sodium polystyrene sulfonate is a non-absorbable cation-exchange resin.",
      "It is not absorbed from the GI tract.",
      "As it passes through the intestines (primarily the large intestine), it exchanges sodium ions for potassium ions.",
      "The resin, now containing potassium, is then excreted in the feces.",
      "This action removes potassium from the body, lowering serum potassium levels."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed systemically.",
      "distribution": "Acts locally in the GI tract.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted in the feces."
    },
    "dose": "Oral: 15 g PO 1-4 times daily (as a suspension in water or syrup). Rectal (enema): 30-50 g every 6 hours.",
    "adverseEffects": {
      "common": ["Constipation", "nausea", "vomiting", "diarrhea", "sodium retention (edema)."],
      "serious": ["Intestinal necrosis (bowel death)", "hypokalemia", "hypocalcemia", "severe constipation/impaction."]
    },
    "precautions": [
      "BOXED WARNING (Intestinal Necrosis): Cases of intestinal necrosis (some fatal) have been reported, especially when administered with sorbitol. Avoid sorbitol.",
      "Risk of electrolyte disturbances (hypokalemia, hypocalcemia, sodium retention). Monitor electrolytes.",
      "Can bind to and inhibit the absorption of other oral medications. Separate doses by at least 3 hours."
    ],
    "contraindications": [
      "Hypersensitivity",
      "hypokalemia",
      "obstructive bowel disease."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Not absorbed; compatible."
  },
  "kombiglyze-xr": {
    "name": "Kombiglyze XR (Saxagliptin/Metformin)",
    "genericName": "Saxagliptin and Metformin",
    "brandNames": ["Kombiglyze XR"],
    "category": "Antidiabetic",
    "drugClass": "DPP-4 Inhibitor / Biguanide Combination",
    "indications": "Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.",
    "moaSteps": [
      "This is a combination product with two mechanisms:",
      "1. **Saxagliptin (DPP-4 Inhibitor):** Inhibits the DPP-4 enzyme, increasing incretin hormone levels. This leads to glucose-dependent insulin release and decreased glucagon secretion.",
      "2. **Metformin (Biguanide):** Decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves peripheral insulin sensitivity."
    ],
    "pharmacokinetics": {
      "absorption": "Biphasic absorption (ER formulation).",
      "distribution": "Low protein binding.",
      "metabolism": "Saxagliptin metabolized by CYP3A4. Metformin is not metabolized.",
      "excretion": "Saxagliptin excreted in urine/feces. Metformin excreted unchanged in urine."
    },
    "dose": "Individualized. e.g., 5 mg saxagliptin / 1000 mg metformin PO once daily with the evening meal.",
    "adverseEffects": {
      "common": ["Nasopharyngitis", "diarrhea", "nausea/vomiting", "headache."],
      "serious": ["Lactic acidosis (Metformin)", "pancreatitis (Saxagliptin)", "heart failure (Saxagliptin)", "severe joint pain."]
    },
    "precautions": [
      "BOXED WARNING (Lactic Acidosis): Metformin can cause a rare but fatal lactic acidosis. Risk increases with renal impairment, age >65, and hypoxia.",
      "Risk of pancreatitis and severe arthralgia from saxagliptin.",
      "Risk of heart failure hospitalization (saxagliptin).",
      "Metformin can cause Vitamin B12 deficiency."
    ],
    "contraindications": [
      "Severe renal impairment (eGFR < 30)",
      "acute or chronic metabolic acidosis (including diabetic ketoacidosis)",
      "hypersensitivity."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Not recommended."
  },
  "kaletra": {
    "name": "Kaletra (Lopinavir/Ritonavir)",
    "genericName": "Lopinavir and Ritonavir",
    "brandNames": ["Kaletra"],
    "category": "Antiretroviral",
    "drugClass": "Antiretroviral, Protease Inhibitor (PI) Combination",
    "indications": "Treatment of HIV-1 infection, always in combination with other antiretroviral agents.",
    "moaSteps": [
      "This is a combination product:",
      "1. **Lopinavir:** A protease inhibitor (PI) that inhibits the HIV-1 protease enzyme, preventing the cleavage of viral polyproteins and the maturation of new, infectious viral particles.",
      "2. **Ritonavir:** Given at a low dose, it acts as a potent inhibitor of the CYP3A4 enzyme. This 'boosts' the concentration of lopinavir by preventing its metabolism, increasing its efficacy."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Must be taken with food (oral solution).",
      "distribution": "Highly protein-bound (~98-99%).",
      "metabolism": "Lopinavir is extensively metabolized by CYP3A4 (inhibited by ritonavir). Ritonavir is also metabolized by CYP3A4.",
      "excretion": "Excreted primarily in feces (via bile)."
    },
    "dose": "Adults: 400 mg lopinavir / 100 mg ritonavir PO twice daily, or 800 mg / 200 mg once daily.",
    "adverseEffects": {
      "common": ["Diarrhea (very common)", "nausea", "vomiting", "headache", "hyperlipidemia (high cholesterol and triglycerides)."],
      "serious": ["Hepatotoxicity", "pancreatitis", "QT and PR interval prolongation", "metabolic changes (fat redistribution, insulin resistance)."]
    },
    "precautions": [
      "**Numerous, life-threatening drug interactions.** As a potent CYP3A4 inhibitor, it can dangerously increase the levels of many drugs (e.g., statins, antiarrhythmics, sedatives). Must review all medications.",
      "Can cause hepatotoxicity and pancreatitis.",
      "Can cause QT and PR interval prolongation. Use with caution in patients with heart conditions.",
      "Associated with metabolic changes (hyperlipidemia, hyperglycemia)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**concomitant use with a long list of drugs** that are highly dependent on CYP3A4 for clearance (e.g., amiodarone, simvastatin, sildenafil)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Not recommended (HIV transmission risk)."
  },
  "kenalog": {
    "name": "Kenalog (Triamcinolone)",
    "genericName": "Triamcinolone",
    "brandNames": ["Kenalog (topical/injection)", "Nasacort (nasal spray)", "Aristocort (oral)"],
    "category": "Anti-inflammatory, Immunosuppressant",
    "drugClass": "Corticosteroid",
    "indications": "Topical: Relief of inflammatory and pruritic manifestations of skin disorders. Nasal: Management of allergic rhinitis. Systemic (Injection): Treatment of various inflammatory and autoimmune conditions.",
    "moaSteps": [
      "Triamcinolone is a synthetic glucocorticoid.",
      "It binds to intracellular glucocorticoid receptors and modifies gene expression.",
      "It upregulates anti-inflammatory proteins and downregulates pro-inflammatory mediators (cytokines, prostaglandins).",
      "This results in potent anti-inflammatory and immunosuppressive effects."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed systemically from all routes (topical, nasal, injection).",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the liver (CYP3A4).",
      "excretion": "Excreted in urine as metabolites. Biologic half-life is 18-36 hours."
    },
    "dose": "Nasal: 2 sprays per nostril once daily. Topical: Apply a thin film 2-4 times daily. Injection: Varies widely.",
    "adverseEffects": {
      "common": ["(Nasal) Headache", "nasal irritation/burning", "nosebleed.", "(Topical) Skin atrophy", "burning", "itching."],
      "serious": ["(Systemic/High Dose) Adrenal suppression (HPA axis suppression)", "immunosuppression", "Cushing's syndrome", "cataracts/glaucoma."]
    },
    "precautions": [
      "Prolonged or high-dose use (all routes) can cause systemic corticosteroid effects and HPA axis suppression.",
      "Can mask signs of infection and increase susceptibility.",
      "Monitor for hyperglycemia, hypertension, and psychiatric disturbances."
    ],
    "contraindications": [
      "Hypersensitivity",
      "systemic fungal infections."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "kytril": {
    "name": "Kytril (Granisetron)",
    "genericName": "Granisetron",
    "brandNames": ["Kytril", "Sancuso (patch)"],
    "category": "Antiemetic",
    "drugClass": "Serotonin 5-HT3 Receptor Antagonist",
    "indications": "Prevention of nausea and vomiting associated with cancer chemotherapy and radiation. Prevention and treatment of postoperative nausea and vomiting.",
    "moaSteps": [
      "Granisetron is a selective serotonin 5-HT3 receptor antagonist.",
      "Chemotherapy and radiation can cause the release of serotonin from cells in the gut, which activates 5-HT3 receptors on vagal nerves, triggering the vomiting reflex.",
      "Granisetron blocks these 5-HT3 receptors both peripherally (in the gut) and centrally (in the brain's chemoreceptor trigger zone), effectively preventing nausea and vomiting."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally (~60%). Transdermal patch provides continuous release.",
      "distribution": "Widely distributed. Moderately protein-bound (~65%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~6-9 hours."
    },
    "dose": "Chemo (IV): 10 mcg/kg IV infused over 5 minutes, 30 min before chemo. (PO): 2 mg PO once daily, 1 hour before chemo.",
    "adverseEffects": {
      "common": ["Headache", "constipation", "diarrhea", "asthenia (weakness)", "somnolence."],
      "serious": ["QT prolongation", "serotonin syndrome (rare, with other serotonergic drugs)", "hypersensitivity reactions."]
    },
    "precautions": [
      "Can cause dose-dependent QT prolongation. Use with caution in patients with or at risk for QT prolongation (e.g., electrolyte imbalances, concomitant QT-prolonging drugs).",
      "Risk of Serotonin Syndrome when used with other serotonergic agents (e.g., SSRIs).",
      "Transdermal patch (Sancuso) should not be exposed to direct sunlight."
    ],
    "contraindications": [
      "Hypersensitivity to granisetron."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "kadian": {
    "name": "Kadian (Morphine ER)",
    "genericName": "Morphine Sulfate (Extended-Release)",
    "brandNames": ["Kadian", "MS Contin"],
    "category": "Analgesic, Opioid",
    "drugClass": "Opioid Analgesic (Schedule II)",
    "indications": "Management of severe, continuous pain requiring long-term, around-the-clock opioid treatment.",
    "moaSteps": [
      "Morphine is the prototypical opioid agonist.",
      "It binds with high affinity to mu-opioid receptors in the central nervous system (CNS).",
      "This activation mimics endogenous endorphins, causing potent analgesia, sedation, euphoria, and respiratory depression.",
      "The extended-release formulation provides a slow release of morphine over 12-24 hours."
    ],
    "pharmacokinetics": {
      "absorption": "Variable oral absorption (~20-40%) due to high first-pass metabolism. ER forms provide slow absorption.",
      "distribution": "Widely distributed. Moderately protein-bound (~30-35%).",
      "metabolism": "Extensively metabolized in the liver (glucuronidation) to active metabolites (M6G - analgesic).",
      "excretion": "Excreted in urine. Half-life is ~2-3 hours (IR), but duration is extended."
    },
    "dose": "Highly individualized and for opioid-tolerant patients only. e.g., 30 mg ER PO every 12 or 24 hours.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "nausea", "vomiting", "constipation", "pruritus (itching)."],
      "serious": ["Respiratory depression", "abuse, addiction, and overdose", "severe hypotension", "bradycardia."]
    },
    "precautions": [
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse.",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "BOXED WARNING (Neonatal Opioid Withdrawal): Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.",
      "BOXED WARNING (ER forms): ER capsules must be swallowed whole or sprinkled on applesauce; do not crush or chew (causes dose-dumping)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "acute or severe bronchial asthma",
      "paralytic ileus."
    ],
    "pregnancyCategory": "Category C. Can cause neonatal opioid withdrawal.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "korlym": {
    "name": "Korlym (Mifepristone)",
    "genericName": "Mifepristone",
    "brandNames": ["Korlym", "Mifeprex"],
    "category": "Antiglucocorticoid",
    "drugClass": "Cortisol Receptor Blocker",
    "indications": "Control of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance.",
    "moaSteps": [
      "Mifepristone is a potent antagonist of the glucocorticoid receptor (GR-II).",
      "In Cushing's syndrome, excess cortisol causes hyperglycemia and other symptoms.",
      "By blocking the cortisol receptor, mifepristone inhibits the effects of cortisol, thus reducing blood sugar and other symptoms of hypercortisolemia.",
      "It is also a potent progesterone receptor antagonist (its use in Mifeprex)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High-fat meal increases absorption.",
      "distribution": "Highly protein-bound (>98%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted primarily in feces. Long half-life (~85 hours)."
    },
    "dose": "Initial: 300 mg PO once daily with a meal. Titrate up to max 1200 mg/day.",
    "adverseEffects": {
      "common": ["Nausea", "fatigue", "headache", "peripheral edema", "dizziness", "hypokalemia", "vaginal bleeding (in females)."],
      "serious": ["Adrenal insufficiency", "severe hypokalemia", "QT prolongation", "termination of pregnancy."]
    },
    "precautions": [
      "BOXED WARNING (Pregnancy Termination): Mifepristone is a potent antiprogestational agent. It will terminate an existing pregnancy.",
      "**Must exclude pregnancy before starting** and use non-hormonal contraception.",
      "Blocks cortisol, which can lead to adrenal insufficiency. Monitor for signs.",
      "Can cause severe hypokalemia. Monitor potassium.",
      "Potent inhibitor of CYP3A4."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category X)**",
      "concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) or substrates (e.g., simvastatin)."
    ],
    "pregnancyCategory": "Category X. Will cause pregnancy termination.",
    "lactationInfo": "Not recommended."
  },
  "krystexxa": {
    "name": "Krystexxa (Pegloticase)",
    "genericName": "Pegloticase",
    "brandNames": ["Krystexxa"],
    "category": "Antigout Agent",
    "drugClass": "Urate Oxidase (Enzyme)",
    "indications": "Treatment of chronic gout in adult patients refractory to conventional therapy.",
    "moaSteps": [
      "Pegloticase is a pegylated recombinant form of uricase, an enzyme that humans lack.",
      "It converts uric acid into allantoin, which is an inactive and water-soluble metabolite.",
      "Allantoin is easily excreted by the kidneys.",
      "This action rapidly lowers serum uric acid levels, helping to dissolve and remove tophi (uric acid crystals)."
    ],
    "pharmacokinetics": {
      "absorption": "Administered as an IV infusion.",
      "distribution": "Low volume of distribution.",
      "metabolism": "Metabolized by proteolysis.",
      "excretion": "N/A. Half-life is long (~10-14 days)."
    },
    "dose": "8 mg IV infusion every 2 weeks. Must be premedicated.",
    "adverseEffects": {
      "common": ["Gout flares (upon initiation)", "infusion reactions", "nausea", "bruising.", "anaphylaxis."],
      "serious": ["Anaphylaxis", "severe infusion reactions", "hemolysis (in G6PD deficiency)."]
    },
    "precautions": [
      "BOXED WARNING (Anaphylaxis and Infusion Reactions): Can cause severe, life-threatening anaphylaxis and infusion reactions. Must be administered in a healthcare setting with monitoring.",
      "BOXED WARNING (G6PD Deficiency): **Screen for G6PD deficiency** before starting. Can cause severe hemolysis and methemoglobinemia in these patients.",
      "Risk of gout flares upon initiation; co-administer colchicine or an NSAID.",
      "Monitor serum uric acid levels. A rise in uric acid suggests antibody formation and a high risk of anaphylaxis."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**G6PD deficiency**."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "lamotrigine": {
    "name": "Lamotrigine (Lamictal)",
    "genericName": "Lamotrigine",
    "brandNames": ["Lamictal", "Lamictal XR", "Lamictal ODT"],
    "category": "Antiepileptic, Mood Stabilizer",
    "drugClass": "Anticonvulsant, Phenyltriazine",
    "indications": "Adjunctive therapy for partial seizures and generalized seizures of Lennox-Gastaut syndrome. Monotherapy for partial seizures. Maintenance treatment of Bipolar I Disorder.",
    "moaSteps": [
      "Lamotrigine stabilizes neuronal membranes by blocking voltage-gated sodium channels.",
      "This action inhibits the repetitive firing of neurons and reduces the release of excitatory neurotransmitters (like glutamate and aspartate).",
      "It is also thought to have some effect on voltage-gated calcium channels."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. Bioavailability ~98%.",
      "distribution": "Widely distributed. Moderately protein-bound (~55%).",
      "metabolism": "Extensively metabolized in the liver by glucuronidation (UGT).",
      "excretion": "Excreted in the urine as metabolites. Half-life is ~25-33 hours."
    },
    "dose": "Varies widely. Requires slow dose titration to reduce rash risk. e.g., Initial 25 mg PO once daily, titrate slowly over weeks. **Titration is different if taken with valproate (slower) or carbamazepine (faster).**",
    "adverseEffects": {
      "common": ["Dizziness", "headache", "somnolence", "ataxia", "nausea", "blurred vision", "rash (benign)."],
      "serious": ["Severe, life-threatening rash (Stevens-Johnson Syndrome - SJS / TEN)", "aseptic meningitis", "hemophagocytic lymphohistiocytosis (HLH)."]
    },
    "precautions": [
      "BOXED WARNING (Serious Skin Rash): Can cause severe, life-threatening rashes (SJS/TEN), particularly in children and if the dose is escalated too quickly. Discontinue at the first sign of any rash.",
      "Risk of SJS is higher with concomitant valproate use or rapid dose titration.",
      "Follow the titration schedule exactly.",
      "Risk of aseptic meningitis and HLH."
    ],
    "contraindications": [
      "Hypersensitivity to lamotrigine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "lansoprazole": {
    "name": "Lansoprazole (Prevacid)",
    "genericName": "Lansoprazole",
    "brandNames": ["Prevacid"],
    "category": "Antiulcer Agent",
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "indications": "Treatment of GERD. Healing of erosive esophagitis. H. pylori eradication. Risk reduction of NSAID-associated gastric ulcers.",
    "moaSteps": [
      "Lansoprazole is a proton pump inhibitor (PPI).",
      "It irreversibly blocks the H+/K+-ATPase enzyme system (the 'proton pump') in gastric parietal cells.",
      "This is the final step in gastric acid secretion.",
      "It suppresses basal and stimulated gastric acid secretion, leading to a profound and long-lasting reduction of stomach acid."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~80-85%. Food decreases absorption.",
      "distribution": "Highly protein-bound (~97%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C19 and CYP3A4.",
      "excretion": "Excreted in urine and feces as metabolites. Short half-life (~1.5 hours), but long duration of action."
    },
    "dose": "GERD: 15-30 mg PO once daily. Take 30-60 minutes before a meal (usually breakfast).",
    "adverseEffects": {
      "common": ["Diarrhea", "headache", "nausea", "abdominal pain", "constipation."],
      "serious": ["Clostridioides difficile-associated diarrhea (CDAD)", "bone fractures (long-term use)", "hypomagnesemia (long-term use)", "Vitamin B12 deficiency (long-term use)."]
    },
    "precautions": [
      "PPI use is associated with an increased risk of *C. difficile*-associated diarrhea.",
      "Long-term use (>1 year) may be associated with an increased risk of osteoporosis-related bone fractures.",
      "Long-term use can lead to hypomagnesemia and vitamin B12 deficiency.",
      "Take before meals for best effect."
    ],
    "contraindications": [
      "Hypersensitivity to lansoprazole or other PPIs."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "latanoprost": {
    "name": "Latanoprost (Xalatan)",
    "genericName": "Latanoprost",
    "brandNames": ["Xalatan"],
    "category": "Antiglaucoma Agent",
    "drugClass": "Prostaglandin F2-alpha Analog",
    "indications": "Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.",
    "moaSteps": [
      "Latanoprost is a prodrug that is hydrolyzed in the cornea to its active form.",
      "It is a selective prostaglandin F2-alpha analog.",
      "It lowers IOP by increasing the outflow of aqueous humor.",
      "It primarily enhances the uveoscleral outflow pathway, and to a lesser extent, the trabecular meshwork pathway."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed through the cornea (prodrug), then hydrolyzed. Minimal systemic absorption.",
      "distribution": "Acts locally in the eye.",
      "metabolism": "Active acid form is metabolized in the liver.",
      "excretion": "Metabolites excreted in urine."
    },
    "dose": "1 drop in the affected eye(s) once daily in the evening.",
    "adverseEffects": {
      "common": ["Blurred vision", "stinging/burning", "eye redness (hyperemia)", "foreign body sensation.", "Increased eyelash growth (length, thickness)."],
      "serious": ["Permanent increased pigmentation of the iris (turns eyes browner)", "darkening of the eyelid skin", "macular edema."]
    },
    "precautions": [
      "Can cause permanent darkening of the iris (eye color). This is irreversible.",
      "Can cause darkening of the eyelid skin and increased eyelash growth (may be reversible upon stopping).",
      "Use with caution in patients with a history of macular edema or uveitis."
    ],
    "contraindications": [
      "Hypersensitivity to latanoprost or benzalkonium chloride (preservative)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "leflunomide": {
    "name": "Leflunomide (Arava)",
    "genericName": "Leflunomide",
    "brandNames": ["Arava"],
    "category": "Antirheumatic",
    "drugClass": "Disease-Modifying Antirheumatic Drug (DMARD)",
    "indications": "Treatment of active rheumatoid arthritis (RA).",
    "moaSteps": [
      "Leflunomide is a prodrug, rapidly converted to its active metabolite, teriflunomide.",
      "Teriflunomide inhibits the enzyme dihydroorotate dehydrogenase.",
      "This enzyme is essential for the synthesis of pyrimidines (a building block of DNA).",
      "By blocking this, it inhibits the proliferation of rapidly dividing cells, particularly activated lymphocytes (T-cells), which are key drivers of inflammation in RA."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Bioavailability ~80%.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Converted to active teriflunomide, which is then metabolized.",
      "excretion": "Excreted in feces and urine. Undergoes enterohepatic recirculation, leading to a very long half-life (~2 weeks)."
    },
    "dose": "Loading dose: 100 mg PO once daily for 3 days. Maintenance: 10-20 mg PO once daily.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "headache", "rash", "alopecia (hair loss)", "elevated liver enzymes."],
      "serious": ["Hepatotoxicity (severe liver failure)", "interstitial lung disease", "severe immunosuppression (risk of serious infections)", "bone marrow suppression."]
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Can cause severe, fatal liver injury. Monitor LFTs monthly for first 6 months, then every 1-2 months.",
      "BOXED WARNING (Embryo-Fetal Toxicity): Contraindicated in pregnancy. Can cause major birth defects.",
      "Must rule out pregnancy before starting. Women of childbearing potential must use effective contraception.",
      "Due to the long half-life, an accelerated drug elimination procedure (with cholestyramine) is required if a patient becomes pregnant or wants to conceive."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category X)**",
      "severe hepatic impairment",
      "concomitant use with teriflunomide."
    ],
    "pregnancyCategory": "Category X",
    "lactationInfo": "Not recommended."
  },
  "letrozole": {
    "name": "Letrozole (Femara)",
    "genericName": "Letrozole",
    "brandNames": ["Femara"],
    "category": "Antineoplastic Agent",
    "drugClass": "Aromatase Inhibitor (Nonsteroidal)",
    "indications": "Adjuvant and first-line treatment of hormone receptor-positive (ER+/PR+) breast cancer in postmenopausal women.",
    "moaSteps": [
      "Letrozole is a nonsteroidal aromatase inhibitor.",
      "In postmenopausal women, the primary source of estrogen is the conversion of androgens to estrogens by the aromatase enzyme in peripheral tissues.",
      "Letrozole competitively and reversibly binds to the aromatase enzyme, blocking this conversion.",
      "This leads to a profound reduction in systemic estrogen levels, depriving hormone-sensitive breast cancer cells of the estrogen they need to grow."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed.",
      "distribution": "Widely distributed. Low protein binding.",
      "metabolism": "Metabolized in the liver by CYP3A4 and CYP2A6.",
      "excretion": "Excreted in urine as metabolites. Long half-life (~2 days)."
    },
    "dose": "2.5 mg PO once daily.",
    "adverseEffects": {
      "common": ["Hot flashes", "arthralgia (joint pain)", "myalgia (muscle pain)", "fatigue", "headache", "nausea", "hypercholesterolemia."],
      "serious": ["Decreased bone mineral density (risk of osteoporosis and fractures)", "cardiovascular events (e.g., MI, stroke)."]
    },
    "precautions": [
      "Significantly increases the risk of osteoporosis. Monitor bone mineral density and consider calcium/Vitamin D supplementation.",
      "Can cause hypercholesterolemia. Monitor cholesterol levels.",
      "Can cause fatigue and dizziness; caution against driving."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category D)**",
      "premenopausal status."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "levalbuterol": {
    "name": "Levalbuterol (Xopenex)",
    "genericName": "Levalbuterol",
    "brandNames": ["Xopenex", "Xopenex HFA"],
    "category": "Bronchodilator",
    "drugClass": "Short-acting beta-2 adrenergic agonist (SABA)",
    "indications": "Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma, COPD).",
    "moaSteps": [
      "Levalbuterol is the (R)-enantiomer of albuterol.",
      "It is a selective beta-2 adrenergic receptor agonist.",
      "Binding to beta-2 receptors on airway smooth muscle activates adenylyl cyclase, increasing intracellular cAMP.",
      "This leads to relaxation of bronchial smooth muscle and subsequent bronchodilation (opening of the airways).",
      "It is theorized to have fewer side effects than racemic albuterol (which contains the S-enantiomer)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed after inhalation. Onset of action is within 5-15 minutes.",
      "distribution": "Peak effect in 30-60 minutes. Duration of action is 4-6 hours.",
      "metabolism": "Metabolized by sulfation.",
      "excretion": "Excreted in urine."
    },
    "dose": "Inhalation (MDI): 2 inhalations (90 mcg) every 4-6 hours as needed. Nebulization: 0.63-1.25 mg 3-4 times daily as needed.",
    "adverseEffects": {
      "common": ["Tremor", "nervousness", "headache", "tachycardia", "palpitations", "dizziness."],
      "serious": ["Paradoxical bronchospasm", "hypokalemia", "cardiovascular events (arrhythmias)."]
    },
    "precautions": [
      "Use of a SABA more than 2 days/week for symptoms indicates inadequate long-term control.",
      "Use with caution in patients with cardiovascular disease, hyperthyroidism, or diabetes.",
      "Can cause hypokalemia."
    ],
    "contraindications": [
      "Hypersensitivity to levalbuterol or albuterol."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in breast milk; use with caution."
  },
  "levetiracetam": {
    "name": "Levetiracetam (Keppra)",
    "genericName": "Levetiracetam",
    "brandNames": ["Keppra", "Keppra XR", "Elepsia XR", "Spritam"],
    "category": "Antiepileptic",
    "drugClass": "Anticonvulsant",
    "indications": "Adjunctive therapy for partial-onset seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.",
    "moaSteps": [
      "The exact mechanism of levetiracetam is not fully understood.",
      "It binds to the synaptic vesicle protein 2A (SV2A) in the brain.",
      "This binding is thought to modulate neurotransmitter release (specifically glutamate and GABA) by affecting vesicle trafficking, but the exact downstream effect is unknown.",
      "It does not act on traditional sodium channels or GABA receptors."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. High bioavailability (~100%). Not affected by food.",
      "distribution": "Widely distributed. Low protein binding (<10%).",
      "metabolism": "Minimally metabolized; primarily by enzymatic hydrolysis in the blood.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~6-8 hours."
    },
    "dose": "Initial: 500 mg PO twice daily. Titrate up to a max of 3000 mg/day (1500 mg twice daily).",
    "adverseEffects": {
      "common": ["Somnolence (drowsiness)", "asthenia (weakness)", "dizziness", "infection (nasopharyngitis)."],
      "serious": ["Behavioral abnormalities (agitation, aggression, depression, psychosis)", "suicidal thoughts", "severe skin reactions (SJS/TEN)", "anaphylaxis."]
    },
    "precautions": [
      "Can cause behavioral/psychiatric symptoms (e.g., agitation, irritability, depression). Monitor for mood changes.",
      "Can cause significant drowsiness and dizziness; caution against driving.",
      "Abrupt discontinuation can precipitate seizures. Taper dose slowly.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to levetiracetam."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "levocetirizine": {
    "name": "Levocetirizine (Xyzal)",
    "genericName": "Levocetirizine",
    "brandNames": ["Xyzal"],
    "category": "Antihistamine",
    "drugClass": "Antihistamine, 2nd Generation",
    "indications": "Relief of symptoms associated with seasonal and perennial allergic rhinitis. Treatment of chronic idiopathic urticaria (hives).",
    "moaSteps": [
      "Levocetirizine is the active (R)-enantiomer of cetirizine.",
      "It is a potent and selective antagonist of peripheral H1-receptors.",
      "By blocking histamine from binding to H1-receptors, it reduces the symptoms of allergy (e.g., sneezing, itching, runny nose, watery eyes).",
      "It has minimal CNS penetration, making it 'low-sedating'."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and well absorbed. Food delays absorption.",
      "distribution": "Highly protein-bound (~91-92%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~8-9 hours."
    },
    "dose": "5 mg PO once daily in the evening.",
    "adverseEffects": {
      "common": ["Somnolence (drowsiness)", "fatigue", "dry mouth", "nasopharyngitis."],
      "serious": ["Hypersensitivity reactions", "worsening of urinary retention."]
    },
    "precautions": [
      "Can cause somnolence, although less than 1st-gen antihistamines. Use caution when driving.",
      "Avoid alcohol and other CNS depressants.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to levocetirizine or cetirizine",
      "end-stage renal disease (CrCl < 10 mL/min)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "levofloxacin": {
    "name": "Levofloxacin (Levaquin)",
    "genericName": "Levofloxacin",
    "brandNames": ["Levaquin"],
    "category": "Antibiotic",
    "drugClass": "Fluoroquinolone Antibiotic",
    "indications": "Treatment of various bacterial infections, including community-acquired pneumonia, acute bacterial sinusitis, urinary tract infections, and skin infections.",
    "moaSteps": [
      "Levofloxacin is the L-isomer of ofloxacin, a fluoroquinolone.",
      "It inhibits two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV.",
      "Inhibition of these enzymes prevents the replication, transcription, and repair of bacterial DNA, leading to cell death (bactericidal)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed orally. High bioavailability (~99%).",
      "distribution": "Widely distributed into tissues and fluids. Moderately protein-bound (~24-38%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~6-8 hours."
    },
    "dose": "250-750 mg PO or IV once daily. Dose and duration vary by infection.",
    "adverseEffects": {
      "common": ["Nausea", "diarrhea", "headache", "dizziness", "insomnia."],
      "serious": ["Tendinitis and tendon rupture", "peripheral neuropathy", "CNS effects (seizures, confusion)", "QT prolongation", "aortic dissection/aneurysm."]
    },
    "precautions": [
      "BOXED WARNING (Serious Adverse Reactions): Associated with disabling and potentially irreversible serious adverse reactions (tendinitis/rupture, peripheral neuropathy, CNS effects). Discontinue immediately and avoid in patients with these reactions.",
      "BOXED WARNING (Myasthenia Gravis): May exacerbate muscle weakness in patients with myasthenia gravis. Avoid use.",
      "Risk of aortic dissection or aneurysm.",
      "Risk of QT prolongation and Torsades de Pointes.",
      "Risk of photosensitivity."
    ],
    "contraindications": [
      "Hypersensitivity to levofloxacin or other quinolones."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "levothyroxine": {
    "name": "Levothyroxine (Synthroid, Levoxyl)",
    "genericName": "Levothyroxine (T4)",
    "brandNames": ["Synthroid", "Levoxyl", "Unithroid", "Tirosint"],
    "category": "Thyroid Product",
    "drugClass": "Thyroid Hormone",
    "indications": "Treatment of hypothyroidism (as replacement therapy). Pituitary TSH suppression (for thyroid cancer).",
    "moaSteps": [
      "Levothyroxine is the synthetic form of the natural thyroid hormone, thyroxine (T4).",
      "It is a prodrug that is converted in peripheral tissues to its active metabolite, liothyronine (T3), by deiodinase enzymes.",
      "T3 binds to thyroid hormone receptors in the cell nucleus, regulating gene expression.",
      "This action increases the metabolic rate, stimulates protein synthesis, and is essential for normal growth, development, and CNS function."
    ],
    "pharmacokinetics": {
      "absorption": "Erratic and incomplete absorption (40-80%). Must be taken on an empty stomach. Food (especially calcium, iron) significantly decreases absorption.",
      "distribution": "Highly protein-bound (>99%) to thyroxine-binding globulin (TBG).",
      "metabolism": "Converted to T3 in peripheral tissues. Metabolized in the liver.",
      "excretion": "Excreted in urine and feces. Long half-life (~7 days)."
    },
    "dose": "Highly individualized. Average full replacement dose: ~1.6 mcg/kg/day. Initial: 25-50 mcg PO once daily, titrated every 4-6 weeks based on TSH levels. **Must be taken 30-60 minutes before breakfast on an empty stomach.**",
    "adverseEffects": {
      "common": ["(Generally signs of overdose/hyperthyroidism) Tachycardia, palpitations, anxiety, tremor, insomnia, weight loss, heat intolerance, diarrhea."],
      "serious": ["Arrhythmias (atrial fibrillation)", "angina", "myocardial infarction", "decreased bone mineral density (with long-term over-replacement)."]
    },
    "precautions": [
      "BOXED WARNING (Not for Obesity): Not for the treatment of obesity or for weight loss. Large doses can cause serious, life-threatening toxicity.",
      "Dose is highly individualized and must be monitored with TSH levels.",
      "Narrow therapeutic index; switching between brands can affect TSH levels.",
      "Take on an empty stomach, separated from supplements (calcium, iron)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "uncorrected adrenal insufficiency",
      "acute myocardial infarction."
    ],
    "pregnancyCategory": "Category A",
    "lactationInfo": "Compatible; minimal excretion in breast milk."
  },
  "lidocaine": {
    "name": "Lidocaine (Xylocaine, Lidoderm)",
    "genericName": "Lidocaine",
    "brandNames": ["Xylocaine (injection)", "Lidoderm (patch)", "Aspercreme with Lidocaine (topical)"],
    "category": "Local Anesthetic, Antiarrhythmic",
    "drugClass": "Local Anesthetic (Amide), Antiarrhythmic (Class Ib)",
    "indications": "Local/Regional Anesthesia: Infiltration, nerve blocks, epidurals. Antiarrhythmic: Treatment of ventricular arrhythmias (e.g., VT/VF) after MI. Topical: Relief of pain (e.g., postherpetic neuralgia, sunburn, minor burns).",
    "moaSteps": [
      "As a local anesthetic: Lidocaine blocks voltage-gated sodium channels on the inside of the nerve cell membrane.",
      "This action prevents the initiation and conduction of nerve impulses.",
      "It blocks sensory nerves first, leading to a loss of pain sensation, followed by loss of temperature, touch, and motor function.",
      "As an antiarrhythmic: It blocks sodium channels in cardiac muscle, shortening the action potential duration and suppressing arrhythmias."
    ],
    "pharmacokinetics": {
      "absorption": "Completely absorbed after injection. Topical absorption varies by site and duration.",
      "distribution": "Widely distributed. Moderately protein-bound (~60-80%).",
      "metabolism": "Extensively metabolized in the liver by CYP1A2 and CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Short half-life (~1.5-2 hours)."
    },
    "dose": "Varies widely by indication. Patch (Lidoderm): 1-3 patches applied to painful area for up to 12 hours within a 24-hour period.",
    "adverseEffects": {
      "common": ["(Topical) Skin redness, irritation.", "(Systemic) Dizziness, lightheadedness, drowsiness, blurred vision, metallic taste."],
      "serious": ["(Systemic) CNS toxicity (seizures, coma)", "cardiotoxicity (bradycardia, hypotension, cardiac arrest)."]
    },
    "precautions": [
      "Risk of systemic toxicity (CNS and cardiac) if excessive amounts are absorbed (e.g., high doses, application to broken skin, or large areas).",
      "Use with caution in patients with severe hepatic impairment (reduced metabolism) or heart block.",
      "Do not apply topical patches to broken or inflamed skin."
    ],
    "contraindications": [
      "Hypersensitivity to amide-type local anesthetics",
      "severe heart block (for antiarrhythmic use)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "linagliptin": {
    "name": "Linagliptin (Tradjenta)",
    "genericName": "Linagliptin",
    "brandNames": ["Tradjenta"],
    "category": "Antidiabetic",
    "drugClass": "Dipeptidyl Peptidase-4 (DPP-4) Inhibitor",
    "indications": "Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "moaSteps": [
      "Linagliptin is a DPP-4 inhibitor.",
      "It inhibits the enzyme DPP-4, which is responsible for inactivating incretin hormones (GLP-1 and GIP).",
      "By increasing the levels of active incretins, it leads to a glucose-dependent increase in insulin secretion and a decrease in glucagon secretion, thus lowering blood glucose."
    ],
    "pharmacokinetics": {
      "absorption": "Absorption is ~30%.",
      "distribution": "Widely distributed. Highly protein-bound (to DPP-4).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the feces (via bile). **Unique among DPP-4s as it is not significantly eliminated by the kidneys.**"
    },
    "dose": "5 mg PO once daily, with or without food. **No dose adjustment is required in renal or hepatic impairment.**",
    "adverseEffects": {
      "common": ["Nasopharyngitis", "diarrhea", "cough", "headache."],
      "serious": ["Pancreatitis", "severe joint pain (arthralgia)", "bullous pemphigoid", "hypersensitivity reactions."]
    },
    "precautions": [
      "Cases of acute pancreatitis have been reported. Discontinue if suspected.",
      "Can cause severe and disabling joint pain.",
      "Risk of bullous pemphigoid.",
      "Use with caution with strong CYP3A4 inducers (e.g., rifampin) as they can decrease effectiveness."
    ],
    "contraindications": [
      "Hypersensitivity to linagliptin."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "linezolid": {
    "name": "Linezolid (Zyvox)",
    "genericName": "Linezolid",
    "brandNames": ["Zyvox"],
    "category": "Antibiotic",
    "drugClass": "Oxazolidinone Antibiotic",
    "indications": "Treatment of serious Gram-positive infections, including vancomycin-resistant Enterococcus faecium (VRE) infections, nosocomial pneumonia, and complicated skin infections (including MRSA).",
    "moaSteps": [
      "Linezolid is an oxazolidinone antibiotic.",
      "It inhibits bacterial protein synthesis by binding to a unique site on the 50S ribosomal subunit.",
      "This action prevents the formation of the 70S initiation complex, which is a very early step in protein synthesis.",
      "It is typically bacteriostatic, but bactericidal against some strains."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. High bioavailability (100%).",
      "distribution": "Widely distributed into tissues and fluids. Moderately protein-bound (~31%).",
      "metabolism": "Metabolized by oxidation (non-CYP).",
      "excretion": "Excreted in urine as metabolites and unchanged drug. Half-life is ~5-7 hours."
    },
    "dose": "600 mg PO or IV every 12 hours.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "headache", "taste alteration."],
      "serious": ["Myelosuppression (thrombocytopenia, anemia, neutropenia)", "serotonin syndrome", "peripheral and optic neuropathy (with long-term use)."]
    },
    "precautions": [
      "Can cause myelosuppression. Monitor CBCs weekly, especially if used for >2 weeks.",
      "It is a reversible, non-selective monoamine oxidase inhibitor (MAOI). Risk of serotonin syndrome with serotonergic drugs (e.g., SSRIs).",
      "Risk of peripheral and optic neuropathy with long-term use (>28 days).",
      "Avoid large amounts of tyramine-containing foods (aged cheese, red wine)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with or within 2 weeks of MAOIs."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "liothyronine": {
    "name": "Liothyronine (Cytomel)",
    "genericName": "Liothyronine (T3)",
    "brandNames": ["Cytomel", "Triostat"],
    "category": "Thyroid Product",
    "drugClass": "Thyroid Hormone",
    "indications": "Treatment of hypothyroidism. Used for diagnosis in T3 suppression tests.",
    "moaSteps": [
      "Liothyronine is the synthetic form of the active thyroid hormone, triiodothyronine (T3).",
      "It binds to thyroid hormone receptors in the cell nucleus, regulating gene expression.",
      "This action increases the metabolic rate, stimulates protein synthesis, and is essential for normal growth, development, and CNS function.",
      "It has a more rapid onset and shorter half-life than levothyroxine (T4)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed (~95%).",
      "distribution": "Highly protein-bound (>99%) to thyroxine-binding globulin (TBG).",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine. Short half-life (~1-1.5 days)."
    },
    "dose": "Initial: 25 mcg PO once daily. Titrate every 1-2 weeks. Usual maintenance: 25-75 mcg/day.",
    "adverseEffects": {
      "common": ["(Signs of overdose/hyperthyroidism) Tachycardia, palpitations, anxiety, tremor, insomnia, weight loss, heat intolerance."],
      "serious": ["Arrhythmias (atrial fibrillation)", "angina", "myocardial infarction."]
    },
    "precautions": [
      "BOXED WARNING (Not for Obesity): Not for the treatment of obesity or for weight loss.",
      "Rapid onset of action may increase risk of cardiac side effects; use with caution in elderly and those with cardiovascular disease.",
      "Due to short half-life, it must be dosed daily and is harder to maintain stable levels (levothyroxine is preferred)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "uncorrected adrenal insufficiency",
      "acute myocardial infarction."
    ],
    "pregnancyCategory": "Category A",
    "lactationInfo": "Compatible; minimal excretion in breast milk."
  },"meclizine": {
    "name": "Meclizine (Antivert, Bonine)",
    "genericName": "Meclizine",
    "brandNames": ["Antivert", "Bonine", "Dramamine Less Drowsy"],
    "category": "Antiemetic, Antihistamine",
    "drugClass": "Antihistamine, 1st Generation (Anticholinergic)",
    "indications": "Management of nausea, vomiting, and dizziness associated with motion sickness. Management of vertigo associated with vestibular diseases (e.g., labyrinthitis).",
    "moaSteps": [
      "Meclizine is a first-generation antihistamine with anticholinergic properties.",
      "It acts on the chemoreceptor trigger zone (CTZ) and vomiting center in the brain.",
      "It is thought to reduce the excitability of the labyrinth (inner ear) and block conduction in vestibular-cerebellar pathways, which helps to reduce motion sickness and vertigo."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Onset of action in ~1 hour.",
      "distribution": "Widely distributed. Duration of action is 8-24 hours.",
      "metabolism": "Metabolized in the liver, primarily by CYP2D6.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~6 hours."
    },
    "dose": "Motion Sickness: 25-50 mg PO 1 hour before travel, then once daily. Vertigo: 25-100 mg/day PO in divided doses.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "dry mouth", "blurred vision", "fatigue."],
      "serious": ["Anaphylaxis (rare)", "confusion (especially in elderly)."]
    },
    "precautions": [
      "Can cause significant drowsiness and sedation; caution against driving or operating machinery.",
      "High anticholinergic burden; use with caution in the elderly (risk of confusion) and in patients with BPH or narrow-angle glaucoma.",
      "Avoid alcohol and other CNS depressants."
    ],
    "contraindications": [
      "Hypersensitivity to meclizine."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "medroxyprogesterone": {
    "name": "Medroxyprogesterone (Provera, Depo-Provera)",
    "genericName": "Medroxyprogesterone Acetate",
    "brandNames": ["Provera (oral)", "Depo-Provera (IM injection)"],
    "category": "Progestin, Contraceptive",
    "drugClass": "Progestin",
    "indications": "Oral (Provera): Treatment of secondary amenorrhea and abnormal uterine bleeding. IM (Depo-Provera): Long-term contraception. Treatment of endometriosis-associated pain.",
    "moaSteps": [
      "Medroxyprogesterone is a synthetic progestin.",
      "As a contraceptive: It suppresses the LH surge, preventing ovulation. It thickens cervical mucus, impeding sperm transit. It thins the endometrium, making implantation difficult.",
      "For amenorrhea/bleeding: It transforms a proliferative endometrium into a secretory one. A withdrawal bleed occurs when the drug is stopped."
    ],
    "pharmacokinetics": {
      "absorption": "Oral is well absorbed. IM injection (Depo-Provera) provides a slow, sustained release over 3 months.",
      "distribution": "Highly protein-bound (~86-90%).",
      "metabolism": "Extensively metabolized in the liver (CYP3A4).",
      "excretion": "Excreted in urine as metabolites."
    },
    "dose": "Contraception (IM): 150 mg IM every 3 months. Amenorrhea (PO): 5-10 mg PO daily for 5-10 days.",
    "adverseEffects": {
      "common": ["Irregular menstrual bleeding (spotting, amenorrhea)", "weight gain", "headache", "nervousness", "decreased libido.", "injection site reactions."],
      "serious": ["Thromboembolic events (DVT, PE, stroke)", "bone mineral density loss (Depo-Provera)."]
    },
    "precautions": [
      "BOXED WARNING (Depo-Provera): Associated with significant loss of bone mineral density (BMD). Use for >2 years only if other methods are inadequate.",
      "Increased risk of thromboembolic events.",
      "Can cause irregular bleeding, especially in the first few months."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active or history of thromboembolic disease",
      "known or suspected breast cancer",
      "undiagnosed vaginal bleeding",
      "**Pregnancy (Category X)**."
    ],
    "pregnancyCategory": "Category X",
    "lactationInfo": "Compatible (after 6 weeks postpartum)."
  },
  "melatonin": {
    "name": "Melatonin (N-acetyl-5-methoxytryptamine)",
    "genericName": "Melatonin",
    "brandNames": ["Various OTC brands", "Circadin (ER, Rx)", "Hetlioz (Rx, for N24SWD)"],
    "category": "Sedative-Hypnotic, Supplement",
    "drugClass": "Endogenous Hormone, Chronobiotic",
    "indications": "Dietary supplement for insomnia, particularly delayed sleep-wake phase disorder and jet lag. (Hetlioz): Non-24-Hour Sleep-Wake Disorder.",
    "moaSteps": [
      "Melatonin is an endogenous hormone produced by the pineal gland, primarily at night.",
      "It regulates the sleep-wake cycle (circadian rhythm).",
      "It acts as an agonist at melatonin receptors (MT1 and MT2) in the suprachiasmatic nucleus (SCN) of the brain.",
      "Activation of MT1 is thought to promote sleepiness, while MT2 activation helps to shift the circadian rhythm."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed, but high first-pass metabolism (bioavailability ~10-15%).",
      "distribution": "Moderately protein-bound (~60%).",
      "metabolism": "Extensively metabolized in the liver by CYP1A2.",
      "excretion": "Excreted in urine as metabolites. Very short half-life (~30-60 minutes)."
    },
    "dose": "Insomnia (OTC): 0.5-5 mg PO 30-60 minutes before bedtime. (ER): 2 mg PO 1-2 hours before bedtime.",
    "adverseEffects": {
      "common": ["Somnolence (next-day drowsiness)", "headache", "dizziness", "nausea."],
      "serious": ["Hypersensitivity reactions (rare)."]
    },
    "precautions": [
      "Can cause next-day drowsiness; caution against driving.",
      "Avoid alcohol and other CNS depressants.",
      "Use with caution in patients with depression or seizure disorders.",
      "Effectiveness of OTC products can vary. Use lowest effective dose."
    ],
    "contraindications": [
      "Hypersensitivity to melatonin."
    ],
    "pregnancyCategory": "Not rated (Supplement). Use with caution.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "meloxicam": {
    "name": "Meloxicam (Mobic)",
    "genericName": "Meloxicam",
    "brandNames": ["Mobic", "Vivlodex", "Anjeso (IV)"],
    "category": "Anti-inflammatory, Analgesic",
    "drugClass": "Nonsteroidal Anti-inflammatory Drug (NSAID)",
    "indications": "Relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. Management of juvenile rheumatoid arthritis.",
    "moaSteps": [
      "Meloxicam is an NSAID of the oxicam class.",
      "It inhibits cyclooxygenase (COX-1 and COX-2) enzymes, which blocks prostaglandin synthesis.",
      "It is considered 'COX-2 preferential,' meaning it has a higher affinity for COX-2 than COX-1 at lower doses, which may reduce GI side effects compared to nonselective NSAIDs (though the risk is still present)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Bioavailability ~89%.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP2C9.",
      "excretion": "Excreted in urine and feces as metabolites. Long half-life (~15-20 hours)."
    },
    "dose": "7.5-15 mg PO once daily. Take with food.",
    "adverseEffects": {
      "common": ["Dyspepsia", "nausea", "abdominal pain", "diarrhea", "headache", "edema."],
      "serious": ["Gastrointestinal bleeding and ulceration", "cardiovascular thrombotic events (MI, stroke)", "hepatotoxicity", "nephrotoxicity", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "BOXED WARNING (CV Risk): Increased risk of serious cardiovascular thrombotic events (MI, stroke).",
      "BOXED WARNING (GI Risk): Increased risk of serious GI events (bleeding, ulceration, perforation).",
      "Use lowest effective dose for shortest duration.",
      "Use with caution in elderly patients and those with renal or hepatic impairment."
    ],
    "contraindications": [
      "Hypersensitivity to meloxicam or other NSAIDs",
      "history of asthma or urticaria after aspirin/NSAID use",
      "perioperative pain in the setting of CABG surgery."
    ],
    "pregnancyCategory": "Category C (D in 3rd trimester)",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "memantine": {
    "name": "Memantine (Namenda)",
    "genericName": "Memantine",
    "brandNames": ["Namenda", "Namenda XR"],
    "category": "Alzheimer's Agent",
    "drugClass": "NMDA Receptor Antagonist",
    "indications": "Treatment of moderate to severe dementia of the Alzheimer's type.",
    "moaSteps": [
      "Alzheimer's disease is associated with overstimulation of NMDA receptors by the excitatory neurotransmitter glutamate (glutamatergic excitotoxicity).",
      "Memantine is a low-to-moderate affinity, non-competitive NMDA receptor antagonist.",
      "It blocks the NMDA receptor ion channels when they are pathologically over-activated by glutamate, but allows for normal physiological activation.",
      "This is thought to protect neurons from excitotoxicity and improve cognitive function."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. Bioavailability ~100%.",
      "distribution": "Widely distributed. Moderately protein-bound (~45%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is long (~60-80 hours)."
    },
    "dose": "IR: Initial 5 mg PO once daily, titrated weekly up to 10 mg PO twice daily. XR: Initial 7 mg PO once daily, titrated to 28 mg once daily.",
    "adverseEffects": {
      "common": ["Dizziness", "headache", "confusion", "constipation", "diarrhea", "hypertension."],
      "serious": ["Hypersensitivity reactions", "seizures", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "Can cause dizziness and confusion; caution against driving.",
      "Use with caution in patients with seizure disorders.",
      "Requires dose adjustment in severe renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to memantine."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "meperidine": {
    "name": "Meperidine (Demerol)",
    "genericName": "Meperidine (Pethidine)",
    "brandNames": ["Demerol"],
    "category": "Analgesic, Opioid",
    "drugClass": "Opioid Analgesic (Schedule II)",
    "indications": "Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.",
    "moaSteps": [
      "Meperidine is a synthetic opioid agonist.",
      "It binds to and activates mu-opioid receptors in the central nervous system (CNS).",
      "This activation mimics endorphins, causing analgesia, sedation, and euphoria.",
      "It also has some anticholinergic and local anesthetic properties."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally, but high first-pass metabolism (bioavailability ~50-60%).",
      "distribution": "Widely distributed. Moderately protein-bound (~60-80%).",
      "metabolism": "Extensively metabolized in the liver to an active, toxic metabolite, normeperidine.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~3-5 hours (meperidine) but ~15-30 hours (normeperidine)."
    },
    "dose": "50-150 mg PO/IM/SC every 3-4 hours as needed. **Use should be limited to <48 hours.**",
    "adverseEffects": {
      "common": ["Drowsiness", "dizziness", "sedation", "nausea", "vomiting", "constipation", "sweating."],
      "serious": ["Respiratory depression", "abuse, addiction, and overdose", "neurotoxicity (seizures, delirium)", "serotonin syndrome."]
    },
    "precautions": [
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse.",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "**Neurotoxicity:** The active metabolite, normeperidine, can accumulate (especially in renal impairment) and cause seizures, delirium, and tremors. Avoid in renal failure and elderly.",
      "**Serotonin Syndrome:** Has MAOI properties; contraindicated with MAOIs (can be fatal).",
      "**Not recommended for chronic pain.** Use should be short-term."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "paralytic ileus",
      "concomitant use with MAOIs (within 14 days)."
    ],
    "pregnancyCategory": "Category C. Can cause neonatal opioid withdrawal.",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "metformin": {
    "name": "Metformin (Glucophage)",
    "genericName": "Metformin",
    "brandNames": ["Glucophage", "Glucophage XR", "Fortamet", "Glumetza", "Riomet"],
    "category": "Antidiabetic",
    "drugClass": "Biguanide",
    "indications": "Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus. First-line agent for type 2 diabetes.",
    "moaSteps": [
      "Metformin is a biguanide with a multi-faceted mechanism.",
      "1. **Primary Action:** It decreases hepatic glucose production (gluconeogenesis) by activating AMP-activated protein kinase (AMPK) in the liver.",
      "2. It decreases the intestinal absorption of glucose.",
      "3. It improves peripheral insulin sensitivity, enhancing glucose uptake and utilization in muscle and fat cells.",
      "It does *not* stimulate insulin secretion and thus does not cause hypoglycemia when used as monotherapy."
    ],
    "pharmacokinetics": {
      "absorption": "Incompletely absorbed (bioavailability ~50-60%). Food decreases absorption.",
      "distribution": "Negligibly protein-bound. Distributes into red blood cells.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted entirely unchanged in the urine. Half-life is ~6.2 hours."
    },
    "dose": "IR: 500-1000 mg PO twice daily with meals. ER: 500-2000 mg PO once daily with the evening meal.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "flatulence (gas)", "abdominal discomfort", "metallic taste."],
      "serious": ["Lactic acidosis (rare but fatal)", "Vitamin B12 deficiency (long-term use)."]
    },
    "precautions": [
      "BOXED WARNING (Lactic Acidosis): Can cause a rare but serious, life-threatening lactic acidosis. Risk increases with renal impairment, age >65, hypoxia, and hepatic impairment.",
      "GI side effects are very common and dose-related; titrate slowly and take with food.",
      "Can cause Vitamin B12 deficiency with long-term use; monitor levels.",
      "Temporarily hold metformin before and after IV contrast dye procedures."
    ],
    "contraindications": [
      "Severe renal impairment (eGFR < 30 mL/min/1.73m)",
      "acute or chronic metabolic acidosis (including diabetic ketoacidosis)",
      "hypersensitivity."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; generally considered compatible."
  },
  "methadone": {
    "name": "Methadone (Dolophine, Methadose)",
    "genericName": "Methadone",
    "brandNames": ["Dolophine", "Methadose"],
    "category": "Analgesic, Opioid",
    "drugClass": "Opioid Analgesic (Schedule II)",
    "indications": "Management of severe pain. Detoxification and maintenance treatment of opioid use disorder.",
    "moaSteps": [
      "Methadone is a synthetic opioid agonist.",
      "It binds to and activates mu-opioid receptors in the CNS, causing analgesia and sedation.",
      "It also has NMDA receptor antagonist properties, which may help with neuropathic pain and reduce tolerance.",
      "Its long half-life allows for once-daily dosing in addiction treatment, preventing withdrawal symptoms without producing significant euphoria."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. Bioavailability ~80%.",
      "distribution": "Widely distributed, lipophilic. Highly protein-bound (~85-90%).",
      "metabolism": "Extensively metabolized in the liver by multiple CYP enzymes (3A4, 2B6, 2D6).",
      "excretion": "Excreted in urine and feces. Very long and variable half-life (8-59 hours)."
    },
    "dose": "Highly individualized and must be done by specialists. Pain: 2.5-10 mg PO every 8-12 hours. Addiction: Titrated based on withdrawal symptoms.",
    "adverseEffects": {
      "common": ["Drowsiness", "dizziness", "sedation", "nausea", "vomiting", "constipation", "sweating."],
      "serious": ["Respiratory depression", "abuse, addiction, and overdose", "QT prolongation and Torsades de Pointes."]
    },
    "precautions": [
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse.",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "BOXED WARNING (QT Prolongation): Can cause life-threatening QT prolongation and Torsades de Pointes. High risk.",
      "BOXED WARNING (REMS): Only for use in opioid addiction by certified treatment programs.",
      "Due to long, variable half-life, dose titration must be done very slowly."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "acute or severe bronchial asthma",
      "paralytic ileus."
    ],
    "pregnancyCategory": "Category C. Can cause neonatal opioid withdrawal.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "methimazole": {
    "name": "Methimazole (Tapazole)",
    "genericName": "Methimazole",
    "brandNames": ["Tapazole"],
    "category": "Antithyroid Agent",
    "drugClass": "Thionamide",
    "indications": "Treatment of hyperthyroidism (Graves' disease). Used to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy.",
    "moaSteps": [
      "Methimazole is a thionamide antithyroid drug.",
      "It inhibits the synthesis of thyroid hormones (T3 and T4) by blocking the enzyme thyroid peroxidase (TPO).",
      "This action prevents the iodination of tyrosine residues on thyroglobulin and the coupling of these residues to form T3 and T4.",
      "It does not inactivate existing, circulating thyroid hormones."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed.",
      "distribution": "Accumulates in the thyroid gland. Not protein-bound.",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine. Half-life is ~5-6 hours."
    },
    "dose": "Initial: 15-60 mg/day PO in 3 divided doses. Maintenance: 5-15 mg/day PO.",
    "adverseEffects": {
      "common": ["Rash", "pruritus (itching)", "arthralgia (joint pain)", "nausea", "headache", "transient leukopenia."],
      "serious": ["Agranulocytosis (rare but fatal)", "hepatotoxicity (liver failure)", "vasculitis."]
    },
    "precautions": [
      "Risk of agranulocytosis (a severe drop in white blood cells). Patients must report any sign of infection (fever, sore throat) immediately.",
      "Monitor CBC and LFTs.",
      "Can cause hepatotoxicity.",
      "Can cause fetal harm, especially in the first trimester (preferred drug is propylthiouracil in 1st trimester)."
    ],
    "contraindications": [
      "Hypersensitivity to methimazole."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Excreted in breast milk in small amounts; considered preferred antithyroid agent in nursing."
  },
  "methocarbamol": {
    "name": "Methocarbamol (Robaxin)",
    "genericName": "Methocarbamol",
    "brandNames": ["Robaxin"],
    "category": "Skeletal Muscle Relaxant",
    "drugClass": "Skeletal Muscle Relaxant (Central-acting)",
    "indications": "Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.",
    "moaSteps": [
      "Methocarbamol's mechanism of action is not fully understood.",
      "It is a central-acting muscle relaxant that causes general CNS depression.",
      "It is thought to work by causing sedation and inhibiting spinal polysynaptic reflexes, which reduces muscle spasm.",
      "It does not directly relax tense skeletal muscles."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. Onset in ~30 minutes.",
      "distribution": "Widely distributed.",
      "metabolism": "Extensively metabolized in the liver.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~1-2 hours."
    },
    "dose": "Initial: 1500 mg PO 4 times daily for 2-3 days. Maintenance: 750-1000 mg PO 4 times daily.",
    "adverseEffects": {
      "common": ["Drowsiness", "dizziness", "lightheadedness", "nausea", "vomiting", "blurred vision."],
      "serious": ["Bradycardia", "hypotension", "syncope (IV use)", "seizures (IV use)", "anaphylaxis."]
    },
    "precautions": [
      "Can cause significant drowsiness and dizziness; caution against driving or operating machinery.",
      "Avoid alcohol and other CNS depressants.",
      "Use with caution in the elderly.",
      "Can cause harmless discoloration of urine (brown, black, or green)."
    ],
    "contraindications": [
      "Hypersensitivity to methocarbamol."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "methotrexate": {
    "name": "Methotrexate (Trexall, Rasuvo)",
    "genericName": "Methotrexate",
    "brandNames": ["Trexall", "Rasuvo", "Otrexup"],
    "category": "Antirheumatic, Antineoplastic",
    "drugClass": "Antimetabolite, DMARD, Folate Antagonist",
    "indications": "Low Dose (Weekly): Treatment of severe rheumatoid arthritis (RA), psoriatic arthritis, and severe psoriasis. High Dose (Daily): Treatment of various cancers (e.g., leukemia, lymphoma).",
    "moaSteps": [
      "Methotrexate is a folate antimetabolite.",
      "In Cancer: It inhibits the enzyme dihydrofolate reductase (DHFR), which converts folic acid to its active form (tetrahydrofolate). This blocks DNA synthesis (specifically purines and thymidylate), leading to cell death.",
      "In RA/Psoriasis: The mechanism is not fully understood but is thought to involve inhibition of DHFR and other enzymes, leading to increased adenosine levels (which are anti-inflammatory) and suppression of T-cell activation."
    ],
    "pharmacokinetics": {
      "absorption": "Variable oral absorption (dose-dependent).",
      "distribution": "Widely distributed. Moderately protein-bound (~50%).",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~3-10 hours (low dose)."
    },
    "dose": "RA/Psoriasis: 7.5-25 mg PO/SC/IM **ONCE WEEKLY**. Cancer: Varies widely (high dose).",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "stomatitis (mouth sores)", "alopecia", "elevated LFTs."],
      "serious": ["Myelosuppression (anemia, leukopenia, thrombocytopenia)", "hepatotoxicity (fibrosis, cirrhosis)", "pulmonary toxicity (interstitial pneumonitis)", "severe infections", "renal failure."]
    },
    "precautions": [
      "BOXED WARNING (Multiple): Multiple serious toxicities (bone marrow, liver, lung, kidney). Use only for approved indications.",
      "BOXED WARNING (Dosing Errors): **Must be dosed weekly for RA/psoriasis.** Daily dosing has led to fatal toxicity.",
      "BOXED WARNING (Fetal Toxicity): Contraindicated in pregnancy.",
      "BOXED WARNING (Hepatotoxicity): Risk of fatal liver fibrosis/cirrhosis with long-term use.",
      "BOXED WARNING (Infections): Can cause severe immunosuppression.",
      "Must co-administer folic acid (1-5 mg/day, except on methotrexate day) to reduce side effects.",
      "Avoid NSAIDs (can increase methotrexate levels)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category X)**",
      "alcoholism",
      "chronic liver disease",
      "immunodeficiency",
      "pre-existing blood dyscrasias."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "methylcellulose": {
    "name": "Methylcellulose (Citrucel)",
    "genericName": "Methylcellulose",
    "brandNames": ["Citrucel"],
    "category": "Laxative",
    "drugClass": "Bulk-Forming Laxative",
    "indications": "Treatment of constipation. Helps restore and maintain regularity.",
    "moaSteps": [
      "Methylcellulose is a synthetic, bulk-forming fiber.",
      "It is a non-digestible, non-absorbable polymer that passes through the GI tract.",
      "In the intestines, it absorbs water and expands, forming a bulky, soft, gelatinous mass.",
      "This bulk increases the volume of the stool, which stretches the intestinal wall and stimulates peristalsis (muscle contractions), promoting a bowel movement."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed systemically.",
      "distribution": "Acts locally in the GI tract.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted in the feces."
    },
    "dose": "1-2 tablespoons (powder) or 2-4 caplets PO, up to 3 times daily. **Must be taken with a full glass of water (8 oz).**",
    "adverseEffects": {
      "common": ["Bloating", "gas (flatulence)", "abdominal cramping."],
      "serious": ["Esophageal or intestinal obstruction (if taken without enough water)."]
    },
    "precautions": [
      "**Must be taken with at least 8 ounces (a full glass) of water or other liquid** to prevent choking or obstruction.",
      "Onset of action is slow (12-72 hours).",
      "May interfere with the absorption of other drugs; separate doses by 2 hours."
    ],
    "contraindications": [
      "Hypersensitivity",
      "symptoms of appendicitis or intestinal obstruction",
      "difficulty swallowing."
    ],
    "pregnancyCategory": "Category C (but not absorbed, generally considered safe).",
    "lactationInfo": "Compatible (not absorbed)."
  },
  "methyldopa": {
    "name": "Methyldopa (Aldomet)",
    "genericName": "Methyldopa",
    "brandNames": ["Aldomet"],
    "category": "Antihypertensive",
    "drugClass": "Alpha-2 Adrenergic Agonist (Central)",
    "indications": "Treatment of hypertension. (Largely replaced by newer agents, but still a first-line choice for hypertension in pregnancy).",
    "moaSteps": [
      "Methyldopa is a prodrug that is converted in the brain to its active metabolite, alpha-methylnorepinephrine.",
      "Alpha-methylnorepinephrine is a central alpha-2 adrenergic agonist.",
      "It stimulates alpha-2 receptors in the brainstem, which reduces sympathetic outflow from the CNS.",
      "This leads to decreased heart rate, vasodilation, and a reduction in blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Variable absorption (~25-50%).",
      "distribution": "Widely distributed. Low protein binding.",
      "metabolism": "Extensively metabolized in the GI tract and liver.",
      "excretion": "Excreted in urine. Half-life is ~1.5-2 hours."
    },
    "dose": "250 mg PO 2-3 times daily. Titrate up to max 3 g/day.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "headache", "dry mouth", "dizziness", "orthostatic hypotension."],
      "serious": ["Hemolytic anemia (autoimmune)", "hepatotoxicity (liver failure)", "drug-induced lupus", "myocarditis."]
    },
    "precautions": [
      "Can cause autoimmune hemolytic anemia. Monitor Coombs test and CBC.",
      "Can cause hepatotoxicity. Monitor LFTs.",
      "High incidence of sedation and drowsiness.",
      "Can cause a positive Coombs test even without anemia."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active liver disease (e.g., acute hepatitis)",
      "concomitant use with MAOIs."
    ],
    "pregnancyCategory": "Category B. Considered a first-line agent for hypertension in pregnancy.",
    "lactationInfo": "Excreted in breast milk; compatible."
  },
  "methylphenidate": {
    "name": "Methylphenidate (Ritalin, Concerta)",
    "genericName": "Methylphenidate",
    "brandNames": ["Ritalin (IR)", "Concerta (ER)", "Metadate CD (ER)", "Daytrana (patch)"],
    "category": "CNS Stimulant",
    "drugClass": "CNS Stimulant (Schedule II)",
    "indications": "Treatment of Attention Deficit Hyperactivity Disorder (ADHD). Treatment of narcolepsy.",
    "moaSteps": [
      "Methylphenidate is a CNS stimulant.",
      "It primarily works by blocking the reuptake of norepinephrine (NE) and dopamine (DA) into the presynaptic neuron.",
      "This action increases the concentration of these neurotransmitters in the synaptic cleft, particularly in the prefrontal cortex.",
      "This is thought to improve attention, focus, and impulse control."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (IR). ER forms have complex release profiles (e.g., Concerta OROS).",
      "distribution": "Widely distributed. Low protein binding (~10-33%).",
      "metabolism": "Extensively metabolized in the liver (not by CYP enzymes) to an inactive metabolite.",
      "excretion": "Excreted in urine. Half-life is ~3.5 hours."
    },
    "dose": "Highly individualized. IR: 5-20 mg PO 2-3 times daily. ER (Concerta): 18-72 mg PO once daily in the morning.",
    "adverseEffects": {
      "common": ["Insomnia (difficulty sleeping)", "decreased appetite", "weight loss", "headache", "abdominal pain", "nervousness", "tachycardia.", "hypertension."],
      "serious": ["Abuse and dependence", "serious cardiovascular events (sudden death, stroke, MI)", "new or worsening psychiatric symptoms (psychosis, mania)."]
    },
    "precautions": [
      "BOXED WARNING (Abuse and Dependence): CNS stimulants have a high potential for abuse and dependence.",
      "BOXED WARNING (Cardiovascular Risk): Misuse can cause sudden death and serious cardiovascular adverse events.",
      "Monitor blood pressure and heart rate.",
      "Can cause suppression of growth in children.",
      "Monitor for psychiatric symptoms."
    ],
    "contraindications": [
      "Hypersensitivity",
      "marked anxiety or agitation",
      "glaucoma",
      "motor tics or Tourette's syndrome",
      "concomitant use with MAOIs (within 14 days)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "methylprednisolone": {
    "name": "Methylprednisolone (Medrol, Solu-Medrol)",
    "genericName": "Methylprednisolone",
    "brandNames": ["Medrol (oral)", "Solu-Medrol (injection)", "Depo-Medrol (IM injection)"],
    "category": "Anti-inflammatory, Immunosuppressant",
    "drugClass": "Corticosteroid",
    "indications": "Treatment of various inflammatory, allergic, and autoimmune conditions (e.g., asthma exacerbation, rheumatoid arthritis, allergic reactions).",
    "moaSteps": [
      "Methylprednisolone is a synthetic glucocorticoid.",
      "It binds to intracellular glucocorticoid receptors and modifies gene expression.",
      "It upregulates anti-inflammatory proteins and downregulates pro-inflammatory mediators (cytokines, prostaglandins).",
      "This results in potent anti-inflammatory and immunosuppressive effects. It has minimal mineralocorticoid activity."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~2-3 hours (biologic half-life is 18-36 hours)."
    },
    "dose": "Varies widely. Oral: 4-48 mg/day PO. (Medrol Dosepak is a common 6-day tapered dose). IV: 10-250 mg IV every 4-6 hours.",
    "adverseEffects": {
      "common": ["(Short-term) Insomnia", "hyperglycemia", "increased appetite", "nervousness", "fluid retention.", "(Long-term) Cushing's syndrome, osteoporosis, immunosuppression."],
      "serious": ["Adrenal suppression (must taper off)", "severe infections", "psychosis", "peptic ulcer perforation", "osteonecrosis."]
    },
    "precautions": [
      "Prolonged use can cause HPA axis suppression. Dose must be tapered slowly to avoid adrenal crisis.",
      "Can mask signs of infection and increase susceptibility.",
      "Monitor for hyperglycemia, hypertension, and psychiatric disturbances.",
      "Use with caution in patients with peptic ulcer disease or osteoporosis."
    ],
    "contraindications": [
      "Systemic fungal infections",
      "hypersensitivity",
      "administration of live vaccines (if receiving immunosuppressive doses)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },"metoclopramide": {
    "name": "Metoclopramide (Reglan)",
    "genericName": "Metoclopramide",
    "brandNames": ["Reglan", "Metozolv ODT"],
    "category": "Antiemetic, Prokinetic Agent",
    "drugClass": "Dopamine D2 Antagonist, Prokinetic",
    "indications": "Treatment of diabetic gastroparesis. Short-term treatment of symptomatic GERD. Prevention of chemotherapy-induced nausea and vomiting.",
    "moaSteps": [
      "Metoclopramide blocks dopamine D2 receptors in the brain's chemoreceptor trigger zone (CTZ), reducing the urge to vomit.",
      "It also has prokinetic effects on the GI tract by blocking dopamine receptors and promoting acetylcholine release (cholinergic effect).",
      "This increases lower esophageal sphincter tone, enhances gastric contractions, and speeds up gastric emptying, which helps with GERD and gastroparesis."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. Bioavailability ~65-95%.",
      "distribution": "Widely distributed. Low protein binding (~30-40%). Crosses the blood-brain barrier.",
      "metabolism": "Metabolized in the liver (CYP2D6).",
      "excretion": "Excreted in urine as metabolites and unchanged drug. Half-life is ~5-6 hours."
    },
    "dose": "GERD: 10-15 mg PO 4 times daily, 30 min before meals and at bedtime. Gastroparesis: 10 mg PO 4 times daily.",
    "adverseEffects": {
      "common": ["Drowsiness", "restlessness", "fatigue", "dizziness", "diarrhea."],
      "serious": ["Tardive Dyskinesia (TD)", "Neuroleptic Malignant Syndrome (NMS)", "Extrapyramidal Symptoms (EPS, e.g., dystonia, parkinsonism)."]
    },
    "precautions": [
      "BOXED WARNING (Tardive Dyskinesia): Can cause tardive dyskinesia (TD), a serious, often irreversible movement disorder. Risk increases with duration and cumulative dose. Avoid use for >12 weeks.",
      "Risk of EPS, NMS, and depression.",
      "Use with caution in elderly and in patients with Parkinson's disease.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "GI obstruction, perforation, or hemorrhage",
      "pheochromocytoma",
      "history of seizure disorder",
      "concomitant use with drugs likely to cause EPS."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "metoprolol": {
    "name": "Metoprolol (Lopressor, Toprol XL)",
    "genericName": "Metoprolol (Tartrate and Succinate)",
    "brandNames": ["Lopressor (tartrate, IR)", "Toprol XL (succinate, ER)"],
    "category": "Antihypertensive, Antianginal, Anti-Heart Failure",
    "drugClass": "Beta-Blocker (Cardioselective, Beta-1)",
    "indications": "Hypertension. Angina pectoris. Heart failure (Toprol XL only). Acute myocardial infarction.",
    "moaSteps": [
      "Metoprolol is a cardioselective beta-1 adrenergic receptor blocker.",
      "It competitively blocks beta-1 receptors, which are primarily located in cardiac muscle.",
      "This blockade results in decreased heart rate (negative chronotropy), decreased myocardial contractility (negative inotropy), and decreased blood pressure.",
      "It also reduces renin secretion from the kidneys.",
      "At higher doses, it can lose its cardioselectivity and also block beta-2 receptors."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High first-pass metabolism (bioavailability ~50%). Toprol XL is extended-release.",
      "distribution": "Widely distributed. Low protein binding (~12%). Lipophilic, crosses blood-brain barrier.",
      "metabolism": "Extensively metabolized in the liver by CYP2D6.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~3-4 hours."
    },
    "dose": "Hypertension (IR): 50-100 mg PO twice daily. (ER): 25-100 mg PO once daily. Heart Failure (ER): 12.5-25 mg PO once daily, titrate slowly to 200 mg/day.",
    "adverseEffects": {
      "common": ["Fatigue", "dizziness", "bradycardia (slow heart rate)", "hypotension", "depression", "diarrhea."],
      "serious": ["Severe bradycardia", "heart block", "heart failure exacerbation", "bronchospasm (in high doses)."]
    },
    "precautions": [
      "BOXED WARNING (Abrupt Discontinuation): Abruptly stopping beta-blocker therapy can cause exacerbation of angina and, in some cases, MI. Taper the dose slowly.",
      "Can mask the symptoms of hypoglycemia (e.g., tachycardia) in diabetic patients.",
      "Use with caution in patients with asthma or COPD (use low, cardioselective doses).",
      "Take Lopressor (IR) with food. Take Toprol XL (ER) with or without food."
    ],
    "contraindications": [
      "Severe bradycardia",
      "heart block greater than first degree",
      "cardiogenic shock",
      "decompensated heart failure."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "metronidazole": {
    "name": "Metronidazole (Flagyl)",
    "genericName": "Metronidazole",
    "brandNames": ["Flagyl", "MetroGel (topical)"],
    "category": "Antibiotic, Antiprotozoal",
    "drugClass": "Nitroimidazole Antibiotic",
    "indications": "Treatment of anaerobic bacterial infections (e.g., intra-abdominal, C. difficile). Treatment of protozoal infections (e.g., trichomoniasis, amebiasis, giardiasis). Topical: Rosacea.",
    "moaSteps": [
      "Metronidazole is a prodrug that is non-toxic to human cells.",
      "In anaerobic bacteria and protozoa, it is activated by reduction (gaining an electron).",
      "This activation creates highly reactive, short-lived cytotoxic intermediates.",
      "These intermediates bind to and disrupt the helical structure of DNA, causing strand breakage and cell death (bactericidal/protozoacidal)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed orally. High bioavailability (>80%).",
      "distribution": "Widely distributed into all tissues, including CSF and breast milk. Low protein binding (<20%).",
      "metabolism": "Metabolized in the liver by CYP2C9 and CYP3A4.",
      "excretion": "Excreted in urine as metabolites and unchanged drug. Half-life is ~8 hours."
    },
    "dose": "Anaerobic infections: 500 mg PO every 8 hours. C. difficile: 250-500 mg PO 3-4 times daily. Trichomoniasis: 2 g PO as a single dose.",
    "adverseEffects": {
      "common": ["Nausea", "headache", "metallic taste", "diarrhea", "abdominal pain", "darkening of urine (harmless)."],
      "serious": ["Seizures", "peripheral neuropathy", "aseptic meningitis", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "BOXED WARNING (Carcinogenicity): Has been shown to be carcinogenic in mice and rats. Use only for approved indications.",
      "**Disulfiram-like Reaction:** Patients must avoid all alcohol and propylene glycol-containing products during therapy and for at least 3 days after stopping (causes severe nausea, vomiting, flushing).",
      "Can cause seizures and peripheral neuropathy.",
      "Use with caution in patients with liver impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**use of alcohol during or within 3 days of therapy**",
      "**first trimester of pregnancy**",
      "concomitant use of disulfiram."
    ],
    "pregnancyCategory": "Category B (but contraindicated in 1st trimester).",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "miconazole": {
    "name": "Miconazole (Monistat)",
    "genericName": "Miconazole",
    "brandNames": ["Monistat (vaginal)", "Lotrimin AF (topical)", "Desenex (topical)"],
    "category": "Antifungal",
    "drugClass": "Azole Antifungal, Topical",
    "indications": "Topical treatment of tinea corporis (ringworm), tinea cruris (jock itch), and tinea pedis (athlete's foot). Treatment of vaginal candidiasis (yeast infection).",
    "moaSteps": [
      "Miconazole is an azole antifungal agent.",
      "It inhibits the fungal enzyme 14-alpha-sterol demethylase.",
      "This enzyme is essential for converting lanosterol to ergosterol, a vital component of the fungal cell membrane.",
      "By depleting ergosterol, miconazole disrupts the membrane's structure and function, leading to inhibition of fungal growth."
    ],
    "pharmacokinetics": {
      "absorption": "Minimally absorbed systemically from topical or vaginal application.",
      "distribution": "Acts locally.",
      "metabolism": "N/A (topical).",
      "excretion": "N/A (topical)."
    },
    "dose": "Topical: Apply to affected area twice daily. Vaginal: 1 applicatorful or 1 suppository intravaginally at bedtime for 1, 3, or 7 days.",
    "adverseEffects": {
      "common": ["(Topical) Burning", "stinging", "itching", "skin irritation.", "(Vaginal) Burning", "itching", "headache", "abdominal cramping."],
      "serious": ["Severe local hypersensitivity reaction."]
    },
    "precautions": [
      "For external or vaginal use only. Do not ingest.",
      "Vaginal products (creams, suppositories) are oil-based and can weaken latex condoms and diaphragms.",
      "Can inhibit CYP2C9; may increase warfarin levels even with vaginal use."
    ],
    "contraindications": [
      "Hypersensitivity to miconazole."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "minocycline": {
    "name": "Minocycline (Minocin, Solodyn)",
    "genericName": "Minocycline",
    "brandNames": ["Minocin", "Solodyn", "Ximino"],
    "category": "Antibiotic",
    "drugClass": "Tetracycline Antibiotic",
    "indications": "Treatment of various bacterial infections (e.g., respiratory, skin). Treatment of moderate to severe acne vulgaris. Treatment of rheumatoid arthritis (adjunct).",
    "moaSteps": [
      "Minocycline is a tetracycline-class antibiotic.",
      "It inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit.",
      "This action blocks the binding of aminoacyl-tRNA to the ribosome, preventing the addition of amino acids to the growing peptide chain.",
      "It is bacteriostatic."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. High bioavailability (~100%). Food (except high-calcium) does not affect it.",
      "distribution": "Widely distributed, highly lipophilic, penetrates CSF. Moderately protein-bound (~70-75%).",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine and feces. Long half-life (~11-22 hours)."
    },
    "dose": "Acne (Solodyn ER): Dose by weight, e.g., ~1 mg/kg PO once daily. Infections: 200 mg PO initially, then 100 mg PO every 12 hours.",
    "adverseEffects": {
      "common": ["Dizziness", "vertigo (vestibular toxicity)", "headache", "nausea", "vomiting", "photosensitivity."],
      "serious": ["Drug-induced lupus", "hepatotoxicity", "hypersensitivity reactions (DRESS)", "blue-gray skin pigmentation (long-term use)."]
    },
    "precautions": [
      "**Do not use in children < 8 years old.** Can cause permanent discoloration of teeth (yellow-gray-brown) and inhibit bone growth.",
      "Risk of vestibular toxicity (dizziness, vertigo), which is more common than with other tetracyclines.",
      "Risk of photosensitivity; advise sun protection.",
      "Can cause blue-gray pigmentation of skin, nails, and teeth (long-term use).",
      "Take with a full glass of water and remain upright to avoid esophageal irritation."
    ],
    "contraindications": [
      "Hypersensitivity to tetracyclines",
      "**Pregnancy (Category D)**",
      "**Children < 8 years old**."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "minoxidil": {
    "name": "Minoxidil (Rogaine, Loniten)",
    "genericName": "Minoxidil",
    "brandNames": ["Rogaine (topical)", "Loniten (oral)"],
    "category": "Antihypertensive, Hair Loss Agent",
    "drugClass": "Direct Vasodilator (Oral), Hair Growth Stimulant (Topical)",
    "indications": "Oral (Loniten): Treatment of severe, refractory hypertension. Topical (Rogaine): Treatment of androgenetic alopecia (male and female pattern hair loss).",
    "moaSteps": [
      "Oral (Antihypertensive): Minoxidil is a potent, direct-acting peripheral vasodilator. Its active metabolite opens ATP-sensitive potassium channels in vascular smooth muscle, causing hyperpolarization and relaxation. This leads to arteriolar vasodilation and a decrease in blood pressure.",
      "Topical (Hair Growth): The mechanism is not fully understood. It is thought to shorten the telogen (resting) phase of the hair follicle and prolong the anagen (growth) phase, and may also increase follicle size."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Poorly absorbed topically (~1.4%).",
      "distribution": "Widely distributed. Not protein-bound.",
      "metabolism": "Metabolized in the liver (oral form).",
      "excretion": "Excreted in urine as metabolites. Half-life is ~4.2 hours."
    },
    "dose": "Hypertension (Oral): 5-40 mg/day PO. Hair Loss (Topical): 1 mL of 2% or 5% solution applied to scalp twice daily.",
    "adverseEffects": {
      "common": ["(Oral) Tachycardia", "fluid retention (edema)", "hirsutism (excessive hair growth).", "(Topical) Scalp itching, dryness, irritation."],
      "serious": ["(Oral) Pericardial effusion and tamponade", "severe fluid retention", "angina exacerbation."]
    },
    "precautions": [
      "BOXED WARNING (Oral - Serious Adverse Effects): Can cause serious adverse effects (pericardial effusion, angina exacerbation, fluid retention). Must be co-administered with a diuretic and a beta-blocker.",
      "BOXED WARNING (Oral - Appropriate Use): Use only for severe, refractory hypertension.",
      "Topical solution is flammable; avoid fire/flame."
    ],
    "contraindications": [
      "Hypersensitivity",
      "pheochromocytoma (oral form)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk (oral); not recommended."
  },
  "mirtazapine": {
    "name": "Mirtazapine (Remeron)",
    "genericName": "Mirtazapine",
    "brandNames": ["Remeron", "Remeron SolTab"],
    "category": "Antidepressant",
    "drugClass": "Tetracyclic Antidepressant (NaSSA)",
    "indications": "Treatment of major depressive disorder (MDD).",
    "moaSteps": [
      "Mirtazapine is a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA).",
      "It acts as a central presynaptic alpha-2 adrenergic antagonist. This action blocks negative feedback, increasing the release of both norepinephrine (NE) and serotonin (5-HT).",
      "It also potently blocks postsynaptic 5-HT2 and 5-HT3 receptors, which is thought to reduce side effects like anxiety and nausea.",
      "Its potent antagonism of H1 (histamine) receptors causes its significant sedative and appetite-stimulating effects."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~50% (high first-pass metabolism).",
      "distribution": "Widely distributed. Moderately protein-bound (~85%).",
      "metabolism": "Extensively metabolized in the liver by CYP2D6, CYP3A4, and CYP1A2.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~20-40 hours."
    },
    "dose": "Initial: 15 mg PO at bedtime. Titrate up to max 45 mg/day.",
    "adverseEffects": {
      "common": ["Somnolence (sedation)", "increased appetite", "weight gain", "dry mouth", "dizziness", "constipation."],
      "serious": ["Agranulocytosis (rare)", "suicidal thoughts", "serotonin syndrome."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults.",
      "Can cause significant sedation (often dosed at bedtime) and weight gain.",
      "Risk of agranulocytosis. Patients must report any sign of infection (fever, sore throat).",
      "Risk of Serotonin Syndrome, especially with MAOIs."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (within 14 days)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "misoprostol": {
    "name": "Misoprostol (Cytotec)",
    "genericName": "Misoprostol",
    "brandNames": ["Cytotec", "Arthrotec (with diclofenac)"],
    "category": "Antiulcer Agent, Cervical Ripening Agent",
    "drugClass": "Prostaglandin E1 Analog",
    "indications": "Prevention of NSAID-induced gastric ulcers. (Off-label): Cervical ripening and labor induction. Treatment of postpartum hemorrhage.",
    "moaSteps": [
      "Misoprostol is a synthetic prostaglandin E1 analog.",
      "As an antiulcer agent: It binds to prostaglandin receptors on gastric parietal cells, inhibiting acid secretion. It also has a 'cytoprotective' effect by stimulating mucus and bicarbonate secretion.",
      "For cervical ripening/labor: It binds to prostaglandin receptors in the cervix and uterus, causing cervical softening and thinning (ripening) and stimulating uterine contractions."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High first-pass metabolism to active metabolite (misoprostol acid).",
      "distribution": "Widely distributed. Highly protein-bound.",
      "metabolism": "Rapidly metabolized to its active form.",
      "excretion": "Excreted in urine. Short half-life (~20-40 minutes)."
    },
    "dose": "NSAID Ulcer Prophylaxis: 200 mcg PO 4 times daily with food.",
    "adverseEffects": {
      "common": ["Diarrhea (can be severe)", "abdominal pain", "nausea", "flatulence", "headache."],
      "serious": ["Uterine rupture (when used for labor)", "severe diarrhea and dehydration."]
    },
    "precautions": [
      "BOXED WARNING (Pregnancy): **Contraindicated in pregnancy** (for ulcer indication) as it can cause abortion, premature birth, or birth defects. Women of childbearing potential must have a negative pregnancy test and use effective contraception.",
      "Can cause severe diarrhea; often dose-limiting.",
      "When used for labor, can cause uterine hyperstimulation and rupture."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category X)** (for ulcer indication)."
    ],
    "pregnancyCategory": "Category X (for ulcer indication).",
    "lactationInfo": "Metabolite is excreted in breast milk; use with caution."
  },
  "modafinil": {
    "name": "Modafinil (Provigil)",
    "genericName": "Modafinil",
    "brandNames": ["Provigil"],
    "category": "CNS Stimulant",
    "drugClass": "Wakefulness-Promoting Agent (Schedule IV)",
    "indications": "To improve wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).",
    "moaSteps": [
      "The exact mechanism of modafinil is not fully understood.",
      "It is not a typical amphetamine-like stimulant.",
      "It is thought to work by inhibiting the reuptake of dopamine in the brain, which increases dopamine levels and promotes wakefulness.",
      "It may also have effects on other neurotransmitter systems (e.g., norepinephrine, serotonin, histamine)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Food delays absorption.",
      "distribution": "Widely distributed. Moderately protein-bound (~60%).",
      "metabolism": "Extensively metabolized in the liver (CYP3A4).",
      "excretion": "Excreted in urine as metabolites. Half-life is ~15 hours."
    },
    "dose": "200 mg PO once daily in the morning.",
    "adverseEffects": {
      "common": ["Headache", "nausea", "dizziness", "insomnia", "anxiety", "dry mouth."],
      "serious": ["Severe, life-threatening rash (SJS/TEN, DRESS)", "angioedema", "psychiatric symptoms (psychosis, mania)."]
    },
    "precautions": [
      "Can cause severe, life-threatening rashes (SJS/TEN). Discontinue at the first sign of any rash.",
      "Can cause psychiatric symptoms (anxiety, agitation, psychosis).",
      "Can increase heart rate and blood pressure. Monitor cardiovascular status.",
      "Has potential for abuse and dependence (Schedule IV).",
      "Can reduce the effectiveness of hormonal contraceptives."
    ],
    "contraindications": [
      "Hypersensitivity to modafinil or armodafinil."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "montelukast": {
    "name": "Montelukast (Singulair)",
    "genericName": "Montelukast",
    "brandNames": ["Singulair"],
    "category": "Antiasthmatic, Antiallergy",
    "drugClass": "Leukotriene Receptor Antagonist",
    "indications": "Prophylaxis and chronic treatment of asthma. Relief of symptoms of seasonal and perennial allergic rhinitis. Prevention of exercise-induced bronchoconstriction.",
    "moaSteps": [
      "Montelukast is a selective leukotriene receptor antagonist.",
      "Leukotrienes are potent inflammatory mediators released by mast cells and eosinophils.",
      "They cause bronchoconstriction, mucus secretion, and airway inflammation.",
      "Montelukast blocks the action of leukotrienes by binding to the CysLT1 receptor, thus reducing inflammation, relaxing bronchial smooth muscle, and relieving allergy symptoms."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. Bioavailability ~64%.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4 and CYP2C9.",
      "excretion": "Excreted almost exclusively in feces (via bile) as metabolites. Half-life is ~2.7-5.5 hours."
    },
    "dose": "Asthma/Allergies: 10 mg PO once daily in the evening.",
    "adverseEffects": {
      "common": ["Headache", "dizziness", "abdominal pain", "cough", "fatigue."],
      "serious": ["Neuropsychiatric events (agitation, aggression, depression, suicidal thoughts)."]
    },
    "precautions": [
      "BOXED WARNING (Neuropsychiatric Events): Serious neuropsychiatric events have been reported (e.g., agitation, depression, sleep disturbances, suicidal ideation and behavior). Reserve use for allergic rhinitis for patients with an inadequate response to other therapies.",
      "Not for the treatment of acute asthma attacks.",
      "Monitor for mood or behavior changes."
    ],
    "contraindications": [
      "Hypersensitivity to montelukast."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "morphine": {
    "name": "Morphine (MS Contin, Roxanol, Kadian)",
    "genericName": "Morphine Sulfate",
    "brandNames": ["MS Contin (ER)", "Roxanol (IR solution)", "Kadian (ER)", "Duramorph (injection)"],
    "category": "Analgesic, Opioid",
    "drugClass": "Opioid Analgesic (Schedule II)",
    "indications": "Management of moderate to severe pain, acute and chronic.",
    "moaSteps": [
      "Morphine is the prototypical opioid agonist.",
      "It binds with high affinity to mu-opioid receptors in the central nervous system (CNS).",
      "This activation mimics endogenous endorphins, causing potent analgesia, sedation, euphoria, and respiratory depression.",
      "It also decreases GI motility (causing constipation) and stimulates the CTZ (causing nausea)."
    ],
    "pharmacokinetics": {
      "absorption": "Variable oral absorption (bioavailability ~20-40%) due to high first-pass metabolism.",
      "distribution": "Widely distributed. Moderately protein-bound (~30-35%).",
      "metabolism": "Extensively metabolized in the liver (glucuronidation) to active metabolites (M6G - analgesic) and inactive ones (M3G - neuroexcitatory).",
      "excretion": "Excreted in urine. Half-life is ~2-3 hours (IR)."
    },
    "dose": "Highly individualized. Oral (IR): 10-30 mg PO every 4 hours. IV: 2-10 mg IV every 2-4 hours.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "dizziness", "nausea", "vomiting", "constipation", "pruritus (itching)."],
      "serious": ["Respiratory depression", "abuse, addiction, and overdose", "severe hypotension", "bradycardia."]
    },
    "precautions": [
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse.",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "BOXED WARNING (Neonatal Opioid Withdrawal): Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.",
      "BOXA ED WARNING (ER forms): Risk of medication errors, accidental ingestion.",
      "Active metabolites can accumulate in renal failure."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "acute or severe bronchial asthma",
      "paralytic ileus."
    ],
    "pregnancyCategory": "Category C. Can cause neonatal opioid withdrawal.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "mupirocin": {
    "name": "Mupirocin (Bactroban)",
    "genericName": "Mupirocin",
    "brandNames": ["Bactroban", "Centany"],
    "category": "Antibiotic, Topical",
    "drugClass": "Topical Antibiotic",
    "indications": "Topical treatment of impetigo. Eradication of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) (nasal ointment).",
    "moaSteps": [
      "Mupirocin is a unique topical antibiotic.",
      "It inhibits bacterial protein synthesis by reversibly binding to and inhibiting isoleucyl-tRNA synthetase.",
      "This enzyme is essential for incorporating isoleucine into bacterial proteins.",
      "By blocking this, it prevents protein synthesis and is bacteriostatic at low concentrations and bactericidal at high concentrations."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption from intact skin.",
      "distribution": "Acts locally.",
      "metabolism": "If absorbed, rapidly metabolized to an inactive metabolite.",
      "excretion": "Excreted in urine (inactive metabolite)."
    },
    "dose": "Topical: Apply a small amount to the affected area 3 times daily for 3-5 days. Nasal: Apply 1/2 tube into each nostril twice daily for 5 days.",
    "adverseEffects": {
      "common": ["Burning", "stinging", "itching", "rash", "dry skin."],
      "serious": ["Severe local hypersensitivity reaction", "superinfection."]
    },
    "precautions": [
      "For external use only. Do not get in eyes.",
      "Not for use on large, open wounds or burns (polyethylene glycol base can be absorbed and is nephrotoxic).",
      "Prolonged use may result in fungal or bacterial superinfection."
    ],
    "contraindications": [
      "Hypersensitivity to mupirocin."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "mycophenolate": {
    "name": "Mycophenolate (CellCept, Myfortic)",
    "genericName": "Mycophenolate Mofetil / Mycophenolic Acid",
    "brandNames": ["CellCept (mofetil)", "Myfortic (acid, enteric-coated)"],
    "category": "Immunosuppressant",
    "drugClass": "Immunosuppressant",
    "indications": "Prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants (used with cyclosporine and corticosteroids).",
    "moaSteps": [
      "Mycophenolate is a prodrug, rapidly hydrolyzed to its active form, mycophenolic acid (MPA).",
      "MPA is a potent, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH).",
      "This enzyme is crucial for the *de novo* pathway of purine synthesis, which is required by B and T lymphocytes for proliferation.",
      "By blocking this pathway, MPA selectively inhibits the proliferation of lymphocytes, thus suppressing the immune response."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (mofetil). Myfortic is delayed-release.",
      "distribution": "Highly protein-bound (~97%).",
      "metabolism": "Converted to active MPA, then metabolized in the liver to an inactive glucuronide. Undergoes enterohepatic recirculation.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~16-18 hours."
    },
    "dose": "Renal Transplant: 1 g PO twice daily. (Myfortic): 720 mg PO twice daily.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "leukopenia", "anemia", "hypertension."],
      "serious": ["Increased risk of infections (opportunistic)", "increased risk of malignancy (lymphoma, skin cancer)", "myelosuppression."]
    },
    "precautions": [
      "BOXED WARNING (Embryo-Fetal Toxicity): Can cause major birth defects and fetal loss. Women of childbearing potential must use effective contraception.",
      "BOXED WARNING (Infections & Malignancy): Increased risk of serious opportunistic infections and development of lymphoma and other malignancies.",
      "BOXED WARNING (REMS): Available only through a restricted (REMS) program.",
      "Can cause severe myelosuppression (neutropenia). Monitor CBC."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category D)**."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "nabumetone": {
    "name": "Nabumetone (Relafen)",
    "genericName": "Nabumetone",
    "brandNames": ["Relafen"],
    "category": "Anti-inflammatory, Analgesic",
    "drugClass": "Nonsteroidal Anti-inflammatory Drug (NSAID)",
    "indications": "Relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis.",
    "moaSteps": [
      "Nabumetone is a prodrug that is converted in the liver to its active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA).",
      "6-MNA inhibits cyclooxygenase (COX-1 and COX-2) enzymes, which blocks prostaglandin synthesis.",
      "It is considered 'COX-2 preferential' at lower doses, which may reduce GI side effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed, then converted to active metabolite.",
      "distribution": "Active metabolite is highly protein-bound (>99%).",
      "metabolism": "Extensively metabolized in the liver to its active form (6-MNA) and others.",
      "excretion": "Excreted in urine as metabolites. Long half-life of active metabolite (~24 hours)."
    },
    "dose": "1000 mg PO once daily. May increase to 1500-2000 mg/day. Take with or without food.",
    "adverseEffects": {
      "common": ["Dyspepsia", "nausea", "abdominal pain", "diarrhea", "headache", "rash."],
      "serious": ["Gastrointestinal bleeding and ulceration", "cardiovascular thrombotic events (MI, stroke)", "hepatotoxicity", "nephrotoxicity."]
    },
    "precautions": [
      "BOXED WARNING (CV Risk): Increased risk of serious cardiovascular thrombotic events (MI, stroke).",
      "BOXED WARNING (GI Risk): Increased risk of serious GI events (bleeding, ulceration, perforation).",
      "Use lowest effective dose for shortest duration.",
      "Risk of photosensitivity."
    ],
    "contraindications": [
      "Hypersensitivity to nabumetone or other NSAIDs",
      "history of asthma or urticaria after aspirin/NSAID use",
      "perioperative pain in the setting of CABG surgery."
    ],
    "pregnancyCategory": "Category C (D in 3rd trimester)",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "nadolol": {
    "name": "Nadolol (Corgard)",
    "genericName": "Nadolol",
    "brandNames": ["Corgard"],
    "category": "Antihypertensive, Antianginal",
    "drugClass": "Beta-Blocker (Nonselective)",
    "indications": "Management of hypertension. Management of angina pectoris. (Off-label): Migraine prophylaxis, portal hypertension.",
    "moaSteps": [
      "Nadolol is a nonselective beta-adrenergic blocker.",
      "It competitively blocks both beta-1 (in the heart) and beta-2 (in the lungs and vasculature) receptors.",
      "Beta-1 blockade decreases heart rate, contractility, and blood pressure.",
      "Beta-2 blockade can cause bronchoconstriction."
    ],
    "pharmacokinetics": {
      "absorption": "Variable and incomplete absorption (~30-40%).",
      "distribution": "Widely distributed. Low protein binding (~30%).",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted entirely unchanged in the urine. Very long half-life (~20-24 hours)."
    },
    "dose": "Hypertension: 40-80 mg PO once daily. Angina: 40-160 mg PO once daily.",
    "adverseEffects": {
      "common": ["Fatigue", "dizziness", "bradycardia", "hypotension", "cold extremities."],
      "serious": ["Severe bradycardia", "heart block", "heart failure exacerbation", "bronchospasm."]
    },
    "precautions": [
      "BOXED WARNING (Abrupt Discontinuation): Abruptly stopping beta-blocker therapy can cause exacerbation of angina and, in some cases, MI. Taper the dose slowly.",
      "Nonselective; high risk of bronchospasm. Avoid in patients with asthma or severe COPD.",
      "Can mask symptoms of hypoglycemia in diabetics.",
      "Requires dose adjustment in renal impairment (due to 100% renal excretion)."
    ],
    "contraindications": [
      "Severe bradycardia",
      "heart block greater than first degree",
      "cardiogenic shock",
      "bronchial asthma."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },"naloxone": {
    "name": "Naloxone (Narcan)",
    "genericName": "Naloxone",
    "brandNames": ["Narcan (nasal spray)", "Kloxxado (nasal spray)", "Zimhi (injection)"],
    "category": "Opioid Antagonist",
    "drugClass": "Opioid Antagonist",
    "indications": "Complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids. Diagnosis of suspected acute opioid overdose.",
    "moaSteps": [
      "Naloxone is a pure, competitive opioid antagonist.",
      "It has a very high affinity for mu-opioid receptors in the CNS.",
      "It competes with and displaces opioids (like heroin, fentanyl, or oxycodone) from these receptors.",
      "This action rapidly reverses all effects of the opioid, most critically, respiratory depression. It has no effect in the absence of opioids."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed IM/SC/Nasal. High first-pass metabolism (bioavailability ~2%) if given orally.",
      "distribution": "Widely distributed. Crosses the placenta. Onset: 1-2 minutes (IV), 2-5 minutes (IM/Nasal).",
      "metabolism": "Extensively metabolized in the liver (glucuronidation).",
      "excretion": "Excreted in urine as metabolites. Short half-life (~30-90 minutes)."
    },
    "dose": "Overdose (Nasal): 4 mg (1 spray) into one nostril. May repeat every 2-3 minutes. (IV): 0.4-2 mg IV, may repeat.",
    "adverseEffects": {
      "common": ["(In opioid-dependent patients) Acute opioid withdrawal: body aches, nausea, vomiting, diarrhea, tachycardia, fever, sweating.", "(In non-dependent) Generally no effects."],
      "serious": ["Severe opioid withdrawal", "cardiac arrest (rare, due to sudden withdrawal)."]
    },
    "precautions": [
      "Action is short-lived. The half-life of naloxone is often shorter than the opioid it is reversing (e.g., fentanyl, methadone). Patient must be monitored and may require repeat doses.",
      "Will precipitate acute, severe withdrawal in opioid-dependent individuals.",
      "Naloxone is not effective for overdose caused by non-opioid drugs (e.g., benzodiazepines, alcohol, cocaine)."
    ],
    "contraindications": [
      "Hypersensitivity to naloxone."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "naltrexone": {
    "name": "Naltrexone (Vivitrol, ReVia)",
    "genericName": "Naltrexone",
    "brandNames": ["Vivitrol (IM injection)", "ReVia (oral)"],
    "category": "Opioid Antagonist, Anti-Alcohol Agent",
    "drugClass": "Opioid Antagonist",
    "indications": "Treatment of alcohol use disorder (to reduce craving and relapse). Prevention of relapse to opioid dependence, following opioid detoxification.",
    "moaSteps": [
      "Naltrexone is a pure opioid antagonist.",
      "For Opioid Dependence: It competitively blocks mu-opioid receptors, preventing opioids (like heroin) from binding and producing euphoria. This extinguishes the rewarding effect.",
      "For Alcohol Dependence: The mechanism is not fully understood. It is thought to block the endogenous opioid (endorphin) system that is involved in the rewarding effects of alcohol, thus reducing cravings."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally, but high first-pass metabolism. IM injection provides sustained release over 1 month.",
      "distribution": "Widely distributed. Low protein binding (~21%).",
      "metabolism": "Extensively metabolized in the liver to an active metabolite (6-beta-naltrexol).",
      "excretion": "Excreted in urine as metabolites. Half-life is ~4 hours (oral) and ~5-10 days (IM)."
    },
    "dose": "Alcohol Use: 50 mg PO once daily. Opioid Use: 380 mg IM (Vivitrol) every 4 weeks.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "headache", "dizziness", "insomnia", "injection site reactions (IM)."],
      "serious": ["Hepatotoxicity (dose-related)", "severe injection site reactions", "precipitation of severe opioid withdrawal."]
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Can cause dose-related liver damage. Discontinue if signs of hepatitis occur.",
      "**Patient must be opioid-free for at least 7-10 days** before starting to avoid precipitating severe, acute withdrawal.",
      "Patients may have reduced tolerance to opioids after stopping naltrexone; overdose is a risk if they relapse."
    ],
    "contraindications": [
      "Hypersensitivity",
      "patients currently receiving opioids",
      "patients in acute opioid withdrawal",
      "acute hepatitis or liver failure."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "naproxen": {
    "name": "Naproxen (Aleve, Naprosyn)",
    "genericName": "Naproxen",
    "brandNames": ["Aleve (OTC)", "Naprosyn", "Anaprox (naproxen sodium)", "Vimovo (with esomeprazole)"],
    "category": "Anti-inflammatory, Analgesic",
    "drugClass": "Nonsteroidal Anti-inflammatory Drug (NSAID)",
    "indications": "Relief of mild to moderate pain, fever, and inflammation. Management of rheumatoid arthritis, osteoarthritis, and gout. Treatment of primary dysmenorrhea.",
    "moaSteps": [
      "Naproxen is a nonselective inhibitor of cyclooxygenase-1 (COX-1) and COX-2 enzymes.",
      "It blocks the conversion of arachidonic acid to prostaglandins, which are mediators of pain, inflammation, and fever."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed orally.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C9.",
      "excretion": "Excreted in urine as metabolites. Long half-life (~12-17 hours), allowing for once or twice daily dosing."
    },
    "dose": "Pain: 220 mg (OTC) or 250-500 mg (Rx) PO every 8-12 hours. Arthritis: 250-500 mg PO twice daily. Take with food.",
    "adverseEffects": {
      "common": ["Dyspepsia (indigestion)", "nausea", "abdominal pain", "heartburn", "headache", "dizziness.", "constipation."],
      "serious": ["Gastrointestinal bleeding and ulceration", "cardiovascular thrombotic events (MI, stroke)", "hepatotoxicity", "nephrotoxicity."]
    },
    "precautions": [
      "BOXED WARNING (CV Risk): Increased risk of serious cardiovascular thrombotic events (MI, stroke).",
      "BOXED WARNING (GI Risk): Increased risk of serious GI events (bleeding, ulceration, perforation).",
      "Use lowest effective dose for shortest duration.",
      "Take with food or milk to reduce GI upset."
    ],
    "contraindications": [
      "Hypersensitivity to naproxen or other NSAIDs",
      "history of asthma or urticaria after aspirin/NSAID use",
      "perioperative pain in the setting of CABG surgery."
    ],
    "pregnancyCategory": "Category C (D in 3rd trimester)",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "naratriptan": {
    "name": "Naratriptan (Amerge)",
    "genericName": "Naratriptan",
    "brandNames": ["Amerge"],
    "category": "Antimigraine Agent",
    "drugClass": "Serotonin 5-HT1B/1D Receptor Agonist (Triptan)",
    "indications": "Acute treatment of migraine attacks with or without aura.",
    "moaSteps": [
      "Naratriptan is a selective agonist for serotonin (5-HT) receptors, specifically 5-HT1B and 5-HT1D.",
      "It works by three mechanisms:",
      "1. **Cranial Vasoconstriction:** It constricts the dilated intracranial blood vessels that are thought to cause migraine pain.",
      "2. **Inhibition of Neuropeptide Release:** It blocks the release of pro-inflammatory neuropeptides from trigeminal nerve endings.",
      "3. **Inhibition of Pain Pathways:** It reduces pain signal transmission in the trigeminal nucleus."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Bioavailability ~70%.",
      "distribution": "Low protein binding (~28-31%).",
      "metabolism": "Metabolized in the liver by various CYP enzymes.",
      "excretion": "Excreted in urine. Longer half-life than other triptans (~6 hours)."
    },
    "dose": "1 mg or 2.5 mg PO at the onset of migraine. May repeat once after 4 hours. Max 5 mg/24 hours.",
    "adverseEffects": {
      "common": ["Dizziness", "drowsiness", "fatigue", "nausea", "tingling/numbness (paresthesia)."],
      "serious": ["Coronary vasospasm (angina, MI)", "arrhythmias", "stroke", "serotonin syndrome", "severe hypertension."]
    },
    "precautions": [
      "Not for migraine prophylaxis (prevention). Only for acute treatment.",
      "Risk of serious cardiovascular events. Contraindicated in patients with known cardiovascular disease (CAD, stroke, uncontrolled hypertension).",
      "Risk of 'triptan sensations' (chest, neck, or jaw tightness/pressure).",
      "Risk of Serotonin Syndrome when used with SSRIs, SNRIs, or MAOIs."
    ],
    "contraindications": [
      "Hypersensitivity",
      "ischemic heart disease (angina, history of MI)",
      "uncontrolled hypertension",
      "hemiplegic or basilar migraine",
      "use within 24 hours of another triptan or ergotamine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "nebivolol": {
    "name": "Nebivolol (Bystolic)",
    "genericName": "Nebivolol",
    "brandNames": ["Bystolic"],
    "category": "Antihypertensive",
    "drugClass": "Beta-Blocker (Cardioselective, Beta-1) with Vasodilation",
    "indications": "Treatment of hypertension.",
    "moaSteps": [
      "Nebivolol has a dual mechanism of action:",
      "1. **Beta-1 Blockade:** It is a highly cardioselective beta-1 adrenergic receptor blocker. This action decreases heart rate, contractility, and blood pressure.",
      "2. **Vasodilation:** It promotes the release of nitric oxide (NO) from endothelial cells, which causes vasodilation (widening of blood vessels), further reducing blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability is variable (12% in extensive metabolizers, 96% in poor metabolizers) due to CYP2D6.",
      "distribution": "Highly protein-bound (~98%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP2D6.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is variable (~10-19 hours)."
    },
    "dose": "5-10 mg PO once daily. Max 40 mg/day.",
    "adverseEffects": {
      "common": ["Headache", "fatigue", "dizziness", "bradycardia", "nausea."],
      "serious": ["Severe bradycardia", "heart block", "heart failure exacerbation", "bronchospasm (in high doses)."]
    },
    "precautions": [
      "BOXED WARNING (Abrupt Discontinuation): Abruptly stopping beta-blocker therapy can cause exacerbation of angina and, in some cases, MI. Taper the dose slowly.",
      "Can mask symptoms of hypoglycemia in diabetics.",
      "Use with caution in patients with asthma or COPD."
    ],
    "contraindications": [
      "Severe bradycardia",
      "heart block greater than first degree",
      "cardiogenic shock",
      "decompensated heart failure",
      "severe liver impairment."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "neomycin": {
    "name": "Neomycin (Neo-Fradin, Neosporin)",
    "genericName": "Neomycin",
    "brandNames": ["Neo-Fradin (oral)", "Neosporin (topical, in combination)"],
    "category": "Antibiotic",
    "drugClass": "Aminoglycoside Antibiotic",
    "indications": "Oral: Suppression of intestinal bacteria (bowel prep) before surgery. Management of hepatic encephalopathy (to reduce ammonia-forming bacteria). Topical: Prevention of minor skin infections (in combination).",
    "moaSteps": [
      "Neomycin is an aminoglycoside antibiotic.",
      "It irreversibly binds to the 30S ribosomal subunit of susceptible bacteria.",
      "This action interferes with protein synthesis, leading to the production of nonfunctional proteins and bacterial cell death (bactericidal).",
      "It is not absorbed from the GI tract, so it acts locally in the gut."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly absorbed from the GI tract (~3%). Not for systemic infections.",
      "distribution": "Acts locally in the GI tract.",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in feces. Absorbed fraction is excreted in urine."
    },
    "dose": "Hepatic Encephalopathy: 4-12 g/day PO in divided doses. Bowel Prep: Varies, e.g., 1 g PO every hour for 4 doses, then 1 g every 4 hours.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "malabsorption."],
      "serious": ["Ototoxicity", "Nephrotoxicity", "Neuromuscular blockade (if significant amount is absorbed)."]
    },
    "precautions": [
      "BOXED WARNING (Toxicity): Can be absorbed systemically (especially with inflamed gut or renal impairment), leading to severe, irreversible ototoxicity (deafness) and nephrotoxicity (kidney damage).",
      "BOXED WARNING (Neuromuscular Blockade): Can cause respiratory paralysis.",
      "Use with caution in patients with renal impairment or myasthenia gravis.",
      "Can cause malabsorption of vitamins."
    ],
    "contraindications": [
      "Hypersensitivity to aminoglycosides",
      "GI obstruction",
      "inflammatory bowel disease."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "niacin": {
    "name": "Niacin (Niaspan, Niacor)",
    "genericName": "Niacin (Vitamin B3, Nicotinic Acid)",
    "brandNames": ["Niaspan (ER)", "Niacor (IR)", "Slo-Niacin (SR, OTC)"],
    "category": "Antihyperlipidemic, Vitamin",
    "drugClass": "Water-soluble Vitamin, Lipid-Lowering Agent",
    "indications": "Treatment of niacin deficiency (pellagra). Adjunct to diet for the treatment of hyperlipidemia (to lower triglycerides and LDL, and raise HDL).",
    "moaSteps": [
      "As a vitamin: Niacin is converted to NAD and NADP, which are essential coenzymes in cellular metabolism.",
      "As a lipid-lowering agent: The mechanism is not fully understood. It strongly inhibits lipolysis (breakdown of fat) in adipose tissue.",
      "This reduces the transport of free fatty acids to the liver, decreasing the liver's synthesis of VLDL (triglycerides) and, subsequently, LDL."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (IR). ER/SR forms have slower absorption.",
      "distribution": "Widely distributed.",
      "metabolism": "Extensively metabolized in the liver.",
      "excretion": "Excreted in urine. Half-life is ~20-60 minutes."
    },
    "dose": "Lipid-lowering (ER): 500-2000 mg PO once daily at bedtime. (IR): Requires 1.5-6 g/day in divided doses.",
    "adverseEffects": {
      "common": ["Intense flushing (redness, warmth, itching of skin)", "headache", "nausea", "dyspepsia", "pruritus."],
      "serious": ["Hepatotoxicity (especially with SR forms)", "hyperglycemia", "hyperuricemia (can precipitate gout)", "atrial fibrillation."]
    },
    "precautions": [
      "Flushing is very common and can be severe. Taking aspirin 30 minutes before and taking with a low-fat snack can help.",
      "Risk of hepatotoxicity, especially with sustained-release (SR) OTC products. Monitor LFTs.",
      "Can worsen glucose control in diabetics and precipitate gout.",
      "IR has high flushing risk. ER (Niaspan) has less flushing. SR (OTC) has high liver toxicity risk."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active liver disease",
      "active peptic ulcer",
      "arterial bleeding."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution at high doses."
  },
  "nicardipine": {
    "name": "Nicardipine (Cardene)",
    "genericName": "Nicardipine",
    "brandNames": ["Cardene", "Cardene IV", "Cardene SR"],
    "category": "Antihypertensive, Antianginal",
    "drugClass": "Calcium Channel Blocker (Dihydropyridine)",
    "indications": "Management of hypertension. Management of chronic stable angina.",
    "moaSteps": [
      "Nicardipine is a dihydropyridine calcium channel blocker.",
      "It inhibits the influx of calcium ions across cell membranes into vascular smooth muscle cells.",
      "It acts primarily on peripheral blood vessels (arterioles), causing potent vasodilation.",
      "This vasodilation reduces peripheral vascular resistance, which in turn lowers blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Completely absorbed orally, but high first-pass metabolism (bioavailability ~35%).",
      "distribution": "Highly protein-bound (>95%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in urine and feces as metabolites. Short half-life (~2-4 hours)."
    },
    "dose": "Hypertension (PO): 20-40 mg PO 3 times daily. (IV): 5-15 mg/hour continuous infusion.",
    "adverseEffects": {
      "common": ["Flushing", "headache", "dizziness", "peripheral edema", "tachycardia (reflex)."],
      "serious": ["Severe hypotension", "reflex tachycardia", "worsening of angina."]
    },
    "precautions": [
      "Can cause reflex tachycardia; use with caution in patients with angina or heart failure.",
      "Use with caution in patients with hepatic impairment (reduced metabolism).",
      "Potent inhibitor of CYP3A4."
    ],
    "contraindications": [
      "Hypersensitivity to nicardipine",
      "advanced aortic stenosis."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "nicotine": {
    "name": "Nicotine (Nicorette, NicoDerm CQ)",
    "genericName": "Nicotine Polacrilex (gum/lozenge), Nicotine (patch/spray/inhaler)",
    "brandNames": ["Nicorette (gum, lozenge)", "NicoDerm CQ (patch)", "Nicotrol (inhaler, nasal spray)"],
    "category": "Smoking Cessation Aid",
    "drugClass": "Nicotinic Agonist",
    "indications": "Aid to smoking cessation for the relief of nicotine withdrawal symptoms.",
    "moaSteps": [
      "Nicotine is a potent agonist of nicotinic acetylcholine receptors in the autonomic ganglia and CNS.",
      "In smoking cessation, these products provide a controlled, lower dose of nicotine than cigarettes.",
      "This action replaces the nicotine from smoking, reducing the craving and withdrawal symptoms (e.g., irritability, anxiety, difficulty concentrating), allowing the person to focus on behavioral changes."
    ],
    "pharmacokinetics": {
      "absorption": "Variable. Patch: Slow, sustained absorption. Gum/Lozenge: Absorbed through buccal mucosa. Spray: Rapidly absorbed nasally.",
      "distribution": "Widely distributed, crosses blood-brain barrier.",
      "metabolism": "Extensively metabolized in the liver (CYP2A6).",
      "excretion": "Excreted in urine. Half-life is ~2 hours."
    },
    "dose": "Varies by product. Patch: 21 mg/day x 6 weeks, then 14 mg/day x 2 weeks, then 7 mg/day x 2 weeks. Gum: 2-4 mg per piece as needed.",
    "adverseEffects": {
      "common": ["(Patch) Skin irritation", "insomnia", "vivid dreams.", "(Gum/Lozenge) Mouth/throat irritation", "dyspepsia", "hiccups.", "(Spray) Nasal irritation."],
      "serious": ["Tachycardia", "hypertension", "addiction/dependence (to the product)."]
    },
    "precautions": [
      "Use with caution in patients with cardiovascular disease (e.g., recent MI, arrhythmias, severe angina).",
      "Can cause insomnia and vivid dreams (patch may be removed at bedtime).",
      "Keep out of reach of children and pets (can be fatal if ingested).",
      "Do not smoke while using NRT (risk of nicotine overdose)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "non-smokers",
      "severe angina",
      "life-threatening arrhythmias."
    ],
    "pregnancyCategory": "Category D (patch) / C (gum/lozenge).",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "nifedipine": {
    "name": "Nifedipine (Procardia, Adalat CC)",
    "genericName": "Nifedipine",
    "brandNames": ["Procardia", "Adalat CC", "Procardia XL"],
    "category": "Antihypertensive, Antianginal",
    "drugClass": "Calcium Channel Blocker (Dihydropyridine)",
    "indications": "Management of hypertension (ER forms). Management of chronic stable angina and vasospastic (Prinzmetal's) angina.",
    "moaSteps": [
      "Nifedipine is a dihydropyridine calcium channel blocker.",
      "It inhibits the influx of calcium ions across cell membranes into vascular smooth muscle and cardiac muscle.",
      "It acts primarily on peripheral blood vessels (arterioles), causing potent vasodilation.",
      "This vasodilation reduces peripheral vascular resistance, which in turn lowers blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (IR), slowly absorbed (ER). High first-pass metabolism.",
      "distribution": "Highly protein-bound (~92-98%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~2-5 hours (IR)."
    },
    "dose": "Hypertension (ER): 30-90 mg PO once daily. Angina (IR): 10-20 mg PO 3 times daily.",
    "adverseEffects": {
      "common": ["Peripheral edema (swelling of ankles)", "flushing", "headache", "dizziness", "hypotension", "reflex tachycardia.", "gingival hyperplasia."],
      "serious": ["Severe hypotension", "reflex tachycardia", "worsening of angina or MI (especially with IR)."]
    },
    "precautions": [
      "**Short-acting (IR) nifedipine is not recommended for hypertension** as it can cause rapid, dangerous drops in blood pressure and reflex tachycardia, increasing the risk of MI.",
      "Use ER formulations (Procardia XL, Adalat CC) for hypertension.",
      "Avoid grapefruit juice (a strong CYP3A4 inhibitor).",
      "Can cause significant gingival hyperplasia (gum overgrowth)."
    ],
    "contraindications": [
      "Hypersensitivity to nifedipine",
      "cardiogenic shock."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "nitrofurantoin": {
    "name": "Nitrofurantoin (Macrobid, Macrodantin)",
    "genericName": "Nitrofurantoin",
    "brandNames": ["Macrobid (monohydrate/macrocrystals)", "Macrodantin (macrocrystals)"],
    "category": "Antibiotic",
    "drugClass": "Urinary Anti-infective",
    "indications": "Treatment and prophylaxis of acute uncomplicated urinary tract infections (UTIs) (cystitis) caused by susceptible strains of E. coli, Enterococci, S. aureus, and Klebsiella.",
    "moaSteps": [
      "Nitrofurantoin is a prodrug that is activated by bacterial enzymes (flavoproteins) inside the bacterial cell.",
      "This activation creates highly reactive, short-lived intermediates.",
      "These reactive intermediates attack multiple sites within the cell, including ribosomal proteins, DNA, and RNA.",
      "This multi-faceted attack inhibits bacterial synthesis of DNA, RNA, proteins, and the cell wall."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Food increases absorption and bioavailability.",
      "distribution": "Concentrates in the urine. Does not achieve effective systemic levels.",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in the urine. Half-life is ~20-60 minutes."
    },
    "dose": "Treatment (Macrobid): 100 mg PO twice daily for 5-7 days. Prophylaxis: 50-100 mg PO at bedtime.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "headache", "diarrhea", "darkening of urine (brown/yellow)."],
      "serious": ["Pulmonary toxicity (acute pneumonitis or chronic pulmonary fibrosis)", "hepatotoxicity", "peripheral neuropathy", "hemolytic anemia (in G6PD deficiency)."]
    },
    "precautions": [
      "Can cause acute and chronic pulmonary reactions (fibrosis), which can be fatal. Monitor for cough, dyspnea.",
      "Risk of peripheral neuropathy (numbness/tingling).",
      "Risk of hemolytic anemia in patients with G6PD deficiency.",
      "**Take with food or milk** to improve absorption and reduce GI upset.",
      "Can cause a harmless brown/yellow discoloration of urine."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**severe renal impairment (CrCl < 60 mL/min)** (drug won't concentrate in urine and systemic toxicity risk increases)",
      "anuria",
      "G6PD deficiency",
      "pregnancy at term (38-42 weeks)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Compatible, but avoid if infant has G6PD deficiency."
  },
  "nitroglycerin": {
    "name": "Nitroglycerin (Nitrostat, Nitro-Dur, Nitro-Bid)",
    "genericName": "Nitroglycerin",
    "brandNames": ["Nitrostat (sublingual)", "Nitro-Dur (patch)", "Nitro-Bid (ointment)", "NitroMist (spray)"],
    "category": "Antianginal",
    "drugClass": "Nitrate, Vasodilator",
    "indications": "Acute relief of angina pectoris (chest pain) (SL/spray). Prophylaxis of angina (patch/ointment/oral ER). IV: Hypertensive emergency, acute heart failure.",
    "moaSteps": [
      "Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle.",
      "Nitric oxide (NO) activates the enzyme guanylate cyclase.",
      "This increases the production of cyclic GMP (cGMP).",
      "cGMP leads to dephosphorylation of myosin light chains, causing smooth muscle relaxation and vasodilation.",
      "It dilates veins more than arteries, which reduces venous return to the heart (preload). This decreases cardiac workload and oxygen demand, relieving angina."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed SL/spray. Well absorbed transdermally. Very high first-pass metabolism if swallowed (oral ER forms exist).",
      "distribution": "Widely distributed. Highly protein-bound (~60-90%).",
      "metabolism": "Extensively metabolized in the liver.",
      "excretion": "Excreted in urine as metabolites. Very short half-life (1-4 minutes)."
    },
    "dose": "Angina (SL): 0.3-0.6 mg SL every 5 minutes for 3 doses. (Patch): 0.2-0.8 mg/hr, worn for 12-14 hours, then off for 10-12 hours.",
    "adverseEffects": {
      "common": ["Headache (very common, 'nitrate headache')", "dizziness", "flushing", "orthostatic hypotension", "reflex tachycardia."],
      "serious": ["Severe hypotension", "syncope", "methemoglobinemia (rare, high dose)."]
    },
    "precautions": [
      "**Tolerance** develops rapidly with continuous use. Long-acting forms (patch, ointment) must have a 'nitrate-free interval' (e.g., 10-12 hours off) each day.",
      "Can cause severe headache.",
      "Can cause significant orthostatic hypotension and syncope."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe anemia",
      "increased intracranial pressure",
      "**concomitant use with phosphodiesterase-5 (PDE-5) inhibitors** (e.g., sildenafil, tadalafil) - can cause life-threatening hypotension."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "nizatidine": {
    "name": "Nizatidine (Axid)",
    "genericName": "Nizatidine",
    "brandNames": ["Axid", "Axid AR (OTC)"],
    "category": "Antiulcer Agent",
    "drugClass": "Histamine H2-Receptor Antagonist (H2RA)",
    "indications": "Treatment of active duodenal and benign gastric ulcers. Management of gastroesophageal reflux disease (GERD). Prevention of heartburn (OTC).",
    "moaSteps": [
      "Nizatidine is a competitive inhibitor of histamine H2-receptors.",
      "It specifically blocks histamine from binding to H2-receptors on the basolateral membrane of gastric parietal cells.",
      "This action inhibits basal and stimulated gastric acid secretion, reducing both the volume and acid concentration of gastric juice."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. High bioavailability (>70%).",
      "distribution": "Widely distributed. Moderately protein-bound (~35%).",
      "metabolism": "Partially metabolized in the liver.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~1-2 hours."
    },
    "dose": "GERD: 150 mg PO twice daily. Duodenal Ulcer: 300 mg PO at bedtime.",
    "adverseEffects": {
      "common": ["Headache", "dizziness", "constipation", "diarrhea", "somnolence."],
      "serious": ["Hepatotoxicity (rare)", "anaphylaxis", "thrombocytopenia."]
    },
    "precautions": [
      "Requires dose adjustment in moderate to severe renal impairment.",
      "Can cause rare cases of liver injury.",
      "Use with caution in the elderly (risk of confusion)."
    ],
    "contraindications": [
      "Hypersensitivity to nizatidine or other H2-receptor antagonists."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "nortriptyline": {
    "name": "Nortriptyline (Pamelor)",
    "genericName": "Nortriptyline",
    "brandNames": ["Pamelor", "Aventyl"],
    "category": "Antidepressant",
    "drugClass": "Tricyclic Antidepressant (TCA)",
    "indications": "Treatment of depression. (Off-label): Neuropathic pain, smoking cessation.",
    "moaSteps": [
      "Nortriptyline is the active metabolite of amitriptyline.",
      "It inhibits the neuronal reuptake of both norepinephrine (NE) and, to a lesser extent, serotonin (5-HT).",
      "This increases the concentration of these neurotransmitters in the synaptic cleft.",
      "It has less potent anticholinergic and sedative effects compared to other TCAs like amitriptyline."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed, but high first-pass metabolism.",
      "distribution": "Widely distributed. Highly protein-bound (~93-95%).",
      "metabolism": "Extensively metabolized in the liver (CYP2D6).",
      "excretion": "Excreted in urine as metabolites. Long half-life (~18-44 hours)."
    },
    "dose": "Depression: 25 mg PO 3-4 times daily or 75-150 mg once daily at bedtime.",
    "adverseEffects": {
      "common": ["Sedation", "drowsiness", "dry mouth", "constipation", "blurred vision", "urinary retention", "orthostatic hypotension."],
      "serious": ["Cardiotoxicity (arrhythmias, QT prolongation)", "suicidal thoughts", "seizures", "bone marrow suppression."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults.",
      "High risk of overdose, which can be fatal (due to cardiotoxicity).",
      "Use with caution in the elderly (less anticholinergic than other TCAs, but still a risk).",
      "Do not use with MAOIs (risk of serotonin syndrome)."
    ],
    "contraindications": [
      "Hypersensitivity to TCAs",
      "acute recovery period after MI",
      "concomitant use with MAOIs (within 14 days)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "nystatin": {
    "name": "Nystatin (Nystop, Mycostatin)",
    "genericName": "Nystatin",
    "brandNames": ["Nystop", "Mycostatin", "Nyamyc", "Pedi-Dri"],
    "category": "Antifungal",
    "drugClass": "Polyene Antifungal",
    "indications": "Topical: Treatment of cutaneous or mucocutaneous candidiasis (yeast infections) of the skin, mouth (thrush), and vagina.",
    "moaSteps": [
      "Nystatin is a polyene antifungal.",
      "It binds to ergosterol, a key component of the fungal cell membrane.",
      "This binding alters the permeability of the cell membrane, forming pores or channels.",
      "This allows essential intracellular components to leak out, leading to fungal cell death (fungicidal)."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed from the GI tract (oral suspension), skin (topical), or vagina. It acts locally.",
      "distribution": "Acts locally on the surface.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in feces (if swallowed)."
    },
    "dose": "Thrush (Oral Suspension): 400,000-600,000 units PO 4 times daily. (Swish and swallow/spit). Topical: Apply to affected area 2-3 times daily.",
    "adverseEffects": {
      "common": ["(Oral) Nausea", "vomiting", "diarrhea.", "(Topical) Burning", "stinging", "skin irritation."],
      "serious": ["Hypersensitivity reactions (rare)."]
    },
    "precautions": [
      "For oral thrush, the suspension should be 'swished' in the mouth and held for as long as possible before swallowing (or spitting, if directed).",
      "For topical or vaginal use only. Not for systemic infections.",
      "Generally very well-tolerated as it is not absorbed."
    ],
    "contraindications": [
      "Hypersensitivity to nystatin."
    ],
    "pregnancyCategory": "Category C (Oral) / A (Vaginal)",
    "lactationInfo": "Compatible (not absorbed)."
  },"olanzapine": {
    "name": "Olanzapine (Zyprexa)",
    "genericName": "Olanzapine",
    "brandNames": ["Zyprexa", "Zyprexa Zydis (ODT)", "Zyprexa Relprevv (long-acting injection)"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second-Generation)",
    "indications": "Treatment of schizophrenia. Treatment of acute manic or mixed episodes associated with bipolar I disorder. Maintenance treatment of bipolar I disorder.",
    "moaSteps": [
      "Olanzapine is an atypical antipsychotic.",
      "It has a complex mechanism, acting as an antagonist at multiple receptors.",
      "Its antipsychotic effect is thought to be mediated by blocking dopamine D2 receptors (in the mesolimbic pathway) and serotonin 5-HT2A receptors.",
      "It also has high affinity for H1 (histamine) and M1 (muscarinic) receptors, which accounts for its sedative and anticholinergic side effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. High first-pass metabolism.",
      "distribution": "Widely distributed. Highly protein-bound (~93%).",
      "metabolism": "Extensively metabolized in the liver by CYP1A2 and UGT.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~21-54 hours."
    },
    "dose": "Schizophrenia: 5-10 mg PO once daily. Titrate up to max 20 mg/day.",
    "adverseEffects": {
      "common": ["Somnolence (sedation)", "weight gain (significant)", "increased appetite", "dry mouth", "dizziness", "constipation", "orthostatic hypotension.", "elevated triglycerides and glucose."],
      "serious": ["Neuroleptic Malignant Syndrome (NMS)", "Tardive Dyskinesia (TD)", "severe metabolic changes (hyperglycemia, diabetes, dyslipidemia)", "agranulocytosis."]
    },
    "precautions": [
      "BOXED WARNING (Elderly with Dementia): Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death.",
      "BOXED WARNING (Zyprexa Relprevv): Risk of post-injection delirium/sedation syndrome. Must be administered in a certified healthcare facility and patient monitored for 3 hours.",
      "High risk of metabolic side effects (weight gain, diabetes, dyslipidemia). Monitor weight, BMI, blood glucose, and lipids regularly.",
      "Cigarette smoking (an inducer of CYP1A2) can decrease olanzapine levels."
    ],
    "contraindications": [
      "Hypersensitivity to olanzapine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "olmesartan": {
    "name": "Olmesartan (Benicar)",
    "genericName": "Olmesartan Medoxomil",
    "brandNames": ["Benicar"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin II Receptor Blocker (ARB)",
    "indications": "Treatment of hypertension.",
    "moaSteps": [
      "Olmesartan is a prodrug, hydrolyzed to its active form (olmesartan) in the GI tract.",
      "It is a selective angiotensin II receptor blocker (ARB).",
      "It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking its binding to the AT1 receptor.",
      "This blockade results in vasodilation, decreased secretion of aldosterone, and a reduction in blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Prodrug is rapidly hydrolyzed. Bioavailability ~26%.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Prodrug is hydrolyzed to active form. No further metabolism.",
      "excretion": "Excreted in urine and feces (via bile). Half-life is ~13 hours."
    },
    "dose": "20-40 mg PO once daily.",
    "adverseEffects": {
      "common": ["Dizziness", "headache", "hyperkalemia", "diarrhea."],
      "serious": ["Angioedema", "hypotension", "acute renal failure", "sprue-like enteropathy (severe, chronic diarrhea)."]
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected.",
      "Can cause severe, chronic diarrhea with weight loss (sprue-like enteropathy), which may occur months to years after starting. Discontinue if this occurs.",
      "Monitor renal function and serum potassium."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with aliskiren in patients with diabetes",
      "Pregnancy."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Not recommended."
  },
  "olopatadine": {
    "name": "Olopatadine (Patanol, Pataday)",
    "genericName": "Olopatadine",
    "brandNames": ["Patanol (0.1%)", "Pataday (0.2%, 0.7%)", "Patanase (nasal spray)"],
    "category": "Antihistamine, Ophthalmic/Nasal",
    "drugClass": "Antihistamine, Mast Cell Stabilizer",
    "indications": "Ophthalmic (drops): Treatment of ocular itching associated with allergic conjunctivitis. Nasal (spray): Relief of symptoms of seasonal allergic rhinitis.",
    "moaSteps": [
      "Olopatadine has a dual mechanism of action:",
      "1. **Antihistamine:** It is a selective H1-receptor antagonist, blocking histamine from binding and causing itching.",
      "2. **Mast Cell Stabilizer:** It inhibits the release of histamine and other inflammatory mediators from mast cells.",
      "This combined action provides rapid and long-lasting relief from allergy symptoms."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption after ocular or nasal administration.",
      "distribution": "Acts locally.",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted in urine. Half-life is ~3-4 hours."
    },
    "dose": "Ophthalmic: 1 drop in affected eye(s) once or twice daily, depending on strength. Nasal: 2 sprays per nostril twice daily.",
    "adverseEffects": {
      "common": ["(Ophthalmic) Headache", "blurred vision", "eye stinging/burning", "dry eye.", "(Nasal) Bitter taste", "epistaxis (nosebleed)", "headache."],
      "serious": ["Hypersensitivity reaction (rare)."]
    },
    "precautions": [
      "For ocular or nasal use only. Not for injection or oral use.",
      "Do not instill eye drops while wearing contact lenses. Wait 10-15 minutes before reinserting."
    ],
    "contraindications": [
      "Hypersensitivity to olopatadine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "omega-3-acid-ethyl-esters": {
    "name": "Omega-3-Acid Ethyl Esters (Lovaza)",
    "genericName": "Omega-3-Acid Ethyl Esters",
    "brandNames": ["Lovaza", "Omtryg", "Vascepa (icosapent ethyl)"],
    "category": "Antihyperlipidemic",
    "drugClass": "Lipid-Lowering Agent",
    "indications": "Adjunct to diet to reduce triglyceride (TG) levels in adults with severe (500 mg/dL) hypertriglyceridemia.",
    "moaSteps": [
      "The mechanism is not fully understood.",
      "Omega-3 fatty acids (specifically EPA and DHA) are thought to reduce the synthesis of triglycerides in the liver.",
      "They may act as poor substrates for the enzymes that produce triglycerides and may also inhibit the esterification of other fatty acids.",
      "This leads to a significant reduction in VLDL and total triglycerides."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed from the GI tract.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the liver by oxidation, similar to other fatty acids.",
      "excretion": "N/A"
    },
    "dose": "4 grams (4 capsules) PO once daily, or 2 grams (2 capsules) twice daily, with meals.",
    "adverseEffects": {
      "common": ["Eructation (burping)", "dyspepsia (indigestion)", "unpleasant taste (fishy burps)", "diarrhea.", "arthralgia."],
      "serious": ["Increased risk of atrial fibrillation/flutter", "increased bleeding risk", "elevation of LDL-C (in some patients)."]
    },
    "precautions": [
      "Use with caution in patients with fish or shellfish allergies.",
      "Can increase the risk of bleeding, especially in patients on anticoagulants or antiplatelets. Monitor INR if on warfarin.",
      "Can increase the risk of atrial fibrillation or flutter.",
      "Can cause an *increase* in LDL-C ('bad cholesterol') levels. Monitor lipids."
    ],
    "contraindications": [
      "Hypersensitivity to any component."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "omeprazole": {
    "name": "Omeprazole (Prilosec)",
    "genericName": "Omeprazole",
    "brandNames": ["Prilosec", "Prilosec OTC", "Zegerid (with sodium bicarbonate)"],
    "category": "Antiulcer Agent",
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "indications": "Treatment of GERD. Healing of erosive esophagitis. H. pylori eradication. Risk reduction of NSAID-associated gastric ulcers. Treatment of hypersecretory conditions (e.g., Zollinger-Ellison).",
    "moaSteps": [
      "Omeprazole is a proton pump inhibitor (PPI).",
      "It is a prodrug that is activated in the acidic environment of the gastric parietal cells.",
      "The active form irreversibly blocks the H+/K+-ATPase enzyme system (the 'proton pump').",
      "This is the final step in gastric acid secretion.",
      "It suppresses basal and stimulated gastric acid secretion, leading to a profound and long-lasting reduction of stomach acid."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~30-40% (high first-pass metabolism). Food decreases absorption.",
      "distribution": "Highly protein-bound (~95%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP2C19 and CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Short half-life (~1-1.5 hours), but long duration of action."
    },
    "dose": "GERD: 20-40 mg PO once daily. Take 30-60 minutes before a meal (usually breakfast).",
    "adverseEffects": {
      "common": ["Headache", "diarrhea", "nausea", "abdominal pain", "constipation."],
      "serious": ["Clostridioides difficile-associated diarrhea (CDAD)", "bone fractures (long-term use)", "hypomagnesemia (long-term use)", "Vitamin B12 deficiency (long-term use)."]
    },
    "precautions": [
      "PPI use is associated with an increased risk of *C. difficile*-associated diarrhea.",
      "Long-term use (>1 year) may be associated with an increased risk of osteoporosis-related bone fractures.",
      "Long-term use can lead to hypomagnesemia and vitamin B12 deficiency.",
      "Potent inhibitor of CYP2C19; significantly reduces the effectiveness of clopidogrel (Plavix)."
    ],
    "contraindications": [
      "Hypersensitivity to omeprazole or other PPIs."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "ondansetron": {
    "name": "Ondansetron (Zofran)",
    "genericName": "Ondansetron",
    "brandNames": ["Zofran", "Zofran ODT", "Zuplenz (film)"],
    "category": "Antiemetic",
    "drugClass": "Serotonin 5-HT3 Receptor Antagonist",
    "indications": "Prevention of nausea and vomiting associated with cancer chemotherapy and radiation. Prevention and treatment of postoperative nausea and vomiting. (Off-label): Hyperemesis gravidarum (severe N/V in pregnancy).",
    "moaSteps": [
      "Ondansetron is a selective serotonin 5-HT3 receptor antagonist.",
      "Chemotherapy and other triggers can cause the release of serotonin from cells in the gut, which activates 5-HT3 receptors on vagal nerves, triggering the vomiting reflex.",
      "Ondansetron blocks these 5-HT3 receptors both peripherally (in the gut) and centrally (in the brain's chemoreceptor trigger zone), effectively preventing nausea and vomiting."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Bioavailability ~60% (first-pass metabolism).",
      "distribution": "Widely distributed. Moderately protein-bound (~70-76%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4, CYP1A2, and CYP2D6.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~3-6 hours."
    },
    "dose": "Chemo (IV): 0.15 mg/kg IV or 16 mg IV single dose. (PO): 8-24 mg PO 30 min before chemo. Post-op (PO): 16 mg PO 1 hour before anesthesia.",
    "adverseEffects": {
      "common": ["Headache", "constipation", "diarrhea", "dizziness", "fatigue."],
      "serious": ["QT prolongation and Torsades de Pointes", "serotonin syndrome", "severe hypersensitivity reactions."]
    },
    "precautions": [
      "Can cause dose-dependent QT prolongation, increasing the risk of Torsades de Pointes. Avoid single IV doses >16 mg.",
      "Use with caution in patients with or at risk for QT prolongation (e.g., electrolyte imbalances, heart failure).",
      "Risk of Serotonin Syndrome when used with other serotonergic agents (e.g., SSRIs).",
      "Use with caution in patients with severe hepatic impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with apomorphine (causes severe hypotension)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "opium": {
    "name": "Opium (Paregoric)",
    "genericName": "Opium Tincture / Paregoric",
    "brandNames": ["Paregoric"],
    "category": "Antidiarrheal, Analgesic",
    "drugClass": "Opioid (Schedule II/III)",
    "indications": "Symptomatic treatment of severe diarrhea. (Rarely used). Treatment of neonatal opioid withdrawal syndrome (NOWS).",
    "moaSteps": [
      "Opium is a mixture of alkaloids derived from the poppy plant, including morphine, codeine, and papaverine.",
      "It acts as an opioid agonist, primarily binding to mu-opioid receptors in the GI tract.",
      "This action increases smooth muscle tone, decreases GI motility and propulsion, and reduces fluid secretion, leading to a potent antidiarrheal effect.",
      "It also has central analgesic and sedative effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the liver (e.g., morphine component).",
      "excretion": "Excreted in urine."
    },
    "dose": "Diarrhea (Tincture): 0.6 mL (equiv. to 6 mg morphine) PO 4 times daily.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "nausea", "vomiting", "constipation", "dizziness."],
      "serious": ["Respiratory depression", "abuse, addiction, and overdose", "paralytic ileus", "severe hypotension."]
    },
    "precautions": [
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse.",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "High risk of dependence and abuse. Use is highly restricted.",
      "Risk of severe constipation and paralytic ileus."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "paralytic ileus",
      "diarrhea caused by toxins (until toxin is cleared)."
    ],
    "pregnancyCategory": "Category C. Can cause neonatal opioid withdrawal.",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "orlistat": {
    "name": "Orlistat (Xenical, Alli)",
    "genericName": "Orlistat",
    "brandNames": ["Xenical (Rx)", "Alli (OTC)"],
    "category": "Weight Loss Agent",
    "drugClass": "Lipase Inhibitor",
    "indications": "Adjunct to a reduced-calorie diet for obesity management (Xenical: BMI 30 or 27 with risk factors. Alli: BMI 25).",
    "moaSteps": [
      "Orlistat is a reversible inhibitor of gastric and pancreatic lipases.",
      "These enzymes are essential for breaking down dietary fats (triglycerides) into absorbable free fatty acids.",
      "By inhibiting these lipases, orlistat prevents the digestion and absorption of ~25-30% of dietary fat.",
      "The undigested fat is then excreted in the feces, leading to a caloric deficit and weight loss."
    ],
    "pharmacokinetics": {
      "absorption": "Minimally absorbed systemically. It acts locally in the GI tract.",
      "distribution": "Acts locally in the gut.",
      "metabolism": "Metabolized within the GI wall.",
      "excretion": "Excreted primarily in feces (as unchanged drug)."
    },
    "dose": "Rx (Xenical): 120 mg PO 3 times daily, during or up to 1 hour after each main meal containing fat. OTC (Alli): 60 mg PO 3 times daily.",
    "adverseEffects": {
      "common": ["Oily spotting", "flatus with discharge (oily gas)", "fecal urgency", "fatty/oily stools (steatorrhea)", "fecal incontinence.", "abdominal discomfort."],
      "serious": ["Severe liver injury (rare)", "kidney stones (calcium oxalate)", "malabsorption of fat-soluble vitamins."]
    },
    "precautions": [
      "GI side effects are very common and related to the amount of fat in the diet. Adhering to a low-fat diet reduces these effects.",
      "Can interfere with the absorption of fat-soluble vitamins (A, D, E, K). A multivitamin supplement should be taken at least 2 hours apart.",
      "May interfere with the absorption of other drugs (e.g., levothyroxine, cyclosporine). Separate doses.",
      "Rare cases of severe liver injury have been reported."
    ],
    "contraindications": [
      "Hypersensitivity",
      "chronic malabsorption syndrome",
      "cholestasis",
      "**Pregnancy (Category X)**."
    ],
    "pregnancyCategory": "Category X. Weight loss offers no benefit in pregnancy.",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "oseltamivir": {
    "name": "Oseltamivir (Tamiflu)",
    "genericName": "Oseltamivir",
    "brandNames": ["Tamiflu"],
    "category": "Antiviral",
    "drugClass": "Neuraminidase Inhibitor",
    "indications": "Treatment of acute, uncomplicated influenza A and B in patients symptomatic for no more than 2 days. Prophylaxis (prevention) of influenza.",
    "moaSteps": [
      "Oseltamivir is a prodrug, hydrolyzed in the liver to its active form, oseltamivir carboxylate.",
      "The active metabolite is a selective inhibitor of the influenza virus neuraminidase enzyme.",
      "Neuraminidase is an enzyme on the surface of the virus that is essential for viral replication.",
      "It cleaves sialic acid, allowing newly formed viral particles to be released from the infected cell.",
      "By blocking neuraminidase, oseltamivir 'traps' the virus on the cell surface, preventing its release and spread to other cells."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally (prodrug). Bioavailability ~75%.",
      "distribution": "Widely distributed. Low protein binding.",
      "metabolism": "Prodrug is extensively hydrolyzed in the liver to its active form.",
      "excretion": "Active form is excreted unchanged in the urine. Half-life is ~6-10 hours."
    },
    "dose": "Treatment: 75 mg PO twice daily for 5 days. Prophylaxis: 75 mg PO once daily for 10 days.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "headache", "diarrhea."],
      "serious": ["Neuropsychiatric events (e.g., delirium, hallucinations, confusion, abnormal behavior)", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "Must be initiated within 48 hours of symptom onset to be effective for treatment.",
      "Taking with food may reduce nausea and vomiting.",
      "Neuropsychiatric events (confusion, delirium) have been reported, primarily in pediatric patients.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to oseltamivir."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "oxaliplatin": {
    "name": "Oxaliplatin (Eloxatin)",
    "genericName": "Oxaliplatin",
    "brandNames": ["Eloxatin"],
    "category": "Antineoplastic Agent",
    "drugClass": "Platinum-based Chemotherapy Agent",
    "indications": "Treatment of advanced colorectal cancer, usually in combination with 5-fluorouracil (5-FU) and leucovorin (FOLFOX regimen).",
    "moaSteps": [
      "Oxaliplatin is a platinum-based alkylating agent.",
      "It is converted to active forms that bind to DNA.",
      "It forms both intra- and inter-strand DNA cross-links.",
      "These cross-links block DNA replication and transcription, leading to cell cycle arrest and apoptosis (cell death)."
    ],
    "pharmacokinetics": {
      "absorption": "Administered as an IV infusion.",
      "distribution": "Widely distributed. Highly bound to plasma proteins (>90%).",
      "metabolism": "Rapidly biotransformed (non-enzymatically) to active and inactive forms.",
      "excretion": "Excreted primarily in urine."
    },
    "dose": "Varies by protocol, e.g., 85 mg/m IV infusion over 2 hours, repeated every 2 weeks.",
    "adverseEffects": {
      "common": ["Peripheral neuropathy", "nausea", "vomiting", "diarrhea", "myelosuppression (neutropenia, anemia)", "fatigue."],
      "serious": ["Severe peripheral neuropathy (acute and chronic)", "anaphylaxis", "pulmonary fibrosis", "hepatotoxicity."]
    },
    "precautions": [
      "BOXED WARNING (Anaphylaxis): Serious, fatal anaphylactic reactions can occur. Must be administered in a setting equipped to manage anaphylaxis.",
      "**Peripheral Neuropathy:** A dose-limiting toxicity. Can be acute (transient, cold-exacerbated numbness/tingling) or chronic (persistent, sensory loss).",
      "Patients must avoid exposure to cold (e.g., cold drinks, cold air) during and after infusion to prevent acute neuropathy.",
      "Monitor CBC and LFTs."
    ],
    "contraindications": [
      "Hypersensitivity to oxaliplatin or other platinum-containing compounds."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "oxandrolone": {
    "name": "Oxandrolone (Oxandrin)",
    "genericName": "Oxandrolone",
    "brandNames": ["Oxandrin"],
    "category": "Anabolic Steroid",
    "drugClass": "Anabolic Androgenic Steroid (Schedule III)",
    "indications": "Adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma. Relief of bone pain associated with osteoporosis.",
    "moaSteps": [
      "Oxandrolone is a synthetic, oral anabolic-androgenic steroid.",
      "It binds to androgen receptors in target tissues (e.g., muscle, bone).",
      "This action promotes protein synthesis (anabolism) and inhibits protein breakdown (catabolism).",
      "This results in increased muscle mass and bone density. It has high anabolic activity and low androgenic (masculinizing) activity."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine. Half-life is ~9-13 hours."
    },
    "dose": "2.5-20 mg/day PO in 2-4 divided doses.",
    "adverseEffects": {
      "common": ["(In males) Gynecomastia, decreased libido.", "(In females) Virilization (acne, hirsutism, voice deepening), irregular menses."],
      "serious": ["Hepatotoxicity (peliosis hepatis, liver tumors)", "hyperlipidemia (decreased HDL, increased LDL)."]
    },
    "precautions": [
      "Risk of hepatotoxicity. Monitor LFTs.",
      "Can cause significant dyslipidemia. Monitor cholesterol.",
      "Risk of virilization in females.",
      "High potential for abuse."
    ],
    "contraindications": [
      "Hypersensitivity",
      "known or suspected prostate or breast cancer (in males)",
      "severe liver disease",
      "**Pregnancy (Category X)**."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "oxcarbazepine": {
    "name": "Oxcarbazepine (Trileptal)",
    "genericName": "Oxcarbazepine",
    "brandNames": ["Trileptal", "Oxtellar XR"],
    "category": "Antiepileptic",
    "drugClass": "Anticonvulsant",
    "indications": "Monotherapy or adjunctive therapy in the treatment of partial-onset seizures.",
    "moaSteps": [
      "Oxcarbazepine is a prodrug, rapidly converted to its active metabolite, monohydroxy derivative (MHD).",
      "Its mechanism is similar to carbamazepine. It blocks voltage-gated sodium channels, which stabilizes hyperexcited nerve membranes.",
      "This action inhibits the repetitive firing of neurons and prevents the spread of seizure activity.",
      "It also modulates voltage-gated calcium channels."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed (prodrug).",
      "distribution": "Widely distributed. MHD is moderately protein-bound (~40%).",
      "metabolism": "Rapidly metabolized to its active metabolite (MHD), which is then glucuronidated.",
      "excretion": "Excreted in urine as metabolites. Half-life of MHD is ~9 hours."
    },
    "dose": "Initial: 300 mg PO twice daily. Titrate up to a maintenance dose of 1200-2400 mg/day.",
    "adverseEffects": {
      "common": ["Dizziness", "somnolence", "headache", "ataxia", "nausea", "vomiting", "diplopia (double vision)."],
      "serious": ["Hyponatremia (low sodium)", "severe skin reactions (SJS/TEN)", "suicidal thoughts", "hypersensitivity reactions (DRESS)."]
    },
    "precautions": [
      "Can cause clinically significant hyponatremia. Monitor sodium levels, especially in at-risk patients.",
      "Risk of severe skin reactions (SJS/TEN). Patients with the **HLA-B*1502 allele** (common in Asian ancestry) are at high risk.",
      "Risk of suicidal thoughts and behaviors.",
      "Abrupt discontinuation can precipitate seizures. Taper dose slowly."
    ],
    "contraindications": [
      "Hypersensitivity to oxcarbazepine or carbamazepine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "oxybutynin": {
    "name": "Oxybutynin (Ditropan, Oxytrol)",
    "genericName": "Oxybutynin",
    "brandNames": ["Ditropan", "Ditropan XL (ER)", "Oxytrol (patch)", "Gelnique (gel)"],
    "category": "Antispasmodic, Urinary",
    "drugClass": "Anticholinergic, Antimuscarinic",
    "indications": "Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.",
    "moaSteps": [
      "Oxybutynin is a competitive antagonist of muscarinic receptors (anticholinergic).",
      "It blocks muscarinic receptors (primarily M2 and M3) on the bladder detrusor muscle.",
      "This action inhibits involuntary bladder contractions (spasms) and increases bladder capacity, thus reducing the urgency and frequency of urination.",
      "It also has direct antispasmodic effects on smooth muscle."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally, but high first-pass metabolism (bioavailability ~6%). Patch/gel provide continuous absorption and bypass first-pass.",
      "distribution": "Widely distributed. Highly protein-bound (>99%).",
      "metabolism": "Extensively metabolized in the liver (CYP3A4) to an active metabolite.",
      "excretion": "Excreted in urine as metabolites."
    },
    "dose": "IR: 5 mg PO 2-3 times daily. ER (XL): 5-10 mg PO once daily. Patch (Oxytrol): 1 patch applied twice weekly.",
    "adverseEffects": {
      "common": ["Dry mouth (xerostomia)", "constipation", "drowsiness", "dizziness", "blurred vision", "dry eyes."],
      "serious": ["Urinary retention", "heat prostration (heatstroke)", "angioedema", "psychosis", "confusion."]
    },
    "precautions": [
      "High anticholinergic burden; use with caution in the elderly (high risk of confusion, falls).",
      "Can cause significant drowsiness and blurred vision; caution against driving.",
      "Risk of heat prostration in hot environments (due to decreased sweating).",
      "Use with caution in patients with gastric retention, uncontrolled narrow-angle glaucoma, or BPH."
    ],
    "contraindications": [
      "Hypersensitivity",
      "urinary retention",
      "gastric retention",
      "uncontrolled narrow-angle glaucoma."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "oxycodone": {
    "name": "Oxycodone (Roxicodone, OxyContin)",
    "genericName": "Oxycodone",
    "brandNames": ["Roxicodone (IR)", "OxyContin (ER)", "Xtampza ER (ER)"],
    "category": "Analgesic, Opioid",
    "drugClass": "Opioid Analgesic (Schedule II)",
    "indications": "Management of moderate to severe pain (IR). Management of severe, continuous pain requiring long-term opioid treatment (ER).",
    "moaSteps": [
      "Oxycodone is a semi-synthetic opioid agonist.",
      "It binds to and activates mu-opioid receptors in the central nervous system (CNS).",
      "This activation mimics endorphins, causing potent analgesia, sedation, and euphoria.",
      "It also causes respiratory depression and constipation."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. High bioavailability (~60-87%).",
      "distribution": "Widely distributed.",
      "metabolism": "Extensively metabolized in the liver by CYP3A4 and CYP2D6 to active and inactive metabolites.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~3-5 hours."
    },
    "dose": "Highly individualized. IR: 5-15 mg PO every 4-6 hours. ER (OxyContin): 10-80 mg PO every 12 hours.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "dizziness", "nausea", "vomiting", "constipation", "pruritus (itching)."],
      "serious": ["Respiratory depression", "abuse, addiction, and overdose", "severe hypotension", "bradycardia."]
    },
    "precautions": [
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse.",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "BOXED WARNING (Neonatal Opioid Withdrawal): Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.",
      "BOXED WARNING (ER forms): Risk of medication errors, accidental ingestion. ER tablets must be swallowed whole, not crushed or chewed (causes dose-dumping).",
      "Avoid strong CYP3A4 inhibitors (can increase levels)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "acute or severe bronchial asthma",
      "paralytic ileus."
    ],
    "pregnancyCategory": "Category C. Can cause neonatal opioid withdrawal.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "oxytocin": {
    "name": "Oxytocin (Pitocin)",
    "genericName": "Oxytocin",
    "brandNames": ["Pitocin"],
    "category":"Labor and Delivery Agent",
    "drugClass": "Uterine Stimulant, Endogenous Hormone",
    "indications": "Induction of labor at term. Augmentation of dysfunctional labor. Control of postpartum bleeding (hemorrhage).",
    "moaSteps": [
      "Oxytocin is a synthetic version of the endogenous hormone produced by the posterior pituitary.",
      "It binds to oxytocin receptors on the smooth muscle of the uterus.",
      "This action stimulates rhythmic uterine contractions, increasing in frequency and force.",
      "It also causes milk 'let-down' (ejection) by contracting myoepithelial cells in the breast (not an indication for the drug)."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV. Not effective orally (destroyed in GI tract).",
      "distribution": "Distributes to extracellular fluid.",
      "metabolism": "Rapidly metabolized in the liver and kidneys.",
      "excretion": "Excreted in urine. Very short half-life (~1-6 minutes)."
    },
    "dose": "Labor Induction: 0.5-2 milliunits/min IV infusion, titrated slowly every 30-60 min. Postpartum: 10 units IM or 10-40 units in IV infusion.",
    "adverseEffects": {
      "common": ["(Fetal) Bradycardia, distress.", "(Maternal) Nausea, vomiting, headache."],
      "serious": ["(Fetal) Hypoxia, brain damage, death.", "(Maternal) Uterine hyperstimulation/tetany", "uterine rupture", "severe water intoxication (antidiuretic effect at high doses)."]
    },
    "precautions": [
      "BOXED WARNING: Must be administered by trained personnel in a hospital setting with fetal and maternal monitoring. Do not use for elective labor induction.",
      "Can cause uterine hyperstimulation (contractions that are too long or too frequent), which can lead to fetal distress or uterine rupture.",
      "High doses can have an antidiuretic effect (similar to vasopressin), leading to water intoxication and hyponatremia."
    ],
    "contraindications": [
      "Hypersensitivity",
      "cases where vaginal delivery is contraindicated (e.g., placenta previa, cord prolapse, active genital herpes)",
      "fetal distress",
      "uterine hypertonicity."
    ],
    "pregnancyCategory": "Not applicable (used during labor).",
    "lactationInfo": "Compatible."
  },"pantoprazole": {
    "name": "Pantoprazole (Protonix)",
    "genericName": "Pantoprazole",
    "brandNames": ["Protonix"],
    "category": "Antiulcer Agent",
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "indications": "Treatment of GERD. Healing of erosive esophagitis. Treatment of hypersecretory conditions (e.g., Zollinger-Ellison).",
    "moaSteps": [
      "Pantoprazole is a proton pump inhibitor (PPI).",
      "It is a prodrug that is activated in the acidic environment of the gastric parietal cells.",
      "The active form irreversibly blocks the H+/K+-ATPase enzyme system (the 'proton pump').",
      "This is the final step in gastric acid secretion.",
      "It suppresses basal and stimulated gastric acid secretion, leading to a profound and long-lasting reduction of stomach acid."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~77%. Food delays absorption.",
      "distribution": "Highly protein-bound (~98%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP2C19.",
      "excretion": "Excreted in urine as metabolites. Short half-life (~1 hour), but long duration of action."
    },
    "dose": "GERD: 40 mg PO once daily. Take 30-60 minutes before a meal.",
    "adverseEffects": {
      "common": ["Headache", "diarrhea", "nausea", "abdominal pain", "flatulence."],
      "serious": ["Clostridioides difficile-associated diarrhea (CDAD)", "bone fractures (long-term use)", "hypomagnesemia (long-term use)", "Vitamin B12 deficiency (long-term use)."]
    },
    "precautions": [
      "PPI use is associated with an increased risk of *C. difficile*-associated diarrhea.",
      "Long-term use (>1 year) may be associated with an increased risk of osteoporosis-related bone fractures.",
      "Long-term use can lead to hypomagnesemia and vitamin B12 deficiency.",
      "May decrease the effectiveness of clopidogrel (CYP2C19 interaction)."
    ],
    "contraindications": [
      "Hypersensitivity to pantoprazole or other PPIs."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "paracetamol": {
    "name": "Paracetamol (Tylenol, Panadol)",
    "genericName": "Acetaminophen (Paracetamol)",
    "brandNames": ["Tylenol", "Panadol", "Mapap", "Ofirmev (IV)"],
    "category": "Analgesic, Antipyretic",
    "drugClass": "Analgesic (Non-opioid)",
    "indications": "Treatment of mild to moderate pain. Treatment of fever.",
    "moaSteps": [
      "The exact mechanism is not fully understood.",
      "It is thought to inhibit prostaglandin synthesis, but primarily in the central nervous system (CNS).",
      "This central action is believed to be responsible for its analgesic (pain-relieving) and antipyretic (fever-reducing) effects.",
      "It has very weak anti-inflammatory effects in peripheral tissues."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and almost completely absorbed orally.",
      "distribution": "Widely distributed. Variable protein binding.",
      "metabolism": "Extensively metabolized in the liver via glucuronidation and sulfation. A small fraction is metabolized by CYP2E1 to a toxic metabolite, NAPQI.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~2-3 hours."
    },
    "dose": "Adults: 325-650 mg PO every 4-6 hours, or 1000 mg PO every 6 hours. **Max 4000 mg/day from all sources.**",
    "adverseEffects": {
      "common": ["Generally well-tolerated at therapeutic doses. Nausea, rash (rare)."],
      "serious": ["Hepatotoxicity (liver failure) with overdose", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Can cause severe, sometimes fatal, liver injury, especially with doses >4000 mg/day or with concomitant alcohol use.",
      "Advise patients to check all OTC and prescription products for acetaminophen content to avoid accidental overdose.",
      "Use with caution in patients with liver disease or chronic alcohol use.",
      "Antidote for overdose: N-acetylcysteine (NAC)."
    ],
    "contraindications": [
      "Hypersensitivity to acetaminophen",
      "severe active liver disease."
    ],
    "pregnancyCategory": "Category C (but widely considered safe).",
    "lactationInfo": "Compatible."
  },
  "paroxetine": {
    "name": "Paroxetine (Paxil, Brisdelle)",
    "genericName": "Paroxetine",
    "brandNames": ["Paxil", "Paxil CR", "Pexeva", "Brisdelle"],
    "category": "Antidepressant, Anxiolytic",
    "drugClass": "Selective Serotonin Reuptake Inhibitor (SSRI)",
    "indications": "Treatment of major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder, and generalized anxiety disorder (GAD). (Brisdelle): Treatment of moderate to severe hot flashes.",
    "moaSteps": [
      "Paroxetine is a highly potent and selective serotonin reuptake inhibitor (SSRI).",
      "It blocks the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane.",
      "This action increases the concentration of serotonin in the synaptic cleft, enhancing serotonergic neurotransmission.",
      "It has weak effects on norepinephrine reuptake and significant anticholinergic effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. CR formulation is controlled-release.",
      "distribution": "Widely distributed. Highly protein-bound (~95%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP2D6.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~21 hours."
    },
    "dose": "MDD: 20-50 mg PO once daily. Panic Disorder: 10-60 mg PO once daily.",
    "adverseEffects": {
      "common": ["Nausea", "headache", "somnolence", "insomnia", "sexual dysfunction (high incidence)", "dry mouth", "constipation", "sweating."],
      "serious": ["Suicidal thoughts and behaviors", "serotonin syndrome", "severe withdrawal symptoms", "hyponatremia."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults.",
      "**Contraindicated in Pregnancy (Category D).** Can cause congenital malformations, particularly cardiac defects.",
      "High risk of severe, unpleasant withdrawal symptoms (dizziness, nausea, paresthesia). Must be tapered very slowly.",
      "Potent inhibitor of CYP2D6, leading to many drug interactions.",
      "High incidence of sexual side effects."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (within 14 days)",
      "concomitant use with thioridazine or pimozide",
      "**Pregnancy (Category D)**."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "penicillin-v": {
    "name": "Penicillin V (Pen-VK)",
    "genericName": "Penicillin V Potassium",
    "brandNames": ["Pen-VK", "Veetids"],
    "category": "Antibiotic",
    "drugClass": "Penicillin-class Antibiotic (Natural Penicillin)",
    "indications": "Treatment of mild to moderate infections caused by susceptible strains of bacteria, including strep throat (streptococcal pharyngitis), skin infections (e.g., cellulitis), and rheumatic fever prophylaxis.",
    "moaSteps": [
      "Penicillin V is a natural penicillin (a beta-lactam antibiotic).",
      "It inhibits the final transpeptidation step of peptidogylcan synthesis in bacterial cell walls.",
      "It binds to and inactivates penicillin-binding proteins (PBPs), which are enzymes responsible for cross-linking the cell wall.",
      "This inhibition of cell wall synthesis leads to cell lysis and death (bactericidal effect)."
    ],
    "pharmacokinetics": {
      "absorption": "Stable in gastric acid. Well absorbed orally (bioavailability ~60-75%). Food decreases absorption.",
      "distribution": "Widely distributed. Moderately protein-bound (~80%).",
      "metabolism": "Partially metabolized in the liver.",
      "excretion": "Excreted primarily unchanged in the urine. Short half-life (~30-60 minutes)."
    },
    "dose": "Strep Throat: 250 mg PO 4 times daily or 500 mg PO twice daily for 10 days.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "rash", "black hairy tongue."],
      "serious": ["Anaphylaxis (severe allergic reaction)", "Stevens-Johnson syndrome (SJS)", "Clostridioides difficile-associated diarrhea (CDAD)."]
    },
    "precautions": [
      "Risk of severe hypersensitivity reactions (anaphylaxis). Ask about penicillin allergy before prescribing.",
      "Cross-sensitivity with other beta-lactams (e.g., cephalosporins) is possible.",
      "Take on an empty stomach (1 hour before or 2 hours after meals) for best absorption."
    ],
    "contraindications": [
      "History of serious hypersensitivity (e.g., anaphylaxis) to any penicillin."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; compatible."
  },
  "pentobarbital": {
    "name": "Pentobarbital (Nembutal)",
    "genericName": "Pentobarbital",
    "brandNames": ["Nembutal"],
    "category": "Sedative-Hypnotic, Anticonvulsant",
    "drugClass": "Barbiturate (Short-acting) (Schedule II)",
    "indications": "Sedative/hypnotic for short-term treatment of insomnia. Preanesthetic sedation. Emergency treatment of seizures (e.g., status epilepticus).",
    "moaSteps": [
      "Pentobarbital is a short-acting barbiturate.",
      "It is a positive allosteric modulator of the GABA-A receptor.",
      "It binds to the barbiturate site, enhancing the effect of the inhibitory neurotransmitter GABA.",
      "It increases the *duration* of chloride channel opening (distinct from benzodiazepines, which increase frequency).",
      "At high doses, it can directly open the chloride channel, leading to profound CNS depression (sedation, anesthesia, coma, respiratory arrest)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. Also given IV/IM.",
      "distribution": "Widely distributed, crosses blood-brain barrier rapidly.",
      "metabolism": "Extensively metabolized in the liver.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~15-50 hours."
    },
    "dose": "Sedation: 20-40 mg PO 2-4 times daily. Hypnotic: 100 mg PO at bedtime.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "lethargy", "dizziness", "hangover effect", "nausea.", "vomiting."],
      "serious": ["Respiratory depression", "abuse, addiction, and overdose (high risk)", "hypotension", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "High potential for abuse and dependence (Schedule II).",
      "High risk of fatal overdose, especially with alcohol or other CNS depressants. Has a narrow therapeutic index.",
      "Can cause severe respiratory depression and hypotension.",
      "Potent inducer of CYP enzymes, causing many drug interactions.",
      "Abrupt withdrawal can be life-threatening."
    ],
    "contraindications": [
      "Hypersensitivity to barbiturates",
      "marked hepatic impairment",
      "history of porphyria",
      "severe respiratory disease."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "perphenazine": {
    "name": "Perphenazine (Trilafon)",
    "genericName": "Perphenazine",
    "brandNames": ["Trilafon"],
    "category": "Antipsychotic, Antiemetic",
    "drugClass": "Typical Antipsychotic (1st Generation), Phenothiazine",
    "indications": "Treatment of schizophrenia. Management of severe nausea and vomiting.",
    "moaSteps": [
      "Perphenazine is a phenothiazine-class typical antipsychotic.",
      "It primarily works by non-selectively blocking postsynaptic dopamine D2 receptors in the mesolimbic pathway of the brain, reducing positive symptoms of psychosis.",
      "Its antiemetic effect is due to blocking D2 receptors in the chemoreceptor trigger zone (CTZ).",
      "It also has moderate anticholinergic and potent alpha-1 blocking effects."
    ],
    "pharmacokinetics": {
      "absorption": "Variable oral absorption. High first-pass metabolism.",
      "distribution": "Widely distributed, crosses blood-brain barrier. Highly protein-bound.",
      "metabolism": "Extensively metabolized in the liver (CYP2D6).",
      "excretion": "Excreted in urine and feces. Half-life is ~9-12 hours."
    },
    "dose": "Schizophrenia: 4-16 mg PO 2-4 times daily.",
    "adverseEffects": {
      "common": ["Drowsiness", "dizziness", "dry mouth", "constipation", "orthostatic hypotension", "extrapyramidal symptoms (EPS)."],
      "serious": ["Tardive Dyskinesia (TD)", "Neuroleptic Malignant Syndrome (NMS)", "agranulocytosis", "QT prolongation."]
    },
    "precautions": [
      "BOXED WARNING (Elderly with Dementia): Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death.",
      "High risk of Extrapyramidal Symptoms (EPS).",
      "Risk of Tardive Dyskinesia (TD), which may be irreversible.",
      "Risk of Neuroleptic Malignant Syndrome (NMS)."
    ],
    "contraindications": [
      "Hypersensitivity to phenothiazines",
      "severe CNS depression",
      "coma",
      "bone marrow suppression."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "phenazopyridine": {
    "name": "Phenazopyridine (Pyridium, Azo)",
    "genericName": "Phenazopyridine",
    "brandNames": ["Pyridium (Rx)", "Azo Urinary Pain Relief (OTC)", "Uricalm"],
    "category": "Analgesic, Urinary",
    "drugClass": "Urinary Tract Analgesic",
    "indications": "Symptomatic relief of pain, burning, urgency, and frequency associated with urinary tract infections (UTIs) or other urinary tract irritation.",
    "moaSteps": [
      "Phenazopyridine is a urinary tract analgesic.",
      "Its mechanism of action is not fully known.",
      "It is an azo dye that exerts a topical analgesic or local anesthetic effect on the mucosa of the urinary tract.",
      "It does *not* treat the underlying infection (it is not an antibiotic)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Distributes to urinary tract.",
      "metabolism": "Metabolized in the liver and other tissues.",
      "excretion": "Excreted in the urine (as metabolites and unchanged drug)."
    },
    "dose": "Rx: 200 mg PO 3 times daily after meals. OTC: 95-97.5 mg PO 3 times daily. **Use for 2 days maximum.**",
    "adverseEffects": {
      "common": ["Headache", "dizziness", "stomach cramps", "reddish-orange discoloration of urine (harmless)."],
      "serious": ["Hemolytic anemia (in G6PD deficiency)", "methemoglobinemia", "hepatotoxicity", "renal toxicity (rare)."]
    },
    "precautions": [
      "**Causes a reddish-orange discoloration of the urine,** which is harmless but can stain clothing and contact lenses.",
      "Use should be limited to 2 days when taken with an antibiotic for a UTI.",
      "Use with caution in patients with G6PD deficiency (risk of hemolytic anemia).",
      "Can cause a yellowish discoloration of the skin or sclera (eyes) if it accumulates due to renal impairment; discontinue if this occurs."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe renal impairment (glomerulonephritis)",
      "severe hepatitis."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "phenelzine": {
    "name": "Phenelzine (Nardil)",
    "genericName": "Phenelzine",
    "brandNames": ["Nardil"],
    "category": "Antidepressant",
    "drugClass": "Monoamine Oxidase Inhibitor (MAOI)",
    "indications": "Treatment of atypical, nonendogenous, or 'neurotic' depression. Used for treatment-resistant depression.",
    "moaSteps": [
      "Phenelzine is an irreversible, non-selective monoamine oxidase inhibitor (MAOI).",
      "It inhibits the MAO-A and MAO-B enzymes, which are responsible for breaking down neurotransmitters.",
      "This action increases the synaptic concentrations of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) in the brain, which is thought to be responsible for its antidepressant effect.",
      "The effect is long-lasting as the enzyme must be re-synthesized."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "Widely distributed.",
      "metabolism": "Extensively metabolized in the liver (acetylation).",
      "excretion": "Excreted in urine as metabolites. Short half-life (~11 hours) but long duration of effect."
    },
    "dose": "15 mg PO 3 times daily. Titrate up to max 60-90 mg/day.",
    "adverseEffects": {
      "common": ["Orthostatic hypotension (very common)", "dizziness", "headache", "drowsiness", "dry mouth", "constipation", "weight gain.", "sexual dysfunction."],
      "serious": ["Hypertensive Crisis", "serotonin syndrome", "hepatotoxicity", "suicidal thoughts."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults.",
      "**Hypertensive Crisis:** A potentially fatal reaction. **Patient must avoid all tyramine-rich foods** (e.g., aged cheeses, cured meats, tap beer, soy sauce).",
      "**Serotonin Syndrome:** A potentially fatal reaction. **Contraindicated with many drugs**, especially SSRIs, SNRIs, TCAs, triptans, and meperidine. Requires a 2-week washout period (5 weeks for fluoxetine).",
      "High risk of orthostatic hypotension.",
      "Risk of hepatotoxicity."
    ],
    "contraindications": [
      "Hypersensitivity",
      "pheochromocytoma",
      "severe hepatic or renal impairment",
      "**concomitant use of sympathomimetics, SSRIs, SNRIs, TCAs, and many other drugs**",
      "**inability to adhere to strict dietary restrictions**."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "phenobarbital": {
    "name": "Phenobarbital (Luminal)",
    "genericName": "Phenobarbital",
    "brandNames": ["Luminal", "Sezaby"],
    "category": "Antiepileptic, Sedative-Hypnotic",
    "drugClass": "Barbiturate (Long-acting) (Schedule IV)",
    "indications": "Treatment of tonic-clonic (grand mal) seizures, partial seizures, and status epilepticus. Short-term sedative.",
    "moaSteps": [
      "Phenobarbital is a long-acting barbiturate.",
      "It is a positive allosteric modulator of the GABA-A receptor.",
      "It binds to the barbiturate site, enhancing the effect of the inhibitory neurotransmitter GABA.",
      "It increases the *duration* of chloride channel opening, leading to hyperpolarization and CNS depression.",
      "It also has some inhibitory effects on glutamate (AMPA) receptors."
    ],
    "pharmacokinetics": {
      "absorption": "Slowly but completely absorbed orally.",
      "distribution": "Widely distributed. Moderately protein-bound (~45-60%).",
      "metabolism": "Partially metabolized in the liver by CYP2C9.",
      "excretion": "Excreted in urine (25% as unchanged drug). Very long half-life (~50-120 hours)."
    },
    "dose": "Seizures: 60-200 mg/day PO, often at bedtime. Status Epilepticus: 15-20 mg/kg IV.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "lethargy", "dizziness", "cognitive impairment ('brain fog')", "depression."],
      "serious": ["Respiratory depression", "abuse, addiction, and overdose", "severe skin reactions (SJS/TEN)", "hepatotoxicity."]
    },
    "precautions": [
      "Has potential for abuse and dependence (Schedule IV).",
      "Can cause significant sedation and cognitive impairment.",
      "Abrupt withdrawal can be life-threatening (can cause status epilepticus). Taper slowly.",
      "**Potent inducer of many CYP enzymes (e.g., 3A4, 2C9, 1A2)**, causing numerous significant drug interactions (e.g., reduces effectiveness of oral contraceptives, warfarin).",
      "Risk of respiratory depression, especially with alcohol."
    ],
    "contraindications": [
      "Hypersensitivity to barbiturates",
      "marked hepatic impairment",
      "history of porphyria",
      "severe respiratory disease."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "phentermine": {
    "name": "Phentermine (Adipex-P, Lomaira)",
    "genericName": "Phentermine",
    "brandNames": ["Adipex-P", "Lomaira"],
    "category": "Weight Loss Agent, Anorexiant",
    "drugClass": "Sympathomimetic Amine (Schedule IV)",
    "indications": "Short-term (a few weeks) adjunct to a reduced-calorie diet and exercise for obesity management (BMI 30 or 27 with risk factors).",
    "moaSteps": [
      "Phentermine is a sympathomimetic amine, similar in structure to amphetamine.",
      "It stimulates the release of norepinephrine and dopamine from nerve terminals in the hypothalamus.",
      "This action increases the concentration of these neurotransmitters, which suppresses appetite by acting on the satiety center in the brain."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Widely distributed, crosses blood-brain barrier.",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine. Half-life is ~20 hours."
    },
    "dose": "15-37.5 mg PO once daily in the morning.",
    "adverseEffects": {
      "common": ["Tachycardia (fast heart rate)", "palpitations", "hypertension", "restlessness", "insomnia", "dry mouth", "constipation."],
      "serious": ["Primary pulmonary hypertension (fatal)", "valvular heart disease", "psychosis", "abuse and dependence."]
    },
    "precautions": [
      "Risk of primary pulmonary hypertension and valvular heart disease. Do not use for longer than a few weeks.",
      "Has potential for abuse and dependence (Schedule IV).",
      "Can cause significant increases in blood pressure and heart rate. Monitor cardiovascular status.",
      "Can cause insomnia; take in the morning.",
      "Tolerance to the appetite-suppressing effect develops quickly."
    ],
    "contraindications": [
      "Hypersensitivity",
      "history of cardiovascular disease (e.g., coronary artery disease, stroke, uncontrolled hypertension)",
      "hyperthyroidism",
      "glaucoma",
      "agitated states",
      "history of drug abuse",
      "concomitant use with MAOIs (within 14 days)."
    ],
    "pregnancyCategory": "Category X. Weight loss offers no benefit in pregnancy.",
    "lactationInfo": "Not recommended."
  },
  "phenytoin": {
    "name": "Phenytoin (Dilantin)",
    "genericName": "Phenytoin",
    "brandNames": ["Dilantin", "Epanutin", "Phenytek"],
    "category": "Antiepileptic",
    "drugClass": "Anticonvulsant, Hydantoin",
    "indications": "Treatment of tonic-clonic (grand mal) seizures, partial seizures, and status epilepticus. Prevention of seizures following neurosurgery.",
    "moaSteps": [
      "Phenytoin is a non-sedating anticonvulsant.",
      "It primarily works by blocking voltage-gated sodium channels in their inactive state.",
      "This action stabilizes hyperexcited nerve membranes, inhibits the repetitive firing of neurons, and prevents the spread of seizure activity.",
      "It has no effect on normal neuronal activity."
    ],
    "pharmacokinetics": {
      "absorption": "Variable oral absorption. ER forms are slowly absorbed.",
      "distribution": "Widely distributed. Highly protein-bound (~90-95%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C9 and CYP2C19. **Metabolism is saturable (Michaelis-Menten kinetics).**",
      "excretion": "Excreted in urine as metabolites. Half-life is long and highly variable (~7-42 hours)."
    },
    "dose": "Requires loading dose. Maintenance: 100 mg PO 3 times daily or 300 mg ER PO once daily. **Requires therapeutic drug monitoring.**",
    "adverseEffects": {
      "common": ["Drowsiness", "dizziness", "ataxia (impaired coordination)", "nystagmus (involuntary eye movement).", "Gingival hyperplasia (gum overgrowth)."],
      "serious": ["Severe skin reactions (SJS/TEN)", "hepatotoxicity", "agranulocytosis", "drug-induced lupus", "Purple Glove Syndrome (IV)."]
    },
    "precautions": [
      "BOXED WARNING (Cardiovascular Risk - IV): IV fosphenytoin/phenytoin should not exceed 50 mg/min (phenytoin) due to risk of severe hypotension and cardiac arrhythmias.",
      "**Saturable (Zero-Order) Kinetics:** Small increases in dose can lead to very large, toxic increases in serum concentration. Dose adjustments must be small.",
      "**Requires therapeutic drug monitoring** (Therapeutic range: 10-20 mcg/mL).",
      "Risk of severe skin reactions (SJS/TEN). High risk in patients with the **HLA-B*1502 allele**.",
      "Can cause gingival hyperplasia; good dental hygiene is critical.",
      "**Potent inducer of many CYP enzymes (e.g., 3A4, 2C9)**, causing numerous drug interactions."
    ],
    "contraindications": [
      "Hypersensitivity",
      "history of hepatotoxicity from phenytoin",
      "severe bradycardia or heart block."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "pioglitazone": {
    "name": "Pioglitazone (Actos)",
    "genericName": "Pioglitazone",
    "brandNames": ["Actos"],
    "category": "Antidiabetic",
    "drugClass": "Thiazolidinedione (TZD)",
    "indications": "Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.",
    "moaSteps": [
      "Pioglitazone is a thiazolidinedione (TZD).",
      "It is a potent and selective agonist for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma).",
      "PPAR-gamma receptors are found primarily in adipose (fat) tissue, muscle, and liver.",
      "Activating PPAR-gamma regulates the transcription of genes involved in glucose and lipid metabolism.",
      "The primary effect is to increase insulin sensitivity in peripheral tissues, enhancing glucose uptake."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Food delays absorption.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C8 and CYP3A4 to active metabolites.",
      "excretion": "Excreted in feces (via bile) as metabolites. Half-life is ~3-7 hours."
    },
    "dose": "15-45 mg PO once daily.",
    "adverseEffects": {
      "common": ["Weight gain", "edema (fluid retention)", "upper respiratory tract infection", "headache.", "myalgia."],
      "serious": ["Congestive Heart Failure (CHF)", "hepatotoxicity", "macular edema", "increased risk of bone fractures (especially in women)."]
    },
    "precautions": [
      "BOXED WARNING (Congestive Heart Failure): Can cause or exacerbate congestive heart failure. Monitor for signs (e.g., rapid weight gain, edema, shortness of breath).",
      "Can cause significant fluid retention and weight gain.",
      "Increased risk of bone fractures.",
      "May be associated with an increased risk of bladder cancer (data is conflicting)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "NYHA Class III or IV (moderate to severe) heart failure."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "piperacillin-tazobactam": {
    "name": "Piperacillin/Tazobactam (Zosyn)",
    "genericName": "Piperacillin and Tazobactam",
    "brandNames": ["Zosyn"],
    "category": "Antibiotic",
    "drugClass": "Penicillin-class Antibiotic / Beta-Lactamase Inhibitor Combination",
    "indications": "Treatment of moderate to severe infections caused by susceptible bacteria, including intra-abdominal infections, skin infections, pneumonia, and sepsis. Has broad-spectrum activity, including against Pseudomonas aeruginosa.",
    "moaSteps": [
      "This is a combination product:",
      "1. **Piperacillin:** An extended-spectrum penicillin (a beta-lactam). It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis.",
      "2. **Tazobactam:** A beta-lactamase inhibitor. It has no significant antibiotic activity on its own.",
      "Tazobactam binds to and inhibits beta-lactamase enzymes produced by bacteria, which would otherwise destroy piperacillin. This 'protects' piperacillin and extends its spectrum of activity."
    ],
    "pharmacokinetics": {
      "absorption": "Administered as an IV infusion.",
      "distribution": "Widely distributed into tissues and fluids. Low protein binding (~30%).",
      "metabolism": "Piperacillin is partially metabolized. Tazobactam is metabolized to an inactive form.",
      "excretion": "Both are excreted unchanged in the urine. Half-life is ~0.7-1.2 hours."
    },
    "dose": "3.375 g (3 g piperacillin / 0.375 g tazobactam) IV every 6 hours, or 4.5 g IV every 6-8 hours. Requires dose adjustment in renal impairment.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "headache", "rash", "constipation."],
      "serious": ["Anaphylaxis", "severe skin reactions (SJS/TEN)", "myelosuppression (leukopenia, thrombocytopenia)", "C. difficile-associated diarrhea."]
    },
    "precautions": [
      "Risk of severe hypersensitivity reactions (anaphylaxis). Ask about penicillin allergy.",
      "Can cause myelosuppression (leukopenia, neutropenia) with prolonged use. Monitor CBC.",
      "Can cause C. difficile-associated diarrhea.",
      "Requires significant dose adjustment in renal impairment."
    ],
    "contraindications": [
      "History of serious hypersensitivity (e.g., anaphylaxis) to any penicillin, cephalosporin, or beta-lactamase inhibitor."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "piroxicam": {
    "name": "Piroxicam (Feldene)",
    "genericName": "Piroxicam",
    "brandNames": ["Feldene"],
    "category": "Anti-inflammatory, Analgesic",
    "drugClass": "Nonsteroidal Anti-inflammatory Drug (NSAID)",
    "indications": "Relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis.",
    "moaSteps": [
      "Piroxicam is an NSAID of the oxicam class.",
      "It inhibits cyclooxygenase (COX-1 and COX-2) enzymes, which blocks prostaglandin synthesis.",
      "This action provides anti-inflammatory, analgesic, and antipyretic effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Food delays absorption.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Extensively metabolized in the liver (CYP2C9).",
      "excretion": "Excreted in urine and feces as metabolites. Very long half-life (~50 hours)."
    },
    "dose": "20 mg PO once daily. Take with food.",
    "adverseEffects": {
      "common": ["Dyspepsia", "nausea", "abdominal pain", "dizziness", "headache.", "rash."],
      "serious": ["Gastrointestinal bleeding and ulceration", "cardiovascular thrombotic events (MI, stroke)", "hepatotoxicity", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "BOXED WARNING (CV Risk): Increased risk of serious cardiovascular thrombotic events (MI, stroke).",
      "BOXED WARNING (GI Risk): High risk of serious, potentially fatal GI events (bleeding, perforation). Risk is higher than with shorter-acting NSAIDs.",
      "BOXED WARNING (Skin Reactions): Risk of serious, fatal skin reactions (SJS/TEN).",
      "Due to long half-life, side effects may be delayed and prolonged.",
      "Risk of photosensitivity."
    ],
    "contraindications": [
      "Hypersensitivity to piroxicam or other NSAIDs",
      "history of asthma or urticaria after aspirin/NSAID use",
      "perioperative pain in the setting of CABG surgery."
    ],
    "pregnancyCategory": "Category C (D in 3rd trimester)",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "potassium-chloride": {
    "name": "Potassium Chloride (Klor-Con, K-Dur)",
    "genericName": "Potassium Chloride",
    "brandNames": ["Klor-Con", "K-Dur", "Micro-K", "K-Tab"],
    "category": "Electrolyte Supplement",
    "drugClass": "Electrolyte",
    "indications": "Treatment and prevention of hypokalemia (low potassium levels).",
    "moaSteps": [
      "Potassium is the primary intracellular cation.",
      "It is essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction (especially cardiac), and renal function.",
      "Potassium chloride supplements replace potassium, correcting or preventing deficiency."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. ER forms release slowly.",
      "distribution": "Primarily distributes into intracellular fluid.",
      "metabolism": "N/A",
      "excretion": "Excreted primarily in the urine."
    },
    "dose": "Varies. Prevention: 20 mEq/day PO. Treatment: 40-100 mEq/day PO in 2-4 divided doses.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "abdominal discomfort", "flatulence."],
      "serious": ["Hyperkalemia (high potassium)", "GI ulceration and bleeding (especially with tablets)."]
    },
    "precautions": [
      "Risk of hyperkalemia, which can be fatal (causes cardiac arrhythmias). Risk is higher in renal impairment or with ACE inhibitors, ARBs, or potassium-sparing diuretics.",
      "Monitor serum potassium levels regularly.",
      "ER tablets can cause GI ulceration or obstruction. **Must be swallowed whole, not crushed or chewed.**",
      "Take with meals and a full glass of water to reduce GI upset."
    ],
    "contraindications": [
      "Hyperkalemia",
      "severe renal impairment",
      "conditions that delay tablet passage through the GI tract (e.g., GI obstruction)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Compatible."
  },"pramipexole": {
    "name": "Pramipexole (Mirapex)",
    "genericName": "Pramipexole",
    "brandNames": ["Mirapex", "Mirapex ER"],
    "category": "Antiparkinsonian",
    "drugClass": "Dopamine Agonist",
    "indications": "Treatment of Parkinson's disease. Treatment of moderate to severe restless legs syndrome (RLS).",
    "moaSteps": [
      "Pramipexole is a non-ergot dopamine agonist.",
      "It has a high affinity for and selectively stimulates dopamine D2 and D3 receptors in the brain's striatum.",
      "By mimicking the action of dopamine, it helps to alleviate the motor symptoms of Parkinson's disease (which is caused by a dopamine deficiency).",
      "Its mechanism in RLS is less understood but is also thought to involve dopamine receptor stimulation."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High bioavailability (>90%). Food delays absorption.",
      "distribution": "Widely distributed. Low protein binding (~15%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~8-12 hours."
    },
    "dose": "Parkinson's: Initial 0.125 mg PO 3 times daily, titrate slowly. RLS: 0.125 mg PO once daily, 2-3 hours before bedtime.",
    "adverseEffects": {
      "common": ["Nausea", "drowsiness", "somnolence (including sudden 'sleep attacks')", "dizziness", "orthostatic hypotension", "confusion", "hallucinations."],
      "serious": ["Impulse control disorders (e.g., compulsive gambling, hypersexuality)", "hallucinations", "syncope", "worsening of RLS (augmentation)."]
    },
    "precautions": [
      "Can cause sudden onset of sleep ('sleep attacks') without warning. Caution against driving.",
      "Risk of orthostatic hypotension and syncope.",
      "Risk of hallucinations, especially in the elderly.",
      "Risk of impulse control disorders. Monitor for new, compulsive behaviors.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to pramipexole."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Inhibits prolactin; may interfere with lactation. Not recommended."
  },
  "prasugrel": {
    "name": "Prasugrel (Effient)",
    "genericName": "Prasugrel",
    "brandNames": ["Effient"],
    "category": "Antiplatelet",
    "drugClass": "Antiplatelet Agent, P2Y12 Inhibitor",
    "indications": "To reduce the risk of thrombotic cardiovascular events (e.g., stent thrombosis, MI) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).",
    "moaSteps": [
      "Prasugrel is a prodrug that is converted in the liver to its active metabolite.",
      "The active metabolite is an irreversible antagonist of the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface.",
      "By blocking the P2Y12 receptor, it prevents ADP from binding and activating the platelet.",
      "This inhibits platelet activation and aggregation for the life of the platelet (7-10 days)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (prodrug).",
      "distribution": "Active metabolite is highly protein-bound (~98%).",
      "metabolism": "Rapidly metabolized (by hydrolysis, then CYP enzymes) to its active metabolite.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life of active metabolite is ~7 hours."
    },
    "dose": "Loading dose: 60 mg PO once, as soon as possible. Maintenance: 10 mg PO once daily (with aspirin).",
    "adverseEffects": {
      "common": ["Bleeding (e.g., bruising, epistaxis)", "headache", "dizziness", "nausea."],
      "serious": ["Major, life-threatening, or fatal bleeding (e.g., intracranial, GI)", "thrombotic thrombocytopenic purpura (TTP)."]
    },
    "precautions": [
      "BOXED WARNING (Bleeding Risk): Can cause significant, sometimes fatal, bleeding. Do not use in patients with active bleeding or a history of TIA or stroke.",
      "BOXED WARNING (Use in Elderly): Risk of bleeding is higher in patients 75 years old. Generally not recommended.",
      "BOXED WARNING (Low Body Weight): Risk of bleeding is higher in patients < 60 kg. A lower maintenance dose (5 mg) may be needed.",
      "Do not use in patients likely to undergo urgent CABG surgery.",
      "Do not stop prematurely (risk of stent thrombosis)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active pathological bleeding",
      "**history of transient ischemic attack (TIA) or stroke**."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "pravastatin": {
    "name": "Pravastatin (Pravachol)",
    "genericName": "Pravastatin",
    "brandNames": ["Pravachol"],
    "category": "Antihyperlipidemic",
    "drugClass": "HMG-CoA Reductase Inhibitor (Statin)",
    "indications": "Adjunct to diet to lower elevated total cholesterol, LDL-C, and triglycerides. To reduce the risk of MI, stroke, and revascularization procedures.",
    "moaSteps": [
      "Pravastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis in the liver.",
      "This inhibition decreases the production of cholesterol in the liver.",
      "The liver compensates by increasing the number of LDL receptors on its surface, which enhances the uptake and clearance of LDL-C from the blood.",
      "This results in a reduction of LDL-C ('bad cholesterol') and total cholesterol."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. High first-pass metabolism (bioavailability ~17%).",
      "distribution": "Moderately protein-bound (~50%).",
      "metabolism": "Metabolized in the liver (not by CYP enzymes, but by other pathways).",
      "excretion": "Excreted in feces (via bile) and urine. Half-life is ~1.5-2 hours."
    },
    "dose": "10-80 mg PO once daily, usually at bedtime.",
    "adverseEffects": {
      "common": ["Headache", "myalgia (muscle pain)", "arthralgia (joint pain)", "diarrhea", "nausea."],
      "serious": ["Myopathy and Rhabdomyolysis (muscle breakdown)", "Hepatotoxicity (liver injury)."]
    },
    "precautions": [
      "Risk of myopathy and rhabdomyolysis. Advise patients to report unexplained muscle pain or weakness.",
      "Monitor liver function tests (LFTs) at baseline and as clinically indicated.",
      "Use with caution in patients with heavy alcohol use.",
      "Fewer CYP-mediated drug interactions than other statins (e.g., atorvastatin, simvastatin)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active liver disease",
      "**Pregnancy (Category X)**",
      "**Lactation**."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Contraindicated."
  },
  "prazosin": {
    "name": "Prazosin (Minipress)",
    "genericName": "Prazosin",
    "brandNames": ["Minipress"],
    "category": "Antihypertensive",
    "drugClass": "Alpha-1 Adrenergic Blocker",
    "indications": "Treatment of hypertension. (Off-label): Benign prostatic hyperplasia (BPH), PTSD-related nightmares.",
    "moaSteps": [
      "Prazosin is a selective, competitive antagonist of alpha-1 adrenergic receptors.",
      "It blocks alpha-1 receptors on vascular smooth muscle (both arterioles and veins).",
      "This action inhibits the vasoconstricting effect of norepinephrine, leading to vasodilation (widening of blood vessels).",
      "This results in a decrease in peripheral vascular resistance and a reduction in blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Variable oral absorption.",
      "distribution": "Widely distributed. Highly protein-bound (~92-97%).",
      "metabolism": "Extensively metabolized in the liver.",
      "excretion": "Excreted in feces (via bile). Half-life is ~2-3 hours."
    },
    "dose": "Hypertension: Initial 1 mg PO 2-3 times daily. Titrate slowly. (Nightmares): 1-10 mg PO at bedtime.",
    "adverseEffects": {
      "common": ["Dizziness", "headache", "drowsiness", "orthostatic hypotension", "palpitations.", "nausea."],
      "serious": ["First-dose phenomenon (severe orthostatic hypotension and syncope)", "reflex tachycardia."]
    },
    "precautions": [
      "**First-dose phenomenon:** Can cause significant orthostatic hypotension (a drop in blood pressure upon standing) and syncope (fainting), especially with the first dose.",
      "To minimize this, the first dose should be 1 mg and taken at bedtime.",
      "Can cause significant dizziness and drowsiness; caution against driving.",
      "Can cause floppy iris syndrome, which complicates cataract surgery."
    ],
    "contraindications": [
      "Hypersensitivity to prazosin or other quinazolines (e.g., doxazosin)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "prednisolone": {
    "name": "Prednisolone (Orapred, Prelone)",
    "genericName": "Prednisolone",
    "brandNames": ["Orapred", "Prelone", "Pediapred", "Omnipred (ophthalmic)"],
    "category": "Anti-inflammatory, Immunosuppressant",
    "drugClass": "Corticosteroid",
    "indications": "Treatment of various inflammatory, allergic, and autoimmune conditions (e.g., asthma, allergic reactions, rheumatoid arthritis).",
    "moaSteps": [
      "Prednisolone is the active metabolite of prednisone.",
      "It is a potent glucocorticoid.",
      "It binds to intracellular glucocorticoid receptors and modifies gene expression.",
      "It upregulates anti-inflammatory proteins and downregulates pro-inflammatory mediators (cytokines, prostaglandins).",
      "This results in potent anti-inflammatory, immunosuppressive, and anti-allergic effects."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and well absorbed orally.",
      "distribution": "Widely distributed. Protein binding is concentration-dependent.",
      "metabolism": "Metabolized in the liver (and is the active form of prednisone).",
      "excretion": "Excreted in urine as metabolites. Biologic half-life is 18-36 hours."
    },
    "dose": "Varies widely. 5-60 mg/day PO in single or divided doses.",
    "adverseEffects": {
      "common": ["(Short-term) Insomnia", "hyperglycemia", "increased appetite", "nervousness", "fluid retention.", "(Long-term) Cushing's syndrome, osteoporosis, immunosuppression."],
      "serious": ["Adrenal suppression (must taper off)", "severe infections", "psychosis", "peptic ulcer perforation", "osteonecrosis."]
    },
    "precautions": [
      "Prolonged use can cause HPA axis suppression. Dose must be tapered slowly.",
      "Can mask signs of infection and increase susceptibility.",
      "Monitor for hyperglycemia, hypertension, and psychiatric disturbances.",
      "Use with caution in patients with peptic ulcer disease or osteoporosis."
    ],
    "contraindications": [
      "Systemic fungal infections",
      "hypersensitivity",
      "administration of live vaccines (if receiving immunosuppressive doses)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "prednisone": {
    "name": "Prednisone (Deltasone)",
    "genericName": "Prednisone",
    "brandNames": ["Deltasone", "Rayos (delayed-release)"],
    "category": "Anti-inflammatory, Immunosuppressant",
    "drugClass": "Corticosteroid",
    "indications": "Treatment of various inflammatory, allergic, and autoimmune conditions (e.g., asthma, COPD exacerbation, allergic reactions, rheumatoid arthritis, poison ivy).",
    "moaSteps": [
      "Prednisone is a prodrug that is rapidly converted in the liver to its active metabolite, prednisolone.",
      "Prednisolone (a glucocorticoid) binds to intracellular receptors and modifies gene expression.",
      "It suppresses inflammation and the immune response by inhibiting pro-inflammatory mediators.",
      "This results in potent anti-inflammatory and immunosuppressive effects."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "Widely distributed.",
      "metabolism": "**Must be converted in the liver to active prednisolone.**",
      "excretion": "Excreted in urine as metabolites. Biologic half-life is 18-36 hours."
    },
    "dose": "Varies widely. 5-60 mg/day PO in single or divided doses. (e.g., 'steroid burst' 40 mg/day for 5 days).",
    "adverseEffects": {
      "common": ["(Short-term) Insomnia", "hyperglycemia", "increased appetite", "nervousness", "mood changes.", "(Long-term) Cushing's syndrome, osteoporosis, immunosuppression."],
      "serious": ["Adrenal suppression (must taper off)", "severe infections", "psychosis", "peptic ulcer perforation", "osteonecrosis."]
    },
    "precautions": [
      "Prolonged use can cause HPA axis suppression. Dose must be tapered slowly.",
      "Can mask signs of infection and increase susceptibility.",
      "Monitor for hyperglycemia, hypertension, and psychiatric disturbances.",
      "Ineffective in patients with severe liver failure (cannot convert to active form; use prednisolone instead)."
    ],
    "contraindications": [
      "Systemic fungal infections",
      "hypersensitivity",
      "administration of live vaccines (if receiving immunosuppressive doses)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk (as prednisolone); use with caution."
  },
  "pregabalin": {
    "name": "Pregabalin (Lyrica)",
    "genericName": "Pregabalin",
    "brandNames": ["Lyrica", "Lyrica CR"],
    "category": "Anticonvulsant, Analgesic",
    "drugClass": "GABA Analog (Schedule V)",
    "indications": "Management of neuropathic pain (e.g., diabetic peripheral neuropathy, postherpetic neuralgia). Management of fibromyalgia. Adjunctive therapy for partial-onset seizures.",
    "moaSteps": [
      "Pregabalin is a structural analog of the neurotransmitter GABA.",
      "Its mechanism is not fully understood. It does not bind to GABA receptors.",
      "It binds with high affinity to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS.",
      "This binding is thought to reduce the release of excitatory neurotransmitters (like glutamate and substance P), leading to anticonvulsant and analgesic (pain-relieving) effects."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High bioavailability (>90%). Not saturable (unlike gabapentin).",
      "distribution": "Widely distributed. Not protein-bound.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted entirely unchanged in the urine. Half-life is ~6.3 hours."
    },
    "dose": "Neuropathic Pain: Initial 50 mg PO 3 times daily. Titrate up to 100 mg 3 times daily. Max 300 mg/day (or 600 mg/day for some).",
    "adverseEffects": {
      "common": ["Dizziness", "somnolence (drowsiness)", "dry mouth", "peripheral edema", "blurred vision", "weight gain."],
      "serious": ["Angioedema", "suicidal thoughts and behaviors", "respiratory depression (especially with opioids)", "abuse and dependence."]
    },
    "precautions": [
      "Has potential for abuse and dependence (Schedule V).",
      "Can cause significant drowsiness and dizziness; caution against driving.",
      "Can cause peripheral edema and weight gain.",
      "Risk of serious, life-threatening respiratory depression when co-administered with CNS depressants like opioids.",
      "Abrupt discontinuation can cause withdrawal symptoms. Taper dose slowly.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to pregabalin."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "prochlorperazine": {
    "name": "Prochlorperazine (Compazine)",
    "genericName": "Prochlorperazine",
    "brandNames": ["Compazine", "Compro (suppository)"],
    "category": "Antiemetic, Antipsychotic",
    "drugClass": "Typical Antipsychotic (1st Generation), Phenothiazine",
    "indications": "Management of severe nausea and vomiting. Treatment of schizophrenia. Short-term treatment of non-psychotic anxiety.",
    "moaSteps": [
      "Prochlorperazine is a phenothiazine-class typical antipsychotic.",
      "Its primary antiemetic effect is from blocking dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) of the brain.",
      "Its antipsychotic effect is from blocking D2 receptors in the mesolimbic pathway.",
      "It also has significant anticholinergic and alpha-1 blocking effects."
    ],
    "pharmacokinetics": {
      "absorption": "Variable oral absorption. High first-pass metabolism.",
      "distribution": "Widely distributed, crosses blood-brain barrier. Highly protein-bound.",
      "metabolism": "Extensively metabolized in the liver (CYP2D6).",
      "excretion": "Excreted in urine and feces as metabolites."
    },
    "dose": "Nausea/Vomiting: 5-10 mg PO 3-4 times daily. 25 mg rectal suppository twice daily.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "dizziness", "dry mouth", "constipation", "orthostatic hypotension."],
      "serious": ["Extrapyramidal symptoms (EPS, e.g., dystonia)", "Tardive Dyskinesia (TD)", "Neuroleptic Malignant Syndrome (NMS)."]
    },
    "precautions": [
      "BOXED WARNING (Elderly with Dementia): Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death.",
      "High risk of Extrapyramidal Symptoms (EPS), especially acute dystonic reactions (e.g., neck/face muscle spasms).",
      "Risk of Tardive Dyskinesia (TD) with long-term use.",
      "Risk of Neuroleptic Malignant Syndrome (NMS)."
    ],
    "contraindications": [
      "Hypersensitivity to phenothiazines",
      "severe CNS depression",
      "coma",
      "bone marrow suppression",
      "children < 2 years or < 20 lbs."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "progesterone": {
    "name": "Progesterone (Prometrium)",
    "genericName": "Progesterone (Micronized)",
    "brandNames": ["Prometrium", "Crinone (vaginal gel)", "Endometrin (vaginal insert)"],
    "category": "Progestin, Hormone",
    "drugClass": "Progestin",
    "indications": "Prevention of endometrial hyperplasia in postmenopausal women receiving estrogen therapy. Treatment of secondary amenorrhea.",
    "moaSteps": [
      "Progesterone is the natural endogenous progestin.",
      "In hormone replacement: It is given with estrogen to oppose estrogen's effects on the endometrium (uterine lining). It causes the endometrium to transform and be shed, which prevents the overgrowth (hyperplasia) that can lead to uterine cancer.",
      "In amenorrhea: It helps to re-establish a normal menstrual cycle."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (micronized). High first-pass metabolism.",
      "distribution": "Widely distributed. Highly protein-bound (~96-99%).",
      "metabolism": "Extensively metabolized in the liver.",
      "excretion": "Excreted in urine. Short half-life (~5-20 minutes)."
    },
    "dose": "Hyperplasia Prevention: 200 mg PO once daily at bedtime for 12 days per month. Amenorrhea: 400 mg PO at bedtime for 10 days.",
    "adverseEffects": {
      "common": ["Drowsiness", "dizziness", "headache", "breast tenderness", "nausea", "abdominal bloating."],
      "serious": ["Thromboembolic events (DVT, PE, stroke)", "dementia (in combination with estrogen)."]
    },
    "precautions": [
      "BOXED WARNING (Cardiovascular Risks, Dementia): Progestins with estrogens are associated with increased risk of DVT, PE, stroke, MI, and dementia in postmenopausal women.",
      "BOXED WARNING (Breast Cancer): Progestins with estrogens are associated with increased risk of breast cancer.",
      "**Contains peanut oil.** Contraindicated in patients with peanut allergies.",
      "Can cause significant drowsiness; dose at bedtime."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Peanut allergy**",
      "active or history of thromboembolic disease",
      "known or suspected breast cancer",
      "undiagnosed vaginal bleeding",
      "**Pregnancy (Category X)** (for most uses)."
    ],
    "pregnancyCategory": "Category X (for most uses). Category B (for fertility use).",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "promethazine": {
    "name": "Promethazine (Phenergan)",
    "genericName": "Promethazine",
    "brandNames": ["Phenergan", "Phenadoz (suppository)"],
    "category": "Antiemetic, Antihistamine, Sedative",
    "drugClass": "Antihistamine, 1st Generation, Phenothiazine",
    "indications": "Management of nausea and vomiting. Treatment of motion sickness. Sedation (pre/post-operative). Allergic reactions (adjunct).",
    "moaSteps": [
      "Promethazine is a phenothiazine derivative with potent H1-antihistamine, anticholinergic, and sedative properties.",
      "Its antiemetic effect is from blocking dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and reducing vestibular stimulation.",
      "Its sedative effect is from its strong H1-antihistamine and alpha-adrenergic blocking effects.",
      "Its anticholinergic effect causes dry mouth, blurred vision, etc."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally/IM. High first-pass metabolism.",
      "distribution": "Widely distributed, crosses blood-brain barrier. Highly protein-bound (~93%).",
      "metabolism": "Extensively metabolized in the liver (CYP2D6).",
      "excretion": "Excreted in urine and feces. Half-life is ~10-14 hours."
    },
    "dose": "Nausea/Vomiting: 12.5-25 mg PO/IM/Rectal every 4-6 hours.",
    "adverseEffects": {
      "common": ["Profound drowsiness", "sedation", "dizziness", "confusion", "dry mouth", "blurred vision", "disorientation."],
      "serious": ["Respiratory depression (can be fatal)", "Neuroleptic Malignant Syndrome (NMS)", "agranulocytosis", "severe tissue injury (with injection)."]
    },
    "precautions": [
      "BOXED WARNING (Respiratory Depression): Can cause severe, fatal respiratory depression. **Contraindicated in children < 2 years old** and use with caution in children > 2.",
      "BOXED WARNING (Severe Tissue Injury): IV/IM injection can cause severe tissue injury (gangrene, necrosis, thrombophlebitis). Deep IM injection is preferred over IV.",
      "Can cause profound sedation; caution against driving.",
      "High anticholinergic burden; use with caution in elderly.",
      "Can lower the seizure threshold."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**use in children < 2 years old**",
      "severe CNS depression",
      "coma."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "propofol": {
    "name": "Propofol (Diprivan)",
    "genericName": "Propofol",
    "brandNames": ["Diprivan"],
    "category": "Anesthetic, Sedative-Hypnotic",
    "drugClass": "General Anesthetic",
    "indications": "Induction and maintenance of general anesthesia. Sedation for mechanically ventilated patients in the ICU. Procedural sedation.",
    "moaSteps": [
      "Propofol is a short-acting, intravenous general anesthetic.",
      "Its primary mechanism is the potentiation of the GABA-A receptor, the main inhibitory receptor in the brain.",
      "It increases the chloride conductance through the GABA-A channel, hyperpolarizing the neuron and causing profound CNS depression (sedation and anesthesia).",
      "It has a very rapid onset and very short duration of action."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV.",
      "distribution": "Highly lipophilic, rapidly distributes to the brain (rapid onset), then redistributes to fat/muscle (rapid offset). Highly protein-bound (~97-99%).",
      "metabolism": "Extensively and rapidly metabolized in the liver.",
      "excretion": "Excreted in urine as metabolites. Very short half-life (~3-12 minutes for redistribution)."
    },
    "dose": "Anesthesia Induction: 1.5-2.5 mg/kg IV. ICU Sedation: 5-50 mcg/kg/min IV infusion.",
    "adverseEffects": {
      "common": ["Hypotension (vasodilation)", "injection site pain", "bradycardia", "respiratory depression/apnea (transient)."],
      "serious": ["Propofol Infusion Syndrome (PRIS)", "anaphylaxis", "respiratory arrest", "seizures."]
    },
    "precautions": [
      "Must be administered by personnel trained in anesthesia and airway management.",
      "Causes respiratory depression and apnea. Requires continuous monitoring and airway support.",
      "Causes significant hypotension and bradycardia.",
      "**Propofol Infusion Syndrome (PRIS):** A rare, fatal metabolic syndrome (metabolic acidosis, rhabdomyolysis, hyperkalemia, cardiac failure) associated with high-dose, long-term infusions.",
      "Is a lipid emulsion (milky white); strict aseptic technique is required to prevent bacterial contamination."
    ],
    "contraindications": [
      "Hypersensitivity to propofol, **eggs, or soy products** (it is a soy/egg-based emulsion)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "propranolol": {
    "name": "Propranolol (Inderal)",
    "genericName": "Propranolol",
    "brandNames": ["Inderal", "Inderal LA", "InnoPran XL"],
    "category": "Antihypertensive, Antianginal, Antiarrhythmic",
    "drugClass": "Beta-Blocker (Nonselective)",
    "indications": "Hypertension. Angina pectoris. Cardiac arrhythmias. Myocardial infarction. Migraine prophylaxis. Essential tremor. Portal hypertension.",
    "moaSteps": [
      "Propranolol is a nonselective beta-adrenergic blocker.",
      "It competitively blocks both beta-1 (in the heart) and beta-2 (in the lungs and vasculature) receptors.",
      "**Beta-1 Blockade:** Decreases heart rate, contractility, and blood pressure. This reduces cardiac oxygen demand (for angina).",
      "**Beta-2 Blockade:** Can cause bronchoconstriction (a side effect).",
      "Its mechanism in migraine and tremor is not fully known but relates to its CNS effects (it is highly lipophilic and crosses the blood-brain barrier)."
    ],
    "pharmacokinetics": {
      "absorption": "Completely absorbed orally. Very high first-pass metabolism (bioavailability ~25%).",
      "distribution": "Widely distributed, crosses blood-brain barrier. Highly protein-bound (~90%).",
      "metabolism": "Extensively metabolized in the liver by CYP2D6 and CYP1A2.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~3-6 hours."
    },
    "dose": "Hypertension: 40 mg PO twice daily (IR) or 80 mg PO once daily (LA). Migraine: 80-240 mg/day PO.",
    "adverseEffects": {
      "common": ["Fatigue", "dizziness", "bradycardia", "hypotension", "depression", "insomnia", "nightmares.", "sexual dysfunction."],
      "serious": ["Severe bradycardia", "heart block", "heart failure exacerbation", "bronchospasm."]
    },
    "precautions": [
      "BOXED WARNING (Abrupt Discontinuation): Abruptly stopping beta-blocker therapy can cause exacerbation of angina and, in some cases, MI. Taper the dose slowly.",
      "**Nonselective; high risk of bronchospasm.** Avoid in patients with asthma or severe COPD.",
      "Can mask symptoms of hypoglycemia in diabetics.",
      "Can cause significant CNS side effects (depression, fatigue, nightmares) due to high lipophilicity."
    ],
    "contraindications": [
      "Severe bradycardia",
      "heart block greater than first degree",
      "cardiogenic shock",
      "bronchial asthma."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "propylthiouracil": {
    "name": "Propylthiouracil (PTU)",
    "genericName": "Propylthiouracil (PTU)",
    "brandNames": ["N/A (generic only)"],
    "category": "Antithyroid Agent",
    "drugClass": "Thionamide",
    "indications": "Treatment of hyperthyroidism (Graves' disease). Preferred agent for hyperthyroidism in the **first trimester of pregnancy** and in thyroid storm.",
    "moaSteps": [
      "PTU is a thionamide antithyroid drug.",
      "1. **Primary Action:** It inhibits the synthesis of thyroid hormones (T3 and T4) by blocking the enzyme thyroid peroxidase (TPO). This prevents the iodination and coupling of tyrosine residues on thyroglobulin.",
      "2. **Secondary Action:** It also inhibits the peripheral conversion of T4 (prohormone) to T3 (active hormone) by blocking the 5'-deiodinase enzyme. (Methimazole does not do this)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~50-80%.",
      "distribution": "Accumulates in the thyroid. Moderately protein-bound (~60-80%).",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine. Short half-life (~1-2 hours), requiring multiple daily doses."
    },
    "dose": "Initial: 300-450 mg/day PO in 3 divided doses. Maintenance: 100-150 mg/day.",
    "adverseEffects": {
      "common": ["Rash", "pruritus (itching)", "arthralgia (joint pain)", "nausea", "headache.", "transient leukopenia."],
      "serious": ["Severe liver injury (hepatotoxicity)", "agranulocytosis (rare but fatal)", "vasculitis."]
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Can cause severe, sometimes fatal, liver injury and acute liver failure. Reserve for patients who cannot tolerate methimazole (except in 1st trimester pregnancy).",
      "Risk of agranulocytosis (a severe drop in white blood cells). Patients must report any sign of infection (fever, sore throat) immediately.",
      "Monitor CBC and LFTs.",
      "Generally considered second-line to methimazole (due to liver risk and short half-life), *except* in the 1st trimester of pregnancy."
    ],
    "contraindications": [
      "Hypersensitivity to PTU."
    ],
    "pregnancyCategory": "Category D (but preferred over methimazole in 1st trimester).",
    "lactationInfo": "Excreted in breast milk in small amounts; considered safe."
  },
  "quetiapine": {
    "name": "Quetiapine (Seroquel)",
    "genericName": "Quetiapine",
    "brandNames": ["Seroquel", "Seroquel XR"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second-Generation)",
    "indications": "Treatment of schizophrenia. Treatment of acute manic or mixed episodes in bipolar I disorder. Treatment of depressive episodes in bipolar disorder. Adjunctive treatment of major depressive disorder (XR form).",
    "moaSteps": [
      "Quetiapine is an atypical antipsychotic.",
      "Its mechanism is complex, acting as an antagonist at multiple receptors.",
      "Its antipsychotic effect is thought to be mediated by blocking dopamine D2 and serotonin 5-HT2A receptors.",
      "Its active metabolite, norquetiapine, has high affinity for the norepinephrine transporter (NET) and 5-HT1A receptors, which may contribute to its antidepressant effects.",
      "It has very high affinity for H1 (histamine) receptors, causing significant sedation."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Food increases absorption (especially XR).",
      "distribution": "Widely distributed. Moderately protein-bound (~83%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4 to an active metabolite (norquetiapine).",
      "excretion": "Excreted in urine as metabolites. Half-life is ~6-7 hours."
    },
    "dose": "Schizophrenia: Initial 25 mg PO twice daily (IR) or 300 mg/day (XR), titrate up to 400-800 mg/day.",
    "adverseEffects": {
      "common": ["Somnolence (sedation)", "dizziness", "dry mouth", "constipation", "weight gain", "orthostatic hypotension.", "elevated triglycerides and glucose."],
      "serious": ["Neuroleptic Malignant Syndrome (NMS)", "Tardive Dyskinesia (TD)", "metabolic changes (hyperglycemia, diabetes, dyslipidemia)", "suicidal thoughts."]
    },
    "precautions": [
      "BOXED WARNING (Elderly with Dementia): Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death.",
      "BOXED WARNING (Suicidality): Antidepressants (and quetiapine as adjunct) increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults.",
      "High risk of metabolic side effects (weight gain, diabetes, dyslipidemia). Monitor weight, BMI, blood glucose, and lipids regularly.",
      "Can cause significant sedation and orthostatic hypotension, especially during initial titration."
    ],
    "contraindications": [
      "Hypersensitivity to quetiapine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "quinapril": {
    "name": "Quinapril (Accupril)",
    "genericName": "Quinapril",
    "brandNames": ["Accupril", "Accuretic (with HCTZ)"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin-Converting Enzyme (ACE) Inhibitor",
    "indications": "Treatment of hypertension. Adjunctive management of heart failure.",
    "moaSteps": [
      "Quinapril is a prodrug that is hydrolyzed to its active metabolite, quinaprilat.",
      "Quinaprilat competitively inhibits the angiotensin-converting enzyme (ACE).",
      "This prevents the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor).",
      "Decreased angiotensin II leads to vasodilation, reduced secretion of aldosterone, and a decrease in blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~60%.",
      "distribution": "Highly protein-bound (~97%).",
      "metabolism": "Hydrolyzed in the liver to active quinaprilat.",
      "excretion": "Excreted in urine and feces. Half-life of quinaprilat is ~2-3 hours."
    },
    "dose": "Hypertension: 10-80 mg PO once daily or in 2 divided doses.",
    "adverseEffects": {
      "common": ["Dry, persistent cough", "dizziness", "headache", "hyperkalemia", "hypotension."],
      "serious": ["Angioedema", "acute renal failure", "agranulocytosis", "hepatotoxicity."]
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected.",
      "Risk of angioedema, especially in Black patients.",
      "Monitor renal function and serum potassium.",
      "Can cause symptomatic hypotension."
    ],
    "contraindications": [
      "Hypersensitivity to quinapril or other ACE inhibitors",
      "history of angioedema",
      "concomitant use with aliskiren in patients with diabetes",
      "Pregnancy."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },"rabeprazole": {
    "name": "Rabeprazole (Aciphex)",
    "genericName": "Rabeprazole",
    "brandNames": ["Aciphex", "Aciphex Sprinkle"],
    "category": "Antiulcer Agent",
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "indications": "Treatment of GERD. Healing of erosive esophagitis. H. pylori eradication. Treatment of hypersecretory conditions (e.g., Zollinger-Ellison).",
    "moaSteps": [
      "Rabeprazole is a proton pump inhibitor (PPI).",
      "It is a prodrug that is activated in the acidic environment of the gastric parietal cells.",
      "The active form irreversibly blocks the H+/K+-ATPase enzyme system (the 'proton pump').",
      "This is the final step in gastric acid secretion.",
      "It suppresses basal and stimulated gastric acid secretion, leading to a profound and long-lasting reduction of stomach acid."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~52%. Food delays absorption.",
      "distribution": "Highly protein-bound (~97%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C19 and CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Short half-life (~1-1.5 hours), but long duration of action."
    },
    "dose": "GERD: 20 mg PO once daily. Take 30-60 minutes before a meal.",
    "adverseEffects": {
      "common": ["Headache", "diarrhea", "nausea", "abdominal pain", "pharyngitis."],
      "serious": ["Clostridioides difficile-associated diarrhea (CDAD)", "bone fractures (long-term use)", "hypomagnesemia (long-term use)", "Vitamin B12 deficiency (long-term use)."]
    },
    "precautions": [
      "PPI use is associated with an increased risk of *C. difficile*-associated diarrhea.",
      "Long-term use (>1 year) may be associated with an increased risk of osteoporosis-related bone fractures.",
      "Long-term use can lead to hypomagnesemia and vitamin B12 deficiency.",
      "May decrease the effectiveness of clopidogrel."
    ],
    "contraindications": [
      "Hypersensitivity to rabeprazole or other PPIs."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "raloxifene": {
    "name": "Raloxifene (Evista)",
    "genericName": "Raloxifene",
    "brandNames": ["Evista"],
    "category": "Osteoporosis Agent",
    "drugClass": "Selective Estrogen Receptor Modulator (SERM)",
    "indications": "Treatment and prevention of osteoporosis in postmenopausal women. Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.",
    "moaSteps": [
      "Raloxifene is a Selective Estrogen Receptor Modulator (SERM).",
      "It acts as an **estrogen agonist** in bone tissue. It binds to estrogen receptors, decreases bone resorption, and increases bone mineral density, thus protecting against osteoporosis.",
      "It acts as an **estrogen antagonist** in breast and uterine tissue. By blocking estrogen receptors in the breast, it reduces the risk of estrogen-sensitive breast cancer.",
      "Unlike estrogen, it does not stimulate the uterine lining (endometrium)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally (~60%), but very high first-pass metabolism (bioavailability ~2%).",
      "distribution": "Widely distributed. Highly protein-bound (>95%).",
      "metabolism": "Extensively metabolized in the liver (glucuronidation).",
      "excretion": "Excreted primarily in feces (via bile). Long half-life (~27 hours)."
    },
    "dose": "60 mg PO once daily.",
    "adverseEffects": {
      "common": ["Hot flashes", "leg cramps", "peripheral edema", "arthralgia (joint pain)."],
      "serious": ["Thromboembolic events (DVT, PE, stroke)."]
    },
    "precautions": [
      "BOXED WARNING (Thromboembolic Events): Increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).",
      "BOXED WARNING (Stroke): Increased risk of death due to stroke in postmenopausal women with coronary heart disease.",
      "Can cause hot flashes.",
      "Discontinue at least 72 hours prior to and during prolonged immobilization (e.g., surgery, bed rest) due to DVT risk."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active or history of venous thromboembolic (VTE) events",
      "**Pregnancy (Category X)**",
      "women of childbearing potential."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Contraindicated."
  },
  "ramelteon": {
    "name": "Ramelteon (Rozerem)",
    "genericName": "Ramelteon",
    "brandNames": ["Rozerem"],
    "category": "Sedative-Hypnotic",
    "drugClass": "Melatonin Receptor Agonist",
    "indications": "Treatment of insomnia characterized by difficulty with sleep onset.",
    "moaSteps": [
      "Ramelteon is a selective melatonin receptor agonist.",
      "It has a high affinity for melatonin MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) of the brain.",
      "By mimicking the action of endogenous melatonin, it promotes sleepiness (MT1) and helps regulate the sleep-wake cycle (MT2).",
      "It has no affinity for GABA receptors and is not a controlled substance."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Very high first-pass metabolism (bioavailability ~1.8%).",
      "distribution": "Moderately protein-bound (~82%).",
      "metabolism": "Extensively metabolized in the liver by CYP1A2.",
      "excretion": "Excreted in urine as metabolites. Short half-life (~1-2.6 hours)."
    },
    "dose": "8 mg PO 30 minutes before bedtime.",
    "adverseEffects": {
      "common": ["Somnolence (drowsiness)", "dizziness", "fatigue", "nausea."],
      "serious": ["Hypersensitivity reactions (anaphylaxis, angioedema)", "abnormal thinking/behavior", "increased prolactin levels."]
    },
    "precautions": [
      "Can cause drowsiness; caution against driving.",
      "Avoid use with or immediately after a high-fat meal (delays absorption).",
      "Can cause abnormal thinking or complex sleep behaviors (e.g., sleep-driving).",
      "Avoid strong CYP1A2 inhibitors (e.g., fluvoxamine)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with fluvoxamine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "ramipril": {
    "name": "Ramipril (Altace)",
    "genericName": "Ramipril",
    "brandNames": ["Altace"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin-Converting Enzyme (ACE) Inhibitor",
    "indications": "Treatment of hypertension. Reduction of risk of MI, stroke, and death from CV causes in high-risk patients. Heart failure post-MI.",
    "moaSteps": [
      "Ramipril is a prodrug that is hydrolyzed to its active metabolite, ramiprilat.",
      "Ramiprilat competitively inhibits the angiotensin-converting enzyme (ACE).",
      "This prevents the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor).",
      "Decreased angiotensin II leads to vasodilation, reduced secretion of aldosterone, and a decrease in blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (prodrug). Bioavailability ~50-60%.",
      "distribution": "Ramiprilat is highly protein-bound (~73%).",
      "metabolism": "Hydrolyzed in the liver to active ramiprilat.",
      "excretion": "Excreted in urine and feces. Half-life of ramiprilat is long and biphasic (~13-17 hours)."
    },
    "dose": "Hypertension: 2.5-20 mg PO once daily.",
    "adverseEffects": {
      "common": ["Dry, persistent cough", "dizziness", "headache", "hyperkalemia", "hypotension."],
      "serious": ["Angioedema", "acute renal failure", "agranulocytosis", "hepatotoxicity."]
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected.",
      "Risk of angioedema, especially in Black patients.",
      "Monitor renal function and serum potassium.",
      "Can cause symptomatic hypotension, especially in volume-depleted patients."
    ],
    "contraindications": [
      "Hypersensitivity to ramipril or other ACE inhibitors",
      "history of angioedema",
      "concomitant use with aliskiren in patients with diabetes",
      "Pregnancy."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Excreted in breast milk in small amounts; not recommended."
  },
  "ranitidine": {
    "name": "Ranitidine (Zantac)",
    "genericName": "Ranitidine",
    "brandNames": ["Zantac"],
    "category": "Antiulcer Agent",
    "drugClass": "Histamine H2-Receptor Antagonist (H2RA)",
    "indications": "**Note: All forms of ranitidine were withdrawn from the U.S. market in 2020 due to contamination with NDMA.** Indications included: Treatment of active duodenal and gastric ulcers. Management of GERD.",
    "moaSteps": [
      "Ranitidine is a competitive inhibitor of histamine H2-receptors.",
      "It specifically blocks histamine from binding to H2-receptors on the basolateral membrane of gastric parietal cells.",
      "This action inhibits basal and stimulated gastric acid secretion, reducing both the volume and acid concentration of gastric juice."
    ],
    "pharmacokinetics": {
      "absorption": "Incompletely absorbed. Bioavailability ~50%.",
      "distribution": "Low protein binding (~15%).",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine. Half-life is ~2.5-3 hours."
    },
    "dose": "Formerly: 150 mg PO twice daily or 300 mg PO at bedtime.",
    "adverseEffects": {
      "common": ["Headache", "dizziness", "constipation", "diarrhea."],
      "serious": ["Thrombocytopenia", "confusion (rare, in elderly/renal impairment)."]
    },
    "precautions": [
      "**Withdrawn from the U.S. market due to unacceptable levels of N-nitrosodimethylamine (NDMA), a probable human carcinogen.**",
      "Required dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to ranitidine."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "rasagiline": {
    "name": "Rasagiline (Azilect)",
    "genericName": "Rasagiline",
    "brandNames": ["Azilect"],
    "category": "Antiparkinsonian",
    "drugClass": "Monoamine Oxidase (MAO) Type B Inhibitor",
    "indications": "Monotherapy or adjunctive therapy (with levodopa) for the treatment of Parkinson's disease.",
    "moaSteps": [
      "Rasagiline is a potent, irreversible, and selective inhibitor of monoamine oxidase type B (MAO-B).",
      "In the brain, MAO-B is a primary enzyme responsible for breaking down dopamine.",
      "By inhibiting MAO-B, rasagiline decreases the breakdown of dopamine in the striatum.",
      "This increases the levels of dopamine, prolonging the effect of both endogenous and exogenous (levodopa) dopamine, thus improving motor symptoms."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High first-pass metabolism.",
      "distribution": "Widely distributed. Moderately protein-bound (~60-70%).",
      "metabolism": "Extensively metabolized in the liver by CYP1A2.",
      "excretion": "Excreted in urine as metabolites. Short half-life (~3 hours) but irreversible effect."
    },
    "dose": "Monotherapy: 1 mg PO once daily. Adjunct: 0.5-1 mg PO once daily.",
    "adverseEffects": {
      "common": ["Headache", "dizziness", "insomnia", "nausea", "arthralgia", "orthostatic hypotension."],
      "serious": ["Hypertensive Crisis", "serotonin syndrome", "hallucinations/psychosis", "impulse control disorders."]
    },
    "precautions": [
      "**Risk of Hypertensive Crisis:** Although selective for MAO-B, this selectivity can be lost at high doses. Patients should avoid high-tyramine foods (>150 mg).",
      "**Serotonin Syndrome:** Contraindicated with many drugs (e.g., SSRIs, SNRIs, meperidine, dextromethorphan). Requires a 14-day washout period.",
      "Can cause hallucinations and orthostatic hypotension.",
      "Avoid strong CYP1A2 inhibitors (e.g., ciprofloxacin)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use of meperidine, tramadol, methadone, SSRIs, SNRIs, TCAs, dextromethorphan, St. John's Wort",
      "severe hepatic impairment."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "repaglinide": {
    "name": "Repaglinide (Prandin)",
    "genericName": "Repaglinide",
    "brandNames": ["Prandin"],
    "category": "Antidiabetic",
    "drugClass": "Meglitinide",
    "indications": "Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.",
    "moaSteps": [
      "Repaglinide is a meglitinide (a 'short-acting secretagogue').",
      "It stimulates insulin release from pancreatic beta cells, similar to sulfonylureas, by binding to and blocking ATP-sensitive potassium channels.",
      "This leads to membrane depolarization, calcium influx, and insulin exocytosis.",
      "Its action is very rapid and short-lived, making it ideal for post-meal (prandial) glucose control. **It must be taken with meals.**"
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. High bioavailability.",
      "distribution": "Highly protein-bound (>98%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C8 and CYP3A4.",
      "excretion": "Excreted in feces (via bile). Very short half-life (~1 hour)."
    },
    "dose": "0.5-4 mg PO 2, 3, or 4 times daily. **Must be taken 15-30 minutes before each meal.** If a meal is skipped, the dose must be skipped.",
    "adverseEffects": {
      "common": ["Hypoglycemia", "headache", "upper respiratory tract infection", "diarrhea.", "constipation."],
      "serious": ["Severe hypoglycemia", "cardiovascular events."]
    },
    "precautions": [
      "Risk of hypoglycemia, but generally less than sulfonylureas. Risk is highest if dose is taken without a meal.",
      "**Must skip the dose if a meal is skipped.**",
      "Avoid concomitant use with gemfibrozil (a strong CYP2C8 inhibitor), as it can cause severe hypoglycemia."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Type 1 diabetes",
      "diabetic ketoacidosis",
      "**concomitant use with gemfibrozil**."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "ribavirin": {
    "name": "Ribavirin (Copegus, Rebetol)",
    "genericName": "Ribavirin",
    "brandNames": ["Copegus", "Rebetol", "Ribasphere", "Virazole (inhalation)"],
    "category": "Antiviral",
    "drugClass": "Antiviral, Nucleoside Analog",
    "indications": "Oral: Treatment of chronic Hepatitis C (HCV), always in combination with other antiviral agents (e.g., interferons or direct-acting antivirals). Inhalation: Severe respiratory syncytial virus (RSV) in children.",
    "moaSteps": [
      "Ribavirin is a synthetic nucleoside analog (a prodrug).",
      "Its mechanism is not fully understood but is thought to be multi-faceted:",
      "1. It interferes with the synthesis of viral guanosine triphosphate (GTP).",
      "2. It inhibits viral RNA polymerase.",
      "3. It can be incorporated into viral RNA, causing lethal mutations (error catastrophe).",
      "It does not have significant activity against HCV when used alone."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~45-65%.",
      "distribution": "Widely distributed. **Accumulates in red blood cells**, leading to a very long half-life.",
      "metabolism": "Metabolized by phosphorylation.",
      "excretion": "Excreted in urine and feces. Very long terminal half-life (~12 days) due to RBC accumulation."
    },
    "dose": "Varies by HCV genotype and combination regimen. e.g., 800-1400 mg/day PO in 2 divided doses.",
    "adverseEffects": {
      "common": ["Hemolytic anemia", "fatigue", "headache", "insomnia", "nausea", "rash", "pruritus."],
      "serious": ["Severe hemolytic anemia", "teratogenicity", "cardiac events (MI)."]
    },
    "precautions": [
      "BOXED WARNING (Teratogenicity): **Significant teratogenic (birth defects) and/or embryocidal effects.** Contraindicated in pregnancy.",
      "**Pregnancy must be avoided by both female patients and female partners of male patients** during therapy and for 6 months after stopping. Requires two forms of effective contraception.",
      "BOXED WARNING (Hemolytic Anemia): Can cause severe, life-threatening hemolytic anemia. Monitor hemoglobin/hematocrit."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category X)**",
      "male partners of pregnant women",
      "autoimmune hepatitis",
      "severe anemia."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "rifaximin": {
    "name": "Rifaximin (Xifaxan)",
    "genericName": "Rifaximin",
    "brandNames": ["Xifaxan"],
    "category": "Antibiotic",
    "drugClass": "Rifamycin Antibiotic",
    "indications": "Treatment of traveler's diarrhea caused by noninvasive E. coli. Reduction of risk of overt hepatic encephalopathy (HE) recurrence. Treatment of irritable bowel syndrome with diarrhea (IBS-D).",
    "moaSteps": [
      "Rifaximin is a rifamycin-class antibiotic.",
      "It inhibits bacterial protein synthesis by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase.",
      "This action blocks the transcription step, preventing RNA synthesis.",
      "It is *not* absorbed from the GI tract, so it acts locally in the gut."
    ],
    "pharmacokinetics": {
      "absorption": "Very poorly absorbed (<0.4%). It is not for systemic infections.",
      "distribution": "Acts locally in the GI tract.",
      "metabolism": "N/A (not absorbed).",
      "excretion": "Excreted primarily unchanged in the feces."
    },
    "dose": "Traveler's Diarrhea: 200 mg PO 3 times daily for 3 days. Hepatic Encephalopathy: 550 mg PO twice daily. IBS-D: 550 mg PO 3 times daily for 14 days.",
    "adverseEffects": {
      "common": ["Nausea", "headache", "peripheral edema", "dizziness", "fatigue."],
      "serious": ["Hypersensitivity reactions", "C. difficile-associated diarrhea (rare)."]
    },
    "precautions": [
      "Not effective for diarrhea complicated by fever, bloody stools, or invasive pathogens (e.g., Salmonella, Shigella).",
      "Prolonged use may result in fungal or bacterial superinfection.",
      "Generally well-tolerated due to lack of systemic absorption."
    ],
    "contraindications": [
      "Hypersensitivity to rifaximin or other rifamycins (e.g., rifampin)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "riluzole": {
    "name": "Riluzole (Rilutek)",
    "genericName": "Riluzole",
    "brandNames": ["Rilutek", "Tiglutik (oral suspension)", "Exservan (oral film)"],
    "category": "ALS Agent",
    "drugClass": "Glutamate Inhibitor",
    "indications": "Treatment of amyotrophic lateral sclerosis (ALS) to extend life or the time to mechanical ventilation.",
    "moaSteps": [
      "The mechanism of riluzole is not fully understood, but it is thought to be neuroprotective in ALS.",
      "It is believed to inhibit the release of glutamate (an excitatory neurotransmitter) in the CNS.",
      "It may also block voltage-gated sodium channels in their inactive state.",
      "This action reduces the excitotoxicity that is thought to damage motor neurons in ALS."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. High-fat meal decreases absorption.",
      "distribution": "Widely distributed, crosses blood-brain barrier. Highly protein-bound (~96%).",
      "metabolism": "Extensively metabolized in the liver by CYP1A2.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~12 hours."
    },
    "dose": "50 mg PO every 12 hours. Must be taken on an empty stomach.",
    "adverseEffects": {
      "common": ["Asthenia (weakness)", "nausea", "dizziness", "decreased lung function", "abdominal pain."],
      "serious": ["Hepatotoxicity (liver injury)", "neutropenia", "interstitial lung disease."]
    },
    "precautions": [
      "Can cause hepatotoxicity. Monitor LFTs (liver enzymes) monthly for the first 3 months, then periodically.",
      "Can cause neutropenia. Advise patients to report any fever.",
      "Take on an empty stomach (1 hour before or 2 hours after a meal)."
    ],
    "contraindications": [
      "Hypersensitivity to riluzole."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "risperidone": {
    "name": "Risperidone (Risperdal)",
    "genericName": "Risperidone",
    "brandNames": ["Risperdal", "Risperdal Consta (long-acting injection)", "Risperdal M-Tab (ODT)"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second-Generation)",
    "indications": "Treatment of schizophrenia. Acute treatment of manic or mixed episodes associated with bipolar I disorder. Treatment of irritability associated with autistic disorder.",
    "moaSteps": [
      "Risperidone is an atypical antipsychotic.",
      "It has a high affinity for blocking both serotonin 5-HT2A receptors and dopamine D2 receptors.",
      "Its antipsychotic effect is thought to be mediated by this combined antagonism.",
      "It also has high affinity for alpha-1 and H1 (histamine) receptors, which accounts for its side effects of orthostatic hypotension and sedation."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally.",
      "distribution": "Widely distributed. Highly protein-bound (~90%).",
      "metabolism": "Extensively metabolized in the liver by CYP2D6 to an active metabolite (paliperidone).",
      "excretion": "Excreted in urine. Half-life is ~3-20 hours (depends on metabolizer status)."
    },
    "dose": "Schizophrenia: Initial 1 mg PO twice daily. Titrate up to 4-8 mg/day.",
    "adverseEffects": {
      "common": ["Drowsiness", "somnolence", "dizziness", "orthostatic hypotension", "weight gain", "anxiety", "extrapyramidal symptoms (EPS)."],
      "serious": ["Neuroleptic Malignant Syndrome (NMS)", "Tardive Dyskinesia (TD)", "hyperprolactinemia", "metabolic changes (hyperglycemia)."]
    },
    "precautions": [
      "BOXED WARNING (Elderly with Dementia): Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death.",
      "High risk of Extrapyramidal Symptoms (EPS), especially at higher doses (>6 mg/day).",
      "Risk of NMS and TD.",
      "**High risk of hyperprolactinemia,** which can cause gynecomastia (breast enlargement in men), galactorrhea (milk production), and amenorrhea."
    ],
    "contraindications": [
      "Hypersensitivity to risperidone or paliperidone."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "ritonavir": {
    "name": "Ritonavir (Norvir)",
    "genericName": "Ritonavir",
    "brandNames": ["Norvir", "Kaletra (with lopinavir)"],
    "category": "Antiretroviral",
    "drugClass": "Antiretroviral, Protease Inhibitor (PI), CYP3A4 Inhibitor",
    "indications": "Treatment of HIV-1 infection, always in combination with other antiretrovirals. **Primarily used as a pharmacokinetic enhancer (booster)** for other protease inhibitors.",
    "moaSteps": [
      "As an antiviral: Ritonavir inhibits the HIV-1 protease enzyme, which is essential for cleaving viral polyproteins into functional proteins, preventing the maturation of new, infectious viral particles.",
      "**As a booster (primary use):** Ritonavir is a **potent inhibitor of the CYP3A4 enzyme.** By giving it at a low dose with another protease inhibitor (e.g., darunavir), it blocks the metabolism of the other drug, 'boosting' its concentration and half-life, allowing for lower or less frequent dosing."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Food increases absorption.",
      "distribution": "Highly protein-bound (~98-99%).",
      "metabolism": "Extensively metabolized by CYP3A4 and CYP2D6. Potent inhibitor of CYP3A4.",
      "excretion": "Excreted primarily in feces (via bile)."
    },
    "dose": "As a booster: 100-200 mg PO once or twice daily, taken with the other protease inhibitor.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea (very common)", "asthenia (weakness)", "paresthesia (tingling),", "hyperlipidemia."],
      "serious": ["Hepatotoxicity", "pancreatitis", "severe drug interactions", "metabolic changes (fat redistribution, insulin resistance)."]
    },
    "precautions": [
      "**Numerous, life-threatening drug interactions.** As a potent CYP3A4 inhibitor, it can dangerously increase the levels of many drugs (e.g., statins, antiarrhythmics, sedatives). Must review all medications.",
      "Can cause hepatotoxicity and pancreatitis.",
      "Associated with metabolic changes (hyperlipidemia, hyperglycemia, fat redistribution)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**concomitant use with a long list of drugs** that are highly dependent on CYP3A4 for clearance (e.g., amiodarone, simvastatin, sildenafil)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; not recommended (HIV transmission risk)."
  },
  "rivaroxaban": {
    "name": "Rivaroxaban (Xarelto)",
    "genericName": "Rivaroxaban",
    "brandNames": ["Xarelto"],
    "category": "Anticoagulant",
    "drugClass": "Factor Xa Inhibitor (Direct Oral Anticoagulant - DOAC)",
    "indications": "Prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Prophylaxis of DVT following hip or knee replacement. Treatment of DVT and PE. Reduction in risk of recurrent DVT/PE.",
    "moaSteps": [
      "Rivaroxaban is a direct, selective, and reversible inhibitor of Factor Xa (FXa).",
      "It inhibits both free and clot-bound Factor Xa.",
      "By inhibiting FXa, it decreases the conversion of prothrombin (Factor II) to thrombin (Factor IIa).",
      "This reduces thrombin generation and ultimately prevents the formation of fibrin clots."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High bioavailability (doses 15 mg **must be taken with food**).",
      "distribution": "Highly protein-bound (~92-95%).",
      "metabolism": "Metabolized in the liver by CYP3A4/3A5 and CYP2J2.",
      "excretion": "Excreted in urine and feces. Half-life is ~5-9 hours."
    },
    "dose": "A-fib: 20 mg PO once daily **with the evening meal**. DVT/PE Treatment: 15 mg PO twice daily **with food** for 21 days, then 20 mg PO once daily **with food**.",
    "adverseEffects": {
      "common": ["Bleeding (e.g., bruising, epistaxis)."],
      "serious": ["Major bleeding (intracranial hemorrhage, GI bleed)", "epidural or spinal hematoma."]
    },
    "precautions": [
      "BOXED WARNING (Premature Discontinuation): Discontinuing rivaroxaban prematurely increases the risk of thrombotic events (e.g., stroke).",
      "BOXED WARNING (Spinal/Epidural Hematoma): Patients receiving neuraxial anesthesia (spinal/epidural) are at risk of developing an epidural or spinal hematoma, which can result in long-term or permanent paralysis.",
      "**Doses of 15 mg and 20 mg must be taken with food** to ensure adequate absorption.",
      "Reversal agent: Andexanet alfa."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active pathological bleeding",
      "severe renal impairment (CrCl < 15 mL/min)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "rivastigmine": {
    "name": "Rivastigmine (Exelon)",
    "genericName": "Rivastigmine",
    "brandNames": ["Exelon", "Exelon Patch"],
    "category": "Alzheimer's Agent",
    "drugClass": "Cholinesterase Inhibitor",
    "indications": "Treatment of mild to moderate dementia of the Alzheimer's type. Treatment of mild to moderate dementia associated with Parkinson's disease.",
    "moaSteps": [
      "Rivastigmine is a reversible cholinesterase inhibitor.",
      "It inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), enzymes that break down acetylcholine in the synaptic cleft.",
      "By inhibiting these enzymes, it increases the concentration and duration of action of acetylcholine, a neurotransmitter in the brain that is deficient in Alzheimer's disease.",
      "This is thought to improve cognitive function."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally, but high first-pass metabolism. Patch: Slow, continuous absorption, bypasses first-pass.",
      "distribution": "Widely distributed. Low protein binding (~40%).",
      "metabolism": "Extensively metabolized by cholinesterases (not CYP enzymes).",
      "excretion": "Excreted in urine as metabolites. Short half-life (~1.5 hours)."
    },
    "dose": "Oral: Initial 1.5 mg PO twice daily, titrate slowly. Patch: Initial 4.6 mg/24 hr patch applied once daily. **Must take oral form with food.**",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "anorexia", "weight loss", "dizziness", "headache.", "(Patch) Application site reactions."],
      "serious": ["Bradycardia", "syncope", "GI bleeding", "severe nausea/vomiting."]
    },
    "precautions": [
      "Can cause significant nausea, vomiting, and diarrhea, especially with the oral form and during dose titration. **Patch has fewer GI side effects.**",
      "Oral form must be taken with meals.",
      "Can cause bradycardia and heart block; use with caution.",
      "Can increase gastric acid secretion; monitor for GI bleeding."
    ],
    "contraindications": [
      "Hypersensitivity to rivastigmine."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "rizatriptan": {
    "name": "Rizatriptan (Maxalt)",
    "genericName": "Rizatriptan",
    "brandNames": ["Maxalt", "Maxalt-MLT (ODT)"],
    "category": "Antimigraine Agent",
    "drugClass": "Serotonin 5-HT1B/1D Receptor Agonist (Triptan)",
    "indications": "Acute treatment of migraine attacks with or without aura.",
    "moaSteps": [
      "Rizatriptan is a selective agonist for serotonin 5-HT1B and 5-HT1D receptors.",
      "It works by three mechanisms:",
      "1. **Cranial Vasoconstriction:** It constricts the dilated intracranial blood vessels that are thought to cause migraine pain.",
      "2. **Inhibition of Neuropeptide Release:** It blocks the release of pro-inflammatory neuropeptides.",
      "3. **Inhibition of Pain Pathways:** It reduces pain signal transmission in the trigeminal nucleus.",
      "It has a faster onset of action than sumatriptan."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~45% (first-pass metabolism).",
      "distribution": "Low protein binding (~14%).",
      "metabolism": "Extensively metabolized in the liver, primarily by MAO-A.",
      "excretion": "Excreted in urine. Short half-life (~2-3 hours)."
    },
    "dose": "5-10 mg PO at the onset of migraine. May repeat once after 2 hours. Max 30 mg/24 hours.",
    "adverseEffects": {
      "common": ["Dizziness", "somnolence", "fatigue", "nausea", "tingling/numbness (paresthesia)."],
      "serious": ["Coronary vasospasm (angina, MI)", "arrhythmias", "stroke", "serotonin syndrome."]
    },
    "precautions": [
      "Not for migraine prophylaxis (prevention). Only for acute treatment.",
      "Risk of serious cardiovascular events. Contraindicated in patients with known cardiovascular disease (CAD, stroke, uncontrolled hypertension).",
      "Risk of 'triptan sensations' (chest, neck, or jaw tightness/pressure).",
      "**Contraindicated with MAOIs.** Requires a 2-week washout period.",
      "Reduce dose if taking propranolol."
    ],
    "contraindications": [
      "Hypersensitivity",
      "ischemic heart disease (angina, history of MI)",
      "uncontrolled hypertension",
      "hemiplegic or basilar migraine",
      "**concomitant use with MAOIs (within 14 days)**."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },"ropinirole": {
    "name": "Ropinirole (Requip)",
    "genericName": "Ropinirole",
    "brandNames": ["Requip", "Requip XL"],
    "category": "Antiparkinsonian",
    "drugClass": "Dopamine Agonist",
    "indications": "Treatment of Parkinson's disease. Treatment of moderate to severe restless legs syndrome (RLS).",
    "moaSteps": [
      "Ropinirole is a non-ergot dopamine agonist.",
      "It has a high affinity for and selectively stimulates dopamine D2 and D3 receptors in the brain's striatum.",
      "By mimicking the action of dopamine, it helps to alleviate the motor symptoms of Parkinson's disease.",
      "Its mechanism in RLS is also thought to involve dopamine receptor stimulation."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High first-pass metabolism (bioavailability ~50%).",
      "distribution": "Widely distributed. Moderately protein-bound (~40%).",
      "metabolism": "Extensively metabolized in the liver by CYP1A2.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~6 hours."
    },
    "dose": "Parkinson's: Initial 0.25 mg PO 3 times daily, titrate slowly. RLS: 0.25 mg PO once daily, 1-3 hours before bedtime.",
    "adverseEffects": {
      "common": ["Nausea", "drowsiness", "somnolence (including sudden 'sleep attacks')", "dizziness", "orthostatic hypotension", "confusion", "hallucinations."],
      "serious": ["Impulse control disorders (e.g., compulsive gambling, hypersexuality)", "hallucinations", "syncope", "worsening of RLS (augmentation)."]
    },
    "precautions": [
      "Can cause sudden onset of sleep ('sleep attacks') without warning. Caution against driving.",
      "Risk of orthostatic hypotension and syncope.",
      "Risk of hallucinations, especially in the elderly.",
      "Risk of impulse control disorders. Monitor for new, compulsive behaviors.",
      "Avoid strong CYP1A2 inhibitors (e.G., ciprofloxacin)."
    ],
    "contraindications": [
      "Hypersensitivity to ropinirole."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Inhibits prolactin; may interfere with lactation. Not recommended."
  },
  "rosiglitazone": {
    "name": "Rosiglitazone (Avandia)",
    "genericName": "Rosiglitazone",
    "brandNames": ["Avandia"],
    "category": "Antidiabetic",
    "drugClass": "Thiazolidinedione (TZD)",
    "indications": "Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus. (Use is highly restricted).",
    "moaSteps": [
      "Rosiglitazone is a thiazolidinedione (TZD).",
      "It is a potent and selective agonist for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma).",
      "Activating PPAR-gamma (found in fat, muscle, and liver) regulates genes involved in glucose and lipid metabolism.",
      "The primary effect is to increase insulin sensitivity in peripheral tissues, enhancing glucose uptake."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High bioavailability (~99%).",
      "distribution": "Highly protein-bound (>99.8%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C8.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~3-4 hours."
    },
    "dose": "4-8 mg PO once daily or in 2 divided doses.",
    "adverseEffects": {
      "common": ["Weight gain", "edema (fluid retention)", "upper respiratory tract infection", "headache.", "anemia."],
      "serious": ["Congestive Heart Failure (CHF)", "myocardial infarction", "hepatotoxicity", "macular edema", "increased risk of bone fractures."]
    },
    "precautions": [
      "BOXED WARNING (Congestive Heart Failure): Can cause or exacerbate congestive heart failure. Monitor for signs.",
      "BOXED WARNING (Myocardial Infarction): Increased risk of myocardial infarction. Use is highly restricted.",
      "Can cause significant fluid retention and weight gain.",
      "Increased risk of bone fractures.",
      "Avoid strong CYP2C8 inhibitors (e.g., gemfibrozil)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "NYHA Class III or IV (moderate to severe) heart failure.",
      "concomitant use with gemfibrozil."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "rosuvastatin": {
    "name": "Rosuvastatin (Crestor)",
    "genericName": "Rosuvastatin",
    "brandNames": ["Crestor", "Ezallor Sprinkle"],
    "category": "Antihyperlipidemic",
    "drugClass": "HMG-CoA Reductase Inhibitor (Statin)",
    "indications": "Adjunct to diet to lower elevated total cholesterol, LDL-C, and triglycerides. To reduce the risk of MI, stroke, and revascularization procedures in patients at high risk.",
    "moaSteps": [
      "Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis in the liver.",
      "This inhibition decreases the production of cholesterol in the liver.",
      "The liver compensates by increasing the number of LDL receptors on its surface, which enhances the uptake and clearance of LDL-C from the blood.",
      "This results in a potent reduction of LDL-C ('bad cholesterol') and total cholesterol."
    ],
    "pharmacokinetics": {
      "absorption": "Incompletely absorbed. Bioavailability ~20%.",
      "distribution": "Highly protein-bound (~88%).",
      "metabolism": "Minimally metabolized (10%), primarily by CYP2C9.",
      "excretion": "Excreted primarily in feces (via bile). Half-life is ~19 hours."
    },
    "dose": "5-40 mg PO once daily.",
    "adverseEffects": {
      "common": ["Headache", "myalgia (muscle pain)", "arthralgia (joint pain)", "nausea", "abdominal pain."],
      "serious": ["Myopathy and Rhabdomyolysis (muscle breakdown)", "Hepatotoxicity (liver injury).", "proteinuria."]
    },
    "precautions": [
      "Risk of myopathy and rhabdomyolysis. Risk is dose-related. Advise patients to report unexplained muscle pain.",
      "Monitor liver function tests (LFTs) at baseline and as clinically indicated.",
      "Use with caution in patients with heavy alcohol use.",
      "Patients of Asian ancestry may have increased drug levels; consider starting at a lower dose (5 mg)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active liver disease",
      "**Pregnancy (Category X)**",
      "**Lactation**."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Contraindicated."
  },
  "sacubitril-valsartan": {
    "name": "Sacubitril/Valsartan (Entresto)",
    "genericName": "Sacubitril and Valsartan",
    "brandNames": ["Entresto"],
    "category": "Anti-Heart Failure",
    "drugClass": "Angiotensin Receptor-Neprilysin Inhibitor (ARNI)",
    "indications": "To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (HFrEF, NYHA Class II-IV).",
    "moaSteps": [
      "This is a combination product with two mechanisms:",
      "1. **Sacubitril:** A prodrug that is converted to an active metabolite (LBQ657) which inhibits the enzyme neprilysin.",
      "Neprilysin normally breaks down natriuretic peptides (e.g., ANP, BNP). By inhibiting it, sacubitril increases levels of these peptides, which promote vasodilation, sodium/water excretion (natriuresis), and reduce cardiac hypertrophy.",
      "2. **Valsartan (ARB):** Selectively blocks the AT1 angiotensin II receptor, inhibiting the harmful effects of the renin-angiotensin-aldosterone system (RAAS), such as vasoconstriction, aldosterone release, and cardiac remodeling."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~60% (sacubitril), ~23% (valsartan).",
      "distribution": "Both are highly protein-bound (>94%).",
      "metabolism": "Sacubitril is converted to active LBQ657. Valsartan is minimally metabolized.",
      "excretion": "Excreted in urine and feces."
    },
    "dose": "Initial: 49/51 mg (sacubitril/valsartan) PO twice daily. Titrate after 2-4 weeks to target 97/103 mg twice daily.",
    "adverseEffects": {
      "common": ["Hypotension (low blood pressure)", "hyperkalemia", "cough", "dizziness", "renal impairment."],
      "serious": ["Angioedema", "severe hypotension", "acute renal failure."]
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected.",
      "**Must not be co-administered with an ACE inhibitor.** Must allow a 36-hour washout period when switching from an ACE-I to Entresto (or vice versa) due to high risk of angioedema.",
      "Monitor renal function and serum potassium."
    ],
    "contraindications": [
      "Hypersensitivity",
      "history of angioedema related to ACE-I or ARB",
      "**concomitant use with an ACE inhibitor**",
      "concomitant use with aliskiren in patients with diabetes",
      "**Pregnancy (Category D)**."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Not recommended."
  },
  "salmeterol": {
    "name": "Salmeterol (Serevent)",
    "genericName": "Salmeterol",
    "brandNames": ["Serevent Diskus", "Advair (with fluticasone)", "Symbicort (with budesonide)"],
    "category": "Bronchodilator",
    "drugClass": "Long-Acting Beta-2 Adrenergic Agonist (LABA)",
    "indications": "Maintenance treatment of asthma and prevention of bronchospasm. Maintenance treatment of bronchospasm associated with COPD. Prevention of exercise-induced bronchospasm.",
    "moaSteps": [
      "Salmeterol is a long-acting beta-2 adrenergic receptor agonist (LABA).",
      "It has a long side chain that anchors it to the receptor site.",
      "It selectively binds to and activates beta-2 receptors on airway smooth muscle, leading to an increase in intracellular cAMP.",
      "This results in relaxation of bronchial smooth muscle and bronchodilation, with a duration of action of 12 hours."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed systemically after inhalation.",
      "distribution": "Acts locally. Highly protein-bound (~96%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in feces. Long half-life (~12 hours)."
    },
    "dose": "Asthma/COPD: 1 inhalation (50 mcg) twice daily (12 hours apart).",
    "adverseEffects": {
      "common": ["Headache", "pharyngitis (sore throat)", "cough", "tremor", "nervousness", "tachycardia."],
      "serious": ["Asthma-related death (when used as monotherapy)", "paradoxical bronchospasm", "hypokalemia", "cardiovascular events (arrhythmias)."]
    },
    "precautions": [
      "BOXED WARNING (Asthma-Related Death): **LABAs should not be used as monotherapy for asthma.** Must always be used in combination with an inhaled corticosteroid (e.g., in a product like Advair or Symbicort).",
      "**Not for acute bronchospasm.** Use a SABA (e.g., albuterol) for rescue.",
      "Use with caution in patients with cardiovascular disease.",
      "Can cause hypokalemia."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**monotherapy for asthma**",
      "acute bronchospasm (status asthmaticus)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "sertraline": {
    "name": "Sertraline (Zoloft)",
    "genericName": "Sertraline",
    "brandNames": ["Zoloft"],
    "category": "Antidepressant, Anxiolytic",
    "drugClass": "Selective Serotonin Reuptake Inhibitor (SSRI)",
    "indications": "Treatment of major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder, posttraumatic stress disorder (PTSD), and social anxiety disorder.",
    "moaSteps": [
      "Sertraline is a potent and selective serotonin reuptake inhibitor (SSRI).",
      "It blocks the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane.",
      "This action increases the concentration of serotonin in the synaptic cleft, enhancing serotonergic neurotransmission.",
      "It has very weak effects on norepinephrine or dopamine reuptake."
    ],
    "pharmacokinetics": {
      "absorption": "Slowly absorbed. Food increases absorption.",
      "distribution": "Widely distributed. Highly protein-bound (~98%).",
      "metabolism": "Extensively metabolized in the liver (CYP2B6, 2C19, 3A4) to a less active metabolite.",
      "excretion": "Excreted in urine and feces as metabolites. Long half-life (~26 hours)."
    },
    "dose": "MDD: Initial 50 mg PO once daily. Titrate up to max 200 mg/day.",
    "adverseEffects": {
      "common": ["Nausea", "diarrhea", "headache", "insomnia", "somnolence", "sexual dysfunction", "dry mouth", "sweating."],
      "serious": ["Suicidal thoughts and behaviors", "serotonin syndrome", "hyponatremia", "QT prolongation."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults.",
      "Risk of Serotonin Syndrome, especially with other serotonergic drugs (e.g., MAOIs, triptans).",
      "Abrupt discontinuation can cause withdrawal symptoms. Taper slowly.",
      "Can cause QT prolongation at higher doses."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (within 14 days)",
      "concomitant use with pimozide."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "sevelamer": {
    "name": "Sevelamer (Renvela, Renagel)",
    "genericName": "Sevelamer (Carbonate or Hydrochloride)",
    "brandNames": ["Renvela (carbonate)", "Renagel (hydrochloride)"],
    "category": "Phosphate Binder",
    "drugClass": "Phosphate Binder, Non-calcium",
    "indications": "Control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.",
    "moaSteps": [
      "Sevelamer is a non-absorbable, calcium-free polymer.",
      "It is not absorbed from the GI tract.",
      "In the intestines, its amine groups become protonated and bind to dietary phosphate ions.",
      "This action prevents the absorption of phosphate from the diet.",
      "The sevelamer-phosphate complex is then excreted in the feces, leading to a reduction in serum phosphorus levels."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed from the GI tract.",
      "distribution": "Acts locally in the gut.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted in the feces."
    },
    "dose": "Initial: 800-1600 mg PO 3 times daily **with meals**. Dose is titrated based on serum phosphorus levels.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "constipation", "dyspepsia", "abdominal pain."],
      "serious": ["Bowel obstruction", "ileus", "severe GI distress."]
    },
    "precautions": [
      "**Must be taken with meals** to bind dietary phosphate.",
      "Tablets must be swallowed whole; do not crush or chew.",
      "Can interfere with the absorption of other drugs (e.g., levothyroxine, ciprofloxacin). Administer other drugs 1 hour before or 3 hours after.",
      "Can cause GI distress."
    ],
    "contraindications": [
      "Hypersensitivity",
      "bowel obstruction."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Not absorbed; compatible."
  },
  "sildenafil": {
    "name": "Sildenafil (Viagra, Revatio)",
    "genericName": "Sildenafil",
    "brandNames": ["Viagra", "Revatio"],
    "category": "Erectile Dysfunction Agent, Antihypertensive",
    "drugClass": "Phosphodiesterase-5 (PDE-5) Inhibitor",
    "indications": "Viagra: Treatment of erectile dysfunction (ED). Revatio: Treatment of pulmonary arterial hypertension (PAH).",
    "moaSteps": [
      "Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE-5).",
      "For ED: Sexual stimulation causes the release of nitric oxide (NO), which increases cyclic GMP (cGMP). cGMP causes smooth muscle relaxation and inflow of blood to the corpus cavernosum (erection). PDE-5 breaks down cGMP. By inhibiting PDE-5, sildenafil enhances the effect of NO, increasing cGMP levels and facilitating an erection.",
      "For PAH: PDE-5 is also present in the pulmonary vasculature. By inhibiting it, sildenafil causes vasodilation (widening) of the pulmonary arteries, reducing pulmonary pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High-fat meal decreases absorption. Bioavailability ~40% (high first-pass metabolism).",
      "distribution": "Widely distributed. Highly protein-bound (~96%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4 (primary) and CYP2C9.",
      "excretion": "Excreted primarily in feces (via bile) as metabolites. Half-life is ~3-4 hours."
    },
    "dose": "ED: 50 mg PO as needed, 30 min to 4 hours before sexual activity. Max 100 mg/dose. PAH: 20 mg PO 3 times daily.",
    "adverseEffects": {
      "common": ["Headache", "flushing", "dyspepsia (indigestion)", "visual changes (blue tinge, blurred vision)", "nasal congestion."],
      "serious": ["Priapism (painful erection > 4 hours)", "sudden vision loss (NAION)", "sudden hearing loss", "severe hypotension."]
    },
    "precautions": [
      "Risk of severe, life-threatening hypotension.",
      "Risk of priapism (a medical emergency).",
      "Risk of sudden vision or hearing loss.",
      "Use with caution with alpha-blockers (e.g., prazosin) and strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**concomitant use with nitrates (e.g., nitroglycerin)** in any form (can cause life-threatening hypotension).",
      "concomitant use with riociguat."
    ],
    "pregnancyCategory": "Category B (for Revatio/PAH)",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "simvastatin": {
    "name": "Simvastatin (Zocor)",
    "genericName": "Simvastatin",
    "brandNames": ["Zocor", "Vytorin (with ezetimibe)"],
    "category": "Antihyperlipidemic",
    "drugClass": "HMG-CoA Reductase Inhibitor (Statin)",
    "indications": "Adjunct to diet to lower elevated total cholesterol, LDL-C, and triglycerides. To reduce the risk of MI, stroke, and revascularization procedures.",
    "moaSteps": [
      "Simvastatin is a prodrug that is hydrolyzed to its active beta-hydroxyacid form.",
      "It competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis in the liver.",
      "This inhibition decreases the production of cholesterol in the liver.",
      "The liver compensates by increasing the number of LDL receptors on its surface, which enhances the uptake and clearance of LDL-C from the blood."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (prodrug). Very high first-pass metabolism (bioavailability <5%).",
      "distribution": "Highly protein-bound (>95%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted primarily in feces (via bile). Half-life is ~1.9 hours."
    },
    "dose": "10-40 mg PO once daily in the evening. **The 80 mg dose is restricted** due to high myopathy risk.",
    "adverseEffects": {
      "common": ["Headache", "myalgia (muscle pain)", "arthralgia (joint pain)", "nausea", "constipation."],
      "serious": ["Myopathy and Rhabdomyolysis (muscle breakdown)", "Hepatotoxicity (liver injury)."]
    },
    "precautions": [
      "Risk of myopathy and rhabdomyolysis. Risk is dose-related and **significantly increased by concomitant use with strong CYP3A4 inhibitors.**",
      "**The 80 mg dose is restricted** to patients who have been on it for >12 months without myopathy, due to high muscle risk.",
      "Monitor liver function tests (LFTs).",
      "Take in the evening (cholesterol synthesis is highest at night)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active liver disease",
      "**Pregnancy (Category X)**",
      "**Lactation**",
      "**concomitant use with strong CYP3A4 inhibitors** (e.g., ritonavir, ketoconazole, clarithromycin, gemfibrozil)."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Contraindicated."
  },
  "solifenacin": {
    "name": "Solifenacin (Vesicare)",
    "genericName": "Solifenacin",
    "brandNames": ["Vesicare", "Vesicare LS (oral suspension)"],
    "category": "Antispasmodic, Urinary",
    "drugClass": "Anticholinergic, Antimuscarinic",
    "indications": "Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.",
    "moaSteps": [
      "Solifenacin is a competitive, selective antagonist of muscarinic M3 receptors.",
      "The bladder detrusor muscle is rich in M3 receptors, which mediate bladder contraction.",
      "By blocking these receptors, solifenacin inhibits involuntary bladder contractions (spasms) and increases bladder capacity, thus reducing the urgency and frequency of urination."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. High bioavailability (~90%).",
      "distribution": "Widely distributed. Highly protein-bound (~98%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in urine. Long half-life (~45-68 hours)."
    },
    "dose": "5-10 mg PO once daily.",
    "adverseEffects": {
      "common": ["Dry mouth (xerostomia)", "constipation", "blurred vision", "dizziness", "dyspepsia."],
      "serious": ["Urinary retention", "heat prostration", "angioedema", "QT prolongation", "confusion."]
    },
    "precautions": [
      "High anticholinergic burden; use with caution in the elderly (risk of confusion, falls).",
      "Can cause blurred vision and drowsiness; caution against driving.",
      "Risk of heat prostration in hot environments.",
      "Use with caution in patients with gastric retention, uncontrolled narrow-angle glaucoma, or BPH.",
      "Avoid strong CYP3A4 inhibitors (limit dose to 5 mg)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "urinary retention",
      "gastric retention",
      "uncontrolled narrow-angle glaucoma."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "sotalol": {
    "name": "Sotalol (Betapace)",
    "genericName": "Sotalol",
    "brandNames": ["Betapace", "Betapace AF", "Sotylize", "Sorine"],
    "category": "Antiarrhythmic",
    "drugClass": "Antiarrhythmic (Class II & III)",
    "indications": "Betapace/Sotylize: Treatment of life-threatening ventricular arrhythmias (e.g., VT). Betapace AF: Maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation/flutter (AFIB/AFL).",
    "moaSteps": [
      "Sotalol has a dual mechanism of action:",
      "1. **Class II (Beta-Blocker):** It is a nonselective beta-adrenergic blocker (blocks beta-1 and beta-2). This action decreases heart rate and blood pressure.",
      "2. **Class III (Potassium Channel Blocker):** It blocks potassium channels in the cardiac muscle. This action prolongs the repolarization phase and the effective refractory period (ERP) of the action potential, which helps to suppress arrhythmias."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~90-100%. Food decreases absorption.",
      "distribution": "Widely distributed. Not protein-bound.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted entirely unchanged in the urine. Half-life is ~12 hours."
    },
    "dose": "Varies. Ventricular Arrhythmias: 80-160 mg PO twice daily. AFIB: 80-160 mg PO twice daily.",
    "adverseEffects": {
      "common": ["Fatigue", "dizziness", "bradycardia", "hypotension", "diarrhea.", "dyspnea."],
      "serious": ["QT prolongation and Torsades de Pointes", "severe bradycardia", "heart block", "heart failure exacerbation", "bronchospasm."]
    },
    "precautions": [
      "BOXED WARNING (Life-Threatening Arrhythmias): Can cause life-threatening ventricular arrhythmias (Torsades de Pointes) related to QT prolongation. **Initiation or re-initiation must be done in a hospital** with cardiac monitoring for at least 3 days.",
      "**Requires significant dose adjustment in renal impairment** (CrCl < 60 mL/min).",
      "Risk of bronchospasm (nonselective beta-blocker).",
      "Do not stop abruptly."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe bradycardia",
      "heart block",
      "long QT syndrome",
      "bronchial asthma",
      "severe renal impairment (CrCl < 40 mL/min for AFIB)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  
  "sucralfate": {
    "name": "Sucralfate (Carafate)",
    "genericName": "Sucralfate",
    "brandNames": ["Carafate", "Orafate"],
    "category": "Antiulcer Agent",
    "drugClass": "Cytoprotectant",
    "indications": "Short-term (up to 8 weeks) treatment of active duodenal ulcers. Maintenance therapy for duodenal ulcers.",
    "moaSteps": [
      "Sucralfate is a complex of aluminum hydroxide and sulfated sucrose.",
      "It is *not* absorbed and has no acid-neutralizing capacity.",
      "In the acidic environment of the stomach, it polymerizes and forms a sticky, viscous paste.",
      "This paste selectively binds to the ulcer crater, forming a protective barrier ('bandage') over the ulcer site.",
      "This barrier protects the ulcer from acid, pepsin, and bile salts, allowing it to heal."
    ],
    "pharmacokinetics": {
      "absorption": "Minimally absorbed systemically (<5%). It acts locally.",
      "distribution": "Acts locally in the GI tract.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in the feces."
    },
    "dose": "Treatment: 1 gram PO 4 times daily (1 hour before meals and at bedtime). Maintenance: 1 gram PO twice daily.",
    "adverseEffects": {
      "common": ["Constipation (most common)", "dry mouth", "nausea", "dizziness."],
      "serious": ["Bezoar formation (rare)", "aluminum toxicity (in renal failure)."]
    },
    "precautions": [
      "**Must be taken on an empty stomach** (1 hour before meals or 2 hours after) to work properly.",
      "Can bind to and inhibit the absorption of many other drugs (e.g., digoxin, warfarin, phenytoin, fluoroquinolones). **Separate administration by at least 2 hours.**",
      "Antacids should not be taken within 30 minutes of a sucralfate dose.",
      "Use with caution in chronic renal failure (risk of aluminum accumulation)."
    ],
    "contraindications": [
      "Hypersensitivity to sucralfate."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Compatible (not absorbed)."
  },
  "sulfamethoxazole-trimethoprim": {
    "name": "Sulfamethoxazole/Trimethoprim (Bactrim, Septra)",
    "genericName": "Sulfamethoxazole and Trimethoprim",
    "brandNames": ["Bactrim", "Septra", "Bactrim DS (Double Strength)"],
    "category": "Antibiotic",
    "drugClass": "Sulfonamide Antibiotic Combination",
    "indications": "Treatment of urinary tract infections (UTIs), acute otitis media, acute exacerbations of chronic bronchitis, and traveler's diarrhea. Treatment and prophylaxis of Pneumocystis jirovecii pneumonia (PJP).",
    "moaSteps": [
      "This is a combination product that causes sequential blockade of bacterial folic acid synthesis:",
      "1. **Sulfamethoxazole (Sulfa):** A sulfonamide. It inhibits dihydropteroate synthetase, preventing the synthesis of dihydrofolic acid (DHF) from PABA.",
      "2. **Trimethoprim (TMP):** Inhibits dihydrofolate reductase (DHFR), preventing the conversion of DHF to tetrahydrofolic acid (THF).",
      "THF is essential for synthesizing DNA. By blocking two steps in this pathway, the combination is bactericidal (in most cases)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and well absorbed orally.",
      "distribution": "Widely distributed into tissues and fluids, including CSF.",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted in urine. Half-life is ~8-11 hours."
    },
    "dose": "UTI (DS): 1 DS (800 mg/160 mg) tablet PO twice daily for 3-14 days. PJP Prophylaxis: 1 DS tablet PO once daily.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "rash", "photosensitivity", "hyperkalemia."],
      "serious": ["Severe skin reactions (SJS/TEN)", "myelosuppression (agranulocytosis, aplastic anemia)", "hepatotoxicity", "hyperkalemia (life-threatening)."]
    },
    "precautions": [
      "**Contraindicated in sulfa allergy.**",
      "Risk of severe, fatal skin reactions (SJS/TEN).",
      "Risk of blood dyscrasias. Monitor CBC.",
      "Risk of life-threatening hyperkalemia, especially in the elderly or those on ACE inhibitors/ARBs.",
      "Risk of photosensitivity; advise sun protection.",
      "Take with a full glass of water to prevent crystalluria."
    ],
    "contraindications": [
      "Hypersensitivity to sulfonamides or trimethoprim",
      "**sulfa allergy**",
      "history of drug-induced thrombocytopenia",
      "severe renal or hepatic impairment",
      "megaloblastic anemia due to folate deficiency",
      "**infants < 2 months old**",
      "**pregnancy at term (Category D)**."
    ],
    "pregnancyCategory": "Category D. (Contraindicated at term).",
    "lactationInfo": "Excreted in breast milk; not recommended (risk of kernicterus in infant)."
  },"tiagabine": {
    "name": "Tiagabine (Gabitril)",
    "genericName": "Tiagabine",
    "brandNames": ["Gabitril"],
    "category": "Antiepileptic",
    "drugClass": "Anticonvulsant, GABA Reuptake Inhibitor",
    "indications": "Adjunctive therapy in the treatment of partial-onset seizures.",
    "moaSteps": [
      "Tiagabine is an anticonvulsant that enhances the activity of GABA, the primary inhibitory neurotransmitter in the brain.",
      "It selectively inhibits the GABA transporter 1 (GAT-1).",
      "This action blocks the reuptake of GABA into presynaptic neurons and glial cells.",
      "This increases the concentration of GABA in the synaptic cleft, prolonging its inhibitory effect and suppressing seizure activity."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and almost completely absorbed. Food delays absorption.",
      "distribution": "Widely distributed. Highly protein-bound (~96%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Excreted in feces (via bile) and urine as metabolites. Half-life is ~7-9 hours."
    },
    "dose": "Initial: 4 mg PO once daily. Titrate slowly weekly up to a max of 32-56 mg/day in 2-4 divided doses. **Must be taken with food.**",
    "adverseEffects": {
      "common": ["Dizziness", "somnolence (drowsiness)", "asthenia (weakness)", "nausea", "nervousness", "tremor."],
      "serious": ["Seizures (can *cause* seizures in non-epileptic patients)", "status epilepticus", "suicidal thoughts", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "Can cause seizures, especially when used off-label (e.g., for anxiety) in patients without epilepsy. Use only for epilepsy.",
      "Can cause significant drowsiness and dizziness; caution against driving.",
      "Abrupt discontinuation can precipitate seizures. Taper dose slowly.",
      "Risk of suicidal thoughts and behaviors."
    ],
    "contraindications": [
      "Hypersensitivity to tiagabine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "ticagrelor": {
    "name": "Ticagrelor (Brilinta)",
    "genericName": "Ticagrelor",
    "brandNames": ["Brilinta"],
    "category": "Antiplatelet",
    "drugClass": "Antiplatelet Agent, P2Y12 Inhibitor",
    "indications": "To reduce the risk of thrombotic cardiovascular events (e.g., stent thrombosis, MI, stroke) in patients with acute coronary syndrome (ACS).",
    "moaSteps": [
      "Ticagrelor is a direct-acting and **reversible** antagonist of the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface.",
      "It binds to a site distinct from the ADP binding site (allosteric antagonist).",
      "By blocking the P2Y12 receptor, it prevents ADP from binding and activating the platelet.",
      "This inhibits platelet activation and aggregation. Because it is reversible, its effect wears off faster than clopidogrel or prasugrel."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~36%.",
      "distribution": "Widely distributed. Highly protein-bound (>99%).",
      "metabolism": "Metabolized in the liver by CYP3A4 to an active metabolite.",
      "excretion": "Excreted in feces (via bile) and urine. Half-life is ~7 hours."
    },
    "dose": "Loading dose: 180 mg PO once. Maintenance: 90 mg PO twice daily for 1 year, then 60 mg PO twice daily. **Must be taken with low-dose aspirin (75-100 mg).**",
    "adverseEffects": {
      "common": ["Bleeding (e.g., bruising, epistaxis)", "dyspnea (shortness of breath)", "headache", "dizziness.", "nausea."],
      "serious": ["Major, life-threatening, or fatal bleeding (e.g., intracranial, GI)", "bradyarrhythmias."]
    },
    "precautions": [
      "BOXED WARNING (Bleeding Risk): Can cause significant, sometimes fatal, bleeding.",
      "BOXED WARNING (Aspirin Dose): **Maintenance doses of aspirin >100 mg/day reduce the effectiveness of ticagrelor.** Must be used with aspirin 75-100 mg/day.",
      "Can cause dyspnea (shortness of breath), which is usually transient.",
      "Avoid strong CYP3A4 inhibitors (e.g., ketoconazole) and inducers (e.g., rifampin)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active pathological bleeding",
      "history of intracranial hemorrhage."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk (animal studies); not recommended."
  },
  "timolol": {
    "name": "Timolol (Timoptic, Betimol, Blocadren)",
    "genericName": "Timolol",
    "brandNames": ["Timoptic", "Betimol", "Istalol (ophthalmic)", "Blocadren (oral)"],
    "category": "Antiglaucoma Agent, Antihypertensive",
    "drugClass": "Beta-Blocker (Nonselective)",
    "indications": "Ophthalmic (drops): Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Oral (tablets): Treatment of hypertension. Migraine prophylaxis.",
    "moaSteps": [
      "Timolol is a nonselective beta-adrenergic blocker.",
      "For Glaucoma: It is applied topically to the eye. It is thought to lower IOP by **reducing the production of aqueous humor** in the ciliary body. It does not affect pupil size.",
      "For Hypertension: It blocks beta-1 receptors in the heart, decreasing heart rate, contractility, and blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Ophthalmic: Rapidly absorbed from the eye and can reach significant systemic concentrations. Oral: Well absorbed.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the liver (CYP2D6).",
      "excretion": "Excreted in urine. Half-life is ~4 hours."
    },
    "dose": "Glaucoma: 1 drop of 0.25% or 0.5% solution in affected eye(s) once or twice daily.",
    "adverseEffects": {
      "common": ["(Ophthalmic) Eye stinging/burning", "blurred vision", "dry eyes."],
      "serious": ["(Systemic effects from absorption) Bradycardia", "heart block", "bronchospasm", "hypotension", "worsening of heart failure."]
    },
    "precautions": [
      "**Ophthalmic drops can be absorbed systemically** and cause the same side effects as oral beta-blockers, including bronchospasm and bradycardia.",
      "Use with extreme caution in patients with asthma, COPD, severe bradycardia, or heart failure.",
      "Can mask symptoms of hypoglycemia in diabetics.",
      "Use nasolacrimal occlusion (pressing on the inner corner of the eye) after instillation to reduce systemic absorption."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**bronchial asthma**",
      "**severe COPD**",
      "severe bradycardia",
      "heart block greater than first degree",
      "cardiogenic shock."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "tinidazole": {
    "name": "Tinidazole (Tindamax)",
    "genericName": "Tinidazole",
    "brandNames": ["Tindamax"],
    "category": "Antibiotic, Antiprotozoal",
    "drugClass": "Nitroimidazole Antibiotic",
    "indications": "Treatment of protozoal infections (e.g., trichomoniasis, giardiasis, amebiasis). Treatment of bacterial vaginosis.",
    "moaSteps": [
      "Tinidazole is a nitroimidazole, similar to metronidazole.",
      "It is a prodrug that is activated by reduction in anaerobic bacteria and protozoa.",
      "This activation creates highly reactive, short-lived cytotoxic intermediates.",
      "These intermediates bind to and disrupt the helical structure of DNA, causing strand breakage and cell death (bactericidal/protozoacidal)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. High bioavailability (100%).",
      "distribution": "Widely distributed, including into CSF. Low protein binding (~12%).",
      "metabolism": "Metabolized in the liver (CYP3A4).",
      "excretion": "Excreted in urine. Longer half-life than metronidazole (~12-14 hours)."
    },
    "dose": "Trichomoniasis/Giardiasis: 2 g PO as a single dose. Bacterial Vaginosis: 2 g PO once daily for 2 days.",
    "adverseEffects": {
      "common": ["Metallic taste", "nausea", "vomiting", "headache", "dizziness", "darkening of urine (harmless)."],
      "serious": ["Seizures", "peripheral neuropathy", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "BOXED WARNING (Carcinogenicity): Has been shown to be carcinogenic in mice and rats. Use only for approved indications.",
      "**Disulfiram-like Reaction:** Patients must avoid all alcohol during therapy and for at least 3 days after stopping (causes severe nausea, vomiting, flushing).",
      "Can cause seizures and peripheral neuropathy.",
      "Longer half-life than metronidazole."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**use of alcohol during or within 3 days of therapy**",
      "**first trimester of pregnancy**."
    ],
    "pregnancyCategory": "Category C (but contraindicated in 1st trimester).",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "tiotropium": {
    "name": "Tiotropium (Spiriva)",
    "genericName": "Tiotropium",
    "brandNames": ["Spiriva HandiHaler (DPI)", "Spiriva Respimat (SMI)"],
    "category": "Bronchodilator",
    "drugClass": "Long-Acting Muscarinic Antagonist (LAMA)",
    "indications": "Long-term, once-daily maintenance treatment of bronchospasm associated with COPD. Long-term maintenance treatment of asthma.",
    "moaSteps": [
      "Tiotropium is a long-acting muscarinic antagonist (LAMA), an anticholinergic agent.",
      "It has a high affinity for muscarinic receptors (M1-M5) but dissociates slowly from M1 and M3 receptors, giving it a long duration of action.",
      "It blocks muscarinic (M3) receptors on bronchial smooth muscle, inhibiting the effect of acetylcholine.",
      "This action prevents bronchoconstriction and leads to significant, long-lasting bronchodilation (opening of the airways)."
    ],
    "pharmacokinetics": {
      "absorption": "Minimally absorbed systemically after inhalation (~19%), maximizing local effects.",
      "distribution": "Acts locally. Moderately protein-bound (~72%).",
      "metabolism": "Minimally metabolized (CYP2C8, CYP3A4).",
      "excretion": "Excreted primarily unchanged in the urine. Long half-life (~25 hours)."
    },
    "dose": "COPD (HandiHaler): 1 inhalation (18 mcg) once daily. (Respimat): 2 inhalations (2.5 mcg/puff) once daily.",
    "adverseEffects": {
      "common": ["Dry mouth (xerostomia)", "upper respiratory tract infection", "cough", "pharyngitis", "constipation."],
      "serious": ["Paradoxical bronchospasm", "acute narrow-angle glaucoma (if sprayed in eyes)", "worsening of urinary retention."]
    },
    "precautions": [
      "**Not for acute bronchospasm.** This is a long-term maintenance inhaler, not a rescue inhaler.",
      "Use with caution in patients with narrow-angle glaucoma or prostatic hyperplasia (BPH) / urinary retention.",
      "Avoid spraying in the eyes.",
      "Spiriva HandiHaler capsules are for inhalation only and are not to be swallowed."
    ],
    "contraindications": [
      "Hypersensitivity to tiotropium or ipratropium."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "tizanidine": {
    "name": "Tizanidine (Zanaflex)",
    "genericName": "Tizanidine",
    "brandNames": ["Zanaflex"],
    "category": "Skeletal Muscle Relaxant",
    "drugClass": "Alpha-2 Adrenergic Agonist (Central)",
    "indications": "Management of spasticity (muscle stiffness and spasms) associated with multiple sclerosis, spinal cord injury, or other CNS conditions.",
    "moaSteps": [
      "Tizanidine is a central-acting alpha-2 adrenergic agonist.",
      "It stimulates alpha-2 receptors in the spinal cord and brain.",
      "This action reduces spasticity by increasing presynaptic inhibition of motor neurons.",
      "It inhibits the release of excitatory amino acids (like glutamate) from spinal interneurons, which reduces the firing rate of motor neurons."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High first-pass metabolism (bioavailability ~40%). Food increases absorption.",
      "distribution": "Widely distributed. Low protein binding (~30%).",
      "metabolism": "Extensively metabolized in the liver by CYP1A2.",
      "excretion": "Excreted in urine and feces as metabolites. Short half-life (~2.5 hours)."
    },
    "dose": "Initial: 2 mg PO up to 3 times daily. Titrate slowly up to max 36 mg/day.",
    "adverseEffects": {
      "common": ["Dry mouth", "somnolence (drowsiness)", "dizziness", "asthenia (weakness)", "bradycardia", "hypotension."],
      "serious": ["Hepatotoxicity (liver injury)", "severe hypotension", "syncope", "hallucinations/psychosis."]
    },
    "precautions": [
      "Can cause significant drowsiness, sedation, and dizziness; caution against driving.",
      "Can cause hypotension and bradycardia; titrate dose slowly.",
      "Risk of hepatotoxicity. Monitor LFTs at baseline, 1, 3, and 6 months.",
      "Avoid strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) as they can dangerously increase tizanidine levels."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**concomitant use with strong CYP1A2 inhibitors** (e.g., fluvoxamine, ciprofloxacin)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "tolbutamide": {
    "name": "Tolbutamide",
    "genericName": "Tolbutamide",
    "brandNames": ["Orinase"],
    "category": "Antidiabetic",
    "drugClass": "Sulfonylurea (1st Generation)",
    "indications": "Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus. (Rarely used today).",
    "moaSteps": [
      "Tolbutamide is a first-generation sulfonylurea.",
      "It stimulates insulin release from the pancreatic beta cells.",
      "It binds to and blocks the ATP-sensitive potassium channels (K-ATP) on the beta cell membrane.",
      "This blockage leads to membrane depolarization, calcium influx, and the exocytosis (release) of insulin."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Highly protein-bound (~95%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C9.",
      "excretion": "Excreted in urine as metabolites. Shortest half-life of 1st-gen (~4.5-6.5 hours)."
    },
    "dose": "500-2000 mg/day PO in 2-3 divided doses.",
    "adverseEffects": {
      "common": ["Hypoglycemia", "nausea", "heartburn", "rash.", "weight gain."],
      "serious": ["Severe hypoglycemia", "agranulocytosis", "hemolytic anemia", "hepatotoxicity."]
    },
    "precautions": [
      "High risk of hypoglycemia, especially in the elderly and those with renal/hepatic impairment.",
      "Can cause sulfa allergic reactions.",
      "Associated with increased cardiovascular mortality (class effect).",
      "Can cause a disulfiram-like reaction with alcohol.",
      "Largely replaced by second-generation sulfonylureas (e.g., glipizide)."
    ],
    "contraindications": [
      "Hypersensitivity to tolbutamide or sulfonamides",
      "diabetic ketoacidosis",
      "Type 1 diabetes."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "tolcapone": {
    "name": "Tolcapone (Tasmar)",
    "genericName": "Tolcapone",
    "brandNames": ["Tasmar"],
    "category": "Antiparkinsonian",
    "drugClass": "Catechol-O-Methyltransferase (COMT) Inhibitor",
    "indications": "Adjunctive treatment to carbidopa/levodopa in patients with Parkinson's disease experiencing 'wearing-off' episodes. (Use is highly restricted).",
    "moaSteps": [
      "Tolcapone is a selective and reversible inhibitor of Catechol-O-Methyltransferase (COMT).",
      "It inhibits COMT in both the periphery and the CNS (unlike entacapone, which is peripheral-only).",
      "It decreases the breakdown of levodopa (in the periphery) and dopamine (in the brain).",
      "This increases the plasma half-life of levodopa and increases the duration of dopamine's effect in the brain, thus prolonging the therapeutic effect."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~65%.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Extensively metabolized by glucuronidation.",
      "excretion": "Excreted in urine and feces. Half-life is ~2-3 hours."
    },
    "dose": "100-200 mg PO 3 times daily, with each dose of carbidopa/levodopa.",
    "adverseEffects": {
      "common": ["Dyskinesias (worsening)", "nausea", "diarrhea (can be severe, delayed)", "urine discoloration (brownish-orange)", "hallucinations.", "orthostatic hypotension."],
      "serious": ["Hepatotoxicity (acute liver failure)."]
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Can cause acute, fatal liver failure. **Use is reserved for patients who do not respond to other therapies (e.g., entacapone).**",
      "**Requires monitoring of LFTs** (baseline, every 2-4 weeks for first 6 months, then periodically). Discontinue if LFTs are elevated.",
      "Patient must provide written informed consent.",
      "Can cause delayed, severe diarrhea.",
      "Avoid abrupt discontinuation."
    ],
    "contraindications": [
      "Hypersensitivity",
      "liver disease",
      "history of tolcapone-induced liver injury",
      "concomitant use with non-selective MAO inhibitors."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "tolterodine": {
    "name": "Tolterodine (Detrol)",
    "genericName": "Tolterodine",
    "brandNames": ["Detrol", "Detrol LA (ER)"],
    "category": "Antispasmodic, Urinary",
    "drugClass": "Anticholinergic, Antimuscarinic",
    "indications": "Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.",
    "moaSteps": [
      "Tolterodine is a competitive antagonist of muscarinic receptors.",
      "It has a high affinity for muscarinic receptors in the bladder, which mediate detrusor muscle contraction.",
      "By blocking these receptors, it inhibits involuntary bladder contractions (spasms) and increases bladder capacity, thus reducing the urgency and frequency of urination."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High first-pass metabolism (bioavailability ~74% in poor metabolizers, ~17% in extensive).",
      "distribution": "Highly protein-bound (~96%).",
      "metabolism": "Extensively metabolized in the liver by CYP2D6 (primary) and CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~2-4 hours."
    },
    "dose": "IR: 2 mg PO twice daily. ER (LA): 4 mg PO once daily.",
    "adverseEffects": {
      "common": ["Dry mouth (xerostomia)", "constipation", "headache", "dizziness", "dyspepsia.", "blurred vision."],
      "serious": ["Urinary retention", "heat prostration", "angioedema", "QT prolongation", "confusion."]
    },
    "precautions": [
      "High anticholinergic burden; use with caution in the elderly (risk of confusion, falls).",
      "Can cause blurred vision and drowsiness; caution against driving.",
      "Risk of heat prostration in hot environments.",
      "Use with caution in patients with gastric retention, uncontrolled narrow-angle glaucoma, or BPH.",
      "Reduce dose in renal/hepatic impairment or with strong CYP3A4 inhibitors."
    ],
    "contraindications": [
      "Hypersensitivity",
      "urinary retention",
      "gastric retention",
      "uncontrolled narrow-angle glaucoma."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "topiramate": {
    "name": "Topiramate (Topamax)",
    "genericName": "Topiramate",
    "brandNames": ["Topamax", "Trokendi XR", "Qudexy XR"],
    "category": "Antiepileptic, Antimigraine Agent",
    "drugClass": "Anticonvulsant",
    "indications": "Monotherapy or adjunctive therapy for partial-onset seizures and primary generalized tonic-clonic seizures. Prophylaxis of migraine headache.",
    "moaSteps": [
      "The exact mechanism of topiramate is not fully known, but it is multi-faceted:",
      "1. It blocks voltage-gated sodium channels.",
      "2. It enhances the activity of the inhibitory neurotransmitter GABA at GABA-A receptors.",
      "3. It blocks the excitatory glutamate (AMPA/kainate) receptors.",
      "4. It is a weak carbonic anhydrase inhibitor."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~80%.",
      "distribution": "Low protein binding (~15-41%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~21 hours."
    },
    "dose": "Migraine: Initial 25 mg PO at bedtime. Titrate slowly up to 100 mg/day in 2 divided doses. Seizures: Titrate to 200-400 mg/day.",
    "adverseEffects": {
      "common": ["Tingling/numbness (paresthesia)", "dizziness", "somnolence/fatigue", "difficulty with memory/concentration ('brain fog')", "weight loss", "decreased appetite.", "diarrhea."],
      "serious": ["Metabolic acidosis", "acute angle-closure glaucoma", "suicidal thoughts", "decreased sweating (oligohidrosis) and fever.", "kidney stones."]
    },
    "precautions": [
      "Risk of acute angle-closure glaucoma. Report any eye pain or blurred vision immediately.",
      "Risk of metabolic acidosis. Monitor serum bicarbonate levels.",
      "Risk of suicidal thoughts and behaviors.",
      "Can cause cognitive impairment ('brain fog'); caution against driving.",
      "Risk of decreased sweating (hyperthermia), especially in hot weather.",
      "Maintain good fluid intake to reduce risk of kidney stones."
    ],
    "contraindications": [
      "Hypersensitivity to topiramate."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm (cleft lip/palate).",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "torsemide": {
    "name": "Torsemide (Demadex)",
    "genericName": "Torsemide",
    "brandNames": ["Demadex"],
    "category": "Diuretic",
    "drugClass": "Loop Diuretic",
    "indications": "Treatment of edema associated with congestive heart failure (CHF), cirrhosis of the liver, and renal disease. Treatment of hypertension.",
    "moaSteps": [
      "Torsemide is a potent loop diuretic.",
      "It inhibits the reabsorption of sodium, chloride, and water by blocking the Na+/K+/2Cl- cotransporter in the thick ascending limb of the Loop of Henle.",
      "This action leads to a significant increase in the excretion of sodium, chloride, potassium, and water.",
      "This results in profound diuresis and a reduction in fluid volume."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High bioavailability (~80-90%). Not affected by food.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Metabolized in the liver by CYP2C9.",
      "excretion": "Excreted in urine as metabolites and unchanged drug. Half-life is ~3.5 hours."
    },
    "dose": "Edema: 10-20 mg PO or IV once daily. Max 200 mg/day. Hypertension: 5-10 mg PO once daily.",
    "adverseEffects": {
      "common": ["Hypokalemia", "hypomagnesemia", "hyponatremia", "hypovolemia", "hypotension", "hyperuricemia (can precipitate gout)."],
      "serious": ["Severe electrolyte imbalances", "ototoxicity (hearing loss, rare)", "renal failure", "sulfa allergy reactions (SJS/TEN)."]
    },
    "precautions": [
      "Can lead to profound diuresis with water and electrolyte depletion. Strict medical supervision is required.",
      "Risk of ototoxicity, though less than furosemide.",
      "Can cause a sulfa allergic reaction in patients with a history of sulfa allergy.",
      "Monitor electrolytes (especially potassium), renal function, and fluid status."
    ],
    "contraindications": [
      "Hypersensitivity to torsemide or sulfonamides (potential cross-reactivity)",
      "anuria (inability to produce urine)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "tramadol": {
    "name": "Tramadol (Ultram)",
    "genericName": "Tramadol",
    "brandNames": ["Ultram", "Ultram ER", "ConZip"],
    "category": "Analgesic",
    "drugClass": "Opioid Analgesic / SNRI (Schedule IV)",
    "indications": "Management of moderate to moderately severe pain.",
    "moaSteps": [
      "Tramadol has a dual mechanism of action:",
      "1. **Opioid Agonist:** It is a weak agonist at the mu-opioid receptor. Its active metabolite (O-desmethyltramadol) is a much more potent mu-agonist.",
      "2. **SNRI Activity:** It inhibits the neuronal reuptake of both norepinephrine (NE) and serotonin (5-HT), which modulates descending pain pathways.",
      "This combination makes it effective for both nociceptive and neuropathic pain."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Bioavailability ~75%.",
      "distribution": "Widely distributed. Low protein binding (~20%).",
      "metabolism": "Extensively metabolized in the liver by CYP2D6 (to active metabolite) and CYP3A4.",
      "excretion": "Excreted in urine. Half-life is ~6-7 hours."
    },
    "dose": "IR: 50-100 mg PO every 4-6 hours. Max 400 mg/day.",
    "adverseEffects": {
      "common": ["Dizziness", "somnolence", "headache", "nausea", "vomiting", "constipation", "sweating."],
      "serious": ["Seizures", "serotonin syndrome", "respiratory depression", "abuse, addiction, and overdose."]
    },
    "precautions": [
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse (Schedule IV).",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "BOXED WARNING (CYP2D6 Ultra-Rapid Metabolism): Ultra-rapid metabolizers (of CYP2D6) have a higher risk of opioid toxicity.",
      "**Risk of Seizures:** Can lower the seizure threshold. Risk is higher with other serotonergic drugs or at high doses.",
      "**Risk of Serotonin Syndrome:** High risk with MAOIs, SSRIs, SNRIs."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "acute or severe bronchial asthma",
      "paralytic ileus",
      "**concomitant use with MAOIs (within 14 days)**",
      "children < 12 years old."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "trandolapril": {
    "name": "Trandolapril (Mavik)",
    "genericName": "Trandolapril",
    "brandNames": ["Mavik", "Tarka (with verapamil)"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin-Converting Enzyme (ACE) Inhibitor",
    "indications": "Treatment of hypertension. Heart failure post-MI or left ventricular dysfunction post-MI.",
    "moaSteps": [
      "Trandolapril is a prodrug that is hydrolyzed to its active metabolite, trandolaprilat.",
      "Trandolaprilat competitively inhibits the angiotensin-converting enzyme (ACE).",
      "This prevents the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor).",
      "Decreased angiotensin II leads to vasodilation, reduced secretion of aldosterone, and a decrease in blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (prodrug).",
      "distribution": "Active metabolite is highly protein-bound (~80%).",
      "metabolism": "Hydrolyzed in the liver to active trandolaprilat.",
      "excretion": "Excreted in urine and feces. Long half-life of metabolite (~16-24 hours)."
    },
    "dose": "Hypertension: 1-4 mg PO once daily. Heart Failure: Initial 1 mg, titrate to 4 mg PO once daily.",
    "adverseEffects": {
      "common": ["Dry, persistent cough", "dizziness", "headache", "hyperkalemia", "hypotension."],
      "serious": ["Angioedema", "acute renal failure", "agranulocytosis", "hepatotoxicity."]
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected.",
      "Risk of angioedema, especially in Black patients.",
      "Monitor renal function and serum potassium.",
      "Can cause symptomatic hypotension."
    ],
    "contraindications": [
      "Hypersensitivity to trandolapril or other ACE inhibitors",
      "history of angioedema",
      "concomitant use with aliskiren in patients with diabetes",
      "Pregnancy."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "tranexamic-acid": {
    "name": "Tranexamic Acid (Lysteda, Cyklokapron)",
    "genericName": "Tranexamic Acid",
    "brandNames": ["Lysteda (oral)", "Cyklokapron (IV)"],
    "category": "Anti-Fibrinolytic",
    "drugClass": "Antifibrinolytic Agent",
    "indications": "Oral (Lysteda): Treatment of heavy menstrual bleeding (menorrhagia). IV: Short-term use to reduce or prevent hemorrhage (e.g., in surgery, trauma, postpartum hemorrhage).",
    "moaSteps": [
      "Tranexamic acid is an antifibrinolytic agent.",
      "It is a synthetic analog of the amino acid lysine.",
      "It competitively and reversibly binds to plasminogen.",
      "This action blocks the binding of plasminogen to fibrin, which prevents its conversion to plasmin.",
      "Plasmin is the enzyme responsible for breaking down fibrin clots (fibrinolysis). By inhibiting plasmin, tranexamic acid stabilizes the clot and prevents it from being broken down prematurely, thus reducing bleeding."
    ],
    "pharmacokinetics": {
      "absorption": "Moderately absorbed orally (~45%). 100% IV.",
      "distribution": "Widely distributed. Low protein binding (~3%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~2-11 hours."
    },
    "dose": "Menorrhagia: 1300 mg PO 3 times daily for up to 5 days during menstruation.",
    "adverseEffects": {
      "common": ["Headache", "abdominal pain", "nausea", "diarrhea", "back pain", "myalgia."],
      "serious": ["Thromboembolic events (DVT, PE, stroke)", "seizures (high dose IV)", "visual disturbances."]
    },
    "precautions": [
      "Risk of venous and arterial thrombosis (blood clots). Use with caution in patients with a history of thrombosis.",
      "Risk of seizures, especially with high IV doses in cardiac surgery.",
      "Risk of visual disturbances; discontinue if this occurs.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active thromboembolic disease (e.g., DVT, PE)",
      "history of thrombosis",
      "acquired defective color vision (oral)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "tranylcypromine": {
    "name": "Tranylcypromine (Parnate)",
    "genericName": "Tranylcypromine",
    "brandNames": ["Parnate"],
    "category": "Antidepressant",
    "drugClass": "Monoamine Oxidase Inhibitor (MAOI)",
    "indications": "Treatment of major depressive disorder in adults who have not responded adequately to other antidepressants.",
    "moaSteps": [
      "Tranylcypromine is an irreversible, non-selective monoamine oxidase inhibitor (MAOI).",
      "It inhibits the MAO-A and MAO-B enzymes, which are responsible for breaking down neurotransmitters.",
      "This action increases the synaptic concentrations of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) in the brain.",
      "The effect is long-lasting as the enzyme must be re-synthesized."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "Widely distributed.",
      "metabolism": "Extensively metabolized in the liver (CYP2A6, 2C19, 3A4).",
      "excretion": "Excreted in urine as metabolites. Short half-life (~2.5 hours) but long duration of effect."
    },
    "dose": "Initial: 30 mg/day PO in divided doses. Titrate up to max 60 mg/day.",
    "adverseEffects": {
      "common": ["Orthostatic hypotension (very common)", "dizziness", "headache", "insomnia", "dry mouth", "constipation."],
      "serious": ["Hypertensive Crisis", "serotonin syndrome", "hepatotoxicity", "suicidal thoughts."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior.",
      "**Hypertensive Crisis:** A potentially fatal reaction. **Patient must avoid all tyramine-rich foods** (e.g., aged cheeses, cured meats, tap beer, soy sauce).",
      "**Serotonin Syndrome:** A potentially fatal reaction. **Contraindicated with many drugs**, especially SSRIs, SNRIs, TCAs, triptans, and meperidine. Requires a 2-week washout period.",
      "High risk of orthostatic hypotension.",
      "Can cause insomnia; avoid dosing in the evening."
    ],
    "contraindications": [
      "Hypersensitivity",
      "pheochromocytoma",
      "**concomitant use of sympathomimetics, SSRIs, SNRIs, TCAs, and many other drugs**",
      "**inability to adhere to strict dietary restrictions**."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },"trazodone": {
    "name": "Trazodone (Desyrel)",
    "genericName": "Trazodone",
    "brandNames": ["Desyrel", "Oleptro (ER)"],
    "category": "Antidepressant, Sedative-Hypnotic",
    "drugClass": "Serotonin Antagonist and Reuptake Inhibitor (SARI)",
    "indications": "Treatment of major depressive disorder (MDD). (Off-label): Widely used at low doses for insomnia.",
    "moaSteps": [
      "Trazodone has a complex, multi-faceted mechanism.",
      "It is an antagonist at serotonin 5-HT2A receptors, which is thought to contribute to its antidepressant and anxiolytic effects.",
      "It is a weak inhibitor of serotonin reuptake (SSRI effect).",
      "It is a potent antagonist at H1 (histamine) receptors, which causes its significant sedative (sleep-inducing) effects.",
      "It is also an antagonist at alpha-1 adrenergic receptors, which can cause orthostatic hypotension."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed orally. Food delays absorption.",
      "distribution": "Widely distributed. Highly protein-bound (~89-95%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Half-life is biphasic (~3-6 hours and 5-9 hours)."
    },
    "dose": "Depression: Initial 150 mg/day PO in divided doses, titrate up. Insomnia: 25-100 mg PO at bedtime.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "dizziness", "dry mouth", "headache", "nausea", "orthostatic hypotension."],
      "serious": ["Priapism (rare but serious)", "suicidal thoughts", "serotonin syndrome", "QT prolongation."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults.",
      "Can cause significant sedation and orthostatic hypotension; dose at bedtime.",
      "**Risk of priapism** (a prolonged, painful erection), which is a medical emergency.",
      "Risk of Serotonin Syndrome, especially with MAOIs.",
      "Risk of QT prolongation."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (within 14 days)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "tretinoin": {
    "name": "Tretinoin (Retin-A, Vesanoid)",
    "genericName": "Tretinoin (All-trans Retinoic Acid)",
    "brandNames": ["Retin-A", "Retin-A Micro (topical)", "Atralin (topical)", "Vesanoid (oral)"],
    "category": "Antiacne, Antineoplastic",
    "drugClass": "Retinoid",
    "indications": "Topical: Treatment of acne vulgaris. Treatment of fine wrinkles and skin roughness (photoaging). Oral (Vesanoid): Induction of remission in acute promyelocytic leukemia (APL).",
    "moaSteps": [
      "Tretinoin is a derivative of Vitamin A.",
      "As an antiacne agent: It binds to retinoic acid receptors (RARs) in the skin, modifying gene expression. It increases the turnover (shedding) of follicular epithelial cells, which prevents the formation of comedones (blackheads/whiteheads). It also has anti-inflammatory effects.",
      "As an antineoplastic (APL): It binds to RARs on leukemic cells, causing them to differentiate (mature) into normal cells, thus inducing remission."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption from topical application. Well absorbed orally.",
      "distribution": "Acts locally in the skin. Systemically, highly protein-bound.",
      "metabolism": "Metabolized by CYP enzymes (oral).",
      "excretion": "Excreted in urine and feces (oral)."
    },
    "dose": "Acne (Topical): Apply a thin film to the affected area once daily in the evening.",
    "adverseEffects": {
      "common": ["(Topical) Skin irritation", "burning", "stinging", "itching", "redness", "peeling", "dryness.", "photosensitivity."],
      "serious": ["(Topical) Severe skin irritation.", "(Oral) Retinoic acid syndrome (fever, dyspnea, weight gain), leukocytosis."]
    },
    "precautions": [
      "BOXED WARNING (Oral - APL): Risk of retinoic acid syndrome. High risk of thrombosis and leukocytosis.",
      "(Topical) Risk of photosensitivity. Patients must use sunscreen and protective clothing and avoid sun exposure.",
      "(Topical) Skin irritation is common and expected. May need to reduce frequency.",
      "(Topical) Acne may worsen during the first few weeks of treatment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category X - Oral, Category C - Topical, but often avoided)**."
    ],
    "pregnancyCategory": "Category C (Topical) / Category X (Oral).",
    "lactationInfo": "Unknown if excreted in human milk (topical); not recommended (oral)."
  },
  "triamcinolone": {
    "name": "Triamcinolone (Kenalog, Nasacort)",
    "genericName": "Triamcinolone",
    "brandNames": ["Kenalog (topical/injection)", "Nasacort (nasal spray)", "Aristocort (oral)"],
    "category": "Anti-inflammatory, Immunosuppressant",
    "drugClass": "Corticosteroid",
    "indications": "Topical: Relief of inflammatory and pruritic manifestations of skin disorders. Nasal: Management of allergic rhinitis. Systemic: Treatment of various inflammatory and autoimmune conditions.",
    "moaSteps": [
      "Triamcinolone is a synthetic glucocorticoid.",
      "It binds to intracellular glucocorticoid receptors and modifies gene expression.",
      "It upregulates anti-inflammatory proteins and downregulates pro-inflammatory mediators (cytokines, prostaglandins).",
      "This results in potent anti-inflammatory and immunosuppressive effects."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed systemically from all routes (topical, nasal, oral).",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized in the liver (CYP3A4).",
      "excretion": "Excreted in urine as metabolites. Biologic half-life is 18-36 hours."
    },
    "dose": "Nasal: 2 sprays per nostril once daily. Topical: Apply a thin film 2-4 times daily.",
    "adverseEffects": {
      "common": ["(Nasal) Headache", "nasal irritation/burning", "nosebleed.", "(Topical) Skin atrophy", "burning", "itching."],
      "serious": ["(Systemic/High Dose) Adrenal suppression (HPA axis suppression)", "immunosuppression", "Cushing's syndrome", "cataracts/glaucoma."]
    },
    "precautions": [
      "Prolonged or high-dose use (all routes) can cause systemic corticosteroid effects and HPA axis suppression.",
      "Can mask signs of infection and increase susceptibility.",
      "Monitor for hyperglycemia, hypertension, and psychiatric disturbances."
    ],
    "contraindications": [
      "Hypersensitivity",
      "systemic fungal infections (oral/IV use)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "triamterene": {
    "name": "Triamterene (Dyrenium)",
    "genericName": "Triamterene",
    "brandNames": ["Dyrenium", "Dyazide (with HCTZ)", "Maxzide (with HCTZ)"],
    "category": "Diuretic",
    "drugClass": "Potassium-sparing Diuretic",
    "indications": "Treatment of edema (e.g., in CHF, cirrhosis). Used in combination with other diuretics (e.g., HCTZ) to treat hypertension and prevent hypokalemia.",
    "moaSteps": [
      "Triamterene is a potassium-sparing diuretic.",
      "It acts directly on the distal convoluted tubule and collecting duct of the kidney.",
      "It blocks the epithelial sodium channels (ENaC) on the luminal side.",
      "This action inhibits the reabsorption of sodium and, in turn, reduces the excretion of potassium.",
      "This results in a mild diuresis and potassium retention."
    ],
    "pharmacokinetics": {
      "absorption": "Variably absorbed (~30-70%).",
      "distribution": "Moderately protein-bound (~67%).",
      "metabolism": "Extensively metabolized in the liver to an active metabolite.",
      "excretion": "Excreted in urine. Half-life is ~1.5-2.5 hours."
    },
    "dose": "100-300 mg/day PO in 1-2 divided doses.",
    "adverseEffects": {
      "common": ["Hyperkalemia", "dizziness", "headache", "nausea", "vomiting.", "leg cramps."],
      "serious": ["Severe hyperkalemia (can be fatal)", "nephrotoxicity (kidney stones)", "thrombocytopenia."]
    },
    "precautions": [
      "BOXED WARNING (Hyperkalemia): Can cause severe, life-threatening hyperkalemia. Risk is highest in renal impairment or with ACE inhibitors, ARBs, or potassium supplements.",
      "Monitor serum potassium and renal function (BUN/Cr) regularly.",
      "Can cause kidney stones.",
      "Can cause a harmless blue fluorescence of the urine."
    ],
    "contraindications": [
      "Hypersensitivity",
      "hyperkalemia",
      "severe renal impairment",
      "concomitant use with other potassium-sparing diuretics."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "trimethoprim": {
    "name": "Trimethoprim (Primsol)",
    "genericName": "Trimethoprim",
    "brandNames": ["Primsol", "Bactrim (with sulfamethoxazole)", "Septra (with sulfamethoxazole)"],
    "category": "Antibiotic",
    "drugClass": "Folate Antagonist",
    "indications": "Treatment and prophylaxis of acute uncomplicated urinary tract infections (UTIs). (Primarily used in combination with sulfamethoxazole).",
    "moaSteps": [
      "Trimethoprim is a folate antagonist antibiotic.",
      "It inhibits the bacterial enzyme dihydrofolate reductase (DHFR).",
      "This action prevents the conversion of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF).",
      "THF is the active form of folic acid, essential for synthesizing bacterial DNA and proteins.",
      "It is bacteriostatic or bactericidal, depending on conditions."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed.",
      "distribution": "Widely distributed into tissues and fluids. Moderately protein-bound (~44%).",
      "metabolism": "Metabolized in the liver.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~8-10 hours."
    },
    "dose": "UTI Treatment: 100 mg PO every 12 hours or 200 mg PO every 24 hours for 10 days.",
    "adverseEffects": {
      "common": ["Rash", "pruritus (itching)", "nausea", "vomiting", "glossitis (sore tongue)."],
      "serious": ["Hyperkalemia", "hyponatremia", "myelosuppression (thrombocytopenia, leukopenia)", "severe skin reactions (SJS/TEN)."]
    },
    "precautions": [
      "Risk of hyperkalemia, especially at high doses or in renal impairment.",
      "Risk of hematologic (blood) disorders, especially in folate-deficient patients. Monitor CBC.",
      "Use with caution in patients with renal or hepatic impairment.",
      "Take with a full glass of water."
    ],
    "contraindications": [
      "Hypersensitivity to trimethoprim",
      "megaloblastic anemia due to folate deficiency",
      "severe renal impairment."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "ursodiol": {
    "name": "Ursodiol (Actigall, Urso)",
    "genericName": "Ursodiol (Ursodeoxycholic Acid)",
    "brandNames": ["Actigall", "Urso", "Urso Forte"],
    "category": "Gallstone Dissolution Agent, Hepatoprotectant",
    "drugClass": "Bile Acid",
    "indications": "Prevention and treatment of gallstones (in certain patients). Treatment of primary biliary cholangitis (PBC).",
    "moaSteps": [
      "Ursodiol is a naturally occurring, hydrophilic (water-soluble) bile acid.",
      "For Gallstones: It reduces the cholesterol content of bile by decreasing the liver's synthesis and secretion of cholesterol. This desaturates the bile, allowing cholesterol-based gallstones to slowly dissolve.",
      "For PBC: It protects liver cells (hepatocytes) from the toxic effects of other, more hydrophobic bile acids. It also has anti-inflammatory and immunomodulatory effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Enters enterohepatic circulation. Highly protein-bound.",
      "metabolism": "Metabolized in the liver and by gut bacteria.",
      "excretion": "Excreted primarily in feces."
    },
    "dose": "PBC: 13-15 mg/kg/day PO in 2-4 divided doses. Gallstones: 8-10 mg/kg/day PO in 2-3 divided doses.",
    "adverseEffects": {
      "common": ["Headache", "dizziness", "diarrhea", "nausea", "back pain.", "constipation."],
      "serious": ["Hepatotoxicity (worsening of liver disease, rare)."]
    },
    "precautions": [
      "Use with caution in patients with advanced liver disease.",
      "Monitor liver function tests (LFTs).",
      "Antacids (aluminum-based) and bile acid sequestrants (e.g., cholestyramine) can bind ursodiol and decrease its absorption. Separate doses."
    ],
    "contraindications": [
      "Hypersensitivity",
      "patients requiring cholecystectomy (surgical gallstone removal)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "ustekinumab": {
    "name": "Ustekinumab (Stelara)",
    "genericName": "Ustekinumab",
    "brandNames": ["Stelara"],
    "category": "Immunosuppressant",
    "drugClass": "Monoclonal Antibody, Interleukin Inhibitor",
    "indications": "Treatment of moderate to severe plaque psoriasis. Treatment of active psoriatic arthritis. Treatment of moderate to severe Crohn's disease and ulcerative colitis.",
    "moaSteps": [
      "Ustekinumab is a human monoclonal antibody.",
      "It targets the shared p40 protein subunit of two key pro-inflammatory cytokines: Interleukin-12 (IL-12) and Interleukin-23 (IL-23).",
      "IL-12 and IL-23 are involved in activating natural killer (NK) cells and differentiating T-cells, which are central to the inflammatory response in psoriasis and inflammatory bowel disease.",
      "By binding to and neutralizing IL-12 and IL-23, ustekinumab disrupts this inflammatory cascade."
    ],
    "pharmacokinetics": {
      "absorption": "Administered via subcutaneous (SC) injection. Slow absorption. Bioavailability ~57%.",
      "distribution": "Confined to vascular and interstitial fluid.",
      "metabolism": "Degraded into peptides and amino acids by general protein catabolism.",
      "excretion": "N/A. Very long half-life (~15-32 days)."
    },
    "dose": "Psoriasis: 45 mg or 90 mg (by weight) SC at weeks 0 and 4, then every 12 weeks. Crohn's/UC: Starts with a one-time IV loading dose, then 90 mg SC every 8 weeks.",
    "adverseEffects": {
      "common": ["Upper respiratory tract infection", "nasopharyngitis", "headache", "fatigue", "injection site reactions."],
      "serious": ["Serious infections (e.g., TB, fungal infections)", "malignancy (cancers)", "hypersensitivity reactions", "reversible posterior leukoencephalopathy syndrome (RPLS)."]
    },
    "precautions": [
      "**Serious Infections:** Increased risk of serious bacterial, fungal, and viral infections. Must test for latent TB before starting.",
      "**Malignancy:** Increased risk of cancers. Monitor for skin cancers.",
      "Risk of severe hypersensitivity reactions (anaphylaxis).",
      "Risk of RPLS (a rare brain syndrome); report neurologic symptoms."
    ],
    "contraindications": [
      "Hypersensitivity to ustekinumab",
      "clinically significant, active infection."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "valacyclovir": {
    "name": "Valacyclovir (Valtrex)",
    "genericName": "Valacyclovir",
    "brandNames": ["Valtrex"],
    "category": "Antiviral",
    "drugClass": "Antiviral, Nucleoside Analog",
    "indications": "Treatment of herpes zoster (shingles). Treatment of initial or recurrent genital herpes. Suppressive therapy for recurrent genital herpes. Treatment of cold sores (herpes labialis).",
    "moaSteps": [
      "Valacyclovir is a prodrug of acyclovir.",
      "After oral ingestion, it is rapidly and almost completely converted to acyclovir in the liver.",
      "Acyclovir is selectively phosphorylated by viral thymidine kinase (TK) to its monophosphate form.",
      "Cellular enzymes then convert it to acyclovir triphosphate (ACV-TP).",
      "ACV-TP inhibits viral DNA polymerase and acts as a chain terminator when incorporated into the viral DNA strand, thus halting viral replication."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (prodrug). High first-pass metabolism to acyclovir. Bioavailability of acyclovir is ~55% (much higher than oral acyclovir).",
      "distribution": "Widely distributed. Acyclovir has low protein binding.",
      "metabolism": "Converted to acyclovir.",
      "excretion": "Acyclovir is excreted unchanged in the urine. Half-life is ~2.5-3.3 hours."
    },
    "dose": "Shingles: 1 gram PO 3 times daily for 7 days. Genital Herpes (Initial): 1 gram PO twice daily for 10 days. (Recurrent): 500 mg PO twice daily for 3 days.",
    "adverseEffects": {
      "common": ["Headache", "nausea", "vomiting", "diarrhea", "abdominal pain."],
      "serious": ["Renal failure (especially in high doses or dehydration)", "neurotoxicity (confusion, hallucinations, seizures)", "thrombotic thrombocytopenic purpura (TTP) (in high doses in immunocompromised)."]
    },
    "precautions": [
      "Risk of renal impairment, especially in elderly or dehydrated patients. Ensure adequate hydration.",
      "Requires dose adjustment in renal impairment.",
      "Risk of neurotoxicity, especially in elderly.",
      "Must be initiated as early as possible (within 48-72 hours of symptom onset) for best effect."
    ],
    "contraindications": [
      "Hypersensitivity to valacyclovir or acyclovir."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Acyclovir is excreted in breast milk; use with caution."
  },
  "valganciclovir": {
    "name": "Valganciclovir (Valcyte)",
    "genericName": "Valganciclovir",
    "brandNames": ["Valcyte"],
    "category": "Antiviral",
    "drugClass": "Antiviral, Nucleoside Analog",
    "indications": "Treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Prevention of CMV disease in high-risk kidney, heart, and pancreas transplant recipients.",
    "moaSteps": [
      "Valganciclovir is a prodrug of ganciclovir.",
      "After oral ingestion, it is rapidly converted to ganciclovir by enzymes in the intestine and liver.",
      "Ganciclovir is phosphorylated by a viral protein kinase (in CMV-infected cells) to its monophosphate form.",
      "Cellular enzymes then convert it to the active triphosphate form.",
      "Ganciclovir triphosphate competitively inhibits viral DNA polymerase and can be incorporated into the viral DNA chain, terminating elongation."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (prodrug). High first-pass metabolism to ganciclovir. Bioavailability of ganciclovir is ~60%. **Must be taken with food.**",
      "distribution": "Widely distributed.",
      "metabolism": "Converted to ganciclovir.",
      "excretion": "Ganciclovir is excreted unchanged in the urine. Half-life is ~4 hours."
    },
    "dose": "Treatment (Induction): 900 mg PO twice daily for 21 days. (Maintenance): 900 mg PO once daily. **Must be taken with food.**",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "fever", "anemia", "neutropenia.", "thrombocytopenia."],
      "serious": ["Severe neutropenia, anemia, and thrombocytopenia (myelosuppression)", "carcinogenicity", "teratogenicity."]
    },
    "precautions": [
      "BOXED WARNING (Myelosuppression): Can cause severe leukopenia, neutropenia, anemia, and thrombocytopenia. Monitor complete blood counts.",
      "BOXED WARNING (Fetal Toxicity): Can cause birth defects. Use effective contraception during and after treatment.",
      "BOXED WARNING (Impaired Fertility): May cause temporary or permanent infertility.",
      "BOXED WARNING (Carcinogenicity): Has caused tumors in animal studies.",
      "Requires dose adjustment in renal impairment. **Handle as a hazardous drug.**"
    ],
    "contraindications": [
      "Hypersensitivity to valganciclovir or ganciclovir",
      "severe neutropenia (ANC < 500) or thrombocytopenia (platelets < 25,000)."
    ],
    "pregnancyCategory": "Category C (but with boxed warnings for teratogenicity).",
    "lactationInfo": "Not recommended."
  },
  "valproic-acid": {
    "name": "Valproic Acid (Depakote, Depakene)",
    "genericName": "Valproic Acid / Divalproex Sodium",
    "brandNames": ["Depakote (divalproex ER)", "Depakene (valproic acid)", "Stavzor (valproic acid DR)"],
    "category": "Antiepileptic, Mood Stabilizer",
    "drugClass": "Anticonvulsant, Histone Deacetylase Inhibitor",
    "indications": "Monotherapy and adjunctive therapy for complex partial seizures and absence seizures. Treatment of acute manic episodes in bipolar disorder. Prophylaxis of migraine headache.",
    "moaSteps": [
      "The mechanism of valproic acid is not fully understood, but it is multi-faceted:",
      "1. **GABAergic Effects:** It increases the concentration of the inhibitory neurotransmitter GABA in the brain (by inhibiting its breakdown and increasing its synthesis).",
      "2. **Sodium Channel Blockade:** It blocks voltage-gated sodium channels, similar to phenytoin.",
      "3. **T-type Calcium Channel Blockade:** It blocks T-type calcium channels, which is particularly important for its effect on absence seizures."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. ER forms are slow-release.",
      "distribution": "Widely distributed. Highly protein-bound (~90-95%).",
      "metabolism": "Extensively metabolized in the liver by multiple pathways (glucuronidation, beta-oxidation).",
      "excretion": "Excreted in urine as metabolites. Half-life is ~9-16 hours."
    },
    "dose": "Varies by indication. Requires therapeutic drug monitoring (Range: 50-100 mcg/mL). e.g., Seizures: 10-15 mg/kg/day PO, increase as needed.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "dyspepsia", "drowsiness", "dizziness", "tremor", "weight gain", "alopecia (hair loss)."],
      "serious": ["Hepatotoxicity (liver failure)", "pancreatitis", "teratogenicity (fetal harm)", "hyperammonemia", "thrombocytopenia."]
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Can cause severe, fatal liver failure, especially in children < 2 years old. Monitor LFTs.",
      "BOXED WARNING (Fetal Toxicity): **Contraindicated in pregnancy for migraine prophylaxis.** Can cause major birth defects (e.g., neural tube defects like spina bifida).",
      "BOXED WARNING (Pancreatitis): Can cause life-threatening pancreatitis. Discontinue if suspected.",
      "Can cause hyperammonemic encephalopathy (confusion due to high ammonia).",
      "Can cause thrombocytopenia (low platelets). Monitor CBC."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe liver disease",
      "urea cycle disorders",
      "**Pregnancy (Category X for migraine prophylaxis; Category D for epilepsy/bipolar)**."
    ],
    "pregnancyCategory": "Category X (migraine) / D (epilepsy).",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "valsartan": {
    "name": "Valsartan (Diovan)",
    "genericName": "Valsartan",
    "brandNames": ["Diovan", "Diovan HCT (with HCTZ)", "Entresto (with sacubitril)"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin II Receptor Blocker (ARB)",
    "indications": "Treatment of hypertension. Treatment of heart failure (HFrEF, NYHA Class II-IV). Reduction of CV mortality in post-MI patients with LV dysfunction.",
    "moaSteps": [
      "Valsartan is a selective angiotensin II receptor blocker (ARB).",
      "It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking its binding to the AT1 receptor.",
      "This blockade results in vasodilation, decreased secretion of aldosterone, and a reduction in blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Low bioavailability (~25%).",
      "distribution": "Highly protein-bound (>95%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily in feces (via bile). Half-life is ~6 hours."
    },
    "dose": "Hypertension: 80-320 mg PO once daily. Heart Failure: Initial 40 mg PO twice daily, titrate to 160 mg twice daily.",
    "adverseEffects": {
      "common": ["Dizziness", "headache", "hyperkalemia", "hypotension.", "fatigue."],
      "serious": ["Angioedema", "acute renal failure", "severe hyperkalemia."]
    },
    "precautions": [
      "BOXED WARNING (Fetal Toxicity): Can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected.",
      "Can cause symptomatic hypotension, especially in volume-depleted patients.",
      "Monitor renal function and serum potassium."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with aliskiren in patients with diabetes",
      "Pregnancy."
    ],
    "pregnancyCategory": "Category D",
    "lactationInfo": "Not recommended."
  },
  "vancomycin": {
    "name": "Vancomycin (Vancocin)",
    "genericName": "Vancomycin",
    "brandNames": ["Vancocin (oral)", "Firvanq (oral solution)"],
    "category": "Antibiotic",
    "drugClass": "Glycopeptide Antibiotic",
    "indications": "IV: Treatment of serious, invasive Gram-positive infections, including Methicillin-resistant Staphylococcus aureus (MRSA) (e.g., bacteremia, endocarditis, pneumonia). Oral: Treatment of Clostridioides difficile-associated diarrhea (CDAD).",
    "moaSteps": [
      "Vancomycin is a glycopeptide antibiotic.",
      "It inhibits bacterial cell wall synthesis at a step different from beta-lactams.",
      "It binds with high affinity to the D-alanyl-D-alanine terminus of the growing peptidoglycan chain.",
      "This action blocks transpeptidation and transglycosylation, preventing the cross-linking of the cell wall and leading to cell lysis (bactericidal)."
    ],
    "pharmacokinetics": {
      "absorption": "**Not absorbed from the GI tract.** Oral (PO) route is for local GI infections (C. diff) only. Must be given IV for systemic infections.",
      "distribution": "Widely distributed into tissues and fluids.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted primarily unchanged in the urine (IV). Excreted in feces (PO). Half-life is ~4-6 hours."
    },
    "dose": "IV: 15-20 mg/kg IV every 8-12 hours. **Requires therapeutic drug monitoring (trough levels).** C. diff (PO): 125 mg PO 4 times daily for 10 days.",
    "adverseEffects": {
      "common": ["(IV) 'Red Man Syndrome' (flushing, itching, rash on face/neck/torso)", "nausea", "abdominal pain."],
      "serious": ["Nephrotoxicity (kidney damage)", "Ototoxicity (hearing loss)", "myelosuppression (neutropenia)."]
    },
    "precautions": [
      "**Nephrotoxicity** and **Ototoxicity** are major risks, especially with high doses, prolonged therapy, or concomitant nephro/ototoxic drugs (e.g., aminoglycosides).",
      "**Requires therapeutic drug monitoring** (Trough levels typically 10-20 mcg/mL, or 15-20 mcg/mL for severe infections).",
      "**'Red Man Syndrome'** (an infusion reaction, not a true allergy) is caused by rapid IV infusion. Infuse slowly over at least 60 minutes.",
      "**Oral (PO) vancomycin is for C. diff only** and cannot be used for systemic infections."
    ],
    "contraindications": [
      "Hypersensitivity to vancomycin."
    ],
    "pregnancyCategory": "Category B (Oral) / C (IV)",
    "lactationInfo": "Excreted in breast milk (IV); use with caution."
  },
  "varenicline": {
    "name": "Varenicline (Chantix)",
    "genericName": "Varenicline",
    "brandNames": ["Chantix", "Champix"],
    "category": "Smoking Cessation Aid",
    "drugClass": "Nicotinic Receptor Partial Agonist",
    "indications": "Aid to smoking cessation.",
    "moaSteps": [
      "Varenicline is a partial agonist at the alpha-4-beta-2 nicotinic acetylcholine receptor, the receptor that mediates nicotine addiction.",
      "It has a dual mechanism:",
      "1. **Agonist activity:** It provides a low-to-moderate level of dopamine release by partially stimulating the receptor. This helps to reduce the symptoms of nicotine withdrawal and craving.",
      "2. **Antagonist activity:** It binds with high affinity and blocks nicotine from cigarettes from binding to the receptor. This reduces the rewarding (pleasurable) effects of smoking."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. High bioavailability (~90%). Not affected by food.",
      "distribution": "Widely distributed. Low protein binding (<20%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~24 hours."
    },
    "dose": "Start 1 week *before* quit date. Day 1-3: 0.5 mg PO once daily. Day 4-7: 0.5 mg PO twice daily. Day 8 onward: 1 mg PO twice daily for 12 weeks.",
    "adverseEffects": {
      "common": ["Nausea (very common)", "insomnia", "abnormal/vivid dreams", "headache", "constipation."],
      "serious": ["Neuropsychiatric events (e.g., depression, agitation, suicidal thoughts)", "seizures", "severe skin reactions (SJS)."]
    },
    "precautions": [
      "**Neuropsychiatric Events:** Post-marketing reports of serious events, including depression, agitation, and suicidal ideation/behavior. Monitor for mood changes.",
      "Can cause vivid or abnormal dreams.",
      "Nausea is very common; take with food and a full glass of water to reduce.",
      "May increase the intoxicating effects of alcohol.",
      "Requires dose adjustment in severe renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to varenicline."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "venlafaxine": {
    "name": "Venlafaxine (Effexor XR)",
    "genericName": "Venlafaxine",
    "brandNames": ["Effexor", "Effexor XR"],
    "category": "Antidepressant, Anxiolytic",
    "drugClass": "Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)",
    "indications": "Treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder.",
    "moaSteps": [
      "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI).",
      "It potently inhibits the neuronal reuptake of both serotonin (5-HT) and norepinephrine (NE).",
      "It is dose-dependent: at low doses, it acts like an SSRI; at moderate-to-high doses, it also inhibits NE reuptake.",
      "This action increases the concentration of 5-HT and NE in the synaptic cleft, enhancing neurotransmission."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. High first-pass metabolism.",
      "distribution": "Widely distributed. Low protein binding (~27%).",
      "metabolism": "Extensively metabolized in the liver by CYP2D6 to an active metabolite, desvenlafaxine (O-desmethylvenlafaxine).",
      "excretion": "Excreted in urine as metabolites. Short half-life (~5 hours)."
    },
    "dose": "ER: Initial 37.5-75 mg PO once daily. Titrate up to max 225 mg/day.",
    "adverseEffects": {
      "common": ["Nausea", "headache", "drowsiness", "dizziness", "insomnia", "dry mouth", "constipation", "sweating.", "sexual dysfunction."],
      "serious": ["Suicidal thoughts and behaviors", "serotonin syndrome", "hypertension (dose-related).", "severe withdrawal symptoms."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults.",
      "**Risk of severe withdrawal syndrome** (nausea, dizziness, 'brain zaps'). Must be tapered very slowly.",
      "Can cause a dose-related increase in blood pressure. Monitor BP.",
      "Risk of Serotonin Syndrome, especially with MAOIs."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (within 14 days)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },"verapamil": {
    "name": "Verapamil (Calan, Verelan)",
    "genericName": "Verapamil",
    "brandNames": ["Calan", "Verelan", "Isoptin SR"],
    "category": "Antihypertensive, Antianginal, Antiarrhythmic",
    "drugClass": "Calcium Channel Blocker (Non-dihydropyridine)",
    "indications": "Management of hypertension. Management of angina pectoris. Management of supraventricular tachyarrhythmias (e.g., atrial fibrillation rate control).",
    "moaSteps": [
      "Verapamil is a non-dihydropyridine calcium channel blocker.",
      "It inhibits the influx of calcium ions across cell membranes into vascular smooth muscle and cardiac muscle.",
      "It has effects on both the heart and blood vessels:",
      "1. **Cardiac Effects (negative inotropy/chronotropy):** It slows conduction through the AV node, decreases heart rate, and reduces myocardial contractility.",
      "2. **Vascular Effects (vasodilation):** It causes peripheral vasodilation, which reduces blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally (>90%). Very high first-pass metabolism (bioavailability ~20-35%).",
      "distribution": "Widely distributed. Highly protein-bound (~90%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4 to an active metabolite (norverapamil).",
      "excretion": "Excreted in urine as metabolites. Half-life is ~3-7 hours."
    },
    "dose": "Hypertension (ER): 120-480 mg PO once daily. Angina (IR): 80-120 mg PO 3 times daily.",
    "adverseEffects": {
      "common": ["Constipation (very common)", "dizziness", "headache", "bradycardia", "hypotension", "peripheral edema.", "gingival hyperplasia."],
      "serious": ["Severe bradycardia", "heart block (AV block)", "heart failure exacerbation", "hepatotoxicity."]
    },
    "precautions": [
      "Can cause severe bradycardia and heart block. Monitor heart rate and EKG.",
      "Can worsen heart failure due to its negative inotropic effect.",
      "Can cause severe constipation.",
      "Potent inhibitor of CYP3A4, leading to many drug interactions (e.g., increases statin levels).",
      "Avoid grapefruit juice."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe bradycardia or heart block (2nd/3rd degree)",
      "cardiogenic shock",
      "severe heart failure (HFrEF) unless patient has a pacemaker."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "vilazodone": {
    "name": "Vilazodone (Viibryd)",
    "genericName": "Vilazodone",
    "brandNames": ["Viibryd"],
    "category": "Antidepressant",
    "drugClass": "SSRI / 5-HT1A Partial Agonist",
    "indications": "Treatment of major depressive disorder (MDD).",
    "moaSteps": [
      "Vilazodone has a dual mechanism of action:",
      "1. **SSRI Activity:** It is a selective serotonin reuptake inhibitor (SSRI), which blocks the reuptake of serotonin (5-HT) and increases its concentration in the synapse.",
      "2. **Partial Agonist:** It is a partial agonist at the serotonin 5-HT1A receptor.",
      "This combination is thought to provide antidepressant effects."
    ],
    "pharmacokinetics": {
      "absorption": "Moderately absorbed. **Must be taken with food** (bioavailability ~72% with food).",
      "distribution": "Highly protein-bound (~96-99%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~25 hours."
    },
    "dose": "Initial: 10 mg PO once daily for 7 days, then 20 mg once daily. Max 40 mg/day. **Must be taken with food.**",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "vomiting", "headache", "dizziness", "insomnia.", "dry mouth."],
      "serious": ["Suicidal thoughts and behaviors", "serotonin syndrome", "seizures."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults.",
      "**Must be taken with food** to ensure adequate absorption.",
      "High incidence of GI side effects (diarrhea, nausea).",
      "Risk of Serotonin Syndrome, especially with MAOIs.",
      "Abrupt discontinuation can cause withdrawal symptoms. Taper slowly."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (within 14 days)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "vildagliptin": {
    "name": "Vildagliptin (Galvus)",
    "genericName": "Vildagliptin",
    "brandNames": ["Galvus", "Eucreas (with metformin)"],
    "category": "Antidiabetic",
    "drugClass": "Dipeptidyl Peptidase-4 (DPP-4) Inhibitor",
    "indications": "**Note: Not approved for use in the United States.** Used in Europe and other countries for the treatment of type 2 diabetes mellitus.",
    "moaSteps": [
      "Vildagliptin is a DPP-4 inhibitor.",
      "It inhibits the enzyme DPP-4, which is responsible for inactivating incretin hormones (like GLP-1 and GIP).",
      "By preventing their breakdown, it increases the levels of active incretins.",
      "This leads to a glucose-dependent increase in insulin secretion and a decrease in glucagon secretion, ultimately lowering blood glucose."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~85%.",
      "distribution": "Widely distributed. Low protein binding (~9%).",
      "metabolism": "Metabolized primarily by hydrolysis (not CYP enzymes).",
      "excretion": "Excreted in urine as metabolites. Half-life is ~3 hours."
    },
    "dose": "50 mg PO once or twice daily.",
    "adverseEffects": {
      "common": ["Nasopharyngitis", "headache", "dizziness", "nausea.", "tremor."],
      "serious": ["Hepatotoxicity (liver injury)", "pancreatitis", "severe skin reactions (SJS, bullous pemphigoid)."]
    },
    "precautions": [
      "Risk of hepatotoxicity. Monitor LFTs.",
      "Cases of acute pancreatitis have been reported. Discontinue if suspected.",
      "Can cause severe joint pain.",
      "Risk of bullous pemphigoid."
    ],
    "contraindications": [
      "Hypersensitivity."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "vinblastine": {
    "name": "Vinblastine",
    "genericName": "Vinblastine",
    "brandNames": ["Velban"],
    "category": "Antineoplastic Agent",
    "drugClass": "Vinca Alkaloid, Microtubule Inhibitor",
    "indications": "Treatment of various cancers, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, and testicular cancer (often in combination regimens like ABVD).",
    "moaSteps": [
      "Vinblastine is a vinca alkaloid (derived from the periwinkle plant).",
      "It is a microtubule inhibitor (a 'spindle poison').",
      "It binds to tubulin, the protein that forms microtubules.",
      "This action inhibits the assembly of microtubules, which are essential for forming the mitotic spindle.",
      "This arrests the cell cycle in the M-phase (mitosis), leading to cell death."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV only. **Fatal if given intrathecally.**",
      "distribution": "Widely distributed. Highly protein-bound.",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted primarily in feces (via bile). Half-life is long and triphasic (~25 hours)."
    },
    "dose": "Varies by protocol. e.g., 3.7-6 mg/m IV.",
    "adverseEffects": {
      "common": ["Myelosuppression (neutropenia, leukopenia)", "nausea", "vomiting", "constipation", "alopecia (hair loss)."],
      "serious": ["Severe myelosuppression (dose-limiting)", "neurotoxicity (less than vincristine)", "severe tissue injury (vesicant)."]
    },
    "precautions": [
      "BOXED WARNING (For IV Use Only): **Fatal if given by the intrathecal route.** Must be dispensed in an over-wrap stating 'FOR IV USE ONLY'.",
      "**Potent vesicant.** Can cause severe tissue necrosis if extravasation (leakage) occurs. Administer through a free-flowing IV line.",
      "Dose-limiting toxicity is myelosuppression (low white blood cells). Monitor CBC.",
      "Requires dose adjustment in hepatic impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**intrathecal administration**",
      "severe leukopenia."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "vincristine": {
    "name": "Vincristine (Oncovin)",
    "genericName": "Vincristine",
    "brandNames": ["Oncovin", "Vincasar PFS"],
    "category": "Antineoplastic Agent",
    "drugClass": "Vinca Alkaloid, Microtubule Inhibitor",
    "indications": "Treatment of various cancers, including acute lymphoblastic leukemia (ALL), Hodgkin's lymphoma, and non-Hodgkin's lymphoma (often in combination regimens like CHOP).",
    "moaSteps": [
      "Vincristine is a vinca alkaloid (derived from the periwinkle plant).",
      "It is a microtubule inhibitor (a 'spindle poison').",
      "It binds to tubulin and inhibits the assembly of microtubules.",
      "This action arrests the cell cycle in the M-phase (mitosis), leading to cell death."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV only. **Fatal if given intrathecally.**",
      "distribution": "Widely distributed. Highly protein-bound.",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted primarily in feces (via bile). Long half-life (~85 hours)."
    },
    "dose": "Varies by protocol. Usually capped at 2 mg per dose. e.g., 1.4 mg/m IV.",
    "adverseEffects": {
      "common": ["Peripheral neuropathy (numbness, tingling, weakness)", "constipation (paralytic ileus)", "alopecia (hair loss)."],
      "serious": ["Severe, progressive neurotoxicity (dose-limiting)", "severe constipation/paralytic ileus", "severe tissue injury (vesicant)."]
    },
    "precautions": [
      "BOXED WARNING (For IV Use Only): **Fatal if given by the intrathecal route.** Must be dispensed in an over-wrap stating 'FOR IV USE ONLY'.",
      "**Potent vesicant.** Can cause severe tissue necrosis if extravasation (leakage) occurs.",
      "**Dose-limiting toxicity is neurotoxicity** (peripheral neuropathy). Monitor for numbness, tingling, weakness, and constipation.",
      "Dose is almost always capped at 2 mg, regardless of BSA, to reduce neurotoxicity.",
      "Requires dose adjustment in hepatic impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**intrathecal administration**",
      "patients with demyelinating forms of Charcot-Marie-Tooth syndrome."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "vinorelbine": {
    "name": "Vinorelbine (Navelbine)",
    "genericName": "Vinorelbine",
    "brandNames": ["Navelbine"],
    "category": "Antineoplastic Agent",
    "drugClass": "Vinca Alkaloid, Microtubule Inhibitor",
    "indications": "Treatment of non-small cell lung cancer (NSCLC). Treatment of breast cancer.",
    "moaSteps": [
      "Vinorelbine is a semi-synthetic vinca alkaloid.",
      "It is a microtubule inhibitor.",
      "It binds to tubulin and inhibits the assembly of microtubules, arresting the cell cycle in the M-phase (mitosis) and leading to cell death."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV. **Fatal if given intrathecally.**",
      "distribution": "Widely distributed. Highly protein-bound.",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted primarily in feces (via bile). Long half-life (~28-44 hours)."
    },
    "dose": "Varies by protocol. e.g., 30 mg/m IV weekly.",
    "adverseEffects": {
      "common": ["Myelosuppression (neutropenia)", "nausea", "vomiting", "constipation", "fatigue", "alopecia (hair loss)."],
      "serious": ["Severe myelosuppression (dose-limiting)", "neurotoxicity (less than vincristine)", "severe tissue injury (vesicant)."]
    },
    "precautions": [
      "BOXED WARNING (For IV Use Only): **Fatal if given by the intrathecal route.**",
      "**Potent vesicant.** Can cause severe tissue necrosis if extravasation occurs.",
      "Dose-limiting toxicity is myelosuppression (low white blood cells). Monitor CBC.",
      "Requires dose adjustment in hepatic impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**intrathecal administration**",
      "severe neutropenia."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "vortioxetine": {
    "name": "Vortioxetine (Trintellix)",
    "genericName": "Vortioxetine",
    "brandNames": ["Trintellix", "Brintellix"],
    "category": "Antidepressant",
    "drugClass": "SSRI / Serotonin Modulator",
    "indications": "Treatment of major depressive disorder (MDD).",
    "moaSteps": [
      "Vortioxetine has a multimodal mechanism of action:",
      "1. **SSRI Activity:** It inhibits the reuptake of serotonin (5-HT).",
      "2. **Receptor Activity:** It is an antagonist at 5-HT3 and 5-HT7 receptors, and a partial agonist at 5-HT1A receptors.",
      "This combination is thought to modulate the release of several neurotransmitters (serotonin, norepinephrine, dopamine, acetylcholine) and provide antidepressant effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Bioavailability ~75%.",
      "distribution": "Widely distributed. Highly protein-bound (~98%).",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP2D6.",
      "excretion": "Excreted in urine and feces as metabolites. Very long half-life (~66 hours)."
    },
    "dose": "Initial: 10 mg PO once daily. Titrate up to max 20 mg/day.",
    "adverseEffects": {
      "common": ["Nausea (very common)", "diarrhea", "vomiting", "headache", "dizziness", "dry mouth.", "sexual dysfunction."],
      "serious": ["Suicidal thoughts and behaviors", "serotonin syndrome", "hyponatremia", "abnormal bleeding."]
    },
    "precautions": [
      "BOXED WARNING (Suicidality): Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults.",
      "High incidence of nausea, especially when starting.",
      "Risk of Serotonin Syndrome, especially with MAOIs.",
      "Abrupt discontinuation can cause withdrawal symptoms. Taper slowly."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with MAOIs (within 21 days)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "warfarin": {
    "name": "Warfarin (Coumadin, Jantoven)",
    "genericName": "Warfarin",
    "brandNames": ["Coumadin", "Jantoven"],
    "category": "Anticoagulant",
    "drugClass": "Vitamin K Antagonist",
    "indications": "Prophylaxis and treatment of venous thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation with embolization. Prevention of thromboembolic events after MI or with prosthetic heart valves.",
    "moaSteps": [
      "Warfarin is a Vitamin K antagonist.",
      "It inhibits the enzyme Vitamin K epoxide reductase complex 1 (VKORC1).",
      "This inhibition prevents the activation (gamma-carboxylation) of Vitamin K-dependent clotting factors: II (Prothrombin), VII, IX, and X, as well as anticoagulant proteins C and S.",
      "By depleting these active clotting factors, it reduces the blood's ability to clot. It takes several days for the existing factors to be depleted."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed. Bioavailability ~100%.",
      "distribution": "Highly protein-bound (~99%).",
      "metabolism": "Metabolized in the liver by CYP2C9 (S-warfarin) and CYP3A4/1A2 (R-warfarin).",
      "excretion": "Excreted in urine as metabolites. Long half-life (~20-60 hours)."
    },
    "dose": "Highly individualized. 2-10 mg PO once daily, adjusted based on INR (International Normalized Ratio).",
    "adverseEffects": {
      "common": ["Bleeding (e.g., bruising, epistaxis, hematuria)."],
      "serious": ["Major hemorrhage (GI, intracranial)", "skin necrosis", "purple toe syndrome."]
    },
    "precautions": [
      "BOXED WARNING (Bleeding Risk): Can cause major or fatal bleeding. Requires regular INR monitoring.",
      "**Narrow therapeutic index.** Requires frequent monitoring with INR (target usually 2.0-3.0).",
      "**Numerous, significant drug-drug interactions** (especially CYP2C9 inhibitors/inducers like amiodarone, fluconazole, rifampin).",
      "**Numerous drug-food interactions** (Vitamin K-containing foods, e.g., leafy greens). Patients must maintain a consistent diet.",
      "Reversal agent: Vitamin K (phytonadione)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "hemorrhagic tendencies",
      "recent surgery",
      "active bleeding",
      "**Pregnancy (Category X)**."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Compatible (does not enter breast milk)."
  },"wegovy": {
    "name": "Wegovy (Semaglutide)",
    "genericName": "Semaglutide",
    "brandNames": ["Wegovy", "Ozempic", "Rybelsus"],
    "category": "Weight Loss Agent, Antidiabetic",
    "drugClass": "Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist",
    "indications": "Chronic weight management in adults and children aged 12+ with obesity, or overweight with at least one weight-related comorbidity. Used in conjunction with diet and exercise.",
    "moaSteps": [
      "Semaglutide is a GLP-1 receptor agonist.",
      "It mimics the action of the incretin hormone GLP-1, which increases glucose-dependent insulin secretion, decreases glucagon secretion, and slows gastric emptying.",
      "For weight management, it acts on brain centers to suppress appetite and increase feelings of fullness (satiety)."
    ],
    "pharmacokinetics": {
      "absorption": "Slowly absorbed after SC injection. Peak in 1-3 days.",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Metabolized by cleavage of the peptide backbone.",
      "excretion": "Excreted in urine and feces as metabolites. Very long half-life (~1 week)."
    },
    "dose": "Dose is escalated over 16 weeks to a maintenance dose of 2.4 mg SC once weekly. Start at 0.25 mg weekly for 4 weeks.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "constipation", "abdominal pain", "headache", "fatigue."],
      "serious": ["Pancreatitis", "thyroid C-cell tumors", "acute kidney injury", "severe gastrointestinal distress."]
    },
    "precautions": [
      "BOXED WARNING (Thyroid C-cell Tumors): Has caused thyroid C-cell tumors in rodents. Unknown risk in humans. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).",
      "Risk of pancreatitis. Discontinue if suspected.",
      "Risk of dehydration from GI side effects, which can lead to acute kidney injury."
    ],
    "contraindications": [
      "Hypersensitivity",
      "personal or family history of MTC",
      "patients with MEN 2 syndrome."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "welchol": {
    "name": "Welchol (Colesevelam)",
    "genericName": "Colesevelam",
    "brandNames": ["Welchol"],
    "category": "Antihyperlipidemic, Antidiabetic",
    "drugClass": "Bile Acid Sequestrant",
    "indications": "Adjunct to diet and exercise to reduce elevated LDL-C in adults. Adjunct to diet and exercise to improve glycemic control in type 2 diabetes.",
    "moaSteps": [
      "Colesevelam is a non-absorbable, bile acid sequestrant.",
      "It binds to bile acids in the intestine, forming an insoluble complex that is excreted in the feces.",
      "This prevents the reabsorption of bile acids.",
      "To compensate, the liver must convert more cholesterol into bile acids, which it does by increasing the number of LDL receptors on its surface.",
      "This action increases the clearance of LDL-C from the blood."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed from the GI tract.",
      "distribution": "Acts locally in the GI tract.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted in feces as an insoluble complex."
    },
    "dose": "3.75 grams (6 tablets or 1 packet) PO once daily, or 1.875 grams (3 tablets) twice daily. **Must be taken with a meal and liquid.**",
    "adverseEffects": {
      "common": ["Constipation", "dyspepsia (indigestion)", "nausea", "bloating", "flatulence."],
      "serious": ["Bowel obstruction", "pancreatitis (due to increase in triglycerides)."]
    },
    "precautions": [
      "Can cause or worsen constipation. Use with caution in patients with history of bowel obstruction.",
      "Can increase triglyceride levels, especially in patients with pre-existing hypertriglyceridemia.",
      "Can interfere with the absorption of many other drugs (e.g., levothyroxine, warfarin, oral contraceptives). Administer other drugs at least 4 hours before Welchol."
    ],
    "contraindications": [
      "Hypersensitivity",
      "bowel obstruction",
      "serum triglyceride levels > 500 mg/dL."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Not absorbed; compatible."
  },
  "welireg": {
    "name": "Welireg (Belzutifan)",
    "genericName": "Belzutifan",
    "brandNames": ["Welireg"],
    "category": "Antineoplastic Agent",
    "drugClass": "Hypoxia-Inducible Factor (HIF) Inhibitor",
    "indications": "Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.",
    "moaSteps": [
      "Belzutifan is a first-in-class inhibitor of hypoxia-inducible factor 2 alpha (HIF-2).",
      "In VHL disease, the VHL protein is non-functional, leading to a buildup of HIF-2.",
      "HIF-2 then forms a complex that turns on genes promoting cell growth, proliferation, and blood vessel formation (angiogenesis).",
      "Belzutifan blocks HIF-2, preventing this complex from forming and thereby inhibiting tumor growth."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally. Peak in 1-2 hours.",
      "distribution": "Moderately protein-bound (~45%).",
      "metabolism": "Metabolized primarily by UGT2B17 and CYP2C19.",
      "excretion": "Excreted in feces and urine. Half-life is ~14 hours."
    },
    "dose": "120 mg PO once daily, with or without food.",
    "adverseEffects": {
      "common": ["Anemia", "fatigue", "headache", "dizziness", "nausea", "increased creatinine."],
      "serious": ["Severe anemia", "severe hypoxia (low oxygen levels)."]
    },
    "precautions": [
      "Can cause severe anemia, which may require blood transfusions. Monitor hemoglobin.",
      "Can cause severe hypoxia. Monitor oxygen saturation, especially at rest and with exercise.",
      "Can cause fetal harm. Use effective non-hormonal contraception.",
      "May render hormonal contraceptives ineffective."
    ],
    "contraindications": [
      "Hypersensitivity to belzutifan."
    ],
    "pregnancyCategory": "Category D (based on fetal harm).",
    "lactationInfo": "Not recommended."
  },
  "winlevi": {
    "name": "Winlevi (Clascoterone)",
    "genericName": "Clascoterone",
    "brandNames": ["Winlevi"],
    "category": "Antiacne",
    "drugClass": "Topical Androgen Receptor Inhibitor",
    "indications": "Topical treatment of acne vulgaris in patients 12 years of age and older.",
    "moaSteps": [
      "Clascoterone is a topical androgen receptor inhibitor.",
      "The exact mechanism is unknown, but it is thought to compete with androgens (like DHT) for binding to androgen receptors within the skin's sebaceous glands.",
      "By blocking this binding, it is believed to reduce sebum (oil) production and inflammation, which are key drivers of acne."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal percutaneous (skin) absorption.",
      "distribution": "Acts locally in the skin.",
      "metabolism": "Metabolized in the skin to an active metabolite.",
      "excretion": "N/A (topical)."
    },
    "dose": "Apply a thin layer to the affected skin area twice daily (morning and evening).",
    "adverseEffects": {
      "common": ["Local skin reactions (erythema/redness, scaling/dryness, itching, burning)."],
      "serious": ["Hypothalamic-pitituitary-adrenal (HPA) axis suppression (rare, with high doses/large areas)", "hyperkalemia (rare)."]
    },
    "precautions": [
      "Can cause local skin irritation.",
      "Systemic absorption can lead to HPA axis suppression, especially in children or with use over large areas."
    ],
    "contraindications": [
      "Hypersensitivity to clascoterone."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "winrevair": {
    "name": "Winrevair (Sotatercept-csrk)",
    "genericName": "Sotatercept-csrk",
    "brandNames": ["Winrevair"],
    "category": "Antihypertensive (PAH)",
    "drugClass": "Activin Signaling Inhibitor",
    "indications": "Treatment of adults with pulmonary arterial hypertension (PAH) to increase exercise capacity, improve functional class, and reduce the risk of clinical worsening events.",
    "moaSteps": [
      "Sotatercept is a fusion protein that acts as a ligand trap.",
      "It binds to and traps activins and growth differentiation factors (GDFs).",
      "In PAH, there is an imbalance in signaling pathways, favoring pro-proliferative pathways (like activin) over anti-proliferative ones.",
      "By trapping these ligands, Sotatercept helps to rebalance signaling, promoting anti-proliferative and pro-apoptotic effects in the pulmonary artery walls, thereby reducing vascular remodeling."
    ],
    "pharmacokinetics": {
      "absorption": "Administered via subcutaneous (SC) injection. Peak in ~7 days.",
      "distribution": "Widely distributed.",
      "metabolism": "Degraded into peptides and amino acids by general protein catabolism.",
      "excretion": "N/A. Long half-life (~24 days)."
    },
    "dose": "Initial: 0.3 mg/kg SC every 3 weeks. Target: 0.7 mg/kg SC every 3 weeks.",
    "adverseEffects": {
      "common": ["Increased hemoglobin (erythrocytosis)", "thrombocytopenia (low platelets)", "headache", "dizziness", "rash", "bleeding (e.g., epistaxis)."],
      "serious": ["Severe erythrocytosis (can cause stroke/clots)", "severe thrombocytopenia", "serious bleeding", "impaired fertility."]
    },
    "precautions": [
      "Can increase hemoglobin. Monitor hemoglobin before each dose for the first 5 doses. Dose may need to be adjusted.",
      "Can decrease platelet count. Do not initiate if platelets are < 50,000/mm.",
      "Can cause fetal harm. Use effective contraception.",
      "May impair fertility in males and females."
    ],
    "contraindications": [
      "Hypersensitivity",
      "platelet count < 50,000/mm."
    ],
    "pregnancyCategory": "Category D (based on fetal harm).",
    "lactationInfo": "Not recommended."
  },
  "wytensin": {
    "name": "Wytensin (Guanabenz)",
    "genericName": "Guanabenz",
    "brandNames": ["Wytensin"],
    "category": "Antihypertensive",
    "drugClass": "Alpha-2 Adrenergic Agonist (Central)",
    "indications": "Treatment of hypertension, alone or in combination with a thiazide diuretic.",
    "moaSteps": [
      "Guanabenz is a central alpha-2 adrenergic agonist.",
      "It stimulates alpha-2 receptors in the brainstem, which reduces sympathetic outflow from the CNS.",
      "This reduction in sympathetic activity leads to decreased heart rate, vasodilation (relaxation of blood vessels), and a reduction in blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (~75%). High first-pass metabolism.",
      "distribution": "Highly protein-bound (~90%).",
      "metabolism": "Extensively metabolized in the liver.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~6 hours."
    },
    "dose": "Initial: 4 mg PO twice daily. Titrate up to max 32 mg twice daily.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "dizziness", "dry mouth", "weakness.", "headache."],
      "serious": ["Severe rebound hypertension (if stopped abruptly)", "severe orthostatic hypotension", "bradycardia."]
    },
    "precautions": [
      "Can cause significant drowsiness and sedation; caution against driving.",
      "**Do not stop abruptly.** Must be tapered slowly to avoid severe rebound hypertension.",
      "Use with caution in the elderly and in patients with severe coronary disease or renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to guanabenz."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "wakix": {
    "name": "Wakix (Pitolisant)",
    "genericName": "Pitolisant",
    "brandNames": ["Wakix"],
    "category": "Narcolepsy Agent",
    "drugClass": "Histamine-3 (H3) Receptor Antagonist/Inverse Agonist",
    "indications": "Treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.",
    "moaSteps": [
      "Pitolisant is a histamine-3 (H3) receptor antagonist and inverse agonist.",
      "The H3 receptor is an autoreceptor in the brain that normally inhibits the release of histamine.",
      "By blocking the H3 receptor, pitolisant increases the synthesis and release of histamine in the brain.",
      "This increase in histaminergic neurotransmission in the brain promotes wakefulness."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~84%.",
      "distribution": "Widely distributed. Highly protein-bound (~91-99%).",
      "metabolism": "Extensively metabolized in the liver by CYP2D6 and CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~20 hours."
    },
    "dose": "Initial: 8.9 mg PO once daily in the morning. Titrate slowly over 3 weeks to a max of 35.6 mg once daily.",
    "adverseEffects": {
      "common": ["Headache", "insomnia", "nausea", "anxiety", "upper respiratory tract infection."],
      "serious": ["QT prolongation", "hallucinations", "anxiety", "psychosis."]
    },
    "precautions": [
      "Can cause QT prolongation. Avoid in patients with long QT syndrome or with other QT-prolonging drugs.",
      "Can cause psychiatric symptoms (e.g., anxiety, hallucinations).",
      "May reduce the effectiveness of hormonal contraceptives.",
      "Requires dose adjustment in renal and hepatic impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe hepatic impairment (Child-Pugh C)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "wainua": {
    "name": "Wainua (Eplontersen)",
    "genericName": "Eplontersen",
    "brandNames": ["Wainua"],
    "category": "hATTR Amyloidosis Agent",
    "drugClass": "LICA, Antisense Oligonucleotide",
    "indications": "Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN).",
    "moaSteps": [
      "Eplontersen is a ligand-conjugated antisense oligonucleotide (LICA).",
      "It is designed to target and bind to the messenger RNA (mRNA) for the transthyretin (TTR) protein.",
      "This binding causes the degradation of the TTR mRNA.",
      "By destroying the mRNA, it prevents the production of both normal (wild-type) and mutated TTR protein, reducing the TTR protein levels in the blood and slowing disease progression."
    ],
    "pharmacokinetics": {
      "absorption": "Administered via subcutaneous (SC) injection. Peak in 4 hours.",
      "distribution": "Distributes to the liver. Highly protein-bound (>98%).",
      "metabolism": "Metabolized by nucleases.",
      "excretion": "Excreted in urine. Long half-life (~26-30 days)."
    },
    "dose": "45 mg SC once monthly.",
    "adverseEffects": {
      "common": ["Decreased Vitamin A levels", "vomiting", "injection site reactions."],
      "serious": ["Severe vitamin A deficiency."]
    },
    "precautions": [
      "**Causes a reduction in serum Vitamin A levels.** Patients must take the recommended daily allowance of Vitamin A (supplementation).",
      "Monitor liver function tests.",
      "Monitor renal function."
    ],
    "contraindications": [
      "Hypersensitivity to eplontersen."
    ],
    "pregnancyCategory": "Category D (based on fetal harm in animals).",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "wayrilz": {
    "name": "Wayrilz (Rilzabrutinib)",
    "genericName": "Rilzabrutinib",
    "brandNames": ["Wayrilz"],
    "category": "ITP Agent",
    "drugClass": "Bruton's Tyrosine Kinase (BTK) Inhibitor",
    "indications": "Treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.",
    "moaSteps": [
      "Rilzabrutinib is an oral, reversible inhibitor of Bruton's tyrosine kinase (BTK).",
      "BTK is a key enzyme in the B-cell receptor signaling pathway.",
      "In ITP, B-cells produce autoantibodies that destroy platelets.",
      "By inhibiting BTK, rilzabrutinib blocks B-cell activation, reducing the production of autoantibodies and decreasing platelet destruction."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Peak in 1 hour.",
      "distribution": "Moderately protein-bound (~68%).",
      "metabolism": "Metabolized by CYP3A4 and CYP2D6.",
      "excretion": "Excreted in feces and urine. Half-life is ~1.5 hours."
    },
    "dose": "400 mg PO twice daily, with or without food.",
    "adverseEffects": {
      "common": ["Diarrhea", "nausea", "fatigue", "vomiting", "muscle pain.", "headache."],
      "serious": ["Serious infections", "hypertension", "diarrhea."]
    },
    "precautions": [
      "Risk of serious infections (bacterial, fungal, viral).",
      "Can cause hypertension. Monitor blood pressure.",
      "Can cause fetal harm. Use effective contraception.",
      "Avoid strong CYP3A4 inhibitors (e.g., ketoconazole) and inducers (e.g., rifampin)."
    ],
    "contraindications": [
      "Hypersensitivity to rilzabrutinib."
    ],
    "pregnancyCategory": "Category D (based on fetal harm).",
    "lactationInfo": "Not recommended."
  },
  "wilate": {
    "name": "Wilate (von Willebrand Factor/Coagulation Factor VIII)",
    "genericName": "von Willebrand Factor/Coagulation Factor VIII Complex (Human)",
    "brandNames": ["Wilate", "Humate-P", "Alphanate"],
    "category": "Antihemophilic Agent",
    "drugClass": "Hemostatic Agent",
    "indications": "Treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) and in patients with mild or moderate VWD where desmopressin is ineffective.",
    "moaSteps": [
      "This product is a human plasma-derived concentrate.",
      "It replaces the deficient or defective von Willebrand Factor (VWF) and Factor VIII (FVIII) in patients with VWD.",
      "**VWF** is essential for platelet adhesion to the wound site.",
      "**FVIII** is a co-factor in the intrinsic coagulation cascade, necessary for forming a stable fibrin clot.",
      "This replacement therapy allows for normal clot formation."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV.",
      "distribution": "Distributed in the plasma.",
      "metabolism": "N/A",
      "excretion": "Half-life of VWF is ~10-17 hours; FVIII is ~10-15 hours."
    },
    "dose": "Dose is individualized based on patient weight, severity of bleeding, and VWF/FVIII levels. Administered as an IV infusion.",
    "adverseEffects": {
      "common": ["Headache", "nausea", "vomiting", "infusion site reactions."],
      "serious": ["Hypersensitivity reactions (anaphylaxis)", "thromboembolic events (DVT, PE, stroke)", "inhibitor antibody formation."]
    },
    "precautions": [
      "Can cause severe hypersensitivity reactions. Discontinue if symptoms occur.",
      "Risk of thromboembolic events, especially with high or frequent doses. Monitor FVIII levels.",
      "Risk of transmitting infectious agents, as it is derived from human plasma.",
      "Patients may develop inhibitor antibodies to VWF or FVIII."
    ],
    "contraindications": [
      "Known hypersensitivity to the product or its components."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "winrho-sdf": {
    "name": "WinRho SDF (Rho(D) Immune Globulin)",
    "genericName": "Rho(D) Immune Globulin (Human)",
    "brandNames": ["WinRho SDF", "RhoGAM", "Rhophylac"],
    "category": "Immunizing Agent",
    "drugClass": "Immune Globulin",
    "indications": "Treatment of Immune Thrombocytopenic Purpura (ITP) in Rh(D)-positive patients. Prevention of Rh alloimmunization in Rh(D)-negative pregnant women.",
    "moaSteps": [
      "For ITP: The mechanism is not fully understood. It is thought that the anti-D antibodies bind to the patient's Rh(D)-positive red blood cells (RBCs), which are then cleared by the spleen. This 'saturates' the spleen, sparing the antibody-coated platelets from destruction.",
      "For Pregnancy: It prevents the Rh-negative mother from developing antibodies against Rh-positive fetal RBCs that may enter her circulation. The injected antibodies clear any fetal RBCs before the mother's immune system can react to them."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV or IM. Peak in 2 hours (IV) or 5-10 days (IM).",
      "distribution": "Widely distributed.",
      "metabolism": "N/A",
      "excretion": "Long half-life (~24 days)."
    },
    "dose": "ITP: 50 mcg/kg IV as a single dose. Pregnancy: 300 mcg IM or IV at 28 weeks gestation and within 72 hours of delivery.",
    "adverseEffects": {
      "common": ["Headache", "fever", "chills", "injection site pain", "nausea."],
      "serious": ["Intravascular hemolysis (IVH)", "anaphylaxis", "thromboembolic events", "renal failure."]
    },
    "precautions": [
      "BOXED WARNING (Intravascular Hemolysis): Can cause severe, life-threatening intravascular hemolysis (RBC destruction), anemia, and renal failure when used for ITP. Monitor patients for 8 hours after administration.",
      "Risk of transmitting infectious agents, as it is derived from human plasma.",
      "Risk of thromboembolic events."
    ],
    "contraindications": [
      "Hypersensitivity",
      "IgA deficiency with known antibodies to IgA",
      "use in Rh(D)-negative patients for ITP.",
      "use in Rh(D)-positive patients for pregnancy prophylaxis."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Compatible."
  },
  "wynzora": {
    "name": "Wynzora (Betamethasone/Calcipotriene)",
    "genericName": "Betamethasone Dipropionate and Calcipotriene",
    "brandNames": ["Wynzora", "Taclonex", "Enstilar"],
    "category": "Antipsoriatic",
    "drugClass": "Corticosteroid / Vitamin D Analog Combination",
    "indications": "Topical treatment of plaque psoriasis in adults.",
    "moaSteps": [
      "This is a combination product:",
      "1. **Betamethasone (Corticosteroid):** A potent topical steroid that binds to glucocorticoid receptors, suppressing inflammation, itching, and vasoconstriction.",
      "2. **Calcipotriene (Vitamin D Analog):** A synthetic Vitamin D analog that binds to the Vitamin D receptor (VDR). This inhibits skin cell proliferation (keratinocyte proliferation) and promotes normal cell differentiation."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption from intact skin.",
      "distribution": "Acts locally in the skin.",
      "metabolism": "If absorbed, both are metabolized (Betamethasone by CYPs, Calcipotriene to inactive metabolites).",
      "excretion": "N/A (topical)."
    },
    "dose": "Apply a thin layer to the affected area once daily for up to 8 weeks.",
    "adverseEffects": {
      "common": ["Local skin irritation (burning, itching, redness)", "folliculitis", "upper respiratory tract infection.", "headache."],
      "serious": ["Adrenal suppression (HPA axis suppression)", "hypercalcemia (high calcium levels)", "Cushing's syndrome", "glaucoma/cataracts (if used near eyes)."]
    },
    "precautions": [
      "Risk of systemic absorption, which can cause HPA axis suppression or hypercalcemia. Do not exceed max dose or use for >8 weeks.",
      "Do not apply to face, groin, or axillae.",
      "Can cause photosensitivity. Avoid sun exposure."
    ],
    "contraindications": [
      "Hypersensitivity to either component."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "wart-off": {
    "name": "Wart-Off (Salicylic Acid)",
    "genericName": "Salicylic Acid",
    "brandNames": ["Wart-Off", "Compound W", "Dr. Scholl's Wart Remover"],
    "category": "Keratolytic Agent",
    "drugClass": "Keratolytic",
    "indications": "Topical treatment for the removal of common and plantar warts.",
    "moaSteps": [
      "Salicylic acid is a keratolytic agent.",
      "It works by softening and breaking down keratin, a protein that makes up the outer layer of skin and the structure of the wart.",
      "This action causes the wart to peel away slowly.",
      "It may also cause a mild irritation that triggers an immune response against the wart virus."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed percutaneously (through the skin). Systemic toxicity is rare with normal use.",
      "distribution": "Acts locally.",
      "metabolism": "Metabolized to salicyluric acid and other metabolites.",
      "excretion": "Excreted in urine."
    },
    "dose": "Apply 1-2 drops of liquid or a thin layer of gel to the wart once or twice daily, for up to 12 weeks. Soak wart in warm water for 5 minutes before applying.",
    "adverseEffects": {
      "common": ["Local skin irritation", "burning", "stinging", "peeling", "dryness."],
      "serious": ["Severe skin irritation or chemical burn", "salicylate toxicity (rare, with overuse on large areas)."]
    },
    "precautions": [
      "For external use only. Do not use on face, moles, birthmarks, or genital warts.",
      "**Do not use in patients with diabetes or poor blood circulation** (risk of infection/ulceration).",
      "Avoid contact with healthy skin, eyes, and mucous membranes.",
      "Flammable (liquid/gel forms). Keep away from fire or flame."
    ],
    "contraindications": [
      "Hypersensitivity to salicylic acid",
      "patients with diabetes",
      "patients with poor blood circulation."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Use with caution; avoid applying to areas that may contact the infant."
  },
  "wyost": {
    "name": "Wyost (Denosumab)",
    "genericName": "Denosumab",
    "brandNames": ["Wyost", "Xgeva", "Prolia"],
    "category": "Bone Resorption Inhibitor",
    "drugClass": "RANK Ligand (RANKL) Inhibitor, Monoclonal Antibody",
    "indications": "Wyost/Xgeva: Prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Prolia: Treatment of osteoporosis in postmenopausal women at high risk for fracture.",
    "moaSteps": [
      "Denosumab is a human monoclonal antibody (IgG2).",
      "It targets and binds with high affinity to RANK Ligand (RANKL), a protein essential for the formation, function, and survival of osteoclasts (cells that break down bone).",
      "By binding to and inhibiting RANKL, denosumab prevents the activation of osteoclasts.",
      "This action decreases bone resorption (breakdown), increases bone mineral density, and reduces the risk of fractures or SREs."
    ],
    "pharmacokinetics": {
      "absorption": "Administered via subcutaneous (SC) injection. Slow absorption. Bioavailability ~61-64%.",
      "distribution": "Confined to vascular compartment.",
      "metabolism": "Degraded into peptides and amino acids by general protein catabolism.",
      "excretion": "N/A. Long half-life (~25-32 days)."
    },
    "dose": "Wyost/Xgeva: 120 mg SC once every 4 weeks. Prolia: 60 mg SC once every 6 months.",
    "adverseEffects": {
      "common": ["Back pain", "arthralgia (joint pain)", "fatigue", "nausea", "hypocalcemia", "hypophosphatemia."],
      "serious": ["Severe hypocalcemia", "Osteonecrosis of the Jaw (ONJ)", "atypical femur fractures", "serious infections."]
    },
    "precautions": [
      "Can cause severe, symptomatic hypocalcemia. **Must correct pre-existing hypocalcemia** before starting. Ensure adequate calcium and vitamin D intake.",
      "Risk of Osteonecrosis of the Jaw (ONJ). Dental exam and preventive dentistry are recommended before starting.",
      "Risk of atypical femur fractures.",
      "Risk of serious infections."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**pre-existing hypocalcemia**",
      "**Pregnancy (Category X)**."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "wera": {
    "name": "Wera (Ethinyl Estradiol/Norethindrone)",
    "genericName": "Ethinyl Estradiol and Norethindrone",
    "brandNames": ["Wera", "Loestrin", "Junel", "Microgestin"],
    "category": "Contraceptive",
    "drugClass": "Oral Contraceptive, Combination (Estrogen/Progestin)",
    "indications": "Prevention of pregnancy. Treatment of moderate acne vulgaris.",
    "moaSteps": [
      "This is a combination oral contraceptive:",
      "1. **Norethindrone (Progestin):** Suppresses the luteinizing hormone (LH) surge, which prevents ovulation. It also thickens cervical mucus, impeding sperm transit.",
      "2. **Ethinyl Estradiol (Estrogen):** Suppresses follicle-stimulating hormone (FSH) to prevent follicular development and stabilizes the endometrial lining to prevent irregular bleeding."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed.",
      "distribution": "Highly protein-bound (to albumin and SHBG).",
      "metabolism": "Both components are extensively metabolized in the liver (CYP3A4).",
      "excretion": "Excreted in urine and feces as metabolites."
    },
    "dose": "1 tablet PO once daily at the same time each day.",
    "adverseEffects": {
      "common": ["Breakthrough bleeding/spotting", "nausea", "headache", "breast tenderness", "weight gain", "mood changes."],
      "serious": ["Thromboembolic events (DVT, PE, stroke, MI)", "hypertension", "liver tumors."]
    },
    "precautions": [
      "BOXED WARNING (Smoking and Cardiovascular Risk): Cigarette smoking increases the risk of serious cardiovascular events. This risk increases with age and heavy smoking (>15 cigarettes/day). **Not recommended for women over 35 who smoke.**",
      "Increased risk of blood clots.",
      "Does not protect against STDs."
    ],
    "contraindications": [
      "Hypersensitivity",
      "high risk of arterial or venous thrombotic disease (e.g., history of DVT/PE, stroke, MI)",
      "**women >35 who smoke**",
      "uncontrolled hypertension",
      "migraine with aura",
      "known or suspected breast cancer."
    ],
    "pregnancyCategory": "Category X",
    "lactationInfo": "Not recommended; can reduce milk production."
  },"xanax": {
    "name": "Xanax (Alprazolam)",
    "genericName": "Alprazolam",
    "brandNames": ["Xanax", "Xanax XR", "Niravam"],
    "category": "Anxiolytic, Sedative-Hypnotic",
    "drugClass": "Benzodiazepine (Short-acting) (Schedule IV)",
    "simpleSummary": "Xanax is used to treat anxiety and panic disorders. It works by calming the brain.<br><br><strong>Most Important Things to Know:</strong><br>1. This medicine can be habit-forming. Only take it as prescribed.<br>2. Do not mix with alcohol or opioids, as this can be fatal.<br>3. Do not stop taking it suddenly, as this can cause dangerous withdrawal.",
    "indications": "Management of anxiety disorders. Short-term relief of anxiety. Treatment of panic disorder, with or without agoraphobia.",
    "moaSteps": [
      "Alprazolam is a positive allosteric modulator of the GABA-A receptor.",
      "It binds to the benzodiazepine site, enhancing the effect of the inhibitory neurotransmitter GABA.",
      "This increases the *frequency* of chloride channel opening, leading to hyperpolarization and CNS depression (anxiolytic and sedative effects)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and well absorbed from the GI tract. Peak concentration in 1-2 hours.",
      "distribution": "Widely distributed. 80% bound to plasma proteins.",
      "metabolism": "Extensively metabolized in the liver, primarily by CYP3A4.",
      "excretion": "Excreted in the urine as metabolites. Half-life is ~11.2 hours."
    },
    "dose": "Anxiety: 0.25-0.5 mg PO 3 times daily, titrate to max 4 mg/day. Panic Disorder: 0.5-1 mg PO 3 times daily, titrate to max 10 mg/day.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "dizziness", "ataxia", "fatigue", "slurred speech."],
      "serious": ["Respiratory depression", "abuse, misuse, and addiction", "severe hypotension."]
    },
    "precautions": [
      "BOXED WARNING (Risks with Opioids): Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.",
      "BOXED WARNING (Abuse, Misuse, Addiction): Risk of abuse, misuse, and addiction.",
      "BOXED WARNING (Dependence and Withdrawal): Physical dependence and severe, life-threatening withdrawal reactions can occur. Taper dose slowly."
    ],
    "contraindications": [
      "Hypersensitivity to benzodiazepines",
      "acute narrow-angle glaucoma",
      "concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole)."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "xarelto": {
    "name": "Xarelto (Rivaroxaban)",
    "genericName": "Rivaroxaban",
    "brandNames": ["Xarelto"],
    "category": "Anticoagulant",
    "drugClass": "Factor Xa Inhibitor (Direct Oral Anticoagulant - DOAC)",
    "simpleSummary": "Xarelto is a blood thinner used to treat and prevent dangerous blood clots, which can cause a stroke or clots in the legs/lungs.<br><br><strong>Most Important Things to Know:</strong><br>1. <strong>Doses of 15 mg and 20 mg must be taken with food</strong> to work correctly.<br>2. Do not stop taking this suddenly without your doctor's permission, as this can increase your risk of a stroke.<br>3. You may bruise or bleed more easily. Call your doctor for any severe or uncontrollable bleeding.",
    "indications": "Prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Prophylaxis of DVT following hip or knee replacement. Treatment of DVT and PE.",
    "moaSteps": [
      "Rivaroxaban is a direct, selective, and reversible inhibitor of Factor Xa (FXa).",
      "It inhibits both free and clot-bound Factor Xa.",
      "By inhibiting FXa, it decreases the conversion of prothrombin (Factor II) to thrombin (Factor IIa), thus preventing fibrin clot formation."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High bioavailability (doses 15 mg **must be taken with food**).",
      "distribution": "Highly protein-bound (~92-95%).",
      "metabolism": "Metabolized in the liver by CYP3A4/3A5 and CYP2J2.",
      "excretion": "Excreted in urine and feces. Half-life is ~5-9 hours."
    },
    "dose": "A-fib: 20 mg PO once daily **with the evening meal**. DVT/PE Treatment: 15 mg PO twice daily **with food** for 21 days, then 20 mg PO once daily **with food**.",
    "adverseEffects": {
      "common": ["Bleeding (e.g., bruising, epistaxis)."],
      "serious": ["Major bleeding (intracranial hemorrhage, GI bleed)", "epidural or spinal hematoma."]
    },
    "precautions": [
      "BOXED WARNING (Premature Discontinuation): Discontinuing rivaroxaban prematurely increases the risk of thrombotic events (e.g., stroke).",
      "BOXED WARNING (Spinal/Epidural Hematoma): Patients receiving neuraxial anesthesia (spinal/epidural) are at risk of developing an epidural or spinal hematoma, which can result in long-term or permanent paralysis.",
      "Reversal agent: Andexanet alfa."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active pathological bleeding",
      "severe renal impairment (CrCl < 15 mL/min)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "xeljanz": {
    "name": "Xeljanz (Tofacitinib)",
    "genericName": "Tofacitinib",
    "brandNames": ["Xeljanz", "Xeljanz XR"],
    "category": "Antirheumatic, Immunosuppressant",
    "drugClass": "Janus Kinase (JAK) Inhibitor, DMARD",
    "indications": "Treatment of moderate to severe rheumatoid arthritis (RA). Treatment of active psoriatic arthritis. Treatment of moderate to severe ulcerative colitis.",
    "moaSteps": [
      "Tofacitinib is a Janus Kinase (JAK) inhibitor.",
      "JAKs are intracellular enzymes that are part of the signaling pathway for many inflammatory cytokines.",
      "By inhibiting JAKs, tofacitinib prevents the signaling of these cytokines, thus reducing inflammation and immune cell function."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~74%.",
      "distribution": "Moderately protein-bound (~40%).",
      "metabolism": "Metabolized in the liver by CYP3A4 and CYP2C19.",
      "excretion": "Excreted in urine as metabolites and unchanged drug. Half-life is ~3 hours."
    },
    "dose": "RA: 5 mg PO twice daily (IR) or 11 mg PO once daily (XR).",
    "adverseEffects": {
      "common": ["Upper respiratory tract infection", "nasopharyngitis", "headache", "diarrhea", "hypertension."],
      "serious": ["Serious infections (e.g., TB, fungal infections)", "malignancy (lymphoma)", "thrombosis (blood clots)", "GI perforation."]
    },
    "precautions": [
      "BOXED WARNING (Serious Infections): Increased risk of serious infections that may lead to hospitalization or death (e.g., TB, bacterial sepsis, invasive fungal infections). Must test for latent TB before starting.",
      "BOXED WARNING (Malignancy): Lymphoma and other malignancies have been reported.",
      "BOXED WARNING (Thrombosis): Increased risk of thrombosis (DVT, PE, arterial thrombosis).",
      "BOXED WARNING (Mortality): Increased risk of all-cause mortality, especially with higher doses in certain patients."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active serious infection",
      "severe hepatic impairment."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Not recommended."
  },
  "xolair": {
    "name": "Xolair (Omalizumab)",
    "genericName": "Omalizumab",
    "brandNames": ["Xolair"],
    "category": "Antiasthmatic",
    "drugClass": "Monoclonal Antibody, Anti-IgE",
    "indications": "Treatment of moderate to severe persistent asthma in patients with a positive skin test to a perennial allergen. Treatment of chronic idiopathic urticaria (hives). Treatment of nasal polyps.",
    "moaSteps": [
      "Omalizumab is a recombinant humanized monoclonal antibody.",
      "It selectively binds to free human immunoglobulin E (IgE) in the blood.",
      "By binding to IgE, it prevents IgE from attaching to its receptor on mast cells and basophils.",
      "This action inhibits the release of inflammatory mediators (like histamine and leukotrienes) that cause the allergic and inflammatory response in asthma."
    ],
    "pharmacokinetics": {
      "absorption": "Slowly absorbed after SC injection. Peak in 7-8 days.",
      "distribution": "Low volume of distribution.",
      "metabolism": "Degraded by general protein catabolism.",
      "excretion": "Excreted in bile. Long half-life (~26 days)."
    },
    "dose": "Dose is based on body weight and pre-treatment IgE levels. 150-375 mg SC every 2 or 4 weeks.",
    "adverseEffects": {
      "common": ["Injection site reactions", "headache", "pharyngitis", "viral infections.", "arthralgia."],
      "serious": ["Anaphylaxis", "malignancy (cancers)."]
    },
    "precautions": [
      "BOXED WARNING (Anaphylaxis): Can cause severe, life-threatening anaphylaxis. Can occur after any dose, even if previous doses were tolerated. Must be administered in a healthcare setting equipped to manage anaphylaxis."
    ],
    "contraindications": [
      "Hypersensitivity to omalizumab."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "xopenex": {
    "name": "Xopenex (Levalbuterol)",
    "genericName": "Levalbuterol",
    "brandNames": ["Xopenex", "Xopenex HFA"],
    "category": "Bronchodilator",
    "drugClass": "Short-acting beta-2 adrenergic agonist (SABA)",
    "indications": "Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma, COPD).",
    "moaSteps": [
      "Levalbuterol is the (R)-enantiomer of albuterol.",
      "It is a selective beta-2 adrenergic receptor agonist.",
      "Binding to beta-2 receptors on airway smooth muscle activates adenylyl cyclase, increasing intracellular cAMP.",
      "This leads to relaxation of bronchial smooth muscle and subsequent bronchodilation (opening of the airways)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed after inhalation. Onset: 5-15 minutes.",
      "distribution": "Peak effect in 30-60 minutes. Duration: 4-6 hours.",
      "metabolism": "Metabolized by sulfation.",
      "excretion": "Excreted in urine."
    },
    "dose": "Inhalation (MDI): 2 inhalations (90 mcg) every 4-6 hours as needed. Nebulization: 0.63-1.25 mg 3-4 times daily as needed.",
    "adverseEffects": {
      "common": ["Tremor", "nervousness", "headache", "tachycardia", "palpitations", "dizziness."],
      "serious": ["Paradoxical bronchospasm", "hypokalemia", "cardiovascular events (arrhythmias)."]
    },
    "precautions": [
      "Use of a SABA more than 2 days/week for symptoms indicates inadequate long-term control.",
      "Use with caution in patients with cardiovascular disease, hyperthyroidism, or diabetes.",
      "Can cause hypokalemia."
    ],
    "contraindications": [
      "Hypersensitivity to levalbuterol or albuterol."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "xifaxan": {
    "name": "Xifaxan (Rifaximin)",
    "genericName": "Rifaximin",
    "brandNames": ["Xifaxan"],
    "category": "Antibiotic",
    "drugClass": "Rifamycin Antibiotic",
    "indications": "Treatment of traveler's diarrhea caused by noninvasive E. coli. Reduction of risk of overt hepatic encephalopathy (HE) recurrence. Treatment of irritable bowel syndrome with diarrhea (IBS-D).",
    "moaSteps": [
      "Rifaximin is a rifamycin-class antibiotic.",
      "It inhibits bacterial protein synthesis by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase.",
      "This action blocks the transcription step, preventing RNA synthesis.",
      "It is *not* absorbed from the GI tract, so it acts locally in the gut."
    ],
    "pharmacokinetics": {
      "absorption": "Very poorly absorbed (<0.4%). It is not for systemic infections.",
      "distribution": "Acts locally in the GI tract.",
      "metabolism": "N/A (not absorbed).",
      "excretion": "Excreted primarily unchanged in the feces."
    },
    "dose": "Traveler's Diarrhea: 200 mg PO 3 times daily for 3 days. Hepatic Encephalopathy: 550 mg PO twice daily. IBS-D: 550 mg PO 3 times daily for 14 days.",
    "adverseEffects": {
      "common": ["Nausea", "headache", "peripheral edema", "dizziness", "fatigue."],
      "serious": ["Hypersensitivity reactions", "C. difficile-associated diarrhea (rare)."]
    },
    "precautions": [
      "Not effective for diarrhea complicated by fever, bloody stools, or invasive pathogens (e.g., Salmonella, Shigella).",
      "Prolonged use may result in fungal or bacterial superinfection.",
      "Generally well-tolerated due to lack of systemic absorption."
    ],
    "contraindications": [
      "Hypersensitivity to rifaximin or other rifamycins (e.g., rifampin)."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "xalkori": {
    "name": "Xalkori (Crizotinib)",
    "genericName": "Crizotinib",
    "brandNames": ["Xalkori"],
    "category": "Antineoplastic Agent",
    "drugClass": "Tyrosine Kinase Inhibitor (TKI), ALK Inhibitor",
    "indications": "Treatment of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS1-positive.",
    "moaSteps": [
      "Crizotinib is a tyrosine kinase inhibitor (TKI).",
      "It targets and inhibits the ALK and ROS1 receptor tyrosine kinases.",
      "In certain lung cancers, a gene fusion (e.g., EML4-ALK) creates a constitutively active ALK protein, which drives uncontrolled cell growth.",
      "By blocking ALK, crizotinib inhibits the signaling pathways that promote cancer cell proliferation and survival."
    ],
    "pharmacokinetics": {
      "absorption": "Moderately absorbed. Bioavailability ~43%.",
      "distribution": "Widely distributed. Highly protein-bound (~95%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted primarily in feces. Long half-life (~42 hours)."
    },
    "dose": "250 mg PO twice daily, with or without food.",
    "adverseEffects": {
      "common": ["Vision disorders (visual impairment, floaters)", "nausea", "vomiting", "diarrhea", "constipation", "edema", "fatigue.", "elevated LFTs."],
      "serious": ["Hepatotoxicity (liver failure)", "interstitial lung disease (ILD)", "QT prolongation", "bradycardia."]
    },
    "precautions": [
      "Risk of severe, fatal hepatotoxicity. Monitor LFTs frequently.",
      "Risk of severe, fatal interstitial lung disease (ILD).",
      "Risk of QT prolongation and bradycardia. Monitor EKG and electrolytes.",
      "Can cause severe vision disorders. Advise patients to use caution when driving."
    ],
    "contraindications": [
      "Hypersensitivity",
      "concomitant use with strong CYP3A4 inhibitors or inducers."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "xgeva": {
    "name": "Xgeva (Denosumab)",
    "genericName": "Denosumab",
    "brandNames": ["Xgeva", "Prolia", "Wyost"],
    "category": "Bone Resorption Inhibitor",
    "drugClass": "RANK Ligand (RANKL) Inhibitor, Monoclonal Antibody",
    "indications": "Prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Treatment of giant cell tumor of bone.",
    "moaSteps": [
      "Denosumab is a human monoclonal antibody (IgG2).",
      "It targets and binds with high affinity to RANK Ligand (RANKL), a protein essential for the formation, function, and survival of osteoclasts (cells that break down bone).",
      "By binding to and inhibiting RANKL, denosumab prevents the activation of osteoclasts.",
      "This action decreases bone resorption (breakdown) and reduces the risk of fractures or SREs."
    ],
    "pharmacokinetics": {
      "absorption": "Administered via subcutaneous (SC) injection. Slow absorption.",
      "distribution": "Confined to vascular compartment.",
      "metabolism": "Degraded into peptides and amino acids by general protein catabolism.",
      "excretion": "N/A. Long half-life (~25-32 days)."
    },
    "dose": "120 mg SC once every 4 weeks.",
    "adverseEffects": {
      "common": ["Back pain", "arthralgia (joint pain)", "fatigue", "nausea", "hypocalcemia", "hypophosphatemia."],
      "serious": ["Severe hypocalcemia", "Osteonecrosis of the Jaw (ONJ)", "atypical femur fractures", "serious infections."]
    },
    "precautions": [
      "Can cause severe, symptomatic hypocalcemia. **Must correct pre-existing hypocalcemia** before starting. Ensure adequate calcium and vitamin D intake.",
      "Risk of Osteonecrosis of the Jaw (ONJ). Dental exam and preventive dentistry are recommended before starting.",
      "Risk of atypical femur fractures."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**pre-existing hypocalcemia**",
      "**Pregnancy (Category X)**."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "xyzal": {
    "name": "Xyzal (Levocetirizine)",
    "genericName": "Levocetirizine",
    "brandNames": ["Xyzal"],
    "category": "Antihistamine",
    "drugClass": "Antihistamine, 2nd Generation",
    "indications": "Relief of symptoms associated with seasonal and perennial allergic rhinitis. Treatment of chronic idiopathic urticaria (hives).",
    "moaSteps": [
      "Levocetirizine is the active (R)-enantiomer of cetirizine.",
      "It is a potent and selective antagonist of peripheral H1-receptors.",
      "By blocking histamine from binding to H1-receptors, it reduces the symptoms of allergy (e.g., sneezing, itching, runny nose, watery eyes).",
      "It has minimal CNS penetration, making it 'low-sedating'."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and well absorbed. Food delays absorption.",
      "distribution": "Highly protein-bound (~91-92%).",
      "metabolism": "Minimally metabolized.",
      "excretion": "Excreted primarily unchanged in the urine. Half-life is ~8-9 hours."
    },
    "dose": "5 mg PO once daily in the evening.",
    "adverseEffects": {
      "common": ["Somnolence (drowsiness)", "fatigue", "dry mouth", "nasopharyngitis."],
      "serious": ["Hypersensitivity reactions", "worsening of urinary retention."]
    },
    "precautions": [
      "Can cause somnolence, although less than 1st-gen antihistamines. Use caution when driving.",
      "Avoid alcohol and other CNS depressants.",
      "Requires dose adjustment in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to levocetirizine or cetirizine",
      "end-stage renal disease (CrCl < 10 mL/min)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "xultophy": {
    "name": "Xultophy (Insulin Degludec/Liraglutide)",
    "genericName": "Insulin Degludec and Liraglutide",
    "brandNames": ["Xultophy"],
    "category": "Antidiabetic",
    "drugClass": "Long-Acting Insulin / GLP-1 Receptor Agonist Combination",
    "indications": "Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.",
    "moaSteps": [
      "This is a combination product:",
      "1. **Insulin Degludec (Long-Acting Insulin):** Provides basal insulin coverage. It binds to insulin receptors to promote glucose uptake by cells and inhibit hepatic glucose production.",
      "2. **Liraglutide (GLP-1 Agonist):** Mimics the GLP-1 hormone, which increases glucose-dependent insulin secretion, decreases glucagon secretion, and slows gastric emptying."
    ],
    "pharmacokinetics": {
      "absorption": "Slow, sustained absorption from SC injection.",
      "distribution": "Both components are highly protein-bound.",
      "metabolism": "Both are metabolized (peptides).",
      "excretion": "Both have long half-lives (Degludec ~25h, Liraglutide ~13h)."
    },
    "dose": "Individualized. Administered as a SC injection once daily. Start at 10 units (10 units degludec/0.36 mg liraglutide) daily.",
    "adverseEffects": {
      "common": ["Hypoglycemia", "nausea", "diarrhea", "headache", "nasopharyngitis."],
      "serious": ["Pancreatitis", "thyroid C-cell tumors", "severe hypoglycemia."]
    },
    "precautions": [
      "BOXED WARNING (Thyroid C-cell Tumors): Liraglutide has caused thyroid C-cell tumors in rodents. Contraindicated in patients with a personal or family history of MTC or MEN 2.",
      "Risk of pancreatitis.",
      "Do not mix with other insulins.",
      "Risk of hypoglycemia; monitor blood glucose."
    ],
    "contraindications": [
      "Hypersensitivity",
      "during episodes of hypoglycemia",
      "personal or family history of MTC or MEN 2."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Not recommended."
  },
  "xofigo": {
    "name": "Xofigo (Radium-223)",
    "genericName": "Radium Ra 223 Dichloride",
    "brandNames": ["Xofigo"],
    "category": "Antineoplastic Agent",
    "drugClass": "Radiopharmaceutical, Alpha-emitter",
    "indications": "Treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases.",
    "moaSteps": [
      "Xofigo is a radiopharmaceutical.",
      "Radium-223 is an alpha-particle emitter that mimics calcium.",
      "It forms a complex with hydroxyapatite (a bone mineral) and is selectively taken up in areas of high bone turnover, such as bone metastases.",
      "The high-energy alpha particles it emits cause localized, double-strand DNA breaks in the adjacent tumor cells, leading to cell death.",
      "The short path length of alpha particles minimizes damage to surrounding healthy tissue."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV.",
      "distribution": "Rapidly clears from blood and localizes to bone.",
      "metabolism": "Radioactive decay. Does not involve CYP enzymes.",
      "excretion": "Excreted primarily in feces. Half-life is ~11.4 days."
    },
    "dose": "55 kBq/kg (1.49 microcurie/kg) IV, given every 4 weeks for 6 cycles.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "peripheral edema", "anemia", "neutropenia.", "thrombocytopenia."],
      "serious": ["Severe myelosuppression (neutropenia, thrombocytopenia)", "renal failure."]
    },
    "precautions": [
      "**Radiopharmaceutical:** Must be handled with appropriate safety measures to minimize radiation exposure.",
      "Can cause severe bone marrow suppression. Monitor CBCs before each dose.",
      "Handle patient's bodily fluids with care (radiation precaution)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "**Pregnancy (Category X)**."
    ],
    "pregnancyCategory": "Category X. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "xylocaine": {
    "name": "Xylocaine (Lidocaine)",
    "genericName": "Lidocaine",
    "brandNames": ["Xylocaine (injection)", "Lidoderm (patch)"],
    "category": "Local Anesthetic, Antiarrhythmic",
    "drugClass": "Local Anesthetic (Amide), Antiarrhythmic (Class Ib)",
    "indications": "Local/Regional Anesthesia: Infiltration, nerve blocks, epidurals. Antiarrhythmic: Treatment of ventricular arrhythmias (e.g., VT/VF) after MI. Topical: Relief of pain.",
    "moaSteps": [
      "As a local anesthetic: Lidocaine blocks voltage-gated sodium channels on the inside of the nerve cell membrane.",
      "This action prevents the initiation and conduction of nerve impulses, leading to a loss of pain sensation.",
      "As an antiarrhythmic: It blocks sodium channels in cardiac muscle, shortening the action potential duration and suppressing arrhythmias."
    ],
    "pharmacokinetics": {
      "absorption": "Completely absorbed after injection. Topical absorption varies.",
      "distribution": "Widely distributed. Moderately protein-bound (~60-80%).",
      "metabolism": "Extensively metabolized in the liver by CYP1A2 and CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Short half-life (~1.5-2 hours)."
    },
    "dose": "Varies widely by indication and formulation. e.g., Infiltration: 0.5-1% solution.",
    "adverseEffects": {
      "common": ["(Topical) Skin redness, irritation.", "(Systemic) Dizziness, lightheadedness, drowsiness, metallic taste."],
      "serious": ["(Systemic) CNS toxicity (seizures, coma)", "cardiotoxicity (bradycardia, hypotension, cardiac arrest)."]
    },
    "precautions": [
      "Risk of systemic toxicity (CNS and cardiac) if excessive amounts are absorbed.",
      "Use with caution in patients with severe hepatic impairment or heart block.",
      "Ensure correct formulation is used (e.g., formulations with epinephrine are for local anesthesia only, NEVER IV)."
    ],
    "contraindications": [
      "Hypersensitivity to amide-type local anesthetics",
      "severe heart block (for antiarrhythmic use)."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk in small amounts; use with caution."
  },
  "xigduo": {
    "name": "Xigduo XR (Dapagliflozin/Metformin)",
    "genericName": "Dapagliflozin and Metformin",
    "brandNames": ["Xigduo XR"],
    "category": "Antidiabetic",
    "drugClass": "SGLT2 Inhibitor / Biguanide Combination",
    "indications": "Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "moaSteps": [
      "This is a combination product:",
      "1. **Dapagliflozin (SGLT2 Inhibitor):** Inhibits SGLT2 in the renal tubules, blocking glucose reabsorption and increasing urinary glucose excretion.",
      "2. **Metformin (Biguanide):** Decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves peripheral insulin sensitivity."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed as an extended-release formulation.",
      "distribution": "Widely distributed.",
      "metabolism": "Dapagliflozin is metabolized by UGT. Metformin is not metabolized.",
      "excretion": "Dapagliflozin excreted in urine/feces. Metformin excreted unchanged in urine."
    },
    "dose": "Individualized. e.g., 5 mg dapagliflozin / 1000 mg metformin ER PO once daily in the morning.",
    "adverseEffects": {
      "common": ["Genital mycotic infections", "UTIs", "diarrhea", "nausea/vomiting", "headache."],
      "serious": ["Lactic acidosis (Metformin)", "ketoacidosis (Dapagliflozin)", "acute kidney injury", "Fournier's gangrene."]
    },
    "precautions": [
      "BOXED WARNING (Lactic Acidosis): Metformin can cause a rare but fatal lactic acidosis. Risk increases with renal impairment.",
      "Risk of ketoacidosis (can occur with normal blood glucose).",
      "Risk of serious genital and urinary tract infections.",
      "Can cause volume depletion and hypotension."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe renal impairment (eGFR < 30)",
      "acute or chronic metabolic acidosis (including diabetic ketoacidosis)."
    ],
    "pregnancyCategory": "Category C. Not recommended in 2nd/3rd trimesters.",
    "lactationInfo": "Not recommended."
  },
  "xospata": {
    "name": "Xospata (Gilteritinib)",
    "genericName": "Gilteritinib",
    "brandNames": ["Xospata"],
    "category": "Antineoplastic Agent",
    "drugClass": "Tyrosine Kinase Inhibitor (TKI), FLT3 Inhibitor",
    "indications": "Treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.",
    "moaSteps": [
      "Gilteritinib is a potent inhibitor of FLT3 and AXL receptor tyrosine kinases.",
      "In many AML patients, the FLT3 gene is mutated (e.g., ITD, TKD), leading to constitutively active signaling that drives cancer cell proliferation.",
      "By inhibiting FLT3, gilteritinib blocks these signaling pathways, inducing cell cycle arrest and apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "Slowly absorbed. Peak in 4-6 hours.",
      "distribution": "Widely distributed. Highly protein-bound (~94%).",
      "metabolism": "Metabolized in the liver by CYP3A4.",
      "excretion": "Excreted primarily in feces. Long half-life (~113 hours)."
    },
    "dose": "120 mg PO once daily, with or without food.",
    "adverseEffects": {
      "common": ["Elevated LFTs", "myalgia/arthralgia", "fatigue", "diarrhea", "nausea", "cough."],
      "serious": ["Differentiation Syndrome", "QT prolongation", "pancreatitis", "posterior reversible encephalopathy syndrome (PRES)."]
    },
    "precautions": [
      "BOXED WARNING (Differentiation Syndrome): Can cause a life-threatening differentiation syndrome. If suspected (fever, dyspnea, fluid retention, organ failure), treat with corticosteroids immediately.",
      "Risk of QT prolongation. Monitor EKG and electrolytes.",
      "Risk of pancreatitis. Monitor lipase/amylase.",
      "Avoid strong CYP3A4 inhibitors or inducers."
    ],
    "contraindications": [
      "Hypersensitivity to gilteritinib."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "xpovio": {
    "name": "Xpovio (Selinexor)",
    "genericName": "Selinexor",
    "brandNames": ["Xpovio"],
    "category": "Antineoplastic Agent",
    "drugClass": "Selective Inhibitor of Nuclear Export (SINE)",
    "indications": "Treatment of relapsed or refractory multiple myeloma. Treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).",
    "moaSteps": [
      "Selinexor is a first-in-class Selective Inhibitor of Nuclear Export (SINE).",
      "It works by blocking the protein exportin 1 (XPO1).",
      "XPO1 is responsible for transporting many tumor suppressor proteins (TSPs) from the cell's nucleus to the cytoplasm.",
      "By blocking XPO1, selinexor 'traps' these TSPs inside the nucleus.",
      "This accumulation of TSPs in the nucleus enhances their anti-cancer function, forcing the cancer cell to undergo apoptosis (cell death)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Peak in 2-4 hours.",
      "distribution": "Highly protein-bound (~95%).",
      "metabolism": "Metabolized by CYP3A4 and UGT.",
      "excretion": "Excreted in urine and feces as metabolites. Half-life is ~6-7 hours."
    },
    "dose": "Varies. e.g., 80-100 mg PO once or twice weekly (in combination with other drugs).",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "diarrhea", "fatigue", "anorexia", "weight loss", "thrombocytopenia", "neutropenia.", "hyponatremia."],
      "serious": ["Severe thrombocytopenia", "neutropenia", "severe GI toxicity", "hyponatremia", "neurological toxicity (confusion, dizziness)."]
    },
    "precautions": [
      "High incidence of severe nausea, vomiting, and anorexia. Prophylactic antiemetics are required.",
      "Risk of severe thrombocytopenia and neutropenia. Monitor CBC frequently.",
      "Risk of hyponatremia. Monitor sodium levels.",
      "Can cause dizziness and confusion; caution against driving."
    ],
    "contraindications": [
      "Hypersensitivity to selinexor."
    ],
    "pregnancyCategory": "Category D. Can cause fetal harm.",
    "lactationInfo": "Not recommended."
  },
  "xhance": {
    "name": "Xhance (Fluticasone Propionate)",
    "genericName": "Fluticasone Propionate",
    "brandNames": ["Xhance"],
    "category": "Anti-inflammatory, Nasal",
    "drugClass": "Corticosteroid",
    "indications": "Treatment of nasal polyps in adults.",
    "moaSteps": [
      "Xhance uses a unique 'Exhalation Delivery System' to deliver fluticasone (a potent corticosteroid) deep into the nasal passages.",
      "Fluticasone binds to intracellular glucocorticoid receptors, modifying gene expression.",
      "This suppresses inflammation, inhibits pro-inflammatory mediators, and reduces immune cell activity, which helps to shrink nasal polyps."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption from nasal use. High first-pass metabolism.",
      "distribution": "Acts locally.",
      "metabolism": "Metabolized by CYP3A4.",
      "excretion": "N/A (topical)."
    },
    "dose": "1 spray (93 mcg) in each nostril twice daily. Patient must exhale into the device to deliver the medication.",
    "adverseEffects": {
      "common": ["Nosebleed (epistaxis)", "nasal ulceration", "headache", "nasal irritation."],
      "serious": ["Nasal septal perforation", "glaucoma/cataracts", "immunosuppression", "HPA axis suppression (rare)."]
    },
    "precautions": [
      "Can cause local nasal problems (e.g., ulceration, nosebleeds).",
      "Risk of localized Candida albicans (yeast) infection.",
      "Use with caution with strong CYP3A4 inhibitors (e.g., ritonavir)."
    ],
    "contraindications": [
      "Hypersensitivity to fluticasone."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "xuriden": {
    "name": "Xuriden (Uridine Triacetate)",
    "genericName": "Uridine Triacetate",
    "brandNames": ["Xuriden"],
    "category": "Hereditary Orotic Aciduria Agent",
    "drugClass": "Pyrimidine Analog",
    "indications": "Treatment of hereditary orotic aciduria (a rare metabolic disorder).",
    "moaSteps": [
      "Hereditary orotic aciduria is caused by a defect in the enzyme that converts orotic acid to uridine monophosphate (UMP).",
      "Uridine triacetate is a prodrug that is converted to uridine.",
      "Uridine can be converted to UMP by a different pathway (uridine kinase), bypassing the defective enzyme.",
      "This provides the UMP needed for pyrimidine synthesis, which is essential for RNA, DNA, and cell function.",
      "It also helps reduce the toxic buildup of orotic acid."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed and converted to uridine.",
      "distribution": "Widely distributed.",
      "metabolism": "Prodrug is hydrolyzed to uridine.",
      "excretion": "Uridine is incorporated into the body's natural pathways."
    },
    "dose": "Initial: 60 mg/kg PO once daily. Max 2 g/dose.",
    "adverseEffects": {
      "common": ["Well-tolerated. Nausea, vomiting, diarrhea (rare)."],
      "serious": ["No serious adverse reactions reported in trials."]
    },
    "precautions": [
      "Must be mixed with food (e.g., applesauce) or milk/formula before taking.",
      "Administer immediately after mixing."
    ],
    "contraindications": [
      "Hypersensitivity to uridine triacetate."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "xepi": {
    "name": "Xepi (Ozenoxacin)",
    "genericName": "Ozenoxacin",
    "brandNames": ["Xepi"],
    "category": "Antibiotic, Topical",
    "drugClass": "Quinolone Antibiotic",
    "indications": "Topical treatment of impetigo caused by susceptible strains of Staphylococcus aureus or Streptococcus pyogenes.",
    "moaSteps": [
      "Ozenoxacin is a quinolone antibiotic.",
      "It inhibits two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV.",
      "Inhibition of these enzymes prevents the replication, transcription, and repair of bacterial DNA, leading to cell death (bactericidal)."
    ],
    "pharmacokinetics": {
      "absorption": "Negligible systemic absorption after topical application.",
      "distribution": "Acts locally in the skin.",
      "metabolism": "N/A (topical).",
      "excretion": "N/A (topical)."
    },
    "dose": "Apply a thin layer to the affected area twice daily for 5 days.",
    "adverseEffects": {
      "common": ["Local skin reactions (rosacea, seborrheic dermatitis)."],
      "serious": ["Hypersensitivity reaction (rare)."]
    },
    "precautions": [
      "For external use only. Do not get in eyes or mouth.",
      "Prolonged use may result in fungal or bacterial superinfection."
    ],
    "contraindications": [
      "Hypersensitivity to ozenoxacin or other quinolones."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; use with caution."
  },
  "xartemis-xr": {
    "name": "Xartemis XR (Oxycodone/Acetaminophen ER)",
    "genericName": "Oxycodone and Acetaminophen (Extended-Release)",
    "brandNames": ["Xartemis XR"],
    "category": "Analgesic, Opioid",
    "drugClass": "Opioid Analgesic Combination (Schedule II)",
    "indications": "**Note: This product has been discontinued.** It was indicated for the management of acute pain severe enough to require an opioid.",
    "moaSteps": [
      "This was a combination product:",
      "1. **Oxycodone:** A semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, causing analgesia.",
      "2. **Acetaminophen (APAP):** A central analgesic and antipyretic."
    ],
    "pharmacokinetics": {
      "absorption": "Extended-release formulation.",
      "metabolism": "Oxycodone metabolized by CYP3A4/2D6. Acetaminophen metabolized in the liver.",
      "excretion": "Excreted in urine as metabolites."
    },
    "dose": "Formerly: 2 tablets every 12 hours.",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "constipation", "drowsiness", "dizziness."],
      "serious": ["Respiratory depression", "hepatotoxicity", "abuse and dependence."]
    },
    "precautions": [
      "BOXED WARNING (Hepatotoxicity): Acetaminophen has been associated with acute liver failure.",
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse.",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "BOXED WARNING (Neonatal Opioid Withdrawal): Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "paralytic ileus."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Not recommended."
  },
  "xtampza-er": {
    "name": "Xtampza ER (Oxycodone ER)",
    "genericName": "Oxycodone (Extended-Release)",
    "brandNames": ["Xtampza ER", "OxyContin"],
    "category": "Analgesic, Opioid",
    "drugClass": "Opioid Analgesic (Schedule II)",
    "indications": "Management of severe, continuous pain requiring long-term, around-the-clock opioid treatment.",
    "moaSteps": [
      "Oxycodone is a semi-synthetic opioid agonist.",
      "It binds to and activates mu-opioid receptors in the CNS, causing potent analgesia.",
      "This is an extended-release formulation designed to provide 12 hours of pain relief. It uses a crush-resistant technology (DETERx) to deter abuse."
    ],
    "pharmacokinetics": {
      "absorption": "Slowly absorbed (ER). High-fat meal increases absorption.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized by CYP3A4 and CYP2D6.",
      "excretion": "Excreted in urine as metabolites. Half-life is ~4.5 hours."
    },
    "dose": "Highly individualized and for opioid-tolerant patients only. e.g., 9 mg PO every 12 hours.",
    "adverseEffects": {
      "common": ["Drowsiness", "sedation", "nausea", "vomiting", "constipation", "pruritus."],
      "serious": ["Respiratory depression", "abuse, addiction, and overdose", "severe hypotension."]
    },
    "precautions": [
      "BOXED WARNING (Addiction, Abuse, Misuse): Risk of opioid addiction, abuse, and misuse.",
      "BOXED WARNING (Respiratory Depression): Serious, life-threatening, or fatal respiratory depression may occur.",
      "BOXED WARNING (Risks with Benzodiazepines): Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.",
      "BOXED WARNING (Neonatal Opioid Withdrawal): Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.",
      "BOXED WARNING (ER forms): Risk of medication errors, accidental ingestion."
    ],
    "contraindications": [
      "Hypersensitivity",
      "significant respiratory depression",
      "acute or severe bronchial asthma",
      "paralytic ileus."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Not recommended."
  
},
  "zafirlukast": {
    "name": "Zafirlukast (Accolate)",
    "genericName": "Zafirlukast",
    "brandNames": ["Accolate"],
    "category": "Antiasthmatic",
    "drugClass": "Leukotriene Receptor Antagonist",
    "indications": "Prophylaxis and chronic treatment of asthma.",
    "moaSteps": [
      "Zafirlukast is a selective leukotriene receptor antagonist.",
      "Leukotrienes are potent inflammatory mediators that cause bronchoconstriction, mucus secretion, and airway inflammation.",
      "Zafirlukast blocks the action of leukotrienes by binding to the CysLT1 receptor, thus reducing inflammation and relieving asthma symptoms."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. **Food significantly reduces absorption (~40%).**",
      "distribution": "Highly protein-bound (>99%).",
      "metabolism": "Extensively metabolized in the liver by CYP2C9.",
      "excretion": "Excreted primarily in feces (via bile). Half-life is ~10 hours."
    },
    "dose": "20 mg PO twice daily. **Must be taken on an empty stomach** (1 hour before or 2 hours after meals).",
    "adverseEffects": {
      "common": ["Headache", "nausea", "diarrhea", "pharyngitis."],
      "serious": ["Hepatotoxicity (liver failure)", "neuropsychiatric events", "Churg-Strauss syndrome (rare)."]
    },
    "precautions": [
      "Risk of hepatotoxicity. Monitor LFTs, especially in the first few months.",
      "Neuropsychiatric events (e.g., depression, agitation) have been reported.",
      "**Must be taken on an empty stomach.**",
      "Potent inhibitor of CYP2C9; can increase levels of warfarin.",
      "Not for the treatment of acute asthma attacks."
    ],
    "contraindications": [
      "Hypersensitivity",
      "active or chronic liver disease."
    ],
    "pregnancyCategory": "Category B",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "zaleplon": {
    "name": "Zaleplon (Sonata)",
    "genericName": "Zaleplon",
    "brandNames": ["Sonata"],
    "category": "Sedative-Hypnotic",
    "drugClass": "Non-benzodiazepine Hypnotic (Z-drug) (Schedule IV)",
    "indications": "Short-term treatment of insomnia (for sleep onset).",
    "moaSteps": [
      "Zaleplon is a non-benzodiazepine hypnotic (a 'Z-drug').",
      "It acts as a positive allosteric modulator of the GABA-A receptor, binding to the alpha-1 subunit.",
      "This binding enhances the effect of the inhibitory neurotransmitter GABA, leading to chloride ion influx, hyperpolarization, and CNS depression (sedation).",
      "It has an ultra-short half-life, making it suitable only for sleep onset."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. High first-pass metabolism (bioavailability ~30%).",
      "distribution": "Widely distributed. Moderately protein-bound (~60%).",
      "metabolism": "Extensively metabolized in the liver, primarily by aldehyde oxidase (not CYP enzymes).",
      "excretion": "Excreted in urine as metabolites. **Very short half-life (~1 hour).**"
    },
    "dose": "5-10 mg PO immediately before bedtime or after the patient has gone to bed and has difficulty falling asleep.",
    "adverseEffects": {
      "common": ["Drowsiness", "dizziness", "headache", "nausea", "unpleasant taste."],
      "serious": ["Complex sleep behaviors (e.g., sleep-driving, sleep-eating)", "next-day impairment (if taken too late)", "abuse and dependence."]
    },
    "precautions": [
      "BOXED WARNING (Complex Sleep Behaviors): Cases of complex sleep behaviors have been reported, which may result in serious injury or death. Discontinue immediately.",
      "Has potential for abuse and dependence (Schedule IV).",
      "Can cause drowsiness; do not take unless you have 4+ hours to sleep.",
      "Abrupt withdrawal can cause rebound insomnia.",
      "Avoid alcohol and other CNS depressants."
    ],
    "contraindications": [
      "Hypersensitivity to zaleplon",
      "history of complex sleep behaviors after taking zaleplon."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  },
  "zidovudine": {
    "name": "Zidovudine (Retrovir)",
    "genericName": "Zidovudine (AZT)",
    "brandNames": ["Retrovir", "Combivir (with lamivudine)"],
    "category": "Antiretroviral",
    "drugClass": "Antiretroviral, Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
    "indications": "Treatment of Human Immunodeficiency Virus (HIV-1) infection, always in combination with other antiretroviral agents. Prevention of maternal-fetal HIV transmission.",
    "moaSteps": [
      "Zidovudine (AZT) is a synthetic thymidine nucleoside analog.",
      "It is phosphorylated by cellular enzymes to its active triphosphate form (AZT-TP).",
      "AZT-TP competes with the natural substrate (thymidine triphosphate) for the HIV reverse transcriptase enzyme.",
      "AZT-TP lacks a 3'-hydroxyl group. Once it is incorporated into the growing viral DNA strand, it acts as a chain terminator, halting DNA synthesis and viral replication."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~64% (high first-pass metabolism).",
      "distribution": "Widely distributed, including into CSF. Low protein binding (<38%).",
      "metabolism": "Extensively metabolized in the liver (glucuronidation).",
      "excretion": "Excreted in urine. Short half-life (~1 hour)."
    },
    "dose": "HIV Treatment: 300 mg PO twice daily (in combination).",
    "adverseEffects": {
      "common": ["Nausea", "vomiting", "headache", "malaise (fatigue)", "insomnia", "myalgia.", "skin/nail pigmentation."],
      "serious": ["Myelosuppression (severe anemia, neutropenia)", "lactic acidosis with severe hepatomegaly", "myopathy."]
    },
    "precautions": [
      "BOXED WARNING (Myelosuppression): Can cause severe, life-threatening anemia and neutropenia. Monitor CBC frequently.",
      "BOXED WARNING (Myopathy): Can cause symptomatic myopathy.",
      "BOXED WARNING (Lactic Acidosis): Lactic acidosis and severe hepatomegaly with steatosis have been reported with NRTIs.",
      "Monitor for signs of lactic acidosis and hepatotoxicity."
    ],
    "contraindications": [
      "Hypersensitivity",
      "severe anemia or neutropenia."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Not recommended (to prevent HIV transmission)."
  },
  "ziprasidone": {
    "name": "Ziprasidone (Geodon)",
    "genericName": "Ziprasidone",
    "brandNames": ["Geodon"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second-Generation)",
    "indications": "Treatment of schizophrenia. Acute treatment of manic or mixed episodes associated with bipolar I disorder.",
    "moaSteps": [
      "Ziprasidone is an atypical antipsychotic.",
      "Its mechanism is thought to be mediated by blocking both dopamine D2 receptors and serotonin 5-HT2A receptors.",
      "It also has moderate inhibitory effects on the reuptake of serotonin and norepinephrine, and acts as an antagonist at H1 and alpha-1 receptors."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. **Must be taken with food (absorption is doubled).**",
      "distribution": "Widely distributed. Highly protein-bound (>99%).",
      "metabolism": "Extensively metabolized in the liver (CYP3A4 and aldehyde oxidase).",
      "excretion": "Excreted in feces (via bile) and urine. Half-life is ~7 hours."
    },
    "dose": "Schizophrenia: Initial 20 mg PO twice daily. Titrate up to max 80-100 mg twice daily. **Must be taken with a meal (at least 500 calories).**",
    "adverseEffects": {
      "common": ["Somnolence (drowsiness)", "dizziness", "nausea", "constipation", "EPS (e.g., akathisia, dystonia)."],
      "serious": ["QT prolongation", "Neuroleptic Malignant Syndrome (NMS)", "Tardive Dyskinesia (TD)", "severe skin reactions (DRESS)."]
    },
    "precautions": [
      "BOXED WARNING (Elderly with Dementia): Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death.",
      "**Risk of QT prolongation.** Can increase the QT interval, which can lead to Torsades de Pointes. Avoid in patients with long QT syndrome or other risk factors.",
      "**Must be taken with a 500-calorie meal** to ensure adequate absorption.",
      "Risk of NMS, TD, and EPS.",
      "Risk of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms)."
    ],
    "contraindications": [
      "Hypersensitivity",
      "known history of QT prolongation",
      "concomitant use with other QT-prolonging drugs",
      "recent acute MI."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Unknown if excreted in human milk; not recommended."
  },
  "zolmitriptan": {
    "name": "Zolmitriptan (Zomig)",
    "genericName": "Zolmitriptan",
    "brandNames": ["Zomig", "Zomig-ZMT (ODT)", "Zomig Nasal Spray"],
    "category": "Antimigraine Agent",
    "drugClass": "Serotonin 5-HT1B/1D Receptor Agonist (Triptan)",
    "indications": "Acute treatment of migraine attacks with or without aura.",
    "moaSteps": [
      "Zolmitriptan is a selective agonist for serotonin 5-HT1B and 5-HT1D receptors.",
      "It works by three mechanisms:",
      "1. **Cranial Vasoconstriction:** It constricts the dilated intracranial blood vessels.",
      "2. **Inhibition of Neuropeptide Release:** It blocks the release of pro-inflammatory neuropeptides.",
      "3. **Inhibition of Pain Pathways:** It reduces pain signal transmission in the trigeminal nucleus."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Bioavailability ~40% (first-pass metabolism).",
      "distribution": "Widely distributed. Low protein binding (~25%).",
      "metabolism": "Extensively metabolized in the liver by CYP1A2 and MAO-A to an active metabolite.",
      "excretion": "Excreted in urine. Short half-life (~3 hours)."
    },
    "dose": "Oral: 1.25-2.5 mg PO at the onset of migraine. May repeat once after 2 hours. Max 10 mg/24 hours.",
    "adverseEffects": {
      "common": ["'Triptan sensations' (chest/neck/jaw tightness)", "tingling/numbness (paresthesia)", "dizziness", "somnolence", "nausea."],
      "serious": ["Coronary vasospasm (angina, MI)", "arrhythmias", "stroke", "serotonin syndrome."]
    },
    "precautions": [
      "Not for migraine prophylaxis (prevention). Only for acute treatment.",
      "Risk of serious cardiovascular events. Contraindicated in patients with known cardiovascular disease (CAD, stroke, uncontrolled hypertension).",
      "Risk of 'triptan sensations' (chest, neck, or jaw tightness/pressure).",
      "**Contraindicated with MAOIs.** Requires a 2-week washout period."
    ],
    "contraindications": [
      "Hypersensitivity",
      "ischemic heart disease (angina, history of MI)",
      "uncontrolled hypertension",
      "hemiplegic or basilar migraine",
      "**concomititant use with MAOIs (within 14 days)**",
      "use within 24 hours of another triptan or ergotamine."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "zolpidem": {
    "name": "Zolpidem (Ambien, Intermezzo)",
    "genericName": "Zolpidem",
    "brandNames": ["Ambien (IR)", "Ambien CR (ER)", "Intermezzo (sublingual)", "Edluar (sublingual)"],
    "category": "Sedative-Hypnotic",
    "drugClass": "Non-benzodiazepine Hypnotic (Z-drug) (Schedule IV)",
    "indications": "Short-term treatment of insomnia (for sleep onset).",
    "moaSteps": [
      "Zolpidem is a non-benzodiazepine hypnotic (a 'Z-drug').",
      "It acts as a positive allosteric modulator of the GABA-A receptor, binding selectively to the alpha-1 subunit.",
      "This binding enhances the effect of the inhibitory neurotransmitter GABA, leading to chloride ion influx, hyperpolarization, and CNS depression (sedation).",
      "It has a rapid onset and short half-life."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Food delays absorption.",
      "distribution": "Widely distributed. Highly protein-bound (~92%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in urine as metabolites. Short half-life (~2.5 hours)."
    },
    "dose": "IR: 5-10 mg PO immediately before bedtime. **(Recommended starting dose is 5 mg for women and 6.25 mg for ER).**",
    "adverseEffects": {
      "common": ["Drowsiness", "dizziness", "headache", "nausea", "diarrhea", "anterograde amnesia (memory loss)."],
      "serious": ["Complex sleep behaviors (e.g., sleep-driving, sleep-eating)", "next-day impairment", "abuse and dependence", "anaphylaxis."]
    },
    "precautions": [
      "BOXED WARNING (Complex Sleep Behaviors): Cases of complex sleep behaviors (e.g., sleepwalking, sleep-driving) have been reported, which may result in serious injury or death. Discontinue immediately.",
      "Can cause significant next-day impairment and drowsiness; caution against driving.",
      "Has potential for abuse and dependence (Schedule IV).",
      "Abrupt withdrawal can cause rebound insomnia.",
      "Avoid alcohol and other CNS depressants."
    ],
    "contraindications": [
      "Hypersensitivity to zolpidem",
      "history of complex sleep behaviors after taking zolpidem."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; use with caution."
  },
  "zonisamide": {
    "name": "Zonisamide (Zonegran)",
    "genericName": "Zonisamide",
    "brandNames": ["Zonegran"],
    "category": "Antiepileptic",
    "drugClass": "Anticonvulsant, Sulfonamide",
    "indications": "Adjunctive therapy in the treatment of partial-onset seizures.",
    "moaSteps": [
      "The mechanism of zonisamide is not fully known, but it is multi-faceted:",
      "1. **Sodium Channel Blockade:** It blocks voltage-gated sodium channels, stabilizing neuronal membranes.",
      "2. **T-type Calcium Channel Blockade:** It blocks T-type calcium channels.",
      "3. **Carbonic Anhydrase Inhibition:** It is a weak carbonic anhydrase inhibitor.",
      "4. It may also modulate GABAergic and glutamatergic neurotransmission."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and completely absorbed.",
      "distribution": "Widely distributed. Binds to red blood cells. Low protein binding (~40%).",
      "metabolism": "Extensively metabolized in the liver by CYP3A4.",
      "excretion": "Excreted in urine as metabolites and unchanged drug. Very long half-life (~63 hours)."
    },
    "dose": "Initial: 100 mg PO once daily. Titrate slowly every 2 weeks up to 400-600 mg/day.",
    "adverseEffects": {
      "common": ["Drowsiness", "dizziness", "ataxia", "anorexia", "agitation/irritability", "difficulty with memory/concentration."],
      "serious": ["Severe skin reactions (SJS/TEN)", "metabolic acidosis", "suicidal thoughts", "decreased sweating (oligohidrosis) and fever.", "kidney stones."]
    },
    "precautions": [
      "**Contraindicated in sulfa allergy.** Zonisamide is a sulfonamide derivative.",
      "Risk of severe, fatal skin reactions (SJS/TEN).",
      "Risk of metabolic acidosis. Monitor serum bicarbonate levels.",
      "Risk of suicidal thoughts and behaviors.",
      "Risk of decreased sweating (hyperthermia), especially in hot weather.",
      "Maintain good fluid intake to reduce risk of kidney stones."
    ],
    "contraindications": [
      "Hypersensitivity to zonisamide or **sulfonamides (sulfa allergy)**."
    ],
    "pregnancyCategory": "Category C",
    "lactationInfo": "Excreted in breast milk; not recommended."
  }
}